US20230399312A1 - Substituted pyrimidines and methods of use - Google Patents
Substituted pyrimidines and methods of use Download PDFInfo
- Publication number
- US20230399312A1 US20230399312A1 US18/140,423 US202318140423A US2023399312A1 US 20230399312 A1 US20230399312 A1 US 20230399312A1 US 202318140423 A US202318140423 A US 202318140423A US 2023399312 A1 US2023399312 A1 US 2023399312A1
- Authority
- US
- United States
- Prior art keywords
- pyrimidin
- methyl
- amino
- pyridyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 97
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 68
- 230000001404 mediated effect Effects 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 336
- 125000000623 heterocyclic group Chemical group 0.000 claims description 146
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 119
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 108
- 125000001424 substituent group Chemical group 0.000 claims description 90
- -1 benzodioxanyl Chemical group 0.000 claims description 88
- 206010016654 Fibrosis Diseases 0.000 claims description 85
- 230000004761 fibrosis Effects 0.000 claims description 83
- 201000010099 disease Diseases 0.000 claims description 56
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 54
- 229910052736 halogen Inorganic materials 0.000 claims description 50
- 150000002367 halogens Chemical class 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 43
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 35
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 30
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 30
- 125000004076 pyridyl group Chemical group 0.000 claims description 29
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 25
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 15
- 206010072877 Intestinal fibrosis Diseases 0.000 claims description 14
- 125000001544 thienyl group Chemical group 0.000 claims description 12
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000000335 thiazolyl group Chemical group 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 abstract description 83
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 abstract description 83
- 239000003112 inhibitor Substances 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 25
- 238000011282 treatment Methods 0.000 abstract description 25
- 208000035475 disorder Diseases 0.000 abstract description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 201
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 143
- 239000011541 reaction mixture Substances 0.000 description 126
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 103
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 100
- 239000000203 mixture Substances 0.000 description 95
- 238000002360 preparation method Methods 0.000 description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 85
- 239000000243 solution Substances 0.000 description 82
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 79
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 76
- 230000027455 binding Effects 0.000 description 58
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 239000003814 drug Substances 0.000 description 54
- 208000005069 pulmonary fibrosis Diseases 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 53
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 50
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 49
- 238000004587 chromatography analysis Methods 0.000 description 46
- 238000002953 preparative HPLC Methods 0.000 description 46
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 44
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 44
- 229940045513 CTLA4 antagonist Drugs 0.000 description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 41
- 239000007787 solid Substances 0.000 description 41
- 235000019439 ethyl acetate Nutrition 0.000 description 39
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 38
- 230000015572 biosynthetic process Effects 0.000 description 36
- 125000005647 linker group Chemical group 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 33
- WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- 239000000427 antigen Substances 0.000 description 32
- 102000036639 antigens Human genes 0.000 description 32
- 108091007433 antigens Proteins 0.000 description 32
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 31
- 229940124597 therapeutic agent Drugs 0.000 description 31
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 26
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 24
- 229910000024 caesium carbonate Inorganic materials 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000012043 crude product Substances 0.000 description 22
- 239000012270 PD-1 inhibitor Substances 0.000 description 21
- 239000012668 PD-1-inhibitor Substances 0.000 description 21
- 229940121655 pd-1 inhibitor Drugs 0.000 description 21
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 19
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 19
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 18
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 208000019425 cirrhosis of liver Diseases 0.000 description 17
- 239000002955 immunomodulating agent Substances 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- 208000002815 pulmonary hypertension Diseases 0.000 description 17
- 230000008685 targeting Effects 0.000 description 17
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- XJLSEXAGTJCILF-UHFFFAOYSA-N nipecotic acid Chemical compound OC(=O)C1CCCNC1 XJLSEXAGTJCILF-UHFFFAOYSA-N 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 15
- 230000003176 fibrotic effect Effects 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 125000000304 alkynyl group Chemical group 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 230000011664 signaling Effects 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 208000029523 Interstitial Lung disease Diseases 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 230000009885 systemic effect Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 239000004698 Polyethylene Substances 0.000 description 12
- 125000002947 alkylene group Chemical group 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 12
- 239000006199 nebulizer Substances 0.000 description 12
- JSSXHAMIXJGYCS-UHFFFAOYSA-N piperazin-4-ium-2-carboxylate Chemical compound OC(=O)C1CNCCN1 JSSXHAMIXJGYCS-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 239000000651 prodrug Substances 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 12
- 108010074708 B7-H1 Antigen Proteins 0.000 description 11
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 11
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 11
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 11
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 11
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 11
- 150000002148 esters Chemical group 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 229940071648 metered dose inhaler Drugs 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
- 239000007832 Na2SO4 Substances 0.000 description 10
- 201000009594 Systemic Scleroderma Diseases 0.000 description 10
- 206010042953 Systemic sclerosis Diseases 0.000 description 10
- 125000000524 functional group Chemical group 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 229960002621 pembrolizumab Drugs 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 150000007942 carboxylates Chemical class 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 7
- 201000004384 Alopecia Diseases 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 101710084191 TGF-beta receptor type-1 Proteins 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- GFZWHAAOIVMHOI-UHFFFAOYSA-N azetidine-3-carboxylic acid Chemical compound OC(=O)C1CNC1 GFZWHAAOIVMHOI-UHFFFAOYSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 230000009787 cardiac fibrosis Effects 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 229940112141 dry powder inhaler Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 208000033829 multifocal fibrosclerosis Diseases 0.000 description 7
- 229960003301 nivolumab Drugs 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 7
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 7
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- 206010023421 Kidney fibrosis Diseases 0.000 description 6
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 6
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 6
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 6
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
- 239000002359 drug metabolite Substances 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 229960003073 pirfenidone Drugs 0.000 description 6
- 239000003380 propellant Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 208000010157 sclerosing cholangitis Diseases 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 5
- 206010005042 Bladder fibrosis Diseases 0.000 description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 5
- 241001678559 COVID-19 virus Species 0.000 description 5
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 208000019693 Lung disease Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 235000019502 Orange oil Nutrition 0.000 description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 5
- 206010039710 Scleroderma Diseases 0.000 description 5
- 206010050207 Skin fibrosis Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 101710084188 TGF-beta receptor type-2 Proteins 0.000 description 5
- 108091005735 TGF-beta receptors Proteins 0.000 description 5
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 125000004450 alkenylene group Chemical group 0.000 description 5
- 125000004419 alkynylene group Chemical group 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 229950009791 durvalumab Drugs 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 208000024908 graft versus host disease Diseases 0.000 description 5
- 125000004474 heteroalkylene group Chemical group 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 210000000651 myofibroblast Anatomy 0.000 description 5
- 239000010502 orange oil Substances 0.000 description 5
- 210000003240 portal vein Anatomy 0.000 description 5
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 206010001935 American trypanosomiasis Diseases 0.000 description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 4
- FYVPORFDLDQDTA-UHFFFAOYSA-N CC1=C(C=C(C=C1)O)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCC(CC1)N1CCN(CC1)C Chemical compound CC1=C(C=C(C=C1)O)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCC(CC1)N1CCN(CC1)C FYVPORFDLDQDTA-UHFFFAOYSA-N 0.000 description 4
- FZZVBUSTCRVUKM-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)C=1C=NN(C=1)C1COC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)C=1C=NN(C=1)C1COC1 FZZVBUSTCRVUKM-UHFFFAOYSA-N 0.000 description 4
- YRTPJSHRKNGEMK-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCNCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCNCC1 YRTPJSHRKNGEMK-UHFFFAOYSA-N 0.000 description 4
- CTVWSNJOOLBLLK-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1 CTVWSNJOOLBLLK-UHFFFAOYSA-N 0.000 description 4
- SQNPYMHIBJGKTL-LJQANCHMSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1C[C@@H](NCC1)CO Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1C[C@@H](NCC1)CO SQNPYMHIBJGKTL-LJQANCHMSA-N 0.000 description 4
- FVSDEVPYFNKVON-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CSC(=C1)CN1CCNCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CSC(=C1)CN1CCNCC1 FVSDEVPYFNKVON-UHFFFAOYSA-N 0.000 description 4
- QPCVHACKLGYTEW-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(C=CC=1)NC(=O)C1CNCCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(C=CC=1)NC(=O)C1CNCCC1 QPCVHACKLGYTEW-UHFFFAOYSA-N 0.000 description 4
- GSXQNEHKJFIIEW-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(SC=1)NC(=O)C1CCNCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(SC=1)NC(=O)C1CCNCC1 GSXQNEHKJFIIEW-UHFFFAOYSA-N 0.000 description 4
- ABJSEZJKPBPSNC-OAQYLSRUSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=CC(=C(C=1)CC(=O)O[C@H](C)CC)N1CCNCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=CC(=C(C=1)CC(=O)O[C@H](C)CC)N1CCNCC1 ABJSEZJKPBPSNC-OAQYLSRUSA-N 0.000 description 4
- SATCUGYKPHWPHM-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=NC(=NC=1)N1CCNCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=NC(=NC=1)N1CCNCC1 SATCUGYKPHWPHM-UHFFFAOYSA-N 0.000 description 4
- FSPDYFODTNKBCC-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=NN(C=1)CCN1CCOCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=NN(C=1)CCN1CCOCC1 FSPDYFODTNKBCC-UHFFFAOYSA-N 0.000 description 4
- PNKIKWAHKQPEMM-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)CN1CCNCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)CN1CCNCC1 PNKIKWAHKQPEMM-UHFFFAOYSA-N 0.000 description 4
- FCQCLCLLHHKSDI-UHFFFAOYSA-N CNCCN1N=CC(=C1)C1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound CNCCN1N=CC(=C1)C1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C FCQCLCLLHHKSDI-UHFFFAOYSA-N 0.000 description 4
- 208000024699 Chagas disease Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KDZFQJJKJKEGJE-UHFFFAOYSA-N ClC=1C(=CC(=C(C=1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCNCC1)F)F Chemical compound ClC=1C(=CC(=C(C=1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCNCC1)F)F KDZFQJJKJKEGJE-UHFFFAOYSA-N 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- ISHSCBBWCWUSIC-UHFFFAOYSA-N FC(C1=C(C=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1)F)F Chemical compound FC(C1=C(C=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1)F)F ISHSCBBWCWUSIC-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 4
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- VGQAFGHBRILMFF-UHFFFAOYSA-N N1CC(C1)CN(C1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C)C Chemical compound N1CC(C1)CN(C1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C)C VGQAFGHBRILMFF-UHFFFAOYSA-N 0.000 description 4
- GUYJBZSTTWBKOT-UHFFFAOYSA-N N1CC(C1)CNC1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound N1CC(C1)CNC1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C GUYJBZSTTWBKOT-UHFFFAOYSA-N 0.000 description 4
- QKEWGOSJDAGEKZ-UHFFFAOYSA-N N1CC2(CC1)CC1=CC=C(C=C1C2)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound N1CC2(CC1)CC1=CC=C(C=C1C2)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C QKEWGOSJDAGEKZ-UHFFFAOYSA-N 0.000 description 4
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 4
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 206010034665 Peritoneal fibrosis Diseases 0.000 description 4
- 208000031472 Retinal fibrosis Diseases 0.000 description 4
- 241000223109 Trypanosoma cruzi Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 206010069351 acute lung injury Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229960005386 ipilimumab Drugs 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 206010028537 myelofibrosis Diseases 0.000 description 4
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 4
- 229960004378 nintedanib Drugs 0.000 description 4
- 208000005207 oral submucous fibrosis Diseases 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- BJUYAYXDXZVWEQ-LJQANCHMSA-N C1(=CC=NC(=N1)C1=CC=CC(C)=N1)NC1=NC(=NC=C1)NC1=CC=C(N[C@H]2CNCC2)C=C1 Chemical compound C1(=CC=NC(=N1)C1=CC=CC(C)=N1)NC1=NC(=NC=C1)NC1=CC=C(N[C@H]2CNCC2)C=C1 BJUYAYXDXZVWEQ-LJQANCHMSA-N 0.000 description 3
- QYZSLUBQDNRRTC-UHFFFAOYSA-N C12CNCC(CC1)N2C1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound C12CNCC(CC1)N2C1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C QYZSLUBQDNRRTC-UHFFFAOYSA-N 0.000 description 3
- ZYZBIRUWBGDBLT-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)CC1CNCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)CC1CNCC1 ZYZBIRUWBGDBLT-UHFFFAOYSA-N 0.000 description 3
- GTJQPZHILCJLBC-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)NC(=O)C1CCNCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)NC(=O)C1CCNCC1 GTJQPZHILCJLBC-UHFFFAOYSA-N 0.000 description 3
- QXTQBHRLLBUOQS-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)NC(=O)N1CCNCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)NC(=O)N1CCNCC1 QXTQBHRLLBUOQS-UHFFFAOYSA-N 0.000 description 3
- FGCWXELMOZHOFL-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)NS(=O)(=O)CC1CNCCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)NS(=O)(=O)CC1CNCCC1 FGCWXELMOZHOFL-UHFFFAOYSA-N 0.000 description 3
- IBZJUFRLAHUBDF-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C2CCNCC2=C1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C2CCNCC2=C1 IBZJUFRLAHUBDF-UHFFFAOYSA-N 0.000 description 3
- ZUICFQXXTWIRPS-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=NC=C(C=C1)N1CCNCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=NC=C(C=C1)N1CCNCC1 ZUICFQXXTWIRPS-UHFFFAOYSA-N 0.000 description 3
- MWBWOHNXAAEQIO-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(SC=1)C(=O)O Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(SC=1)C(=O)O MWBWOHNXAAEQIO-UHFFFAOYSA-N 0.000 description 3
- QDNCFALPMVKFLR-UHFFFAOYSA-N CC1=NNC2=CC=CC(=C12)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1 Chemical compound CC1=NNC2=CC=CC(=C12)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1 QDNCFALPMVKFLR-UHFFFAOYSA-N 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 3
- WOPMXVUIWKVWJQ-UHFFFAOYSA-N N(C1=NC(=NC=C1)C1=CC=CC(C)=N1)C1=NC(=NC=C1)NC=1SC(N2CCOCC2)=CN=1 Chemical compound N(C1=NC(=NC=C1)C1=CC=CC(C)=N1)C1=NC(=NC=C1)NC=1SC(N2CCOCC2)=CN=1 WOPMXVUIWKVWJQ-UHFFFAOYSA-N 0.000 description 3
- MFHOKYMIJHPUNT-UHFFFAOYSA-N OCC1(CNC1)C(=O)NC1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound OCC1(CNC1)C(=O)NC1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C MFHOKYMIJHPUNT-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000010425 asbestos Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000002206 pro-fibrotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229910052895 riebeckite Inorganic materials 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- 229950007217 tremelimumab Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- VBLRKUHMIAUAHO-UHFFFAOYSA-N 2-chloro-N-(2-chloropyrimidin-4-yl)pyrimidin-4-amine Chemical compound ClC1=NC(NC2=CC=NC(Cl)=N2)=CC=N1 VBLRKUHMIAUAHO-UHFFFAOYSA-N 0.000 description 2
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DDHUVBLYIRLCLP-UHFFFAOYSA-N BrC1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound BrC1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C DDHUVBLYIRLCLP-UHFFFAOYSA-N 0.000 description 2
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 2
- VGCXWOISDCDFJR-UHFFFAOYSA-N C(C)(C)N1CCC2=C(CC1)C=C(C=C2)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound C(C)(C)N1CCC2=C(CC1)C=C(C=C2)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C VGCXWOISDCDFJR-UHFFFAOYSA-N 0.000 description 2
- DNAKAOAEWOPPKM-UHFFFAOYSA-N C1(=CC=NC(=N1)C1=NC(C)=CC=C1)NC1=NC(NC2=CC=C(C(=O)OCC3CNC3)C=C2)=NC=C1 Chemical compound C1(=CC=NC(=N1)C1=NC(C)=CC=C1)NC1=NC(NC2=CC=C(C(=O)OCC3CNC3)C=C2)=NC=C1 DNAKAOAEWOPPKM-UHFFFAOYSA-N 0.000 description 2
- BFUNYBQOPRVCIN-UHFFFAOYSA-N CC(C1)NCCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C1)NCCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 BFUNYBQOPRVCIN-UHFFFAOYSA-N 0.000 description 2
- GLGRHPNSOAQRJR-UHFFFAOYSA-N CC(CC1)(CCC1OC(C1=CC(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=CS1)=O)N Chemical compound CC(CC1)(CCC1OC(C1=CC(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=CS1)=O)N GLGRHPNSOAQRJR-UHFFFAOYSA-N 0.000 description 2
- RHXYJCMASNDYJN-UHFFFAOYSA-N CC(CNCC1)N1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(CNCC1)N1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 RHXYJCMASNDYJN-UHFFFAOYSA-N 0.000 description 2
- MZLHLJWAQDXUHX-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)N Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)N MZLHLJWAQDXUHX-UHFFFAOYSA-N 0.000 description 2
- PMKYHYRUTKSFKL-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)CO Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)CO PMKYHYRUTKSFKL-UHFFFAOYSA-N 0.000 description 2
- JEHNBHMADFLLKF-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)S(=O)(=O)N Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)S(=O)(=O)N JEHNBHMADFLLKF-UHFFFAOYSA-N 0.000 description 2
- XLLNXSFFIMHFQV-HXUWFJFHSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(CN2C[C@@H](CCC2)C(=O)O)C=C1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(CN2C[C@@H](CCC2)C(=O)O)C=C1 XLLNXSFFIMHFQV-HXUWFJFHSA-N 0.000 description 2
- XYGAWDPNUVZXFX-IRLDBZIGSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)CN1C[C@@H](CCC1)C(=O)O[C@@H]1CN(CC1)C Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)CN1C[C@@H](CCC1)C(=O)O[C@@H]1CN(CC1)C XYGAWDPNUVZXFX-IRLDBZIGSA-N 0.000 description 2
- YHFSQHAJNOZONA-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4N4CCOCC4)=NC=C3)=NC3=C2N=NN3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4N4CCOCC4)=NC=C3)=NC3=C2N=NN3)=N1 YHFSQHAJNOZONA-UHFFFAOYSA-N 0.000 description 2
- SVZJQYJRQSXKFE-UHFFFAOYSA-N CC1=CC=CC(C2=NC(C)=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(C)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC(C)=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(C)CC4)=NC=C3)=N2)=N1 SVZJQYJRQSXKFE-UHFFFAOYSA-N 0.000 description 2
- QZRDXFGFIRTBBK-UHFFFAOYSA-N CC1=CC=CC(C2=NC(C)=CC(NC3=NC(NC(C=C4)=CC=C4N4CCNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC(C)=CC(NC3=NC(NC(C=C4)=CC=C4N4CCNCC4)=NC=C3)=N2)=N1 QZRDXFGFIRTBBK-UHFFFAOYSA-N 0.000 description 2
- KDPOSXFACUJCJR-UHFFFAOYSA-N CC1=CC=CC(C2=NC(NC3=NC(NC(C=C4)=CC=C4N4CCN(C)CC4)=NC=C3)=CC(C(OC)=O)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC(NC3=NC(NC(C=C4)=CC=C4N4CCN(C)CC4)=NC=C3)=CC(C(OC)=O)=N2)=N1 KDPOSXFACUJCJR-UHFFFAOYSA-N 0.000 description 2
- HEISBECSBJRPJY-UHFFFAOYSA-N CC1=CC=CC(C2=NC=C(C(OC)=O)C(NC3=NC(NC(C=C4)=CC=C4N)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=C(C(OC)=O)C(NC3=NC(NC(C=C4)=CC=C4N)=NC=C3)=N2)=N1 HEISBECSBJRPJY-UHFFFAOYSA-N 0.000 description 2
- KSASHNVGJOEKDC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C(CC(O)=O)CNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C(CC(O)=O)CNCC4)=NC=C3)=N2)=N1 KSASHNVGJOEKDC-UHFFFAOYSA-N 0.000 description 2
- JSVBWRJQNSULKT-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)CC5C(NC5CNCC5)=O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)CC5C(NC5CNCC5)=O)C=C4)=NC=C3)=N2)=N1 JSVBWRJQNSULKT-UHFFFAOYSA-N 0.000 description 2
- GBTMDOVZDOIUIO-XMMPIXPASA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)C[C@@H]5C(OCC5CNC5)=O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)C[C@@H]5C(OCC5CNC5)=O)C=C4)=NC=C3)=N2)=N1 GBTMDOVZDOIUIO-XMMPIXPASA-N 0.000 description 2
- MCNLVBIFQLFYNJ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(N5CCNCC5)S4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(N5CCNCC5)S4)=NC=C3)=N2)=N1 MCNLVBIFQLFYNJ-UHFFFAOYSA-N 0.000 description 2
- CSECFXCGOTVCQP-UHFFFAOYSA-N CCOC(CC1=CC(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=NC(C2=CC=CC(C)=N2)=N1)=O Chemical compound CCOC(CC1=CC(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=NC(C2=CC=CC(C)=N2)=N1)=O CSECFXCGOTVCQP-UHFFFAOYSA-N 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 208000001708 Dupuytren contracture Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- PMYZMCFCTNBMSP-UHFFFAOYSA-N FC(C=CC(Cl)=C1)=C1C1=NC=C(C2CC2)C(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=N1 Chemical compound FC(C=CC(Cl)=C1)=C1C1=NC=C(C2CC2)C(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=N1 PMYZMCFCTNBMSP-UHFFFAOYSA-N 0.000 description 2
- 206010016228 Fasciitis Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000674278 Homo sapiens Serine-tRNA ligase, cytoplasmic Proteins 0.000 description 2
- 101000674040 Homo sapiens Serine-tRNA ligase, mitochondrial Proteins 0.000 description 2
- 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 102400000401 Latency-associated peptide Human genes 0.000 description 2
- 101800001155 Latency-associated peptide Proteins 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- GGNKPIOODPVQHB-UHFFFAOYSA-N NC1=CC(=CS1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound NC1=CC(=CS1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C GGNKPIOODPVQHB-UHFFFAOYSA-N 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102100032341 PCNA-interacting partner Human genes 0.000 description 2
- 101710196737 PCNA-interacting partner Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- 241000720974 Protium Species 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 229910006124 SOCl2 Inorganic materials 0.000 description 2
- 102100040516 Serine-tRNA ligase, cytoplasmic Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 230000000893 fibroproliferative effect Effects 0.000 description 2
- 230000009795 fibrotic process Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 125000005241 heteroarylamino group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000013123 lung function test Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- AUTCCPQKLPMHDN-ONEGZZNKSA-N methyl (e)-3-methoxyprop-2-enoate Chemical compound CO\C=C\C(=O)OC AUTCCPQKLPMHDN-ONEGZZNKSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 2
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 description 2
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 description 2
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BRYCUMKDWMEGMK-UHFFFAOYSA-N piperazine-2-carboxamide Chemical compound NC(=O)C1CNCCN1 BRYCUMKDWMEGMK-UHFFFAOYSA-N 0.000 description 2
- CXWQAPHDSYDHBR-UHFFFAOYSA-N piperidine-4-carboxamide Chemical compound NC(=O)C1CCNCC1.NC(=O)C1CCNCC1 CXWQAPHDSYDHBR-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 201000004409 schistosomiasis Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OEHSGMJRKDCQSO-UHFFFAOYSA-N (3-fluoro-6-iodopyridin-2-yl)methanol Chemical compound OCc1nc(I)ccc1F OEHSGMJRKDCQSO-UHFFFAOYSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IDFPQEHZYBXIFO-GFCCVEGCSA-N (R)-(4-fluoro-2-propylphenyl)-(1H-imidazol-2-yl)methanol Chemical compound CCCc1cc(F)ccc1[C@@H](O)c1ncc[nH]1 IDFPQEHZYBXIFO-GFCCVEGCSA-N 0.000 description 1
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 description 1
- AMDUVBKOPJXBBN-UHFFFAOYSA-N 1-(2-morpholin-4-ylethyl)pyrazol-4-amine Chemical compound C1=C(N)C=NN1CCN1CCOCC1 AMDUVBKOPJXBBN-UHFFFAOYSA-N 0.000 description 1
- OCUZFEAUFHOPMC-SRZZPIQSSA-N 1-(4-amino-1,2,5-oxadiazol-3-yl)-n-[(e)-benzylideneamino]-5-(phenylsulfanylmethyl)triazole-4-carboxamide Chemical compound NC1=NON=C1N1C(CSC=2C=CC=CC=2)=C(C(=O)N\N=C\C=2C=CC=CC=2)N=N1 OCUZFEAUFHOPMC-SRZZPIQSSA-N 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- DCYGAPKNVCQNOE-UHFFFAOYSA-N 2,2,2-triphenylacetic acid Chemical class C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-N 0.000 description 1
- KDHXOMQGSQFJBI-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-1h-pyrimidin-6-one Chemical compound CC1=CC=CC(C=2NC(=O)C=CN=2)=N1 KDHXOMQGSQFJBI-UHFFFAOYSA-N 0.000 description 1
- MQFGQCIOGRXOFL-UHFFFAOYSA-N 2-(difluoromethyl)-3-fluoro-6-iodopyridine Chemical compound FC(F)c1nc(I)ccc1F MQFGQCIOGRXOFL-UHFFFAOYSA-N 0.000 description 1
- YNNUSGIPVFPVBX-UHFFFAOYSA-N 2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound CN1CCCC1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UTAFVZLZZYEYDA-UHFFFAOYSA-N 2-[[4-(furan-2-ylmethyl)-5-pyrazin-2-yl-1,2,4-triazol-3-yl]sulfanylmethyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CSC(N1CC=2OC=CC=2)=NN=C1C1=CN=CC=N1 UTAFVZLZZYEYDA-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- LPBDZVNGCNTELM-UHFFFAOYSA-N 2-chloropyrimidin-4-amine Chemical compound NC1=CC=NC(Cl)=N1 LPBDZVNGCNTELM-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- FJNLCHNQVJVCPY-UHFFFAOYSA-N 2-n-methoxy-2-n-methyl-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OC)=N1 FJNLCHNQVJVCPY-UHFFFAOYSA-N 0.000 description 1
- DUTRQVGJYKEYQS-UHFFFAOYSA-N 2-n-phenyl-6-[(5-phenyl-1h-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3,5-triazine-2,4-diamine Chemical compound N=1C(NC=2C=CC=CC=2)=NC(N)=NC=1CSC(N=1)=NNC=1C1=CC=CC=C1 DUTRQVGJYKEYQS-UHFFFAOYSA-N 0.000 description 1
- FRICBZWJFIRJOB-UHFFFAOYSA-N 2-piperazin-1-ylbenzonitrile Chemical compound N#CC1=CC=CC=C1N1CCNCC1 FRICBZWJFIRJOB-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical class C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- DCCLCSXNSPIMIH-UHFFFAOYSA-N 3-fluoro-6-iodo-2-methylpyridine Chemical compound Cc1nc(I)ccc1F DCCLCSXNSPIMIH-UHFFFAOYSA-N 0.000 description 1
- QMMKJWOCHBXUST-UHFFFAOYSA-N 3-fluoro-6-iodopyridine-2-carbaldehyde Chemical compound Fc1ccc(I)nc1C=O QMMKJWOCHBXUST-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MECCSFDHAVAAAW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-propan-2-yl-1,3,2-dioxaborolane Chemical compound CC(C)B1OC(C)(C)C(C)(C)O1 MECCSFDHAVAAAW-UHFFFAOYSA-N 0.000 description 1
- ONOZPOGRUBSLQA-UHFFFAOYSA-N 4-(2-methylbutan-2-yl)phenol;2-phenylphenol Chemical group CCC(C)(C)C1=CC=C(O)C=C1.OC1=CC=CC=C1C1=CC=CC=C1 ONOZPOGRUBSLQA-UHFFFAOYSA-N 0.000 description 1
- MDHKCIIEVIPVLU-JERHFGHZSA-M 4-[(1r)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol;diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide Chemical compound [Br-].C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1.C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 MDHKCIIEVIPVLU-JERHFGHZSA-M 0.000 description 1
- VYWULEPJDHQXQG-UHFFFAOYSA-N 4-[2-(4-nitropyrazol-1-yl)ethyl]morpholine Chemical compound C1=C([N+](=O)[O-])C=NN1CCN1CCOCC1 VYWULEPJDHQXQG-UHFFFAOYSA-N 0.000 description 1
- OSLCKJPJULGQJI-UHFFFAOYSA-N 4-chloro-2-(6-methylpyridin-2-yl)pyrimidine Chemical compound CC1=CC=CC(C=2N=C(Cl)C=CN=2)=N1 OSLCKJPJULGQJI-UHFFFAOYSA-N 0.000 description 1
- WSRWIOBLJDEDRM-UHFFFAOYSA-N 4-cyclopropylpyrimidin-2-amine Chemical compound NC1=NC=CC(C2CC2)=N1 WSRWIOBLJDEDRM-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- BNIMQGKKURUQOH-UHFFFAOYSA-N 6-methylpyridine-2-carboximidamide;hydrochloride Chemical compound Cl.CC1=CC=CC(C(N)=N)=N1 BNIMQGKKURUQOH-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108091007507 ADAM12 Proteins 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 206010066728 Acute interstitial pneumonitis Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 206010001766 Alopecia totalis Diseases 0.000 description 1
- 206010001767 Alopecia universalis Diseases 0.000 description 1
- 241000700587 Alphaherpesvirinae Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 241000710189 Aphthovirus Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 102100026292 Asialoglycoprotein receptor 1 Human genes 0.000 description 1
- 102100026293 Asialoglycoprotein receptor 2 Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000004884 Balkan Nephropathy Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 241000701021 Betaherpesvirinae Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004664 Biliary fibrosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WSTKLSHIGKOQHU-JLHYYAGUSA-N BrC1=CC=C(\C=C/2\CN(CC\2)C(=O)OC(C)(C)C)C=C1 Chemical compound BrC1=CC=C(\C=C/2\CN(CC\2)C(=O)OC(C)(C)C)C=C1 WSTKLSHIGKOQHU-JLHYYAGUSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- YFSZTFWIMRWDHM-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CC(N(CC1)C1=CC=C(C=C1)[N+](=O)[O-])CC(=O)O Chemical compound C(C)(C)(C)OC(=O)N1CC(N(CC1)C1=CC=C(C=C1)[N+](=O)[O-])CC(=O)O YFSZTFWIMRWDHM-UHFFFAOYSA-N 0.000 description 1
- FQBMZZZYPRXVOQ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCN(CC1)C1=C(C=C(C=C1)[N+](=O)[O-])CC(=O)O Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)C1=C(C=C(C=C1)[N+](=O)[O-])CC(=O)O FQBMZZZYPRXVOQ-UHFFFAOYSA-N 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- DBJQCYLMBFLXMZ-UHFFFAOYSA-N C1=C(NC2=NC(=NC=C2)NC=2C=C(SC=2)C(=O)OCC2CNC2)N=C(N=C1)C1=CC=CC(C)=N1 Chemical compound C1=C(NC2=NC(=NC=C2)NC=2C=C(SC=2)C(=O)OCC2CNC2)N=C(N=C1)C1=CC=CC(C)=N1 DBJQCYLMBFLXMZ-UHFFFAOYSA-N 0.000 description 1
- YGNDPZTUXFADMB-UHFFFAOYSA-N C1=C(NC2=NC(NC3=CC=CC(C(=O)OCC4CNC4)=C3)=NC=C2)N=C(N=C1)C1=CC=CC(C)=N1 Chemical compound C1=C(NC2=NC(NC3=CC=CC(C(=O)OCC4CNC4)=C3)=NC=C2)N=C(N=C1)C1=CC=CC(C)=N1 YGNDPZTUXFADMB-UHFFFAOYSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- AQJIPUZRQLOKRW-UHFFFAOYSA-N CC(C)(C)N(CC1)CCN1S(C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)(=O)=O Chemical compound CC(C)(C)N(CC1)CCN1S(C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)(=O)=O AQJIPUZRQLOKRW-UHFFFAOYSA-N 0.000 description 1
- ZCAKWAKEZCWKBL-UHFFFAOYSA-N CC(C)(C)N1CCN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)CC1 Chemical compound CC(C)(C)N1CCN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)CC1 ZCAKWAKEZCWKBL-UHFFFAOYSA-N 0.000 description 1
- FOWOQRLAJVHRKV-GFCCVEGCSA-N CC(C)(C)OC(=O)N1CC[C@H](C1)Nc1ccc(cc1)[N+]([O-])=O Chemical compound CC(C)(C)OC(=O)N1CC[C@H](C1)Nc1ccc(cc1)[N+]([O-])=O FOWOQRLAJVHRKV-GFCCVEGCSA-N 0.000 description 1
- NEFXKUTWAGVWLN-BSYVCWPDSA-N CC(C)(C)OC(N(CC1)C/C\1=C/C(C=C1)=CC=C1N=C(C1=CC=CC=C1)C1=CC=CC=C1)=O Chemical compound CC(C)(C)OC(N(CC1)C/C\1=C/C(C=C1)=CC=C1N=C(C1=CC=CC=C1)C1=CC=CC=C1)=O NEFXKUTWAGVWLN-BSYVCWPDSA-N 0.000 description 1
- UICXOUXDEJJKOH-UHFFFAOYSA-N CC(C)CN(C)C(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C)CN(C)C(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 UICXOUXDEJJKOH-UHFFFAOYSA-N 0.000 description 1
- DWIMAMKWSAXHIY-UHFFFAOYSA-N CC(C)CN(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C)CN(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 DWIMAMKWSAXHIY-UHFFFAOYSA-N 0.000 description 1
- JFLSSLVNVVJAFB-UHFFFAOYSA-N CC(C)CN1CCN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)CC1 Chemical compound CC(C)CN1CCN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)CC1 JFLSSLVNVVJAFB-UHFFFAOYSA-N 0.000 description 1
- JNGSOUHHZZKVQV-UHFFFAOYSA-N CC(C)CNC(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C)CNC(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 JNGSOUHHZZKVQV-UHFFFAOYSA-N 0.000 description 1
- PKXAJZBAJDJTIO-UHFFFAOYSA-N CC(C)CNC(CC1=CC(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=NC(C2=CC=CC(C)=N2)=N1)=O Chemical compound CC(C)CNC(CC1=CC(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=NC(C2=CC=CC(C)=N2)=N1)=O PKXAJZBAJDJTIO-UHFFFAOYSA-N 0.000 description 1
- NUEODOKEVUCWFL-UHFFFAOYSA-N CC(C)CNCC(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C)CNCC(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 NUEODOKEVUCWFL-UHFFFAOYSA-N 0.000 description 1
- BXXZHUCAVOYJKR-UHFFFAOYSA-N CC(C)COC(CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1N1CCNCC1)=O Chemical compound CC(C)COC(CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1N1CCNCC1)=O BXXZHUCAVOYJKR-UHFFFAOYSA-N 0.000 description 1
- YSHOUCFOSBCTAA-UHFFFAOYSA-N CC(C)COC(CC(CNCC1)N1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound CC(C)COC(CC(CNCC1)N1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O YSHOUCFOSBCTAA-UHFFFAOYSA-N 0.000 description 1
- BLTAOLCODYOWJG-UHFFFAOYSA-N CC(C)N(CC1)CCN1C(C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound CC(C)N(CC1)CCN1C(C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O BLTAOLCODYOWJG-UHFFFAOYSA-N 0.000 description 1
- QHCOEBGASHEVLB-UHFFFAOYSA-N CC(C)N(CC1)CCN1C(C1=CC(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=CC=C1)=O Chemical compound CC(C)N(CC1)CCN1C(C1=CC(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=CC=C1)=O QHCOEBGASHEVLB-UHFFFAOYSA-N 0.000 description 1
- YOAVGXGMKZFBLN-UHFFFAOYSA-N CC(C)N(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C)N(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 YOAVGXGMKZFBLN-UHFFFAOYSA-N 0.000 description 1
- ZNNLTPOIXFYXAM-UHFFFAOYSA-N CC(C)N(CC1)CCN1C(NC(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound CC(C)N(CC1)CCN1C(NC(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O ZNNLTPOIXFYXAM-UHFFFAOYSA-N 0.000 description 1
- OKXVBAUTXGHSIS-UHFFFAOYSA-N CC(C)N(CC1)CCN1C(NC1=CC(NC2=NC(NC3=CC=NC(C4=NC(C)=CC=C4)=N3)=CC=N2)=CC=C1)=O Chemical compound CC(C)N(CC1)CCN1C(NC1=CC(NC2=NC(NC3=CC=NC(C4=NC(C)=CC=C4)=N3)=CC=N2)=CC=C1)=O OKXVBAUTXGHSIS-UHFFFAOYSA-N 0.000 description 1
- NIOOVOCRJYFRLL-UHFFFAOYSA-N CC(C)N(CC1)CCN1S(C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)(=O)=O Chemical compound CC(C)N(CC1)CCN1S(C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)(=O)=O NIOOVOCRJYFRLL-UHFFFAOYSA-N 0.000 description 1
- YQQVLHZSUGUISO-UHFFFAOYSA-N CC(C)N1CC2=CC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=CC=C2CC1 Chemical compound CC(C)N1CC2=CC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=CC=C2CC1 YQQVLHZSUGUISO-UHFFFAOYSA-N 0.000 description 1
- IDXKVACKGYKYMV-UHFFFAOYSA-N CC(C)N1CCN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)CC1 Chemical compound CC(C)N1CCN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)CC1 IDXKVACKGYKYMV-UHFFFAOYSA-N 0.000 description 1
- XUHLCWJOOPJKOF-UHFFFAOYSA-N CC(C)N1CCN(CCNC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)CC1 Chemical compound CC(C)N1CCN(CCNC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)CC1 XUHLCWJOOPJKOF-UHFFFAOYSA-N 0.000 description 1
- LQDGGUQWXBCIDE-UHFFFAOYSA-N CC(C)N1N=CC(C(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1 Chemical compound CC(C)N1N=CC(C(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1 LQDGGUQWXBCIDE-UHFFFAOYSA-N 0.000 description 1
- XRZIROXFEYZTAL-UHFFFAOYSA-N CC(C)NC(CC1)CC=C1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C)NC(CC1)CC=C1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 XRZIROXFEYZTAL-UHFFFAOYSA-N 0.000 description 1
- RCKLZLACKRXBIJ-UHFFFAOYSA-N CC(C)NC(N(CC1)CCN1S(C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)(=O)=O)=O Chemical compound CC(C)NC(N(CC1)CCN1S(C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)(=O)=O)=O RCKLZLACKRXBIJ-UHFFFAOYSA-N 0.000 description 1
- IFTSHNMALGRDCZ-UHFFFAOYSA-N CC(C1)NC(C)CN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C1)NC(C)CN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 IFTSHNMALGRDCZ-UHFFFAOYSA-N 0.000 description 1
- YRXJQGUHAZCWNS-UHFFFAOYSA-N CC(C1)NC(C)CN1C(NC(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound CC(C1)NC(C)CN1C(NC(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O YRXJQGUHAZCWNS-UHFFFAOYSA-N 0.000 description 1
- CKRPNROOZJBEBL-UHFFFAOYSA-N CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1N Chemical compound CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1N CKRPNROOZJBEBL-UHFFFAOYSA-N 0.000 description 1
- LAQSLWYTGJFKIW-UHFFFAOYSA-N CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1N1CCNCC1 Chemical compound CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1N1CCNCC1 LAQSLWYTGJFKIW-UHFFFAOYSA-N 0.000 description 1
- YUQSZRLLSXKLKW-UHFFFAOYSA-N CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1NC(C1CCNCC1)=O Chemical compound CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1NC(C1CCNCC1)=O YUQSZRLLSXKLKW-UHFFFAOYSA-N 0.000 description 1
- CMHZJEOOVJBKQU-UHFFFAOYSA-N CC(C=C1)=C(CN2C3CNCC2CC3)C=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C=C1)=C(CN2C3CNCC2CC3)C=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 CMHZJEOOVJBKQU-UHFFFAOYSA-N 0.000 description 1
- MZSARISNSRNWJO-UHFFFAOYSA-N CC(C=C1)=C(CN2CCN(C)CC2)C=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C=C1)=C(CN2CCN(C)CC2)C=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 MZSARISNSRNWJO-UHFFFAOYSA-N 0.000 description 1
- SRVYGOQMOBDOCI-UHFFFAOYSA-N CC(C=C1)=C(CN2CCNCC2)C=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C=C1)=C(CN2CCNCC2)C=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 SRVYGOQMOBDOCI-UHFFFAOYSA-N 0.000 description 1
- LKAGVSIOTLOTHR-UHFFFAOYSA-N CC(C=C1)=C(CO)C=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C=C1)=C(CO)C=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 LKAGVSIOTLOTHR-UHFFFAOYSA-N 0.000 description 1
- VDMGKUVAICCFSU-UHFFFAOYSA-N CC(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 VDMGKUVAICCFSU-UHFFFAOYSA-N 0.000 description 1
- FSDQXNVFACPBTC-UHFFFAOYSA-N CC(C=CC(NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=C1)=C1N Chemical compound CC(C=CC(NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=C1)=C1N FSDQXNVFACPBTC-UHFFFAOYSA-N 0.000 description 1
- UKOUSJJWYZKKND-UHFFFAOYSA-N CC(C=CC(NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=C1)=C1NC(C1CCNCC1)=O Chemical compound CC(C=CC(NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=C1)=C1NC(C1CCNCC1)=O UKOUSJJWYZKKND-UHFFFAOYSA-N 0.000 description 1
- HOMMQCVHEOREIE-UHFFFAOYSA-N CC(C=CC(O)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N(CC3)CCC3N(C)C)=NC=C2)=N1 Chemical compound CC(C=CC(O)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N(CC3)CCC3N(C)C)=NC=C2)=N1 HOMMQCVHEOREIE-UHFFFAOYSA-N 0.000 description 1
- NKXKCOZKBWYYGG-UHFFFAOYSA-N CC(C=CC(O)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N(CC3)CCC3NC)=NC=C2)=N1 Chemical compound CC(C=CC(O)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N(CC3)CCC3NC)=NC=C2)=N1 NKXKCOZKBWYYGG-UHFFFAOYSA-N 0.000 description 1
- MZKMIOUEPXQEMS-UHFFFAOYSA-N CC(C=CC(O)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=N1 Chemical compound CC(C=CC(O)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=N1 MZKMIOUEPXQEMS-UHFFFAOYSA-N 0.000 description 1
- CYNZHZCPHGLVRF-UHFFFAOYSA-N CC(C=CC(O)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCOCC3)=NC=C2)=N1 Chemical compound CC(C=CC(O)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCOCC3)=NC=C2)=N1 CYNZHZCPHGLVRF-UHFFFAOYSA-N 0.000 description 1
- CWIQRILBXCGAKN-UHFFFAOYSA-N CC(N(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound CC(N(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O CWIQRILBXCGAKN-UHFFFAOYSA-N 0.000 description 1
- XTMSNXNRUDCXQY-UHFFFAOYSA-N CC(N(CC1)CCN1C1=CC(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=CC=C1)=O Chemical compound CC(N(CC1)CCN1C1=CC(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=CC=C1)=O XTMSNXNRUDCXQY-UHFFFAOYSA-N 0.000 description 1
- IMBAMICFMGYTIZ-UHFFFAOYSA-N CC(N(CC1)CCN1S(C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)(=O)=O)=O Chemical compound CC(N(CC1)CCN1S(C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)(=O)=O)=O IMBAMICFMGYTIZ-UHFFFAOYSA-N 0.000 description 1
- MMQSMTWGTJHMCR-UHFFFAOYSA-N CC(N1CC(CNC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1)=O Chemical compound CC(N1CC(CNC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1)=O MMQSMTWGTJHMCR-UHFFFAOYSA-N 0.000 description 1
- QXFSAILSNPKDBA-UHFFFAOYSA-N CC(N1CC(COC(C2=CC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=CS2)=O)C1)=O Chemical compound CC(N1CC(COC(C2=CC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=CS2)=O)C1)=O QXFSAILSNPKDBA-UHFFFAOYSA-N 0.000 description 1
- LJGKVZUHWKZJGI-UHFFFAOYSA-N CC(N=C(C=C1)C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N4CCN(C)CC4)=NC=C3)=N2)=C1F Chemical compound CC(N=C(C=C1)C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N4CCN(C)CC4)=NC=C3)=N2)=C1F LJGKVZUHWKZJGI-UHFFFAOYSA-N 0.000 description 1
- TXPZPMKQTLTEQQ-UHFFFAOYSA-N CC(N=C(C=C1)C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCOCC4)=NC=C3)=N2)=C1F Chemical compound CC(N=C(C=C1)C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCOCC4)=NC=C3)=N2)=C1F TXPZPMKQTLTEQQ-UHFFFAOYSA-N 0.000 description 1
- OQAMCJBVMKBFRU-UHFFFAOYSA-N CC(NC(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound CC(NC(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O OQAMCJBVMKBFRU-UHFFFAOYSA-N 0.000 description 1
- GJZCOJCPXHLUTO-UHFFFAOYSA-N CC1(C)N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)CCNC1 Chemical compound CC1(C)N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)CCNC1 GJZCOJCPXHLUTO-UHFFFAOYSA-N 0.000 description 1
- NHMQRBOAQSSUHR-UHFFFAOYSA-N CC1(C)NCCN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 Chemical compound CC1(C)NCCN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 NHMQRBOAQSSUHR-UHFFFAOYSA-N 0.000 description 1
- NUFMCZWOFNGSEO-UHFFFAOYSA-N CC1(CN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1)N Chemical compound CC1(CN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1)N NUFMCZWOFNGSEO-UHFFFAOYSA-N 0.000 description 1
- BRWCVZJZLXIQSI-UHFFFAOYSA-N CC1(CN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1)N(C)C Chemical compound CC1(CN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1)N(C)C BRWCVZJZLXIQSI-UHFFFAOYSA-N 0.000 description 1
- JXKBGVHEPDXZJA-UHFFFAOYSA-N CC1(CO)CN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 Chemical compound CC1(CO)CN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 JXKBGVHEPDXZJA-UHFFFAOYSA-N 0.000 description 1
- XATJQTCJVPSQMA-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC2=C(CCNCC2)C=C1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC2=C(CCNCC2)C=C1 XATJQTCJVPSQMA-UHFFFAOYSA-N 0.000 description 1
- ATJIUHKXAAFYLN-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C(=O)O)C=C1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C(=O)O)C=C1 ATJIUHKXAAFYLN-UHFFFAOYSA-N 0.000 description 1
- OZWYCECRUPEZPG-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=O)C=C1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=O)C=C1 OZWYCECRUPEZPG-UHFFFAOYSA-N 0.000 description 1
- UJRLAMSOGNZFSU-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(CN2CC(C2)C(=O)O)C=C1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(CN2CC(C2)C(=O)O)C=C1 UJRLAMSOGNZFSU-UHFFFAOYSA-N 0.000 description 1
- BAGZIXTZBIEFIJ-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(CN2CCC(CC2)C(=O)O)C=C1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(CN2CCC(CC2)C(=O)O)C=C1 BAGZIXTZBIEFIJ-UHFFFAOYSA-N 0.000 description 1
- ZBLZMTCJDZKZLI-HSZRJFAPSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(CN2C[C@@H](CCC2)C(=O)OC(C)(C)C)C=C1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(CN2C[C@@H](CCC2)C(=O)OC(C)(C)C)C=C1 ZBLZMTCJDZKZLI-HSZRJFAPSA-N 0.000 description 1
- FNPIPJOJJGTPPV-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(C(=O)O)C=CC=1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(C(=O)O)C=CC=1 FNPIPJOJJGTPPV-UHFFFAOYSA-N 0.000 description 1
- AUBZNFKILHFHTM-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(SC=1)C(=O)OC Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(SC=1)C(=O)OC AUBZNFKILHFHTM-UHFFFAOYSA-N 0.000 description 1
- QWYFATIZAJQUBA-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(SC=1)C=O Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(SC=1)C=O QWYFATIZAJQUBA-UHFFFAOYSA-N 0.000 description 1
- FQAQGOMOCNDHDU-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(SC=1)CO Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=C(SC=1)CO FQAQGOMOCNDHDU-UHFFFAOYSA-N 0.000 description 1
- CBVXMRCIRBRHDR-GOSISDBHSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=NC=C(C(=O)O[C@H]2CNCC2)C=1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1C=NC=C(C(=O)O[C@H]2CNCC2)C=1 CBVXMRCIRBRHDR-GOSISDBHSA-N 0.000 description 1
- QDLBMJWFTGWSTC-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC(=CN=1)C(=O)O Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC(=CN=1)C(=O)O QDLBMJWFTGWSTC-UHFFFAOYSA-N 0.000 description 1
- QOMBUZFSDZSDQL-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)C(=O)O Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)C(=O)O QOMBUZFSDZSDQL-UHFFFAOYSA-N 0.000 description 1
- FIZRRNPWAHUJNT-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)C(=O)OC Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)C(=O)OC FIZRRNPWAHUJNT-UHFFFAOYSA-N 0.000 description 1
- NZHIGCOGGKLSJL-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)C(=O)OC1CCNCC1 Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)C(=O)OC1CCNCC1 NZHIGCOGGKLSJL-UHFFFAOYSA-N 0.000 description 1
- GYAODWYDTSUNOP-MRXNPFEDSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)CN1C[C@@H](CCC1)C(=O)O Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)CN1C[C@@H](CCC1)C(=O)O GYAODWYDTSUNOP-MRXNPFEDSA-N 0.000 description 1
- OPGMXAUWSOQMGR-UHFFFAOYSA-N CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)CO Chemical compound CC1=CC=CC(=N1)C1=NC=CC(=N1)NC1=NC(=NC=C1)NC=1SC=C(N=1)CO OPGMXAUWSOQMGR-UHFFFAOYSA-N 0.000 description 1
- XHRQSYBZHZWSCZ-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(N4CCC5(CNC5)CC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(N4CCC5(CNC5)CC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 XHRQSYBZHZWSCZ-UHFFFAOYSA-N 0.000 description 1
- GBEKIVWCXZRZEB-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(N4CCNCC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(N4CCNCC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 GBEKIVWCXZRZEB-UHFFFAOYSA-N 0.000 description 1
- WRCBTWIIEGWLHP-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(NC4CCNCC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(NC4CCNCC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 WRCBTWIIEGWLHP-UHFFFAOYSA-N 0.000 description 1
- VNODUTMCAJMORK-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(NC4CNC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(NC4CNC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 VNODUTMCAJMORK-UHFFFAOYSA-N 0.000 description 1
- VLKWHZCGIWUNCJ-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(NCC4CNC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(NCC4CNC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 VLKWHZCGIWUNCJ-UHFFFAOYSA-N 0.000 description 1
- MLFQXJOIASGCET-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(O)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(O)=O)=NC=C3)=NN3C2=CC=C3)=N1 MLFQXJOIASGCET-UHFFFAOYSA-N 0.000 description 1
- LFANTIMCHLFKND-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(OCC4CNC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4C(OCC4CNC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 LFANTIMCHLFKND-UHFFFAOYSA-N 0.000 description 1
- IVQLAXIURVEARJ-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4N)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4N)=NC=C3)=NN3C2=CC=C3)=N1 IVQLAXIURVEARJ-UHFFFAOYSA-N 0.000 description 1
- VYKVYNORIQDCOH-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC(C4(CO)CNC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC(C4(CO)CNC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 VYKVYNORIQDCOH-UHFFFAOYSA-N 0.000 description 1
- MTLHOHUMCTUDCT-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC(C4CCNCC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC(C4CCNCC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 MTLHOHUMCTUDCT-UHFFFAOYSA-N 0.000 description 1
- YMFYBHXTRRJFBJ-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC(C4CNC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC(C4CNC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 YMFYBHXTRRJFBJ-UHFFFAOYSA-N 0.000 description 1
- URKDITWJVGARDK-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC(C4CNCC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC(C4CNCC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 URKDITWJVGARDK-UHFFFAOYSA-N 0.000 description 1
- AVCQVCJZHNYCHJ-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC(C4CNCCC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC(C4CNCCC4)=O)=NC=C3)=NN3C2=CC=C3)=N1 AVCQVCJZHNYCHJ-UHFFFAOYSA-N 0.000 description 1
- KOEYTSSOVHPVTR-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC4CCNCC4)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC4CCNCC4)=NC=C3)=NN3C2=CC=C3)=N1 KOEYTSSOVHPVTR-UHFFFAOYSA-N 0.000 description 1
- ZYYIDRIMOCMLJJ-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC4CNC4)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC4CNC4)=NC=C3)=NN3C2=CC=C3)=N1 ZYYIDRIMOCMLJJ-UHFFFAOYSA-N 0.000 description 1
- JXXUMLIBOILYDD-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC4CNCC4)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NC4CNCC4)=NC=C3)=NN3C2=CC=C3)=N1 JXXUMLIBOILYDD-UHFFFAOYSA-N 0.000 description 1
- SFENBSJZTRBDNT-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NCC4CNC4)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CC=C4NCC4CNC4)=NC=C3)=NN3C2=CC=C3)=N1 SFENBSJZTRBDNT-UHFFFAOYSA-N 0.000 description 1
- YWFNGJXEDFEVHO-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CN=C4C(OC)=O)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC(C=C4)=CN=C4C(OC)=O)=NC=C3)=NN3C2=CC=C3)=N1 YWFNGJXEDFEVHO-UHFFFAOYSA-N 0.000 description 1
- IAMCPCGFCGHXFO-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC4=CC(C(O)=O)=CS4)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC4=CC(C(O)=O)=CS4)=NC=C3)=NN3C2=CC=C3)=N1 IAMCPCGFCGHXFO-UHFFFAOYSA-N 0.000 description 1
- DYGTZMMJNGIYHM-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC4=CC=C(CC(O)=O)C=C4)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC4=CC=C(CC(O)=O)C=C4)=NC=C3)=NN3C2=CC=C3)=N1 DYGTZMMJNGIYHM-UHFFFAOYSA-N 0.000 description 1
- OHCYVECHWFKGBP-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC4=CC=C(CC(OC)=O)C=C4)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC4=CC=C(CC(OC)=O)C=C4)=NC=C3)=NN3C2=CC=C3)=N1 OHCYVECHWFKGBP-UHFFFAOYSA-N 0.000 description 1
- JWGYPOZOMBYSBJ-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC4=CC=CC(C(O)=O)=C4)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC4=CC=CC(C(O)=O)=C4)=NC=C3)=NN3C2=CC=C3)=N1 JWGYPOZOMBYSBJ-UHFFFAOYSA-N 0.000 description 1
- HLXFJUGHVKFBLR-UHFFFAOYSA-N CC1=CC=CC(C(N=C2NC3=NC(NC4=CSC(C(O)=O)=C4)=NC=C3)=NN3C2=CC=C3)=N1 Chemical compound CC1=CC=CC(C(N=C2NC3=NC(NC4=CSC(C(O)=O)=C4)=NC=C3)=NN3C2=CC=C3)=N1 HLXFJUGHVKFBLR-UHFFFAOYSA-N 0.000 description 1
- WFYPDLOOPVJXRS-UHFFFAOYSA-N CC1=CC=CC(C2=CC(NC3=NC(NC(C=C4)=CC=C4N4CCOCC4)=NC=C3)=C(C=CN3)C3=N2)=N1 Chemical compound CC1=CC=CC(C2=CC(NC3=NC(NC(C=C4)=CC=C4N4CCOCC4)=NC=C3)=C(C=CN3)C3=N2)=N1 WFYPDLOOPVJXRS-UHFFFAOYSA-N 0.000 description 1
- ROBFHCJCDCHACP-UHFFFAOYSA-N CC1=CC=CC(C2=CC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCOCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=CC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCOCC4)=NC=C3)=N2)=N1 ROBFHCJCDCHACP-UHFFFAOYSA-N 0.000 description 1
- QVFMLRVGMMVBCC-UHFFFAOYSA-N CC1=CC=CC(C2=NC(C3=CNN=N3)=CC(NC3=NC(NC(C=C4)=CC=C4N4CCNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC(C3=CNN=N3)=CC(NC3=NC(NC(C=C4)=CC=C4N4CCNCC4)=NC=C3)=N2)=N1 QVFMLRVGMMVBCC-UHFFFAOYSA-N 0.000 description 1
- KXVBXXNTKNPMEF-DEOSSOPVSA-N CC1=CC=CC(C2=NC(NC3=CC=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(O[C@@H]4CNCC4)=O)=N3)=CC=N2)=N1 Chemical compound CC1=CC=CC(C2=NC(NC3=CC=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(O[C@@H]4CNCC4)=O)=N3)=CC=N2)=N1 KXVBXXNTKNPMEF-DEOSSOPVSA-N 0.000 description 1
- PHFUIONVGFJCAT-UHFFFAOYSA-N CC1=CC=CC(C2=NC(NC3=CC=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OCC4CNC4)=O)=N3)=CC=N2)=N1 Chemical compound CC1=CC=CC(C2=NC(NC3=CC=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OCC4CNC4)=O)=N3)=CC=N2)=N1 PHFUIONVGFJCAT-UHFFFAOYSA-N 0.000 description 1
- SOXBHLWZLGRARU-UHFFFAOYSA-N CC1=CC=CC(C2=NC(NC3=CC=NC(NC4=CC(C(N5CCN(C)CC5)=O)=CC=C4)=N3)=CC=N2)=N1 Chemical compound CC1=CC=CC(C2=NC(NC3=CC=NC(NC4=CC(C(N5CCN(C)CC5)=O)=CC=C4)=N3)=CC=N2)=N1 SOXBHLWZLGRARU-UHFFFAOYSA-N 0.000 description 1
- MBZBVZQLRMPQRR-UHFFFAOYSA-N CC1=CC=CC(C2=NC(NC3=NC(NC(C=C4)=CC=C4N4CCNCC4)=NC=C3)=CC(CC(NC)=O)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC(NC3=NC(NC(C=C4)=CC=C4N4CCNCC4)=NC=C3)=CC(CC(NC)=O)=N2)=N1 MBZBVZQLRMPQRR-UHFFFAOYSA-N 0.000 description 1
- PYRQAROLQNGXCU-UHFFFAOYSA-N CC1=CC=CC(C2=NC(NC3=NC(NC(C=C4)=CC=C4N4CCNCC4)=NC=C3)=CC(CC(NCCO)=O)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC(NC3=NC(NC(C=C4)=CC=C4N4CCNCC4)=NC=C3)=CC(CC(NCCO)=O)=N2)=N1 PYRQAROLQNGXCU-UHFFFAOYSA-N 0.000 description 1
- YXEJNAGJFVFBHY-UHFFFAOYSA-N CC1=CC=CC(C2=NC(NC3=NC(NC(C=C4)=CC=C4N4CCOCC4)=NC=C3)=CC=C2C#N)=N1 Chemical compound CC1=CC=CC(C2=NC(NC3=NC(NC(C=C4)=CC=C4N4CCOCC4)=NC=C3)=CC=C2C#N)=N1 YXEJNAGJFVFBHY-UHFFFAOYSA-N 0.000 description 1
- ZQHJDJXPAURJKM-UHFFFAOYSA-N CC1=CC=CC(C2=NC(NC3=NC(NC4=CN(C5CNCCC5)N=C4)=NC=C3)=CC=N2)=N1 Chemical compound CC1=CC=CC(C2=NC(NC3=NC(NC4=CN(C5CNCCC5)N=C4)=NC=C3)=CC=N2)=N1 ZQHJDJXPAURJKM-UHFFFAOYSA-N 0.000 description 1
- FFNFRRJHWSHAAA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=C(C(O)=O)C(NC3=NC(NC(C=C4)=CC=C4N)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=C(C(O)=O)C(NC3=NC(NC(C=C4)=CC=C4N)=NC=C3)=N2)=N1 FFNFRRJHWSHAAA-UHFFFAOYSA-N 0.000 description 1
- POXFRVYQUZACPJ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=C(C(OC)=O)C(NC3=NC(NC(C=C4)=CC=C4C(OC)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=C(C(OC)=O)C(NC3=NC(NC(C=C4)=CC=C4C(OC)=O)=NC=C3)=N2)=N1 POXFRVYQUZACPJ-UHFFFAOYSA-N 0.000 description 1
- YUNOZFYKCKOXFT-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=CC=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(OC4CNC4)=O)=N3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=CC=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(OC4CNC4)=O)=N3)=N2)=N1 YUNOZFYKCKOXFT-UHFFFAOYSA-N 0.000 description 1
- IJIAYKXAHMVKKD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=CC=NC(NC4=CC(C(OCC5CNC5)=O)=CS4)=N3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=CC=NC(NC4=CC(C(OCC5CNC5)=O)=CS4)=N3)=N2)=N1 IJIAYKXAHMVKKD-UHFFFAOYSA-N 0.000 description 1
- QHUIAAZZQXJQCL-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=CC=NC(NC4=NC(C(NC5CNC5)=O)=CS4)=N3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=CC=NC(NC4=NC(C(NC5CNC5)=O)=CS4)=N3)=N2)=N1 QHUIAAZZQXJQCL-UHFFFAOYSA-N 0.000 description 1
- SHUWVKVTACGQIK-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(C(OC)=O)=C4N4CCNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(C(OC)=O)=C4N4CCNCC4)=NC=C3)=N2)=N1 SHUWVKVTACGQIK-UHFFFAOYSA-N 0.000 description 1
- OAGXXJYOYPBLHN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CC(O)=O)=C4N4CCNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CC(O)=O)=C4N4CCNCC4)=NC=C3)=N2)=N1 OAGXXJYOYPBLHN-UHFFFAOYSA-N 0.000 description 1
- UCTITIAHIUFSEN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CC(OC5CNC5)=O)=C4N4CCNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CC(OC5CNC5)=O)=C4N4CCNCC4)=NC=C3)=N2)=N1 UCTITIAHIUFSEN-UHFFFAOYSA-N 0.000 description 1
- KPLVVIBWTSBIEQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CC(OCC5CNC5)=O)=C4N4CCNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CC(OCC5CNC5)=O)=C4N4CCNCC4)=NC=C3)=N2)=N1 KPLVVIBWTSBIEQ-UHFFFAOYSA-N 0.000 description 1
- OCJRHQRBAJRQFF-XMMPIXPASA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CC(O[C@H]5CN(C)CC5)=O)=C4N4CCNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CC(O[C@H]5CN(C)CC5)=O)=C4N4CCNCC4)=NC=C3)=N2)=N1 OCJRHQRBAJRQFF-XMMPIXPASA-N 0.000 description 1
- OPZJUMARNXAESW-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CN5C6CNCC5CC6)=C4Cl)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CN5C6CNCC5CC6)=C4Cl)=NC=C3)=N2)=N1 OPZJUMARNXAESW-UHFFFAOYSA-N 0.000 description 1
- WJNSKQXLAVQQIF-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CN5CCN(C)CC5)=C4Cl)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CN5CCN(C)CC5)=C4Cl)=NC=C3)=N2)=N1 WJNSKQXLAVQQIF-UHFFFAOYSA-N 0.000 description 1
- ZLWCDEVGABUTLF-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CN5CCNCC5)=C4Cl)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CN5CCNCC5)=C4Cl)=NC=C3)=N2)=N1 ZLWCDEVGABUTLF-UHFFFAOYSA-N 0.000 description 1
- PMWONSWNSBUCPT-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CN5CCNCC5)=C4F)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CN5CCNCC5)=C4F)=NC=C3)=N2)=N1 PMWONSWNSBUCPT-UHFFFAOYSA-N 0.000 description 1
- SEJHMFWPKSSCTE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CO)=C4Cl)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CO)=C4Cl)=NC=C3)=N2)=N1 SEJHMFWPKSSCTE-UHFFFAOYSA-N 0.000 description 1
- VZQYADUNVHKZBT-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CO)=C4F)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(CO)=C4F)=NC=C3)=N2)=N1 VZQYADUNVHKZBT-UHFFFAOYSA-N 0.000 description 1
- CLYFJLSDKIMXSN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(Cl)=C4N4CCNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(Cl)=C4N4CCNCC4)=NC=C3)=N2)=N1 CLYFJLSDKIMXSN-UHFFFAOYSA-N 0.000 description 1
- BHTAGRYTSPPCNL-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(Cl)=C4NC(C4CCNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(Cl)=C4NC(C4CCNCC4)=O)=NC=C3)=N2)=N1 BHTAGRYTSPPCNL-UHFFFAOYSA-N 0.000 description 1
- YTSFUTRMJQLABN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(F)=C4N(CC4)CCC4N)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(F)=C4N(CC4)CCC4N)=NC=C3)=N2)=N1 YTSFUTRMJQLABN-UHFFFAOYSA-N 0.000 description 1
- YOGMMVJGUGKQHE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(F)=C4N4CCNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(F)=C4N4CCNCC4)=NC=C3)=N2)=N1 YOGMMVJGUGKQHE-UHFFFAOYSA-N 0.000 description 1
- LCSDKSSZOQIBJX-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(N)=C4Cl)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(N)=C4Cl)=NC=C3)=N2)=N1 LCSDKSSZOQIBJX-UHFFFAOYSA-N 0.000 description 1
- KUJVIAPEEWSBFR-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(NC(C5CCNCC5)=O)=C4Cl)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(NC(C5CCNCC5)=O)=C4Cl)=NC=C3)=N2)=N1 KUJVIAPEEWSBFR-UHFFFAOYSA-N 0.000 description 1
- DIYBBKCMUXEJNR-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(OC)=C4N4CCOCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(OC)=C4N4CCOCC4)=NC=C3)=N2)=N1 DIYBBKCMUXEJNR-UHFFFAOYSA-N 0.000 description 1
- QPKNASNCVHFZMP-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(OC)=C4NC(C4CCNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(OC)=C4NC(C4CCNCC4)=O)=NC=C3)=N2)=N1 QPKNASNCVHFZMP-UHFFFAOYSA-N 0.000 description 1
- BQOBWVKLRGKFBS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(OC)=C4NS(C)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC(OC)=C4NS(C)(=O)=O)=NC=C3)=N2)=N1 BQOBWVKLRGKFBS-UHFFFAOYSA-N 0.000 description 1
- XMRDDNZSOZZRRG-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC5=C4NN=N5)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC5=C4NN=N5)=NC=C3)=N2)=N1 XMRDDNZSOZZRRG-UHFFFAOYSA-N 0.000 description 1
- YXHWQLPWOZMPCL-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC5=C4OCCO5)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC5=C4OCCO5)=NC=C3)=N2)=N1 YXHWQLPWOZMPCL-UHFFFAOYSA-N 0.000 description 1
- RQOVDTHTOYRQIS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(CC4)=CCC4N)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(CC4)=CCC4N)=NC=C3)=N2)=N1 RQOVDTHTOYRQIS-UHFFFAOYSA-N 0.000 description 1
- OJDLZLILNTUNRB-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(N4CCNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(N4CCNCC4)=O)=NC=C3)=N2)=N1 OJDLZLILNTUNRB-UHFFFAOYSA-N 0.000 description 1
- ZRDILXXGGVOQFS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(NCC4CNC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(NCC4CNC4)=O)=NC=C3)=N2)=N1 ZRDILXXGGVOQFS-UHFFFAOYSA-N 0.000 description 1
- DFTUWWMAQTXNTG-FQEVSTJZSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(O[C@@H]4CN(C)CC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(O[C@@H]4CN(C)CC4)=O)=NC=C3)=N2)=N1 DFTUWWMAQTXNTG-FQEVSTJZSA-N 0.000 description 1
- DFTUWWMAQTXNTG-HXUWFJFHSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(O[C@H]4CN(C)CC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(O[C@H]4CN(C)CC4)=O)=NC=C3)=N2)=N1 DFTUWWMAQTXNTG-HXUWFJFHSA-N 0.000 description 1
- JVBKBVQIZMQRCF-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CCNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CCNCC4)=NC=C3)=N2)=N1 JVBKBVQIZMQRCF-UHFFFAOYSA-N 0.000 description 1
- KXZNZZPSNHSQAA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(C)N=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(C)N=C4)=NC=C3)=N2)=N1 KXZNZZPSNHSQAA-UHFFFAOYSA-N 0.000 description 1
- RATHZQGMHFDPCO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(C)N=N4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(C)N=N4)=NC=C3)=N2)=N1 RATHZQGMHFDPCO-UHFFFAOYSA-N 0.000 description 1
- WICPYLYHFPYGTJ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(CC5=CC=CC=C5)N=N4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(CC5=CC=CC=C5)N=N4)=NC=C3)=N2)=N1 WICPYLYHFPYGTJ-UHFFFAOYSA-N 0.000 description 1
- HUEMTRPVKAMQHB-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(CCN(C)C)N=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(CCN(C)C)N=C4)=NC=C3)=N2)=N1 HUEMTRPVKAMQHB-UHFFFAOYSA-N 0.000 description 1
- OOWCLRDAFGMZSL-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(CCN)N=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(CCN)N=C4)=NC=C3)=N2)=N1 OOWCLRDAFGMZSL-UHFFFAOYSA-N 0.000 description 1
- MQQFESRYXZPOJZ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(CCNC5)C5=N4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(CCNC5)C5=N4)=NC=C3)=N2)=N1 MQQFESRYXZPOJZ-UHFFFAOYSA-N 0.000 description 1
- UYZKVNCHEKDQFV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(CCO)N=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CN(CCO)N=C4)=NC=C3)=N2)=N1 UYZKVNCHEKDQFV-UHFFFAOYSA-N 0.000 description 1
- VLRAPEUWCYAAJH-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CNN=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C4=CNN=C4)=NC=C3)=N2)=N1 VLRAPEUWCYAAJH-UHFFFAOYSA-N 0.000 description 1
- MCRYNADBNLUPRY-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(C)C4CNC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(C)C4CNC4)=NC=C3)=N2)=N1 MCRYNADBNLUPRY-UHFFFAOYSA-N 0.000 description 1
- NVOCOBBDKYPWQE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(C)C4CNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(C)C4CNCC4)=NC=C3)=N2)=N1 NVOCOBBDKYPWQE-UHFFFAOYSA-N 0.000 description 1
- DGIPNQDHKSNVOZ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(C4)CC4N)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(C4)CC4N)=NC=C3)=N2)=N1 DGIPNQDHKSNVOZ-UHFFFAOYSA-N 0.000 description 1
- DPIYXBOJGKUVFK-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CC4N)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CC4N)=NC=C3)=N2)=N1 DPIYXBOJGKUVFK-UHFFFAOYSA-N 0.000 description 1
- PDZGSFQONZKZRQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(O)=O)=NC=C3)=N2)=N1 PDZGSFQONZKZRQ-UHFFFAOYSA-N 0.000 description 1
- GOBGDOJGPRVUAV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(OC)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(OC)=O)=NC=C3)=N2)=N1 GOBGDOJGPRVUAV-UHFFFAOYSA-N 0.000 description 1
- CZHQLVZBKMVXHS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(OC4CN(C)CC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(OC4CN(C)CC4)=O)=NC=C3)=N2)=N1 CZHQLVZBKMVXHS-UHFFFAOYSA-N 0.000 description 1
- SINVHAMJYOTJLE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(OCC4CNC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(OCC4CNC4)=O)=NC=C3)=N2)=N1 SINVHAMJYOTJLE-UHFFFAOYSA-N 0.000 description 1
- KXVBXXNTKNPMEF-XMMPIXPASA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(O[C@H]4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(O[C@H]4CNCC4)=O)=NC=C3)=N2)=N1 KXVBXXNTKNPMEF-XMMPIXPASA-N 0.000 description 1
- BOLLHBOCAPNCDU-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N(C)C)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N(C)C)=NC=C3)=N2)=N1 BOLLHBOCAPNCDU-UHFFFAOYSA-N 0.000 description 1
- RSAGJHXGXWRVMD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N(C)CC4=NC=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N(C)CC4=NC=CC=C4)=NC=C3)=N2)=N1 RSAGJHXGXWRVMD-UHFFFAOYSA-N 0.000 description 1
- SRBGBEGFNYIJKQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N)=NC=C3)=N2)=N1 SRBGBEGFNYIJKQ-UHFFFAOYSA-N 0.000 description 1
- FYGJNWSOPFWQKE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N4CCCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N4CCCC4)=NC=C3)=N2)=N1 FYGJNWSOPFWQKE-UHFFFAOYSA-N 0.000 description 1
- CPRJHPDGVKTJCQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N4CCN(C)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N4CCN(C)CC4)=NC=C3)=N2)=N1 CPRJHPDGVKTJCQ-UHFFFAOYSA-N 0.000 description 1
- XPBUEFBVOKNXBG-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N4CCOCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4N4CCOCC4)=NC=C3)=N2)=N1 XPBUEFBVOKNXBG-UHFFFAOYSA-N 0.000 description 1
- AUQUYGSNCGJGJI-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4NC)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4NC)=NC=C3)=N2)=N1 AUQUYGSNCGJGJI-UHFFFAOYSA-N 0.000 description 1
- ZXVAHUGFIKUWGQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4NCC4=CC=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCC4NCC4=CC=CC=C4)=NC=C3)=N2)=N1 ZXVAHUGFIKUWGQ-UHFFFAOYSA-N 0.000 description 1
- UTJDJALBBXMTMG-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C(CC(CCO4)(C4=O)S)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C(CC(CCO4)(C4=O)S)=O)=NC=C3)=N2)=N1 UTJDJALBBXMTMG-UHFFFAOYSA-N 0.000 description 1
- CLIWOLHKMXCZDN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C(CCO)C(O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C(CCO)C(O)=O)=NC=C3)=N2)=N1 CLIWOLHKMXCZDN-UHFFFAOYSA-N 0.000 description 1
- RAYBPQRNVLSKFD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C(CCO4)C4=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C(CCO4)C4=O)=NC=C3)=N2)=N1 RAYBPQRNVLSKFD-UHFFFAOYSA-N 0.000 description 1
- OMQWWNYXTHHTGA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C(CSC(CCO)C(O)=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C(CSC(CCO)C(O)=O)=O)=NC=C3)=N2)=N1 OMQWWNYXTHHTGA-UHFFFAOYSA-N 0.000 description 1
- MTYYCAFZUXOUKN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C4CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C4CC4)=NC=C3)=N2)=N1 MTYYCAFZUXOUKN-UHFFFAOYSA-N 0.000 description 1
- BFIXDLUJBLPBGO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C4CNC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C4CNC4)=NC=C3)=N2)=N1 BFIXDLUJBLPBGO-UHFFFAOYSA-N 0.000 description 1
- UQDCSVJORXEXQA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C4CNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CC4)CCN4C4CNCC4)=NC=C3)=N2)=N1 UQDCSVJORXEXQA-UHFFFAOYSA-N 0.000 description 1
- FLIRDHLQAIZPPZ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(O)=O)=NC=C3)=N2)=N1 FLIRDHLQAIZPPZ-UHFFFAOYSA-N 0.000 description 1
- AADMMZAXCUVJJB-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OC4CCNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OC4CCNCC4)=O)=NC=C3)=N2)=N1 AADMMZAXCUVJJB-UHFFFAOYSA-N 0.000 description 1
- ISBPNZZNCDPVGG-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OC4CN(C)CC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OC4CN(C)CC4)=O)=NC=C3)=N2)=N1 ISBPNZZNCDPVGG-UHFFFAOYSA-N 0.000 description 1
- DTERFXQZQOWGCC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OC4CNC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OC4CNC4)=O)=NC=C3)=N2)=N1 DTERFXQZQOWGCC-UHFFFAOYSA-N 0.000 description 1
- ICSBYIWXDCSUKO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OC4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OC4CNCC4)=O)=NC=C3)=N2)=N1 ICSBYIWXDCSUKO-UHFFFAOYSA-N 0.000 description 1
- ICSBYIWXDCSUKO-FHZUCYEKSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(O[C@@H]4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(O[C@@H]4CNCC4)=O)=NC=C3)=N2)=N1 ICSBYIWXDCSUKO-FHZUCYEKSA-N 0.000 description 1
- ICSBYIWXDCSUKO-MQNHUJCZSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(O[C@H]4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(O[C@H]4CNCC4)=O)=NC=C3)=N2)=N1 ICSBYIWXDCSUKO-MQNHUJCZSA-N 0.000 description 1
- SAWUHLWOFPIGPU-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCNC4)C4C(O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCNC4)C4C(O)=O)=NC=C3)=N2)=N1 SAWUHLWOFPIGPU-UHFFFAOYSA-N 0.000 description 1
- TZRWVCKVSRTUPT-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCNC4)C4C(OC)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N(CCNC4)C4C(OC)=O)=NC=C3)=N2)=N1 TZRWVCKVSRTUPT-UHFFFAOYSA-N 0.000 description 1
- GWCXETPJDXNIBT-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N)=NC=C3)=N2)=N1 GWCXETPJDXNIBT-UHFFFAOYSA-N 0.000 description 1
- LFNNVGQOELJXRN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C(CC(OC5CNC5)=O)CNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C(CC(OC5CNC5)=O)CNCC4)=NC=C3)=N2)=N1 LFNNVGQOELJXRN-UHFFFAOYSA-N 0.000 description 1
- BDPJSZXKIHROIW-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C(CC(OCC5CNC5)=O)CNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C(CC(OCC5CNC5)=O)CNCC4)=NC=C3)=N2)=N1 BDPJSZXKIHROIW-UHFFFAOYSA-N 0.000 description 1
- GKAFTVYARRNDQL-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CC(CC(OC)=O)NCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CC(CC(OC)=O)NCC4)=NC=C3)=N2)=N1 GKAFTVYARRNDQL-UHFFFAOYSA-N 0.000 description 1
- ABJZCRONMFRQND-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CC(CC5)NC5C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CC(CC5)NC5C4)=NC=C3)=N2)=N1 ABJZCRONMFRQND-UHFFFAOYSA-N 0.000 description 1
- JRPIWYOYIDMXIX-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CC(CN)C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CC(CN)C4)=NC=C3)=N2)=N1 JRPIWYOYIDMXIX-UHFFFAOYSA-N 0.000 description 1
- DNCFWIPTGKIREY-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CC5(CNC5)C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CC5(CNC5)C4)=NC=C3)=N2)=N1 DNCFWIPTGKIREY-UHFFFAOYSA-N 0.000 description 1
- HCTMRXXLEIPNPQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCC(CN)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCC(CN)CC4)=NC=C3)=N2)=N1 HCTMRXXLEIPNPQ-UHFFFAOYSA-N 0.000 description 1
- FDEYABYGGQLZRF-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCC(CNCC5=CC=CC=C5)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCC(CNCC5=CC=CC=C5)CC4)=NC=C3)=N2)=N1 FDEYABYGGQLZRF-UHFFFAOYSA-N 0.000 description 1
- ACPDIIRFMUAJAD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCC(CNCC5=NC=CC=C5)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCC(CNCC5=NC=CC=C5)CC4)=NC=C3)=N2)=N1 ACPDIIRFMUAJAD-UHFFFAOYSA-N 0.000 description 1
- RINGZPHEUNUUPP-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(C)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(C)CC4)=NC=C3)=N2)=N1 RINGZPHEUNUUPP-UHFFFAOYSA-N 0.000 description 1
- YJIRAVXKCXAYHR-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CC(CC5)OC5=O)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CC(CC5)OC5=O)CC4)=NC=C3)=N2)=N1 YJIRAVXKCXAYHR-UHFFFAOYSA-N 0.000 description 1
- JZEANTCBGFXTKV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CC5=CC=CC=C5)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CC5=CC=CC=C5)CC4)=NC=C3)=N2)=N1 JZEANTCBGFXTKV-UHFFFAOYSA-N 0.000 description 1
- IQEOLPTVJQJLFU-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CC5=NC=CC=C5)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CC5=NC=CC=C5)CC4)=NC=C3)=N2)=N1 IQEOLPTVJQJLFU-UHFFFAOYSA-N 0.000 description 1
- RHLVKYOYMUTXQD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CC5CNC5)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CC5CNC5)CC4)=NC=C3)=N2)=N1 RHLVKYOYMUTXQD-UHFFFAOYSA-N 0.000 description 1
- HQKCLHBLGXPLGD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CC5CNCC5)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CC5CNCC5)CC4)=NC=C3)=N2)=N1 HQKCLHBLGXPLGD-UHFFFAOYSA-N 0.000 description 1
- RLDXRXQLXHKZOU-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CCNC)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CCNC)CC4)=NC=C3)=N2)=N1 RLDXRXQLXHKZOU-UHFFFAOYSA-N 0.000 description 1
- MNSOJFMYGNLVJW-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CCO)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCN(CCO)CC4)=NC=C3)=N2)=N1 MNSOJFMYGNLVJW-UHFFFAOYSA-N 0.000 description 1
- WACRVEADIRWHJL-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCNCCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCNCCC4)=NC=C3)=N2)=N1 WACRVEADIRWHJL-UHFFFAOYSA-N 0.000 description 1
- XEKFSWPOIVEULN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCSCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4CCSCC4)=NC=C3)=N2)=N1 XEKFSWPOIVEULN-UHFFFAOYSA-N 0.000 description 1
- UWUUGJNILZJMCR-NRFANRHFSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C[C@@H](C(NC)=O)NCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C[C@@H](C(NC)=O)NCC4)=NC=C3)=N2)=N1 UWUUGJNILZJMCR-NRFANRHFSA-N 0.000 description 1
- JYLCWMWEZYGLDM-FQEVSTJZSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C[C@@H](C(O)=O)NCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C[C@@H](C(O)=O)NCC4)=NC=C3)=N2)=N1 JYLCWMWEZYGLDM-FQEVSTJZSA-N 0.000 description 1
- UWUUGJNILZJMCR-OAQYLSRUSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C[C@H](C(NC)=O)NCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C[C@H](C(NC)=O)NCC4)=NC=C3)=N2)=N1 UWUUGJNILZJMCR-OAQYLSRUSA-N 0.000 description 1
- JYLCWMWEZYGLDM-HXUWFJFHSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C[C@H](C(O)=O)NCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C[C@H](C(O)=O)NCC4)=NC=C3)=N2)=N1 JYLCWMWEZYGLDM-HXUWFJFHSA-N 0.000 description 1
- DZEBYUGLJDRGNN-OAQYLSRUSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C[C@H](C(OC)=O)NCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N4C[C@H](C(OC)=O)NCC4)=NC=C3)=N2)=N1 DZEBYUGLJDRGNN-OAQYLSRUSA-N 0.000 description 1
- OETQTNHJHKFGJM-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C(CC4)CCN4C4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C(CC4)CCN4C4CNCC4)=O)=NC=C3)=N2)=N1 OETQTNHJHKFGJM-UHFFFAOYSA-N 0.000 description 1
- SEXRLRAGRDAVNE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4(CNC4)O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4(CNC4)O)=O)=NC=C3)=N2)=N1 SEXRLRAGRDAVNE-UHFFFAOYSA-N 0.000 description 1
- FCZGIYIKTQGKCZ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4(CNCC4)O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4(CNCC4)O)=O)=NC=C3)=N2)=N1 FCZGIYIKTQGKCZ-UHFFFAOYSA-N 0.000 description 1
- OKNACIQBSWOSOA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4CCN(C)CC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4CCN(C)CC4)=O)=NC=C3)=N2)=N1 OKNACIQBSWOSOA-UHFFFAOYSA-N 0.000 description 1
- XGXBFNMLLNYVSN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4CCN(CCN(C)C)CC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4CCN(CCN(C)C)CC4)=O)=NC=C3)=N2)=N1 XGXBFNMLLNYVSN-UHFFFAOYSA-N 0.000 description 1
- UBJRYRWWBJVEPA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4CNC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4CNC4)=O)=NC=C3)=N2)=N1 UBJRYRWWBJVEPA-UHFFFAOYSA-N 0.000 description 1
- ZRJUIJOSLGFTLQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4CNCC4)=O)=NC=C3)=N2)=N1 ZRJUIJOSLGFTLQ-UHFFFAOYSA-N 0.000 description 1
- HBBGPFBVQISTMD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4CNCCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(C4CNCCC4)=O)=NC=C3)=N2)=N1 HBBGPFBVQISTMD-UHFFFAOYSA-N 0.000 description 1
- GLSLNHYTSPFONF-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(N4CCN(C)CC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(N4CCN(C)CC4)=O)=NC=C3)=N2)=N1 GLSLNHYTSPFONF-UHFFFAOYSA-N 0.000 description 1
- BEEUEDVALLSZQK-HXUWFJFHSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(N4C[C@H](CO)NCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC(N4C[C@H](CO)NCC4)=O)=NC=C3)=N2)=N1 BEEUEDVALLSZQK-HXUWFJFHSA-N 0.000 description 1
- IHNDXBXPFNWMGP-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC4CNC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC4CNC4)=NC=C3)=N2)=N1 IHNDXBXPFNWMGP-UHFFFAOYSA-N 0.000 description 1
- BJUYAYXDXZVWEQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC4CNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC4CNCC4)=NC=C3)=N2)=N1 BJUYAYXDXZVWEQ-UHFFFAOYSA-N 0.000 description 1
- VGWVYSLHBLHMGW-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCC4(CNC4)O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCC4(CNC4)O)=NC=C3)=N2)=N1 VGWVYSLHBLHMGW-UHFFFAOYSA-N 0.000 description 1
- VBJZQIWDFMKEMP-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCC4(CO)CNC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCC4(CO)CNC4)=NC=C3)=N2)=N1 VBJZQIWDFMKEMP-UHFFFAOYSA-N 0.000 description 1
- YWQFQFDVPNFTNR-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCCN)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCCN)=NC=C3)=N2)=N1 YWQFQFDVPNFTNR-UHFFFAOYSA-N 0.000 description 1
- PTJSVNZMJRGYBH-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCCN4CCNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCCN4CCNCC4)=NC=C3)=N2)=N1 PTJSVNZMJRGYBH-UHFFFAOYSA-N 0.000 description 1
- KYJREYCEPMXTBU-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCCN4CCOCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCCN4CCOCC4)=NC=C3)=N2)=N1 KYJREYCEPMXTBU-UHFFFAOYSA-N 0.000 description 1
- XSNGPFURNUCKIC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCCO)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NCCO)=NC=C3)=N2)=N1 XSNGPFURNUCKIC-UHFFFAOYSA-N 0.000 description 1
- CEWMEQOAVMVHQS-HXUWFJFHSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC[C@@H]4NCCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC[C@@H]4NCCC4)=NC=C3)=N2)=N1 CEWMEQOAVMVHQS-HXUWFJFHSA-N 0.000 description 1
- CEWMEQOAVMVHQS-FQEVSTJZSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC[C@H]4NCCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NC[C@H]4NCCC4)=NC=C3)=N2)=N1 CEWMEQOAVMVHQS-FQEVSTJZSA-N 0.000 description 1
- MAMRATZOXSVQEN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(C)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(C)(=O)=O)=NC=C3)=N2)=N1 MAMRATZOXSVQEN-UHFFFAOYSA-N 0.000 description 1
- NWLPIMVUJRYFGU-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(C4CNC4)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(C4CNC4)(=O)=O)=NC=C3)=N2)=N1 NWLPIMVUJRYFGU-UHFFFAOYSA-N 0.000 description 1
- UKFAALSTVZCDBO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(C4CNCC4)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(C4CNCC4)(=O)=O)=NC=C3)=N2)=N1 UKFAALSTVZCDBO-UHFFFAOYSA-N 0.000 description 1
- NZHRPGSVBLAEAQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(N(C)C)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(N(C)C)(=O)=O)=NC=C3)=N2)=N1 NZHRPGSVBLAEAQ-UHFFFAOYSA-N 0.000 description 1
- GRIKODFGMDAXFZ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(N(C)C4CCNCC4)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(N(C)C4CCNCC4)(=O)=O)=NC=C3)=N2)=N1 GRIKODFGMDAXFZ-UHFFFAOYSA-N 0.000 description 1
- HLZXJWCRBXQQDO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(N4CCN(C)CC4)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4NS(N4CCN(C)CC4)(=O)=O)=NC=C3)=N2)=N1 HLZXJWCRBXQQDO-UHFFFAOYSA-N 0.000 description 1
- BJUYAYXDXZVWEQ-IBGZPJMESA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N[C@@H]4CNCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4N[C@@H]4CNCC4)=NC=C3)=N2)=N1 BJUYAYXDXZVWEQ-IBGZPJMESA-N 0.000 description 1
- QAAFMRVFZGGTGC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4O)=NC=C3)=N2)=N1 QAAFMRVFZGGTGC-UHFFFAOYSA-N 0.000 description 1
- OFKIYCMTNQHENG-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4OCCOC)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4OCCOC)=NC=C3)=N2)=N1 OFKIYCMTNQHENG-UHFFFAOYSA-N 0.000 description 1
- LICOTTPABBAFKT-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N(C)C4CCNCC4)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N(C)C4CCNCC4)(=O)=O)=NC=C3)=N2)=N1 LICOTTPABBAFKT-UHFFFAOYSA-N 0.000 description 1
- KMABCBWEMGHTHS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N(C)CCN)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N(C)CCN)(=O)=O)=NC=C3)=N2)=N1 KMABCBWEMGHTHS-UHFFFAOYSA-N 0.000 description 1
- KZRJXTYOTBPDKN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N(CC4)CCC4NC)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N(CC4)CCC4NC)(=O)=O)=NC=C3)=N2)=N1 KZRJXTYOTBPDKN-UHFFFAOYSA-N 0.000 description 1
- QPVBKLJIVPLCHM-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N(CC4)CCN4C4CC4)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N(CC4)CCN4C4CC4)(=O)=O)=NC=C3)=N2)=N1 QPVBKLJIVPLCHM-UHFFFAOYSA-N 0.000 description 1
- VICHNFVSCJEUNZ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N4CCN(C)CC4)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N4CCN(C)CC4)(=O)=O)=NC=C3)=N2)=N1 VICHNFVSCJEUNZ-UHFFFAOYSA-N 0.000 description 1
- MDGUPVZCJHGIKN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N4CCN(CCO)CC4)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N4CCN(CCO)CC4)(=O)=O)=NC=C3)=N2)=N1 MDGUPVZCJHGIKN-UHFFFAOYSA-N 0.000 description 1
- HGIOSXLQDIZLNH-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N4CCNCC4)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N4CCNCC4)(=O)=O)=NC=C3)=N2)=N1 HGIOSXLQDIZLNH-UHFFFAOYSA-N 0.000 description 1
- JONIIUNAIOOGJU-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N4CCOCC4)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(N4CCOCC4)(=O)=O)=NC=C3)=N2)=N1 JONIIUNAIOOGJU-UHFFFAOYSA-N 0.000 description 1
- RUDYITXHRHPNGG-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(NCCN)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(NCCN)(=O)=O)=NC=C3)=N2)=N1 RUDYITXHRHPNGG-UHFFFAOYSA-N 0.000 description 1
- NTQVKWXJZIPOIG-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(NCCNC)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4S(NCCNC)(=O)=O)=NC=C3)=N2)=N1 NTQVKWXJZIPOIG-UHFFFAOYSA-N 0.000 description 1
- DSMCWMCPRSQXSI-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC4CCNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC4CCNCC4)=O)=NC=C3)=N2)=N1 DSMCWMCPRSQXSI-UHFFFAOYSA-N 0.000 description 1
- CVFRVLIWRVKIQA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC4CCNCCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC4CCNCCC4)=O)=NC=C3)=N2)=N1 CVFRVLIWRVKIQA-UHFFFAOYSA-N 0.000 description 1
- SJPIYVBHKKPLET-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCC4(C5)C5CNC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCC4(C5)C5CNC4)=O)=NC=C3)=N2)=N1 SJPIYVBHKKPLET-UHFFFAOYSA-N 0.000 description 1
- PRYNAWBWPSPCJE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCC4CCNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCC4CCNCC4)=O)=NC=C3)=N2)=N1 PRYNAWBWPSPCJE-UHFFFAOYSA-N 0.000 description 1
- ASLZWYIHTHWRRI-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCC4CNC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCC4CNC4)=O)=NC=C3)=N2)=N1 ASLZWYIHTHWRRI-UHFFFAOYSA-N 0.000 description 1
- VAECYISHYOBHAS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCCC4CCNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCCC4CCNCC4)=O)=NC=C3)=N2)=N1 VAECYISHYOBHAS-UHFFFAOYSA-N 0.000 description 1
- BSQKCEWWGBETHC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCCN4CC(CCC5)N5CC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCCN4CC(CCC5)N5CC4)=O)=NC=C3)=N2)=N1 BSQKCEWWGBETHC-UHFFFAOYSA-N 0.000 description 1
- QVGCRZVXGLFUMZ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCCN4CCNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OCCN4CCNCC4)=O)=NC=C3)=N2)=N1 QVGCRZVXGLFUMZ-UHFFFAOYSA-N 0.000 description 1
- XWTYFNVDLPDQFX-KRWDZBQOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@@H]4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@@H]4CNCC4)=O)=NC=C3)=N2)=N1 XWTYFNVDLPDQFX-KRWDZBQOSA-N 0.000 description 1
- VPLNRZZAFKPOJC-SFHVURJKSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@@H]4CNCCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@@H]4CNCCC4)=O)=NC=C3)=N2)=N1 VPLNRZZAFKPOJC-SFHVURJKSA-N 0.000 description 1
- MRXVEJSEBLAKHE-GOSISDBHSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@@H]4NCCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@@H]4NCCC4)=O)=NC=C3)=N2)=N1 MRXVEJSEBLAKHE-GOSISDBHSA-N 0.000 description 1
- QYJKDPSZTCRNKW-LJQANCHMSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@@H]4NCCCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@@H]4NCCCC4)=O)=NC=C3)=N2)=N1 QYJKDPSZTCRNKW-LJQANCHMSA-N 0.000 description 1
- DOZZHWFPGZIZSO-GOSISDBHSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@@H]4OCCNC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@@H]4OCCNC4)=O)=NC=C3)=N2)=N1 DOZZHWFPGZIZSO-GOSISDBHSA-N 0.000 description 1
- XWTYFNVDLPDQFX-QGZVFWFLSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@H]4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@H]4CNCC4)=O)=NC=C3)=N2)=N1 XWTYFNVDLPDQFX-QGZVFWFLSA-N 0.000 description 1
- VPLNRZZAFKPOJC-GOSISDBHSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@H]4CNCCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@H]4CNCCC4)=O)=NC=C3)=N2)=N1 VPLNRZZAFKPOJC-GOSISDBHSA-N 0.000 description 1
- MRXVEJSEBLAKHE-SFHVURJKSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@H]4NCCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@H]4NCCC4)=O)=NC=C3)=N2)=N1 MRXVEJSEBLAKHE-SFHVURJKSA-N 0.000 description 1
- QYJKDPSZTCRNKW-IBGZPJMESA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@H]4NCCCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(OC[C@H]4NCCCC4)=O)=NC=C3)=N2)=N1 QYJKDPSZTCRNKW-IBGZPJMESA-N 0.000 description 1
- ULDIRBXABOKZPJ-KRWDZBQOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(O[C@@H]4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(O[C@@H]4CNCC4)=O)=NC=C3)=N2)=N1 ULDIRBXABOKZPJ-KRWDZBQOSA-N 0.000 description 1
- ARPSQGZIDARCRM-SFHVURJKSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(O[C@@H]4CNCCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(O[C@@H]4CNCCC4)=O)=NC=C3)=N2)=N1 ARPSQGZIDARCRM-SFHVURJKSA-N 0.000 description 1
- ULDIRBXABOKZPJ-QGZVFWFLSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(O[C@H]4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(O[C@H]4CNCC4)=O)=NC=C3)=N2)=N1 ULDIRBXABOKZPJ-QGZVFWFLSA-N 0.000 description 1
- ARPSQGZIDARCRM-GOSISDBHSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(O[C@H]4CNCCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=CN=C4C(O[C@H]4CNCCC4)=O)=NC=C3)=N2)=N1 ARPSQGZIDARCRM-GOSISDBHSA-N 0.000 description 1
- OCDPHXSVJDVQRB-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=NC=C4N4CCN(C)CC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=NC=C4N4CCN(C)CC4)=NC=C3)=N2)=N1 OCDPHXSVJDVQRB-UHFFFAOYSA-N 0.000 description 1
- YCZZQOUAOHXQHA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=NC=C4N4CCOCC4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4)=NC=C4N4CCOCC4)=NC=C3)=N2)=N1 YCZZQOUAOHXQHA-UHFFFAOYSA-N 0.000 description 1
- RXYICEYYSLAHEE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4N)=CC5=C4OCCO5)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4N)=CC5=C4OCCO5)=NC=C3)=N2)=N1 RXYICEYYSLAHEE-UHFFFAOYSA-N 0.000 description 1
- AXUKMRPHPLSEID-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4NC(C5CCNCC5)=O)=CC5=C4OCCO5)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4NC(C5CCNCC5)=O)=CC5=C4OCCO5)=NC=C3)=N2)=N1 AXUKMRPHPLSEID-UHFFFAOYSA-N 0.000 description 1
- OHNNXPNOBDCJCL-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4NS(C)(=O)=O)=CN=C4OC)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=C4NS(C)(=O)=O)=CN=C4OC)=NC=C3)=N2)=N1 OHNNXPNOBDCJCL-UHFFFAOYSA-N 0.000 description 1
- HPWOBGNZVBLFNJ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=CC(N4CCOCC4)=C4)=C4O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=CC(N4CCOCC4)=C4)=C4O)=NC=C3)=N2)=N1 HPWOBGNZVBLFNJ-UHFFFAOYSA-N 0.000 description 1
- CIFPCVLGKLBCDU-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=CC(N4CCOCC4)=C4)=C4OC)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(C=CC(N4CCOCC4)=C4)=C4OC)=NC=C3)=N2)=N1 CIFPCVLGKLBCDU-UHFFFAOYSA-N 0.000 description 1
- QOWODQMSDKCYAS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(O)=O)=NC=C3)=N2)=N1 QOWODQMSDKCYAS-UHFFFAOYSA-N 0.000 description 1
- OIJONLKMCFRRJU-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(OC4CCNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(OC4CCNCC4)=O)=NC=C3)=N2)=N1 OIJONLKMCFRRJU-UHFFFAOYSA-N 0.000 description 1
- PCZDNEGMIRZYNB-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(OCC4CNC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(OCC4CNC4)=O)=NC=C3)=N2)=N1 PCZDNEGMIRZYNB-UHFFFAOYSA-N 0.000 description 1
- PETPJBFJSCCPPH-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(OCCN4CCNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(OCCN4CCNCC4)=O)=NC=C3)=N2)=N1 PETPJBFJSCCPPH-UHFFFAOYSA-N 0.000 description 1
- SIVQYHRKJOZPPW-KRWDZBQOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(O[C@@H]4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(O[C@@H]4CNCC4)=O)=NC=C3)=N2)=N1 SIVQYHRKJOZPPW-KRWDZBQOSA-N 0.000 description 1
- SIVQYHRKJOZPPW-QGZVFWFLSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(O[C@H]4CNCC4)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4C(O[C@H]4CNCC4)=O)=NC=C3)=N2)=N1 SIVQYHRKJOZPPW-QGZVFWFLSA-N 0.000 description 1
- OYGSOPVNPYEMDY-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4S(N)(=O)=O)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC(N=C4)=CC=C4S(N)(=O)=O)=NC=C3)=N2)=N1 OYGSOPVNPYEMDY-UHFFFAOYSA-N 0.000 description 1
- YVJQFJPPQVHUTR-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(C(N5CCNCC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(C(N5CCNCC5)=O)=CS4)=NC=C3)=N2)=N1 YVJQFJPPQVHUTR-UHFFFAOYSA-N 0.000 description 1
- VRHMIVKQNYBBAQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(C(O)=O)=NC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(C(O)=O)=NC=C4)=NC=C3)=N2)=N1 VRHMIVKQNYBBAQ-UHFFFAOYSA-N 0.000 description 1
- LHGSPEATVUGOCK-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(C(OCC5CNC5)=O)=NC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(C(OCC5CNC5)=O)=NC=C4)=NC=C3)=N2)=N1 LHGSPEATVUGOCK-UHFFFAOYSA-N 0.000 description 1
- ZPFKYTYQBDUSAN-QGZVFWFLSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(C(O[C@H]5CN(C)CC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(C(O[C@H]5CN(C)CC5)=O)=CS4)=NC=C3)=N2)=N1 ZPFKYTYQBDUSAN-QGZVFWFLSA-N 0.000 description 1
- QIFZZNCIECYSTB-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(CN5CC(CC6)NC6C5)=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(CN5CC(CC6)NC6C5)=CC=C4)=NC=C3)=N2)=N1 QIFZZNCIECYSTB-UHFFFAOYSA-N 0.000 description 1
- VAHGUYOBXGZMPO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(CN5CCN(C)CC5)=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(CN5CCN(C)CC5)=CC=C4)=NC=C3)=N2)=N1 VAHGUYOBXGZMPO-UHFFFAOYSA-N 0.000 description 1
- BWPSTQXYJQZNRR-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(CN5CCOCC5)=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(CN5CCOCC5)=CC=C4)=NC=C3)=N2)=N1 BWPSTQXYJQZNRR-UHFFFAOYSA-N 0.000 description 1
- JAYPNRVPQMUPBL-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(CN5CCSCC5)=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(CN5CCSCC5)=CC=C4)=NC=C3)=N2)=N1 JAYPNRVPQMUPBL-UHFFFAOYSA-N 0.000 description 1
- REQZRKKTVDUNKJ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(Cl)=C(C(N5CCNCC5)=O)C(F)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(Cl)=C(C(N5CCNCC5)=O)C(F)=C4)=NC=C3)=N2)=N1 REQZRKKTVDUNKJ-UHFFFAOYSA-N 0.000 description 1
- LTXNLXLMXIAXKV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(F)=C(CN5CCOCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(F)=C(CN5CCOCC5)C=C4)=NC=C3)=N2)=N1 LTXNLXLMXIAXKV-UHFFFAOYSA-N 0.000 description 1
- NWAGHAVKKYHXCA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(N5CCN(C)CC5)=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(N5CCN(C)CC5)=CC=C4)=NC=C3)=N2)=N1 NWAGHAVKKYHXCA-UHFFFAOYSA-N 0.000 description 1
- WFONAPMEUWMPLP-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(N5CCNCC5)=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(N5CCNCC5)=CC=C4)=NC=C3)=N2)=N1 WFONAPMEUWMPLP-UHFFFAOYSA-N 0.000 description 1
- JNWQKRZDVIFCRD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(NCC5CNC5)=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(NCC5CNC5)=CC=C4)=NC=C3)=N2)=N1 JNWQKRZDVIFCRD-UHFFFAOYSA-N 0.000 description 1
- WFQPYHVOZABGRE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(S(N5CCNCC5)(=O)=O)=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC(S(N5CCNCC5)(=O)=O)=CC=C4)=NC=C3)=N2)=N1 WFQPYHVOZABGRE-UHFFFAOYSA-N 0.000 description 1
- QWPNIZZOKMLQBR-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(N5CCNCC5)=O)S4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(N5CCNCC5)=O)S4)=NC=C3)=N2)=N1 QWPNIZZOKMLQBR-UHFFFAOYSA-N 0.000 description 1
- ABSJVQWBHFZHRL-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(OC5CCNCC5)=O)S4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(OC5CCNCC5)=O)S4)=NC=C3)=N2)=N1 ABSJVQWBHFZHRL-UHFFFAOYSA-N 0.000 description 1
- BBRDCBUUDTWEMS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(OC5CNC5)=O)S4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(OC5CNC5)=O)S4)=NC=C3)=N2)=N1 BBRDCBUUDTWEMS-UHFFFAOYSA-N 0.000 description 1
- FPQFRTHZOCEWFW-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(OCC5CNC5)=O)S4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(OCC5CNC5)=O)S4)=NC=C3)=N2)=N1 FPQFRTHZOCEWFW-UHFFFAOYSA-N 0.000 description 1
- WMJWAONPQLHSQB-INIZCTEOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(O[C@@H]5CN(C)CC5)=O)S4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(O[C@@H]5CN(C)CC5)=O)S4)=NC=C3)=N2)=N1 WMJWAONPQLHSQB-INIZCTEOSA-N 0.000 description 1
- WMJWAONPQLHSQB-MRXNPFEDSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(O[C@H]5CN(C)CC5)=O)S4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C(O[C@H]5CN(C)CC5)=O)S4)=NC=C3)=N2)=N1 WMJWAONPQLHSQB-MRXNPFEDSA-N 0.000 description 1
- YHLVWFTYDSVKGD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C5CCNCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C5CCNCC5)C=C4)=NC=C3)=N2)=N1 YHLVWFTYDSVKGD-UHFFFAOYSA-N 0.000 description 1
- QGGGUSQOEHBBRW-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C5CNCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C5CNCC5)C=C4)=NC=C3)=N2)=N1 QGGGUSQOEHBBRW-UHFFFAOYSA-N 0.000 description 1
- ATRIAZBCSUWXJN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C5CNCCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C5CNCCC5)C=C4)=NC=C3)=N2)=N1 ATRIAZBCSUWXJN-UHFFFAOYSA-N 0.000 description 1
- MIVMOEMVBPVNFV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C5NCCNC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C5NCCNC5)C=C4)=NC=C3)=N2)=N1 MIVMOEMVBPVNFV-UHFFFAOYSA-N 0.000 description 1
- NZWPBPMUBQADMZ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C5NCCOC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(C5NCCOC5)C=C4)=NC=C3)=N2)=N1 NZWPBPMUBQADMZ-UHFFFAOYSA-N 0.000 description 1
- JVYLKFCMFYNHME-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CC(O)=O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CC(O)=O)C=C4)=NC=C3)=N2)=N1 JVYLKFCMFYNHME-UHFFFAOYSA-N 0.000 description 1
- NDKHOWUVHAHFRR-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CC(OC)=O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CC(OC)=O)C=C4)=NC=C3)=N2)=N1 NDKHOWUVHAHFRR-UHFFFAOYSA-N 0.000 description 1
- UEDPSQHICFLVJE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CC5CCNCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CC5CCNCC5)C=C4)=NC=C3)=N2)=N1 UEDPSQHICFLVJE-UHFFFAOYSA-N 0.000 description 1
- KXGWEKDYIFYVBJ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CC5CNC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CC5CNC5)C=C4)=NC=C3)=N2)=N1 KXGWEKDYIFYVBJ-UHFFFAOYSA-N 0.000 description 1
- VDUIWMRXANELQG-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CCC(OC)=O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CCC(OC)=O)C=C4)=NC=C3)=N2)=N1 VDUIWMRXANELQG-UHFFFAOYSA-N 0.000 description 1
- YEKDCLJXNHXFNG-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CCN(C)C)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CCN(C)C)C=C4)=NC=C3)=N2)=N1 YEKDCLJXNHXFNG-UHFFFAOYSA-N 0.000 description 1
- RUPIZXZKPIWCJV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CCO)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CCO)C=C4)=NC=C3)=N2)=N1 RUPIZXZKPIWCJV-UHFFFAOYSA-N 0.000 description 1
- IVWGVTHFSUPZJQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CCOC)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CCOC)C=C4)=NC=C3)=N2)=N1 IVWGVTHFSUPZJQ-UHFFFAOYSA-N 0.000 description 1
- GARGUWNMIOSZKO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(C)C)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(C)C)C=C4)=NC=C3)=N2)=N1 GARGUWNMIOSZKO-UHFFFAOYSA-N 0.000 description 1
- KTICVOHAYCQVHD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(C5)CC55COCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(C5)CC55COCC5)C=C4)=NC=C3)=N2)=N1 KTICVOHAYCQVHD-UHFFFAOYSA-N 0.000 description 1
- PKPBQYDZUVGHRJ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(C5)CC5O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(C5)CC5O)C=C4)=NC=C3)=N2)=N1 PKPBQYDZUVGHRJ-UHFFFAOYSA-N 0.000 description 1
- MDFPZUWAKUWTSE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(C5)CC5OC)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(C5)CC5OC)C=C4)=NC=C3)=N2)=N1 MDFPZUWAKUWTSE-UHFFFAOYSA-N 0.000 description 1
- ZSWACRSRXUQYDS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CC5)CCC5O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CC5)CCC5O)C=C4)=NC=C3)=N2)=N1 ZSWACRSRXUQYDS-UHFFFAOYSA-N 0.000 description 1
- LWMQEWXFYVXPJS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CC5)CCS5(=O)=O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CC5)CCS5(=O)=O)C=C4)=NC=C3)=N2)=N1 LWMQEWXFYVXPJS-UHFFFAOYSA-N 0.000 description 1
- UKEPAJOSUNLTLN-HXUWFJFHSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CC5)C[C@@H]5O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CC5)C[C@@H]5O)C=C4)=NC=C3)=N2)=N1 UKEPAJOSUNLTLN-HXUWFJFHSA-N 0.000 description 1
- UKEPAJOSUNLTLN-FQEVSTJZSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CC5)C[C@H]5O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CC5)C[C@H]5O)C=C4)=NC=C3)=N2)=N1 UKEPAJOSUNLTLN-FQEVSTJZSA-N 0.000 description 1
- YNAXABBLEJFNSY-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)CC5C(N5CCNCC5)=O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)CC5C(N5CCNCC5)=O)C=C4)=NC=C3)=N2)=N1 YNAXABBLEJFNSY-UHFFFAOYSA-N 0.000 description 1
- GADKOEQLUINELN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)CC5C(NC5CCNCC5)=O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)CC5C(NC5CCNCC5)=O)C=C4)=NC=C3)=N2)=N1 GADKOEQLUINELN-UHFFFAOYSA-N 0.000 description 1
- XLLNXSFFIMHFQV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)CC5C(O)=O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)CC5C(O)=O)C=C4)=NC=C3)=N2)=N1 XLLNXSFFIMHFQV-UHFFFAOYSA-N 0.000 description 1
- XLLNXSFFIMHFQV-FQEVSTJZSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)C[C@H]5C(O)=O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN(CCC5)C[C@H]5C(O)=O)C=C4)=NC=C3)=N2)=N1 XLLNXSFFIMHFQV-FQEVSTJZSA-N 0.000 description 1
- MQWVFTBFAHYWAT-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN)C=C4)=NC=C3)=N2)=N1 MQWVFTBFAHYWAT-UHFFFAOYSA-N 0.000 description 1
- AKEAAUYESGATGV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5C6CNCC5CC6)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5C6CNCC5CC6)C=C4)=NC=C3)=N2)=N1 AKEAAUYESGATGV-UHFFFAOYSA-N 0.000 description 1
- OEOMSKBBGIQDOQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5C6CNCCC5CC6)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5C6CNCCC5CC6)C=C4)=NC=C3)=N2)=N1 OEOMSKBBGIQDOQ-UHFFFAOYSA-N 0.000 description 1
- OSAZKMKPJKIUNS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CC(OC)=O)NCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CC(OC)=O)NCC5)C=C4)=NC=C3)=N2)=N1 OSAZKMKPJKIUNS-UHFFFAOYSA-N 0.000 description 1
- XDIATPGMTOOIRJ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CC6)NC6C5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CC6)NC6C5)C=C4)=NC=C3)=N2)=N1 XDIATPGMTOOIRJ-UHFFFAOYSA-N 0.000 description 1
- BPUMDNREOVYGDT-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CC6)OC6C5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CC6)OC6C5)C=C4)=NC=C3)=N2)=N1 BPUMDNREOVYGDT-UHFFFAOYSA-N 0.000 description 1
- KOGNNOSUVRUIEJ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CCC6)N6CC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CCC6)N6CC5)C=C4)=NC=C3)=N2)=N1 KOGNNOSUVRUIEJ-UHFFFAOYSA-N 0.000 description 1
- KBEKKBAFPFNGMV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CCC6)NC6C5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CCC6)NC6C5)C=C4)=NC=C3)=N2)=N1 KBEKKBAFPFNGMV-UHFFFAOYSA-N 0.000 description 1
- MWBLKGOEBWFSKK-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CO)C5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC(CO)C5)C=C4)=NC=C3)=N2)=N1 MWBLKGOEBWFSKK-UHFFFAOYSA-N 0.000 description 1
- ZNJOVHCLJMQVGI-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC6(CNC6)C5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CC6(CNC6)C5)C=C4)=NC=C3)=N2)=N1 ZNJOVHCLJMQVGI-UHFFFAOYSA-N 0.000 description 1
- BWGZZFMGJRXLPV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CCC(CO)CC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CCC(CO)CC5)C=C4)=NC=C3)=N2)=N1 BWGZZFMGJRXLPV-UHFFFAOYSA-N 0.000 description 1
- WIAIEPFAQWNSPN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CCN(C)CC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CCN(C)CC5)C=C4)=NC=C3)=N2)=N1 WIAIEPFAQWNSPN-UHFFFAOYSA-N 0.000 description 1
- YAMMPORNYWHFJS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CCN(CC6=CC=CC=C6)CC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CCN(CC6=CC=CC=C6)CC5)C=C4)=NC=C3)=N2)=N1 YAMMPORNYWHFJS-UHFFFAOYSA-N 0.000 description 1
- RPITVTDTAJNUDP-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CCOCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CCOCC5)C=C4)=NC=C3)=N2)=N1 RPITVTDTAJNUDP-UHFFFAOYSA-N 0.000 description 1
- WJHIKIIDONNMQK-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CCSCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5CCSCC5)C=C4)=NC=C3)=N2)=N1 WJHIKIIDONNMQK-UHFFFAOYSA-N 0.000 description 1
- QPDQYVSHBKWNDC-NRFANRHFSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5C[C@@H](CO)NCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5C[C@@H](CO)NCC5)C=C4)=NC=C3)=N2)=N1 QPDQYVSHBKWNDC-NRFANRHFSA-N 0.000 description 1
- QPDQYVSHBKWNDC-OAQYLSRUSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5C[C@H](CO)NCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5C[C@H](CO)NCC5)C=C4)=NC=C3)=N2)=N1 QPDQYVSHBKWNDC-OAQYLSRUSA-N 0.000 description 1
- RIKPQRXEGYKBOR-JOCHJYFZSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5C[C@H](COC)NCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5C[C@H](COC)NCC5)C=C4)=NC=C3)=N2)=N1 RIKPQRXEGYKBOR-JOCHJYFZSA-N 0.000 description 1
- BLWGCJVHKHWRML-SFTDATJTSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5[C@@H](C6)CN[C@@H]6C5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5[C@@H](C6)CN[C@@H]6C5)C=C4)=NC=C3)=N2)=N1 BLWGCJVHKHWRML-SFTDATJTSA-N 0.000 description 1
- BLWGCJVHKHWRML-NHCUHLMSSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5[C@H](C6)CN[C@H]6C5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CN5[C@H](C6)CN[C@H]6C5)C=C4)=NC=C3)=N2)=N1 BLWGCJVHKHWRML-NHCUHLMSSA-N 0.000 description 1
- LQITUTDDDLAXQC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CNC)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(CNC)C=C4)=NC=C3)=N2)=N1 LQITUTDDDLAXQC-UHFFFAOYSA-N 0.000 description 1
- SEPUCGWGWMXCSO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(COCCO)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C(COCCO)C=C4)=NC=C3)=N2)=N1 SEPUCGWGWMXCSO-UHFFFAOYSA-N 0.000 description 1
- XEFSGBWTZAYLHT-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C5NN=CC5=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=C5NN=CC5=C4)=NC=C3)=N2)=N1 XEFSGBWTZAYLHT-UHFFFAOYSA-N 0.000 description 1
- YMTTXYDGUVZNLG-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(N5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(N5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 YMTTXYDGUVZNLG-UHFFFAOYSA-N 0.000 description 1
- DXYQOCDVDPJQDN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(N5CCOCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(N5CCOCC5)=O)=C4)=NC=C3)=N2)=N1 DXYQOCDVDPJQDN-UHFFFAOYSA-N 0.000 description 1
- XLDFUNYPCHREHZ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(OC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(OC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 XLDFUNYPCHREHZ-UHFFFAOYSA-N 0.000 description 1
- DFFWDBHIERDMKC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(OCCN5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(OCCN5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 DFFWDBHIERDMKC-UHFFFAOYSA-N 0.000 description 1
- AWUJECZKJKDXFA-FQEVSTJZSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(O[C@@H]5CN(C)CC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(O[C@@H]5CN(C)CC5)=O)=C4)=NC=C3)=N2)=N1 AWUJECZKJKDXFA-FQEVSTJZSA-N 0.000 description 1
- QKKPGTWJGQBEDA-IBGZPJMESA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(O[C@@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(O[C@@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 QKKPGTWJGQBEDA-IBGZPJMESA-N 0.000 description 1
- QKKPGTWJGQBEDA-LJQANCHMSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(O[C@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(C(O[C@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 QKKPGTWJGQBEDA-LJQANCHMSA-N 0.000 description 1
- INELUEFMKWDWRD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(CN5CC(CC(OC)=O)NCC5)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(CN5CC(CC(OC)=O)NCC5)=C4)=NC=C3)=N2)=N1 INELUEFMKWDWRD-UHFFFAOYSA-N 0.000 description 1
- STFFFDVSUBXWAC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(CO)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(CO)=C4)=NC=C3)=N2)=N1 STFFFDVSUBXWAC-UHFFFAOYSA-N 0.000 description 1
- YWHKCQVMKVWZID-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(N(C)C(C5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(N(C)C(C5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 YWHKCQVMKVWZID-UHFFFAOYSA-N 0.000 description 1
- HCWVLZMUNPWHGS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C(CC5)CCN5C5CCN(C)CC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C(CC5)CCN5C5CCN(C)CC5)=O)=C4)=NC=C3)=N2)=N1 HCWVLZMUNPWHGS-UHFFFAOYSA-N 0.000 description 1
- LVUSHQQQAGBDGP-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C(CC5)CCN5C5CCOCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C(CC5)CCN5C5CCOCC5)=O)=C4)=NC=C3)=N2)=N1 LVUSHQQQAGBDGP-UHFFFAOYSA-N 0.000 description 1
- CQGVLWUFQYHVHY-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5(CNCC5)O)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5(CNCC5)O)=O)=C4)=NC=C3)=N2)=N1 CQGVLWUFQYHVHY-UHFFFAOYSA-N 0.000 description 1
- YTCPJSRCXLRIMY-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5(CO)CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5(CO)CNC5)=O)=C4)=NC=C3)=N2)=N1 YTCPJSRCXLRIMY-UHFFFAOYSA-N 0.000 description 1
- UESWXKJISPCDAX-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5CCN(CCN(C)C)CC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5CCN(CCN(C)C)CC5)=O)=C4)=NC=C3)=N2)=N1 UESWXKJISPCDAX-UHFFFAOYSA-N 0.000 description 1
- CMXBMCUJCPYHEE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 CMXBMCUJCPYHEE-UHFFFAOYSA-N 0.000 description 1
- GBPBHXMBLMMBJE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5CNC5)=O)=C4)=NC=C3)=N2)=N1 GBPBHXMBLMMBJE-UHFFFAOYSA-N 0.000 description 1
- KZRAOUFKWOQRQK-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(C5CNCC5)=O)=C4)=NC=C3)=N2)=N1 KZRAOUFKWOQRQK-UHFFFAOYSA-N 0.000 description 1
- UEVXDESMZPDHCD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(CC5CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(CC5CNC5)=O)=C4)=NC=C3)=N2)=N1 UEVXDESMZPDHCD-UHFFFAOYSA-N 0.000 description 1
- ZSBKTERLGKXDKY-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(N5CCN(C)CC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(N5CCN(C)CC5)=O)=C4)=NC=C3)=N2)=N1 ZSBKTERLGKXDKY-UHFFFAOYSA-N 0.000 description 1
- TVZZIODQMZULDR-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(N5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(N5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 TVZZIODQMZULDR-UHFFFAOYSA-N 0.000 description 1
- PDEWSDHGPJMEDW-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(NC5CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(NC5CNC5)=O)=C4)=NC=C3)=N2)=N1 PDEWSDHGPJMEDW-UHFFFAOYSA-N 0.000 description 1
- MVYRMWZWIBBIGB-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(NC5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(NC5CNCC5)=O)=C4)=NC=C3)=N2)=N1 MVYRMWZWIBBIGB-UHFFFAOYSA-N 0.000 description 1
- NNHBKQUSTPPHKT-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(NCC5CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(NC(NCC5CNC5)=O)=C4)=NC=C3)=N2)=N1 NNHBKQUSTPPHKT-UHFFFAOYSA-N 0.000 description 1
- XSLWTUFNAYGEPL-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(S(N(C)C5CCNCC5)(=O)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(S(N(C)C5CCNCC5)(=O)=O)=C4)=NC=C3)=N2)=N1 XSLWTUFNAYGEPL-UHFFFAOYSA-N 0.000 description 1
- GTRFBEZAXMGBEY-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(S(NCCN(C)C)(=O)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(S(NCCN(C)C)(=O)=O)=C4)=NC=C3)=N2)=N1 GTRFBEZAXMGBEY-UHFFFAOYSA-N 0.000 description 1
- WDXAJPOHMMHTPV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(S(NCCN)(=O)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(S(NCCN)(=O)=O)=C4)=NC=C3)=N2)=N1 WDXAJPOHMMHTPV-UHFFFAOYSA-N 0.000 description 1
- MPJHNKLINDTMBC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(S(NCCNC)(=O)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC(S(NCCNC)(=O)=O)=C4)=NC=C3)=N2)=N1 MPJHNKLINDTMBC-UHFFFAOYSA-N 0.000 description 1
- QEDQZEWYZPNNAC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CC=CC=C4)=NC=C3)=N2)=N1 QEDQZEWYZPNNAC-UHFFFAOYSA-N 0.000 description 1
- IJAWVUDXXHRHOO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN(C5CNCC5)N=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN(C5CNCC5)N=C4)=NC=C3)=N2)=N1 IJAWVUDXXHRHOO-UHFFFAOYSA-N 0.000 description 1
- KXOAWDLHXFZSNX-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN(CC5CNC5)N=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN(CC5CNC5)N=C4)=NC=C3)=N2)=N1 KXOAWDLHXFZSNX-UHFFFAOYSA-N 0.000 description 1
- HMFMHQUGGZVDIK-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN(CCC5CCNCC5)N=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN(CCC5CCNCC5)N=C4)=NC=C3)=N2)=N1 HMFMHQUGGZVDIK-UHFFFAOYSA-N 0.000 description 1
- QNCDWTOQYXFWQA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN(CCCN)N=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN(CCCN)N=C4)=NC=C3)=N2)=N1 QNCDWTOQYXFWQA-UHFFFAOYSA-N 0.000 description 1
- TTXUXLRCLPNCQN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN(CCN)N=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN(CCN)N=C4)=NC=C3)=N2)=N1 TTXUXLRCLPNCQN-UHFFFAOYSA-N 0.000 description 1
- FMVUYAFROQVSHG-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=C(CN(C5)CC5C(O)=O)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=C(CN(C5)CC5C(O)=O)C=C4)=NC=C3)=N2)=N1 FMVUYAFROQVSHG-UHFFFAOYSA-N 0.000 description 1
- VPAHUVBUUZKOIE-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(C(OCC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(C(OCC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 VPAHUVBUUZKOIE-UHFFFAOYSA-N 0.000 description 1
- PLTMLVPQIMQLJQ-GOSISDBHSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(C(OC[C@@H]5NCCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(C(OC[C@@H]5NCCC5)=O)=C4)=NC=C3)=N2)=N1 PLTMLVPQIMQLJQ-GOSISDBHSA-N 0.000 description 1
- RHFSJFYELDINSN-LJQANCHMSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(C(OC[C@@H]5NCCCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(C(OC[C@@H]5NCCCC5)=O)=C4)=NC=C3)=N2)=N1 RHFSJFYELDINSN-LJQANCHMSA-N 0.000 description 1
- CBVXMRCIRBRHDR-SFHVURJKSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(C(O[C@@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(C(O[C@@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 CBVXMRCIRBRHDR-SFHVURJKSA-N 0.000 description 1
- AMLLAITWQKBBIY-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(CN(C5)CC5C(O)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(CN(C5)CC5C(O)=O)=C4)=NC=C3)=N2)=N1 AMLLAITWQKBBIY-UHFFFAOYSA-N 0.000 description 1
- WNCNFUKXSIHCCN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(CN(C5)CC5C(OC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(CN(C5)CC5C(OC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 WNCNFUKXSIHCCN-UHFFFAOYSA-N 0.000 description 1
- BRJVADBUKQWVRV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(CN(C5)CC5C(OCC5CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(CN(C5)CC5C(OCC5CNC5)=O)=C4)=NC=C3)=N2)=N1 BRJVADBUKQWVRV-UHFFFAOYSA-N 0.000 description 1
- YONJOAVDSBMEMA-QFIPXVFZSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(CN(C5)CC5C(O[C@@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(CN(C5)CC5C(O[C@@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 YONJOAVDSBMEMA-QFIPXVFZSA-N 0.000 description 1
- YONJOAVDSBMEMA-JOCHJYFZSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(CN(C5)CC5C(O[C@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CN=CC(CN(C5)CC5C(O[C@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 YONJOAVDSBMEMA-JOCHJYFZSA-N 0.000 description 1
- ZBCATBNRWYRSOA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(N5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(N5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 ZBCATBNRWYRSOA-UHFFFAOYSA-N 0.000 description 1
- WGVGUNSJGVAXRZ-QGZVFWFLSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(N5C[C@H](CO)NCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(N5C[C@H](CO)NCC5)=O)=C4)=NC=C3)=N2)=N1 WGVGUNSJGVAXRZ-QGZVFWFLSA-N 0.000 description 1
- NRHIMZCCGMTDHX-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(NC5(CO)CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(NC5(CO)CNCC5)=O)=C4)=NC=C3)=N2)=N1 NRHIMZCCGMTDHX-UHFFFAOYSA-N 0.000 description 1
- IJFIRGUSUFSDOZ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(NC5CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(NC5CNC5)=O)=C4)=NC=C3)=N2)=N1 IJFIRGUSUFSDOZ-UHFFFAOYSA-N 0.000 description 1
- BXANPGCUGIGFBD-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(NCC5(CO)CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(NCC5(CO)CNC5)=O)=C4)=NC=C3)=N2)=N1 BXANPGCUGIGFBD-UHFFFAOYSA-N 0.000 description 1
- PWTSGAKZKXFJIK-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(NCC5CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(NCC5CNC5)=O)=C4)=NC=C3)=N2)=N1 PWTSGAKZKXFJIK-UHFFFAOYSA-N 0.000 description 1
- DQQWIXWIXLAQFI-OAHLLOKOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(N[C@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(N[C@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 DQQWIXWIXLAQFI-OAHLLOKOSA-N 0.000 description 1
- AZHAOBVZXZAKFX-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC(C5)CC5N)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC(C5)CC5N)=O)=C4)=NC=C3)=N2)=N1 AZHAOBVZXZAKFX-UHFFFAOYSA-N 0.000 description 1
- GMWWBUAKJJSYRY-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 GMWWBUAKJJSYRY-UHFFFAOYSA-N 0.000 description 1
- SWRXXCGXWFGDLO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCC(CC5)CCC5N)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCC(CC5)CCC5N)=O)=C4)=NC=C3)=N2)=N1 SWRXXCGXWFGDLO-UHFFFAOYSA-N 0.000 description 1
- JYNHFXPIGMCYIF-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 JYNHFXPIGMCYIF-UHFFFAOYSA-N 0.000 description 1
- SECRPGCFZRYHOI-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCC5CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCC5CNC5)=O)=C4)=NC=C3)=N2)=N1 SECRPGCFZRYHOI-UHFFFAOYSA-N 0.000 description 1
- VOJNPSGKWMRNDW-QGZVFWFLSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCN(CC5)C[C@@H]5N)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCN(CC5)C[C@@H]5N)=O)=C4)=NC=C3)=N2)=N1 VOJNPSGKWMRNDW-QGZVFWFLSA-N 0.000 description 1
- RANPAXYFGNKGAE-GOSISDBHSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCN(CCC5)C[C@@H]5N)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCN(CCC5)C[C@@H]5N)=O)=C4)=NC=C3)=N2)=N1 RANPAXYFGNKGAE-GOSISDBHSA-N 0.000 description 1
- RANPAXYFGNKGAE-SFHVURJKSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCN(CCC5)C[C@H]5N)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCN(CCC5)C[C@H]5N)=O)=C4)=NC=C3)=N2)=N1 RANPAXYFGNKGAE-SFHVURJKSA-N 0.000 description 1
- MHZXZMIUSCSFDQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCN5CC(CCC6)N6CC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCN5CC(CCC6)N6CC5)=O)=C4)=NC=C3)=N2)=N1 MHZXZMIUSCSFDQ-UHFFFAOYSA-N 0.000 description 1
- BCJPPQLWYLBGAZ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCN5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCN5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 BCJPPQLWYLBGAZ-UHFFFAOYSA-N 0.000 description 1
- KNSKVZLNKAVZNU-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCNC5CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OCCNC5CNC5)=O)=C4)=NC=C3)=N2)=N1 KNSKVZLNKAVZNU-UHFFFAOYSA-N 0.000 description 1
- DHLYEVRVJMOGJN-MRXNPFEDSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@@H]5NCCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@@H]5NCCC5)=O)=C4)=NC=C3)=N2)=N1 DHLYEVRVJMOGJN-MRXNPFEDSA-N 0.000 description 1
- HQUBUDLQRDNBHO-QGZVFWFLSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@@H]5NCCCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@@H]5NCCCC5)=O)=C4)=NC=C3)=N2)=N1 HQUBUDLQRDNBHO-QGZVFWFLSA-N 0.000 description 1
- WURAJHPUCSJBRI-QZTJIDSGSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@H](CCC5)C[C@@H]5N)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@H](CCC5)C[C@@H]5N)=O)=C4)=NC=C3)=N2)=N1 WURAJHPUCSJBRI-QZTJIDSGSA-N 0.000 description 1
- WURAJHPUCSJBRI-MSOLQXFVSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@H](CCC5)C[C@H]5N)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@H](CCC5)C[C@H]5N)=O)=C4)=NC=C3)=N2)=N1 WURAJHPUCSJBRI-MSOLQXFVSA-N 0.000 description 1
- DHLYEVRVJMOGJN-INIZCTEOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@H]5NCCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@H]5NCCC5)=O)=C4)=NC=C3)=N2)=N1 DHLYEVRVJMOGJN-INIZCTEOSA-N 0.000 description 1
- HQUBUDLQRDNBHO-KRWDZBQOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@H]5NCCCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(OC[C@H]5NCCCC5)=O)=C4)=NC=C3)=N2)=N1 HQUBUDLQRDNBHO-KRWDZBQOSA-N 0.000 description 1
- SLHKQAIMEXMIGB-KRWDZBQOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(O[C@@H]5CN(C)CC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(O[C@@H]5CN(C)CC5)=O)=C4)=NC=C3)=N2)=N1 SLHKQAIMEXMIGB-KRWDZBQOSA-N 0.000 description 1
- NULQVFBGRMWMHI-INIZCTEOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(O[C@@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(O[C@@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 NULQVFBGRMWMHI-INIZCTEOSA-N 0.000 description 1
- SLHKQAIMEXMIGB-QGZVFWFLSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(O[C@H]5CN(C)CC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(O[C@H]5CN(C)CC5)=O)=C4)=NC=C3)=N2)=N1 SLHKQAIMEXMIGB-QGZVFWFLSA-N 0.000 description 1
- NULQVFBGRMWMHI-MRXNPFEDSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(O[C@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(C(O[C@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 NULQVFBGRMWMHI-MRXNPFEDSA-N 0.000 description 1
- ZMSFKQCNUAHDIA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(NC(C5(CO)CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(NC(C5(CO)CNC5)=O)=C4)=NC=C3)=N2)=N1 ZMSFKQCNUAHDIA-UHFFFAOYSA-N 0.000 description 1
- DALILCCVLIDJAH-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(NC(C5CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(NC(C5CNC5)=O)=C4)=NC=C3)=N2)=N1 DALILCCVLIDJAH-UHFFFAOYSA-N 0.000 description 1
- IWMVVCKWMDGRMV-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(NC(C5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=CSC(NC(C5CNCC5)=O)=C4)=NC=C3)=N2)=N1 IWMVVCKWMDGRMV-UHFFFAOYSA-N 0.000 description 1
- ULXYZIXTYSGIIO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(N5CCNCC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(N5CCNCC5)=O)=CS4)=NC=C3)=N2)=N1 ULXYZIXTYSGIIO-UHFFFAOYSA-N 0.000 description 1
- LAUZDWJAXZBOLZ-OAHLLOKOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(N5C[C@H](CO)NCC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(N5C[C@H](CO)NCC5)=O)=CS4)=NC=C3)=N2)=N1 LAUZDWJAXZBOLZ-OAHLLOKOSA-N 0.000 description 1
- KLFYCGSUKRBXQC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(NC5(CO)CNCC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(NC5(CO)CNCC5)=O)=CS4)=NC=C3)=N2)=N1 KLFYCGSUKRBXQC-UHFFFAOYSA-N 0.000 description 1
- SYOCFNCVYKTPNA-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(NCC5(CO)CNC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(NCC5(CO)CNC5)=O)=CS4)=NC=C3)=N2)=N1 SYOCFNCVYKTPNA-UHFFFAOYSA-N 0.000 description 1
- AHEBLLXGBAVPMN-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(NCC5CNC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(NCC5CNC5)=O)=CS4)=NC=C3)=N2)=N1 AHEBLLXGBAVPMN-UHFFFAOYSA-N 0.000 description 1
- CNCNSEWTMHXZEA-CQSZACIVSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(N[C@H]5CNCC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(N[C@H]5CNCC5)=O)=CS4)=NC=C3)=N2)=N1 CNCNSEWTMHXZEA-CQSZACIVSA-N 0.000 description 1
- RQNHVHXGZJPCCB-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(OCC5CNC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(OCC5CNC5)=O)=CS4)=NC=C3)=N2)=N1 RQNHVHXGZJPCCB-UHFFFAOYSA-N 0.000 description 1
- RBNHMHZKIVLALO-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(OCCN5CCNCC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(OCCN5CCNCC5)=O)=CS4)=NC=C3)=N2)=N1 RBNHMHZKIVLALO-UHFFFAOYSA-N 0.000 description 1
- OUOUDZKYOIAAMP-MRXNPFEDSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(OC[C@@H]5NCCCC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(OC[C@@H]5NCCCC5)=O)=CS4)=NC=C3)=N2)=N1 OUOUDZKYOIAAMP-MRXNPFEDSA-N 0.000 description 1
- KONOSKLBQWTTIQ-OAHLLOKOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(OC[C@H]5CNCC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(OC[C@H]5CNCC5)=O)=CS4)=NC=C3)=N2)=N1 KONOSKLBQWTTIQ-OAHLLOKOSA-N 0.000 description 1
- ZHKYOURXYILPFS-MRXNPFEDSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(OC[C@H]5CNCCC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C(OC[C@H]5CNCCC5)=O)=CS4)=NC=C3)=N2)=N1 ZHKYOURXYILPFS-MRXNPFEDSA-N 0.000 description 1
- NEHXCCYKVQEORW-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C5=CCNC5)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C5=CCNC5)=CS4)=NC=C3)=N2)=N1 NEHXCCYKVQEORW-UHFFFAOYSA-N 0.000 description 1
- VJGLOBXQZJBTLP-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C5=CCNCC5)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(C5=CCNCC5)=CS4)=NC=C3)=N2)=N1 VJGLOBXQZJBTLP-UHFFFAOYSA-N 0.000 description 1
- ONJBSXBAEBOHLS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(CN(C)C5CNC5)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(CN(C)C5CNC5)=CS4)=NC=C3)=N2)=N1 ONJBSXBAEBOHLS-UHFFFAOYSA-N 0.000 description 1
- ZYWNJJLAAFGTNF-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(CN(C5)CC5C(O)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(CN(C5)CC5C(O)=O)=CS4)=NC=C3)=N2)=N1 ZYWNJJLAAFGTNF-UHFFFAOYSA-N 0.000 description 1
- XYGAWDPNUVZXFX-IFMALSPDSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(CN(CCC5)C[C@@H]5C(O[C@H]5CN(C)CC5)=O)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(CN(CCC5)C[C@@H]5C(O[C@H]5CN(C)CC5)=O)=CS4)=NC=C3)=N2)=N1 XYGAWDPNUVZXFX-IFMALSPDSA-N 0.000 description 1
- HDPHYUQENFAVBX-MRXNPFEDSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(CN5C[C@H](CO)NCC5)=CS4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC(CN5C[C@H](CO)NCC5)=CS4)=NC=C3)=N2)=N1 HDPHYUQENFAVBX-MRXNPFEDSA-N 0.000 description 1
- QXRDYICUBHMIBU-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(C(OC5CNC5)=O)S4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(C(OC5CNC5)=O)S4)=NC=C3)=N2)=N1 QXRDYICUBHMIBU-UHFFFAOYSA-N 0.000 description 1
- DFALKRHWMSZKQU-OAHLLOKOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(C(OC[C@@H]5NCCC5)=O)S4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(C(OC[C@@H]5NCCC5)=O)S4)=NC=C3)=N2)=N1 DFALKRHWMSZKQU-OAHLLOKOSA-N 0.000 description 1
- WIQTYLPGHVFPRH-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(C5=CCNC5)S4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(C5=CCNC5)S4)=NC=C3)=N2)=N1 WIQTYLPGHVFPRH-UHFFFAOYSA-N 0.000 description 1
- KJTRPRUOJMGPSS-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(C5=CCNCC5)S4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(C5=CCNCC5)S4)=NC=C3)=N2)=N1 KJTRPRUOJMGPSS-UHFFFAOYSA-N 0.000 description 1
- HGHACGNSWBRVIQ-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(C5CCNCC5)C=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=C(C5CCNCC5)C=C4)=NC=C3)=N2)=N1 HGHACGNSWBRVIQ-UHFFFAOYSA-N 0.000 description 1
- YGMXTKIZRGEJHK-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(O)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(O)=O)=C4)=NC=C3)=N2)=N1 YGMXTKIZRGEJHK-UHFFFAOYSA-N 0.000 description 1
- MELOAGBNDGYLBX-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(OC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(OC5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 MELOAGBNDGYLBX-UHFFFAOYSA-N 0.000 description 1
- VXMWPUUVAJXBNI-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(OC5CNC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(OC5CNC5)=O)=C4)=NC=C3)=N2)=N1 VXMWPUUVAJXBNI-UHFFFAOYSA-N 0.000 description 1
- BSMUCAYVUIWTSC-UHFFFAOYSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(OCCN5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(OCCN5CCNCC5)=O)=C4)=NC=C3)=N2)=N1 BSMUCAYVUIWTSC-UHFFFAOYSA-N 0.000 description 1
- PLISVFYVDUZPIS-KRWDZBQOSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(O[C@@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(O[C@@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 PLISVFYVDUZPIS-KRWDZBQOSA-N 0.000 description 1
- PLISVFYVDUZPIS-QGZVFWFLSA-N CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(O[C@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CC=CC(C2=NC=CC(NC3=NC(NC4=NC=CC(C(O[C@H]5CNCC5)=O)=C4)=NC=C3)=N2)=N1 PLISVFYVDUZPIS-QGZVFWFLSA-N 0.000 description 1
- DCLKPLMLCZMZJJ-UHFFFAOYSA-N CC1=CSC(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=N1 Chemical compound CC1=CSC(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=N1 DCLKPLMLCZMZJJ-UHFFFAOYSA-N 0.000 description 1
- BMLPMMSPOHROHO-UHFFFAOYSA-N CC1=NC(C2=NC(NC3=CC=NC(NC(C=C4)=CC(CN5CCSCC5)=C4Cl)=N3)=CC=N2)=CC=C1 Chemical compound CC1=NC(C2=NC(NC3=CC=NC(NC(C=C4)=CC(CN5CCSCC5)=C4Cl)=N3)=CC=N2)=CC=C1 BMLPMMSPOHROHO-UHFFFAOYSA-N 0.000 description 1
- KUGYSIIOEWFKRK-UHFFFAOYSA-N CC1=NC(C2=NC(NC3=CC=NC(NC(C=C4)=CC(CN5CCSCC5)=C4F)=N3)=CC=N2)=CC=C1 Chemical compound CC1=NC(C2=NC(NC3=CC=NC(NC(C=C4)=CC(CN5CCSCC5)=C4F)=N3)=CC=N2)=CC=C1 KUGYSIIOEWFKRK-UHFFFAOYSA-N 0.000 description 1
- MOOWRBWOVJPIBX-UHFFFAOYSA-N CC1=NC(C2=NC(NC3=CC=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OC)=O)=N3)=CC=N2)=CC=C1 Chemical compound CC1=NC(C2=NC(NC3=CC=NC(NC(C=C4)=CC=C4N(CCC4)CC4C(OC)=O)=N3)=CC=N2)=CC=C1 MOOWRBWOVJPIBX-UHFFFAOYSA-N 0.000 description 1
- YDXGTWFJVSIJPO-UHFFFAOYSA-N CC1=NC(C2=NC(NC3=CC=NC(NC(C=C4F)=CC=C4N4CCOCC4)=N3)=CC=N2)=CC=C1 Chemical compound CC1=NC(C2=NC(NC3=CC=NC(NC(C=C4F)=CC=C4N4CCOCC4)=N3)=CC=N2)=CC=C1 YDXGTWFJVSIJPO-UHFFFAOYSA-N 0.000 description 1
- YMTAUSXGGXXRCJ-UHFFFAOYSA-N CC1=NC(C2=NC(NC3=CC=NC(NC(C=CC(N4CCOCC4)=C4)=C4F)=N3)=CC=N2)=CC=C1 Chemical compound CC1=NC(C2=NC(NC3=CC=NC(NC(C=CC(N4CCOCC4)=C4)=C4F)=N3)=CC=N2)=CC=C1 YMTAUSXGGXXRCJ-UHFFFAOYSA-N 0.000 description 1
- BWASBRUVNCRWJS-UHFFFAOYSA-N CC1=NC(C2=NC(NC3=CC=NC(NC4=CC(CN5CCNCC5)=CC=C4)=N3)=CC=N2)=CC=C1 Chemical compound CC1=NC(C2=NC(NC3=CC=NC(NC4=CC(CN5CCNCC5)=CC=C4)=N3)=CC=N2)=CC=C1 BWASBRUVNCRWJS-UHFFFAOYSA-N 0.000 description 1
- IEWHBQGLAKPXDK-UHFFFAOYSA-N CC1=NC(C2=NC(NC3=CC=NC(NC4=CC(NC(C5CCN(C)CC5)=O)=CC=C4)=N3)=CC=N2)=CC=C1 Chemical compound CC1=NC(C2=NC(NC3=CC=NC(NC4=CC(NC(C5CCN(C)CC5)=O)=CC=C4)=N3)=CC=N2)=CC=C1 IEWHBQGLAKPXDK-UHFFFAOYSA-N 0.000 description 1
- LYGKEPYFTOYAQX-UHFFFAOYSA-N CC1=NC(C2=NC(NC3=CC=NC(NC4=CC=C(CCCN5)C5=C4)=N3)=CC=N2)=CC=C1 Chemical compound CC1=NC(C2=NC(NC3=CC=NC(NC4=CC=C(CCCN5)C5=C4)=N3)=CC=N2)=CC=C1 LYGKEPYFTOYAQX-UHFFFAOYSA-N 0.000 description 1
- ZCNBQLSCKYZPAU-UHFFFAOYSA-N CC1=NC(C2=NC(NC3=NC(NC4=CC=C(CN(C5)CC5C(OCC5CNC5)=O)C=C4)=NC=C3)=CC=N2)=CC=C1 Chemical compound CC1=NC(C2=NC(NC3=NC(NC4=CC=C(CN(C5)CC5C(OCC5CNC5)=O)C=C4)=NC=C3)=CC=N2)=CC=C1 ZCNBQLSCKYZPAU-UHFFFAOYSA-N 0.000 description 1
- UXGLCOUQNSHSQP-UHFFFAOYSA-N CC1=NC(C2=NC(NC3=NC(NC4=CC=C(CN5CCN(CCO)CC5)C=C4)=NC=C3)=CC=N2)=CC=C1 Chemical compound CC1=NC(C2=NC(NC3=NC(NC4=CC=C(CN5CCN(CCO)CC5)C=C4)=NC=C3)=CC=N2)=CC=C1 UXGLCOUQNSHSQP-UHFFFAOYSA-N 0.000 description 1
- DYFONFUMQVBRGC-UHFFFAOYSA-N CC1=NC(C2=NC(NC3=NC(NC4=CC=C(CN5CCNCC5)C=C4)=NC=C3)=CC=N2)=CC=C1 Chemical compound CC1=NC(C2=NC(NC3=NC(NC4=CC=C(CN5CCNCC5)C=C4)=NC=C3)=CC=N2)=CC=C1 DYFONFUMQVBRGC-UHFFFAOYSA-N 0.000 description 1
- OWUZJRJAPSNJTE-UHFFFAOYSA-N CC1=NC(C2=NC=CC(NC3=CC=NC(NC(C=C4)=CC5=C4NCCC5)=N3)=N2)=CC=C1 Chemical compound CC1=NC(C2=NC=CC(NC3=CC=NC(NC(C=C4)=CC5=C4NCCC5)=N3)=N2)=CC=C1 OWUZJRJAPSNJTE-UHFFFAOYSA-N 0.000 description 1
- YABIPWRYSLUDLY-UHFFFAOYSA-N CC1=NC(C2=NC=CC(NC3=CC=NC(NC(C=C4)=CC=C4C(N4CCN(C)CC4)=O)=N3)=N2)=CC=C1 Chemical compound CC1=NC(C2=NC=CC(NC3=CC=NC(NC(C=C4)=CC=C4C(N4CCN(C)CC4)=O)=N3)=N2)=CC=C1 YABIPWRYSLUDLY-UHFFFAOYSA-N 0.000 description 1
- MCSJIOQGUPEBDW-UHFFFAOYSA-N CC1=NC(C2=NC=CC(NC3=CC=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(OC4CCNCC4)=O)=N3)=N2)=CC=C1 Chemical compound CC1=NC(C2=NC=CC(NC3=CC=NC(NC(C=C4)=CC=C4N(CC4)CCC4C(OC4CCNCC4)=O)=N3)=N2)=CC=C1 MCSJIOQGUPEBDW-UHFFFAOYSA-N 0.000 description 1
- FHDUPHFRCDINSG-UHFFFAOYSA-N CC1=NC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(NC4CNC4)=O)=NC=C3)=N2)=CC=C1 Chemical compound CC1=NC(C2=NC=CC(NC3=NC(NC(C=C4)=CC=C4C(NC4CNC4)=O)=NC=C3)=N2)=CC=C1 FHDUPHFRCDINSG-UHFFFAOYSA-N 0.000 description 1
- BOIISMZXYQNPTA-UHFFFAOYSA-N CC1=NOC(C)=C1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CC1=NOC(C)=C1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 BOIISMZXYQNPTA-UHFFFAOYSA-N 0.000 description 1
- LPSYHCCFHRMNNN-UHFFFAOYSA-N CC1NC(C)CN(CC(C=C(C=C2)NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=C2Cl)C1 Chemical compound CC1NC(C)CN(CC(C=C(C=C2)NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=C2Cl)C1 LPSYHCCFHRMNNN-UHFFFAOYSA-N 0.000 description 1
- CUPWBJCLVBJOFZ-UHFFFAOYSA-N CC1NC(C)CN(CC(C=C(C=C2)NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=C2F)C1 Chemical compound CC1NC(C)CN(CC(C=C(C=C2)NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=C2F)C1 CUPWBJCLVBJOFZ-UHFFFAOYSA-N 0.000 description 1
- AZEIFLJHNGOXFC-UHFFFAOYSA-N CC1NC(C)CN(CC(C=C(C=C2)NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=C2OC)C1 Chemical compound CC1NC(C)CN(CC(C=C(C=C2)NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=C2OC)C1 AZEIFLJHNGOXFC-UHFFFAOYSA-N 0.000 description 1
- REJHWXBKKMULHF-UHFFFAOYSA-N CC1NC(C)CN(CC(C=CC(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C2)=C2OC)C1 Chemical compound CC1NC(C)CN(CC(C=CC(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C2)=C2OC)C1 REJHWXBKKMULHF-UHFFFAOYSA-N 0.000 description 1
- TVZMSOKNVQOPGH-UHFFFAOYSA-N CC1NC(C)CN(CC2=C(C)C=CC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=C2)C1 Chemical compound CC1NC(C)CN(CC2=C(C)C=CC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=C2)C1 TVZMSOKNVQOPGH-UHFFFAOYSA-N 0.000 description 1
- LDBVKQOIROSGPO-UHFFFAOYSA-N CC1NC(C)CN(CC2=CC=CC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=C2)C1 Chemical compound CC1NC(C)CN(CC2=CC=CC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=C2)C1 LDBVKQOIROSGPO-UHFFFAOYSA-N 0.000 description 1
- VRTTXDNERZEQNR-UHFFFAOYSA-N CC1NC(C)CN(CC2=CSC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=N2)C1 Chemical compound CC1NC(C)CN(CC2=CSC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=N2)C1 VRTTXDNERZEQNR-UHFFFAOYSA-N 0.000 description 1
- WOPBCIBYEZOXTA-UHFFFAOYSA-N CC1NC(C)CN(CCNC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 Chemical compound CC1NC(C)CN(CCNC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 WOPBCIBYEZOXTA-UHFFFAOYSA-N 0.000 description 1
- LGPXXPXDMSVYCG-UHFFFAOYSA-N CCN(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 Chemical compound CCN(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1 LGPXXPXDMSVYCG-UHFFFAOYSA-N 0.000 description 1
- HVNJAUOYUQVXFO-UHFFFAOYSA-N CCNC(CC1=NC(C2=NC(C)=CC=C2)=NC(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=C1)=O Chemical compound CCNC(CC1=NC(C2=NC(C)=CC=C2)=NC(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=C1)=O HVNJAUOYUQVXFO-UHFFFAOYSA-N 0.000 description 1
- PEZLBISRAPDUDN-UHFFFAOYSA-N CCOC(CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1N1CCNCC1)=O Chemical compound CCOC(CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1N1CCNCC1)=O PEZLBISRAPDUDN-UHFFFAOYSA-N 0.000 description 1
- VOADKOOVHKQEEW-UHFFFAOYSA-N CCOC(CC(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound CCOC(CC(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O VOADKOOVHKQEEW-UHFFFAOYSA-N 0.000 description 1
- IFUDHRBWKFCPSQ-UHFFFAOYSA-N CCOC(CC(CNCC1)N1C(C=C1)=CC=C1NC1=NC(NC2=NC(C3=CC=CC(C)=N3)=NC=C2)=CC=N1)=O Chemical compound CCOC(CC(CNCC1)N1C(C=C1)=CC=C1NC1=NC(NC2=NC(C3=CC=CC(C)=N3)=NC=C2)=CC=N1)=O IFUDHRBWKFCPSQ-UHFFFAOYSA-N 0.000 description 1
- FRJGOVNTGBOKLV-UHFFFAOYSA-N CCOC(CN1N=CC(C(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1)=O Chemical compound CCOC(CN1N=CC(C(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1)=O FRJGOVNTGBOKLV-UHFFFAOYSA-N 0.000 description 1
- ZGFLTMLHCMRCKJ-CILPGNKCSA-N CC[C@@H](C)OC(CC(CNCC1)N1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound CC[C@@H](C)OC(CC(CNCC1)N1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O ZGFLTMLHCMRCKJ-CILPGNKCSA-N 0.000 description 1
- FJNDFQMUIDTMMP-QHELBMECSA-N CC[C@H](C)OC(C(C1)NCCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound CC[C@H](C)OC(C(C1)NCCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O FJNDFQMUIDTMMP-QHELBMECSA-N 0.000 description 1
- ABJSEZJKPBPSNC-NRFANRHFSA-N CC[C@H](C)OC(CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1N1CCNCC1)=O Chemical compound CC[C@H](C)OC(CC(C=C(C=C1)NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=C1N1CCNCC1)=O ABJSEZJKPBPSNC-NRFANRHFSA-N 0.000 description 1
- ZGFLTMLHCMRCKJ-XEGCMXMBSA-N CC[C@H](C)OC(CC(CNCC1)N1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound CC[C@H](C)OC(CC(CNCC1)N1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O ZGFLTMLHCMRCKJ-XEGCMXMBSA-N 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- WUJONGQEBRAUIT-UHFFFAOYSA-N CN(C)C(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=C(C(F)=C3)Cl)=C3F)=NC=C2)=N1 Chemical compound CN(C)C(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=C(C(F)=C3)Cl)=C3F)=NC=C2)=N1 WUJONGQEBRAUIT-UHFFFAOYSA-N 0.000 description 1
- UZZZZYFFGNZZHL-UHFFFAOYSA-N CN(C)C(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=C(C=C3)Cl)=C3F)=NC=C2)=N1 Chemical compound CN(C)C(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=C(C=C3)Cl)=C3F)=NC=C2)=N1 UZZZZYFFGNZZHL-UHFFFAOYSA-N 0.000 description 1
- NGWBELZPQOYQJO-UHFFFAOYSA-N CN(C1=CC=C(C=C1)[N+](=O)[O-])CC1CN(C1)C(=O)OC(C)(C)C Chemical compound CN(C1=CC=C(C=C1)[N+](=O)[O-])CC1CN(C1)C(=O)OC(C)(C)C NGWBELZPQOYQJO-UHFFFAOYSA-N 0.000 description 1
- DEWIMWAGKILBKM-UHFFFAOYSA-N CN(CC1)CCN1C(CC1)CCN1C(C=C1)=CC=C1NC1=NC(NC2=CC=NC(C(C=CC=C3)=C3F)=N2)=CC=N1 Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C=C1)=CC=C1NC1=NC(NC2=CC=NC(C(C=CC=C3)=C3F)=N2)=CC=N1 DEWIMWAGKILBKM-UHFFFAOYSA-N 0.000 description 1
- SOZCODCTWDFDHN-UHFFFAOYSA-N CN(CC1)CCN1C(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=C(C(F)=C3)Cl)=C3F)=NC=C2)=N1 Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=C(C(F)=C3)Cl)=C3F)=NC=C2)=N1 SOZCODCTWDFDHN-UHFFFAOYSA-N 0.000 description 1
- IJQFZWFPAYOISY-UHFFFAOYSA-N CN(CC1)CCN1C(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=C(C=C3)Cl)=C3F)=NC=C2)=N1 Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=C(C=C3)Cl)=C3F)=NC=C2)=N1 IJQFZWFPAYOISY-UHFFFAOYSA-N 0.000 description 1
- DNCYAPRGSWHBRR-UHFFFAOYSA-N CNC(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=C(C=C3)Cl)=C3F)=NC=C2)=N1 Chemical compound CNC(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=C(C=C3)Cl)=C3F)=NC=C2)=N1 DNCYAPRGSWHBRR-UHFFFAOYSA-N 0.000 description 1
- ZTBLGIJACWZMNW-UHFFFAOYSA-N CNC(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=CC=C3)=C3F)=NC=C2)=N1 Chemical compound CNC(CC1)CCN1C(C=C1)=CC=C1NC1=NC=CC(NC2=NC(C(C=CC=C3)=C3F)=NC=C2)=N1 ZTBLGIJACWZMNW-UHFFFAOYSA-N 0.000 description 1
- MIEKPYBFVUAOBH-UHFFFAOYSA-N COC(CC1=C(C=CC(=C1)[N+](=O)[O-])N1CCN(CC1)C(=O)OC(C)(C)C)=O Chemical compound COC(CC1=C(C=CC(=C1)[N+](=O)[O-])N1CCN(CC1)C(=O)OC(C)(C)C)=O MIEKPYBFVUAOBH-UHFFFAOYSA-N 0.000 description 1
- IEYLWNIPHKREOZ-PMACEKPBSA-N C[C@@H]1N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)[C@@H](C)CNC1 Chemical compound C[C@@H]1N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)[C@@H](C)CNC1 IEYLWNIPHKREOZ-PMACEKPBSA-N 0.000 description 1
- AZDKYPFFYYOHKE-VQTJNVASSA-N C[C@@H]1NC[C@@H](C)N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 Chemical compound C[C@@H]1NC[C@@H](C)N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 AZDKYPFFYYOHKE-VQTJNVASSA-N 0.000 description 1
- AZDKYPFFYYOHKE-PMACEKPBSA-N C[C@@H]1NC[C@H](C)N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 Chemical compound C[C@@H]1NC[C@H](C)N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 AZDKYPFFYYOHKE-PMACEKPBSA-N 0.000 description 1
- QSJGQUZIEGWZPC-IYBDPMFKSA-N C[C@H](C1)N[C@@H](C)CN1C1=CN=C(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)S1 Chemical compound C[C@H](C1)N[C@@H](C)CN1C1=CN=C(NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)S1 QSJGQUZIEGWZPC-IYBDPMFKSA-N 0.000 description 1
- IQLCSTBNUDJSNF-GOSISDBHSA-N C[C@H](C1CCNCC1)OC(C(C=C1)=NC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound C[C@H](C1CCNCC1)OC(C(C=C1)=NC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O IQLCSTBNUDJSNF-GOSISDBHSA-N 0.000 description 1
- OAKZFMOZFHFRJS-VQIMIIECSA-N C[C@H](CC1)NC[C@@H]1OC(C(C=C1)=NC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O Chemical compound C[C@H](CC1)NC[C@@H]1OC(C(C=C1)=NC=C1NC1=NC=CC(NC2=NC(C3=NC(C)=CC=C3)=NC=C2)=N1)=O OAKZFMOZFHFRJS-VQIMIIECSA-N 0.000 description 1
- AZDKYPFFYYOHKE-WOJBJXKFSA-N C[C@H]1NC[C@@H](C)N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 Chemical compound C[C@H]1NC[C@@H](C)N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 AZDKYPFFYYOHKE-WOJBJXKFSA-N 0.000 description 1
- AZDKYPFFYYOHKE-UXHICEINSA-N C[C@H]1NC[C@H](C)N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 Chemical compound C[C@H]1NC[C@H](C)N(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 AZDKYPFFYYOHKE-UXHICEINSA-N 0.000 description 1
- YTBPPLZBVDVZCW-BGYRXZFFSA-N C[C@H]1N[C@@H](C)CN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 Chemical compound C[C@H]1N[C@@H](C)CN(CC(C=C2)=CC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)C1 YTBPPLZBVDVZCW-BGYRXZFFSA-N 0.000 description 1
- PAZZXQMWCSATGR-BGYRXZFFSA-N C[C@H]1N[C@@H](C)CN(CCOC(C(C=C2)=NC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=O)C1 Chemical compound C[C@H]1N[C@@H](C)CN(CCOC(C(C=C2)=NC=C2NC2=NC=CC(NC3=NC(C4=NC(C)=CC=C4)=NC=C3)=N2)=O)C1 PAZZXQMWCSATGR-BGYRXZFFSA-N 0.000 description 1
- BNIHBGWCJMWJSE-KDURUIRLSA-N C[C@H]1N[C@@H](C)CN(CCOC(C2=CC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=CS2)=O)C1 Chemical compound C[C@H]1N[C@@H](C)CN(CCOC(C2=CC(NC3=NC=CC(NC4=NC(C5=NC(C)=CC=C5)=NC=C4)=N3)=CS2)=O)C1 BNIHBGWCJMWJSE-KDURUIRLSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 102100024155 Cadherin-11 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- QZBALFGTJQIONI-UHFFFAOYSA-N ClC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound ClC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C QZBALFGTJQIONI-UHFFFAOYSA-N 0.000 description 1
- RBVXDNOGFYEAAA-UHFFFAOYSA-N ClC1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCC(CC1)N(C(OC(C)(C)C)=O)C Chemical compound ClC1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCC(CC1)N(C(OC(C)(C)C)=O)C RBVXDNOGFYEAAA-UHFFFAOYSA-N 0.000 description 1
- SHHMXXMYRMPAFY-UHFFFAOYSA-N ClC1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCN(CC1)C(=O)OC(C)(C)C Chemical compound ClC1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCN(CC1)C(=O)OC(C)(C)C SHHMXXMYRMPAFY-UHFFFAOYSA-N 0.000 description 1
- XEAVMKZGRBCRIA-UHFFFAOYSA-N ClC1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCNCC1 Chemical compound ClC1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCNCC1 XEAVMKZGRBCRIA-UHFFFAOYSA-N 0.000 description 1
- ASZZXQDUPLMXNC-UHFFFAOYSA-N ClC1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1 Chemical compound ClC1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1 ASZZXQDUPLMXNC-UHFFFAOYSA-N 0.000 description 1
- SJAYIJUJHATTSZ-UHFFFAOYSA-N ClCC1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound ClCC1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C SJAYIJUJHATTSZ-UHFFFAOYSA-N 0.000 description 1
- JNWSBDSRCKEIPP-UHFFFAOYSA-N ClCC=1N=C(SC=1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound ClCC=1N=C(SC=1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C JNWSBDSRCKEIPP-UHFFFAOYSA-N 0.000 description 1
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 1
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000003024 Diffuse alopecia Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100038083 Endosialin Human genes 0.000 description 1
- 101710144543 Endosialin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000121268 Erythroparvovirus Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- BGDTXPOECWQHRM-UHFFFAOYSA-N FC(C1=C(C=CC(=N1)B(O)O)F)F Chemical compound FC(C1=C(C=CC(=N1)B(O)O)F)F BGDTXPOECWQHRM-UHFFFAOYSA-N 0.000 description 1
- JIMQXPAKJBOZIK-UHFFFAOYSA-N FC(C=C(C(Cl)=C1)F)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N(CC3)CCC3N3CCCC3)=NC=C2)=N1 Chemical compound FC(C=C(C(Cl)=C1)F)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N(CC3)CCC3N3CCCC3)=NC=C2)=N1 JIMQXPAKJBOZIK-UHFFFAOYSA-N 0.000 description 1
- AIOLRVGTXNLMCN-UHFFFAOYSA-N FC(C=C(C(Cl)=C1)F)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCOCC3)=NC=C2)=N1 Chemical compound FC(C=C(C(Cl)=C1)F)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCOCC3)=NC=C2)=N1 AIOLRVGTXNLMCN-UHFFFAOYSA-N 0.000 description 1
- WQEYBBQPOJWGBO-UHFFFAOYSA-N FC(C=C1)=CC(F)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCOCC3)=NC=C2)=N1 Chemical compound FC(C=C1)=CC(F)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCOCC3)=NC=C2)=N1 WQEYBBQPOJWGBO-UHFFFAOYSA-N 0.000 description 1
- SFVVJZSBJQVKGU-UHFFFAOYSA-N FC(C=CC(Cl)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N(CC3)CCC3N3CCCC3)=NC=C2)=N1 Chemical compound FC(C=CC(Cl)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N(CC3)CCC3N3CCCC3)=NC=C2)=N1 SFVVJZSBJQVKGU-UHFFFAOYSA-N 0.000 description 1
- WMGJNXWBDWXXOY-UHFFFAOYSA-N FC(C=CC(Cl)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=N1 Chemical compound FC(C=CC(Cl)=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCNCC3)=NC=C2)=N1 WMGJNXWBDWXXOY-UHFFFAOYSA-N 0.000 description 1
- RYNKQKRLDOKRHL-UHFFFAOYSA-N FC(C=CC(Cl)=C1)=C1C1=NC=CC(NC2=NC(NC3=CC=C(CN4CCOCC4)C=C3)=NC=C2)=N1 Chemical compound FC(C=CC(Cl)=C1)=C1C1=NC=CC(NC2=NC(NC3=CC=C(CN4CCOCC4)C=C3)=NC=C2)=N1 RYNKQKRLDOKRHL-UHFFFAOYSA-N 0.000 description 1
- XLQKGBXQWZHISL-UHFFFAOYSA-N FC(C=CC=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCOCC3)=NC=C2)=N1 Chemical compound FC(C=CC=C1)=C1C1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCOCC3)=NC=C2)=N1 XLQKGBXQWZHISL-UHFFFAOYSA-N 0.000 description 1
- OAVSLTALMWXKKK-UHFFFAOYSA-N FC=1C(=[N+](C(=CC=1)I)[O-])C Chemical compound FC=1C(=[N+](C(=CC=1)I)[O-])C OAVSLTALMWXKKK-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000701046 Gammaherpesvirinae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 1
- 101150046249 Havcr2 gene Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000785944 Homo sapiens Asialoglycoprotein receptor 1 Proteins 0.000 description 1
- 101000785948 Homo sapiens Asialoglycoprotein receptor 2 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000762236 Homo sapiens Cadherin-11 Proteins 0.000 description 1
- 101001039113 Homo sapiens Leucine-rich repeat-containing protein 15 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 description 1
- 101000600766 Homo sapiens Podoplanin Proteins 0.000 description 1
- 101001098557 Homo sapiens Proteinase-activated receptor 3 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- LRJKINCBNLDEMU-UHFFFAOYSA-N IC1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCNCC1 Chemical compound IC1=NC=CC(=N1)NC1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCNCC1 LRJKINCBNLDEMU-UHFFFAOYSA-N 0.000 description 1
- MRDUTZXJBFQYRJ-UHFFFAOYSA-N IC1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCOCC3)=NC=C2)=N1 Chemical compound IC1=NC=CC(NC2=NC(NC(C=C3)=CC=C3N3CCOCC3)=NC=C2)=N1 MRDUTZXJBFQYRJ-UHFFFAOYSA-N 0.000 description 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 241001500343 Influenzavirus C Species 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100040645 Leucine-rich repeat-containing protein 15 Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 241000700559 Molluscipoxvirus Species 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- HAJIXWUAUFECJE-UHFFFAOYSA-N N(=C=O)C1=CC(=CS1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound N(=C=O)C1=CC(=CS1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C HAJIXWUAUFECJE-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- NDWMTRCKPLYCOL-UHFFFAOYSA-N NC1=CC=C(C=C1)C=1C=NN(C=1)CCN(C(OC(C)(C)C)=O)C Chemical compound NC1=CC=C(C=C1)C=1C=NN(C=1)CCN(C(OC(C)(C)C)=O)C NDWMTRCKPLYCOL-UHFFFAOYSA-N 0.000 description 1
- QVGHKMMYGOYRHL-UHFFFAOYSA-N NC1=CC=C(C=C1)N(C)CC1CN(C1)C(=O)OC(C)(C)C Chemical compound NC1=CC=C(C=C1)N(C)CC1CN(C1)C(=O)OC(C)(C)C QVGHKMMYGOYRHL-UHFFFAOYSA-N 0.000 description 1
- CEDWWLFARPYQPR-UHFFFAOYSA-N NC1=CC=C(C=C1)NCC1CN(C1)C(=O)OC(C)(C)C Chemical compound NC1=CC=C(C=C1)NCC1CN(C1)C(=O)OC(C)(C)C CEDWWLFARPYQPR-UHFFFAOYSA-N 0.000 description 1
- MENYSIYMLBMNQY-JLHYYAGUSA-N NC1=CC=C(\C=C/2\CN(CC\2)C(=O)OC(C)(C)C)C=C1 Chemical compound NC1=CC=C(\C=C/2\CN(CC\2)C(=O)OC(C)(C)C)C=C1 MENYSIYMLBMNQY-JLHYYAGUSA-N 0.000 description 1
- PCFYSGCUQVEZOU-UHFFFAOYSA-N NC=1C=C(C=CC=1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C Chemical compound NC=1C=C(C=CC=1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C PCFYSGCUQVEZOU-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010067472 Organising pneumonia Diseases 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000700732 Orthohepadnavirus Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000700639 Parapoxvirus Species 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 238000003482 Pinner synthesis reaction Methods 0.000 description 1
- QSXMZJGGEWYVCN-UHFFFAOYSA-N Pirbuterol acetate Chemical compound CC(O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 QSXMZJGGEWYVCN-UHFFFAOYSA-N 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 102100037265 Podoplanin Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 206010058989 Portal vein occlusion Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 102100037133 Proteinase-activated receptor 3 Human genes 0.000 description 1
- 208000021072 Pulmonary hypertension owing to lung disease and/or hypoxia Diseases 0.000 description 1
- 208000021085 Pulmonary hypertension with unclear multifactorial mechanism Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 208000030934 Restrictive pulmonary disease Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000122129 Roseolovirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000028347 Sinus disease Diseases 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010043782 Thyroiditis fibrous chronic Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 description 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 241000701067 Varicellovirus Species 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- BJHCGTGJWANTBE-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C(C=C1)NCC1CN(C1)C(=O)OC(C)(C)C Chemical compound [N+](=O)([O-])C1=CC=C(C=C1)NCC1CN(C1)C(=O)OC(C)(C)C BJHCGTGJWANTBE-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000004073 acute interstitial pneumonia Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000032775 alopecia universalis congenita Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- ROLZYTOAMYXLMF-UHFFFAOYSA-N amino(benzyl)carbamic acid Chemical compound OC(=O)N(N)CC1=CC=CC=C1 ROLZYTOAMYXLMF-UHFFFAOYSA-N 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 229940098165 atrovent Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- VALZSZJVEFACEZ-UHFFFAOYSA-N azetidine-3-carboxamide Chemical compound NC(=O)C1CNC1 VALZSZJVEFACEZ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- CIZVQWNPBGYCGK-UHFFFAOYSA-N benzenediazonium Chemical compound N#[N+]C1=CC=CC=C1 CIZVQWNPBGYCGK-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000001054 cardiac fibroblast Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- KEWHKYJURDBRMN-XSAPEOHZSA-M chembl2134724 Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-XSAPEOHZSA-M 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- NVVXJVMOIGXUGC-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane;2-phenylaniline Chemical compound [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 NVVXJVMOIGXUGC-UHFFFAOYSA-M 0.000 description 1
- AHWRJPOOFGXEKF-UHFFFAOYSA-M chlororuthenium(1+);1,2,3,4,5-pentamethylcyclopenta-1,3-diene;triphenylphosphane Chemical compound [Ru+]Cl.CC=1C(C)=C(C)[C-](C)C=1C.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 AHWRJPOOFGXEKF-UHFFFAOYSA-M 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 230000007881 chronic fibrosis Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001496 desquamative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- DHCWLIOIJZJFJE-UHFFFAOYSA-L dichlororuthenium Chemical compound Cl[Ru]Cl DHCWLIOIJZJFJE-UHFFFAOYSA-L 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940121432 dostarlimab Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229940017733 esbriet Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- ZNMRDZZRAFJOKY-UHFFFAOYSA-N ethanesulfonic acid methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate Chemical compound CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O ZNMRDZZRAFJOKY-UHFFFAOYSA-N 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- BWGYNDFMGAWDHP-UHFFFAOYSA-N ethyl 2,3-dihydro-1h-indene-2-carboxylate Chemical compound C1=CC=C2CC(C(=O)OCC)CC2=C1 BWGYNDFMGAWDHP-UHFFFAOYSA-N 0.000 description 1
- HKXZBDGYTOFCAA-UHFFFAOYSA-N ethyl 2-(2-oxoethyl)-1,3-dihydroindene-2-carboxylate Chemical compound C1=CC=C2CC(C(=O)OCC)(CC=O)CC2=C1 HKXZBDGYTOFCAA-UHFFFAOYSA-N 0.000 description 1
- IEMGWBMVQLVHEY-UHFFFAOYSA-N ethyl 2-(3-amino-6,7-dihydro-5h-cyclopenta[b]pyridin-7-yl)acetate Chemical compound NC1=CN=C2C(CC(=O)OCC)CCC2=C1 IEMGWBMVQLVHEY-UHFFFAOYSA-N 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000009791 fibrotic reaction Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940085861 flovent Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000007440 host cell apoptosis Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009681 mesenchymal cell proliferation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- CAWULVIFHWERCD-UHFFFAOYSA-N methyl 2-(2-fluoro-5-nitrophenyl)acetate Chemical compound COC(=O)CC1=CC([N+]([O-])=O)=CC=C1F CAWULVIFHWERCD-UHFFFAOYSA-N 0.000 description 1
- WSBUTZAETFXDTQ-UHFFFAOYSA-N methyl 6-methylpyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC(C)=N1 WSBUTZAETFXDTQ-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- CIIYYOFFNQMRGN-UHFFFAOYSA-N molport-005-956-786 Chemical compound C1=CC(OC)=CC=C1C1=C(N=CC=2C(N(C=3NN=C(SC)N=3)C=CC3=2)=O)N3N=C1C CIIYYOFFNQMRGN-UHFFFAOYSA-N 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NEIPHSHFJXGGOS-UHFFFAOYSA-N n-methyl-n-(4-methylphenyl)nitrous amide Chemical compound O=NN(C)C1=CC=C(C)C=C1 NEIPHSHFJXGGOS-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FAVZGMWROXRERG-UHFFFAOYSA-N n-pyrrolidin-3-ylbenzamide Chemical compound C=1C=CC=CC=1C(=O)NC1CCNC1 FAVZGMWROXRERG-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 208000028396 noncirrhotic portal hypertension Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940015847 ofev Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002913 oxalic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000011129 pharmaceutical packaging material Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 239000012041 precatalyst Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000003102 pulmonary valve Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940090585 serevent Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000002099 shear wave elastography Methods 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000013125 spirometry Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical group S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- SRRQHCQKLIAFPQ-CQSZACIVSA-N tert-butyl (2R)-2-(hydroxymethyl)-4-(4-nitrophenyl)piperazine-1-carboxylate Chemical compound OC[C@@H]1N(CCN(C1)C1=CC=C(C=C1)[N+](=O)[O-])C(=O)OC(C)(C)C SRRQHCQKLIAFPQ-CQSZACIVSA-N 0.000 description 1
- PNVBSYLZLXGBJE-CQSZACIVSA-N tert-butyl (2R)-4-(4-aminophenyl)-2-(hydroxymethyl)piperazine-1-carboxylate Chemical compound NC1=CC=C(C=C1)N1C[C@@H](N(CC1)C(=O)OC(C)(C)C)CO PNVBSYLZLXGBJE-CQSZACIVSA-N 0.000 description 1
- SCQCXXWVNOKLOT-CYBMUJFWSA-N tert-butyl (3r)-3-(4-aminoanilino)pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@H]1NC1=CC=C(N)C=C1 SCQCXXWVNOKLOT-CYBMUJFWSA-N 0.000 description 1
- JTIBQVGPTPTUFM-UHFFFAOYSA-N tert-butyl 3-(2-methoxy-2-oxoethyl)-4-(4-nitrophenyl)piperazine-1-carboxylate Chemical compound COC(CC1CN(CCN1C1=CC=C(C=C1)[N+](=O)[O-])C(=O)OC(C)(C)C)=O JTIBQVGPTPTUFM-UHFFFAOYSA-N 0.000 description 1
- TWUOZUJVPBNSBA-UHFFFAOYSA-N tert-butyl 3-(2-methoxy-2-oxoethyl)-4-[4-[[4-[[2-(6-methylpyridin-2-yl)pyrimidin-4-yl]amino]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylate Chemical compound COC(CC1CN(CCN1C1=CC=C(C=C1)NC1=NC=CC(=N1)NC1=NC(=NC=C1)C1=NC(=CC=C1)C)C(=O)OC(C)(C)C)=O TWUOZUJVPBNSBA-UHFFFAOYSA-N 0.000 description 1
- IJBBMUPLIYKAPN-UHFFFAOYSA-N tert-butyl 4-(4-aminophenyl)-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate Chemical compound NC1=CC=C(C=C1)N1C(CN(CC1)C(=O)OC(C)(C)C)CC(=O)OC IJBBMUPLIYKAPN-UHFFFAOYSA-N 0.000 description 1
- IIGGWVSIWMLZRW-UHFFFAOYSA-N tert-butyl 4-[(2-amino-1,3-thiazol-4-yl)methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CSC(N)=N1 IIGGWVSIWMLZRW-UHFFFAOYSA-N 0.000 description 1
- CGQSVOJORLWSGX-UHFFFAOYSA-N tert-butyl 8-(4-aminophenyl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CC2CCC(C1)N2C1=CC=C(C=C1)N CGQSVOJORLWSGX-UHFFFAOYSA-N 0.000 description 1
- VQFTYHRAVICBMZ-UHFFFAOYSA-N tert-butyl 8-(4-nitrophenyl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CC2CCC(C1)N2C1=CC=C(C=C1)[N+](=O)[O-] VQFTYHRAVICBMZ-UHFFFAOYSA-N 0.000 description 1
- RYZWEYRCZZEMTI-UHFFFAOYSA-N tert-butyl n-[1-(4-aminophenyl)piperidin-4-yl]-n-methylcarbamate Chemical compound C1CC(N(C)C(=O)OC(C)(C)C)CCN1C1=CC=C(N)C=C1 RYZWEYRCZZEMTI-UHFFFAOYSA-N 0.000 description 1
- FZFGXHSORCTJNB-UHFFFAOYSA-N tert-butyl n-methyl-n-[1-(4-nitrophenyl)piperidin-4-yl]carbamate Chemical compound C1CC(N(C)C(=O)OC(C)(C)C)CCN1C1=CC=C([N+]([O-])=O)C=C1 FZFGXHSORCTJNB-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- YNVOMSDITJMNET-UHFFFAOYSA-N thiophene-3-carboxylic acid Chemical compound OC(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-N 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 210000000591 tricuspid valve Anatomy 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002113 ultrasound elastography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Definitions
- fibrotic diseases such as systemic sclerosis (SSc), sclerodermatous graft vs. host disease, nephrogenic system fibrosis, and radiation-induced fibrosis, as well as cardiac, pulmonary, skin, liver, bladder and kidney fibrosis, constitute a major health problem.
- SSc systemic sclerosis
- sclerodermatous graft vs. host disease nephrogenic system fibrosis
- radiation-induced fibrosis as well as cardiac, pulmonary, skin, liver, bladder and kidney fibrosis
- cardiac, pulmonary, skin, liver, bladder and kidney fibrosis constitute a major health problem.
- Activated myofibroblasts may be responsible for replacing normal tissues with nonfunctional fibrotic tissue. Therefore, signaling pathways responsible for stimulating profibrotic reactions in myofibroblasts have potential as targets for development of therapies to treat fibrotic diseases.
- TGF- ⁇ extracellular matrix
- BMP bone morphogenic protein
- TGF- ⁇ signaling is typically initiated by binding of a TGF- ⁇ ligand to a TGF- ⁇ RII. This in turn may recruit and phosphorylate TGF- ⁇ RI, also known as the activin receptor-like kinase 5 (ALK5).
- ALK5 activin receptor-like kinase 5
- Smad2 or Smad3 Once phosphorylated, Smad 2 and 3 proteins then may form heterodimeric complexes with Smad4 which can translocate across the nuclear membrane and modulate Smad-mediated gene expression, including, for example, the production of collagen.
- Smad proteins are intracellular regulators of transcription and therefore may serve as modulators of TGF- ⁇ -regulated genes involving, inter alia, cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis.
- ALK5 is believed to be the most relevant of the activin-like kinases (ALKs) in the fibrotic process (Rosenbloom, et al., Fibrosis: Methods and Protocols, Methods in Molecular Biology, 2017, Vol. 1627, Chapter 1, pp. 1-21).
- ALK5 activin-like kinases
- Several small molecules have been developed to inhibit the activity of ALK5 for various therapeutic indications, related mostly to oncology (see Yingling, et al., Nature Reviews: Drug Discovery , December 2004, Vol. 3, pp. 1011-1022).
- ALK5 inhibitors One of the main problems with ALK5 inhibitors developed to date is that these molecules have been associated with ventricular or cardiac remodeling in preclinical safety studies resulting from significant systemic exposure from oral administration.
- the present disclosure provides these and other related advantages.
- One objective of the present disclosure is to deliver a potent ALK5 inhibitor locally with minimal systemic exposure in order to address any unintended and unwanted systemic side effects of ALK5 inhibition during treatment.
- the present disclosure provides inhaled, long-acting and lung-selective ALK5 inhibitors for the treatment of idiopathic pulmonary fibrosis.
- Compounds of the present disclosure may be used to treat other diseases, including, but not limited to, pulmonary fibrosis, liver fibrosis, renal glomerulosclerosis, and cancer.
- Compounds of the present disclosure may be used as a monotherapy or co-dosed with other therapies, whether delivered by inhalation, orally, intravenously, subcutaneously, or topically.
- the present disclosure provides a compound of Formula (I):
- the compound of Formula (I) may be a compound of Formula (I-A):
- A may be selected from C 6-10 aryl and 5- to 10-membered heteroaryl. In some embodiments, A is selected from phenyl and 5- to 6-membered heteroaryl. In some embodiments, A is selected from phenyl, indanyl, thiazolyl, thiophenyl, pyrazolyl, pyridyl, pyrimidinyl, indazolyl, benzotriazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxanyl, and tetrahydrobenzazepinyl, such as A is phenyl. In some embodiments, A is thiazolyl. In some embodiments, A is thiophenyl. In some embodiments, A is pyridyl.
- the compound of Formula (I) may be a compound of Formula (I-B):
- the compound of Formula (I) may be a compound of Formula (I-C):
- R A may independently be selected at each occurrence from:
- R A is independently selected at each occurrence from:
- R A may independently be selected at each occurrence from:
- R A may independently be selected at each occurrence from:
- R A may be —N(R 1 ) 2 .
- R A is —NR 1 C(O)R 1 .
- R A is C 1-6 alkyl substituted with 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is substituted with —C(O)OR 1 .
- R A is —N(R 1 )—C 1 _6 alkyl substituted with 4- to 8-membered heterocycle.
- R A is 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is optionally substituted with one or more substituents selected from —C(O)OR 1 and R 1 .
- R 1 may independently be selected at each occurrence from hydrogen; and C 1-6 alkyl, 1- to 6-membered heteroalkyl, C 0-3 alkyl-(C 3-s carbocycle), and C 0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —CH 2 CH 2 N(CH 3 ) 2 , —C(O)CH 3 , —C(O)OH, —C(O)NH 2 , ⁇ O, —OH, —CH 2 OH, —CH 2 CH 2 OH, —OCH 3 , —OCH 2 CH 3 , —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , C 3
- R 1 is independently selected at each occurrence from hydrogen; and C 1-6 alkyl and C 0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —OH, —CH 2 OH, —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , and 3- to 6-membered heterocycle.
- m may be 1 or 2, such as m is 1.
- B may be selected from C 6-10 aryl and 5- to 10-membered heteroaryl.
- B is selected from phenyl and pyridyl.
- B is pyridyl, such as 2-pyridyl.
- R B may independently be selected at each occurrence from halogen, —NH 2 , —NHCH 3 , —NHCH 2 CH 3 , —C(O)CH 3 , —OH, —OCH 3 , —OCH 2 CH 3 , —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 F, —CHF 2 , and —CF 3 .
- R B is independently selected at each occurrence from halogen, —OH, —CH 3 , and —CHF 2 , such as —CH 3 .
- n may be 1 or 2, such as n is 1.
- the compound of Formula (I) may be a compound of Formula (I-D):
- the compound of Formula (I) may be a compound of Formula (I-E):
- the present disclosure provides a substantially pure stereoisomer of a compound disclosed herein.
- the stereoisomer may be provided in at least 90% enantiomeric excess.
- the present disclosure provides a compound selected from Table 1. In some embodiments, the present disclosure provides a compound selected from Table 2.
- the present disclosure provides a conjugate of the formula:
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable carrier.
- the pharmaceutical composition may be formulated for inhalation.
- the present disclosure provides a method of inhibiting ALK5, comprising contacting ALK5 with an effective amount of a compound disclosed herein.
- the present disclosure provides a method of treating an ALK5-mediated disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein.
- the disease or condition may be selected from fibrosis, alopecia and cancer.
- the disease or condition is fibrosis.
- the present disclosure provides a method of treating fibrosis, comprising administering to a patient a therapeutically effective amount of a compound disclosed herein.
- the fibrosis may be selected from systemic sclerosis, nephrogenic systemic fibrosis, organ-specific fibrosis, fibrosis associated with cancer, cystic fibrosis, and fibrosis associated with an autoimmune disease.
- the organ-specific fibrosis is selected from cardiac fibrosis, kidney fibrosis, pulmonary fibrosis, liver fibrosis, portal vein fibrosis, skin fibrosis, bladder fibrosis, intestinal fibrosis, peritoneal fibrosis, myelofibrosis, oral submucous fibrosis, and retinal fibrosis.
- the organ-specific fibrosis is intestinal fibrosis.
- the pulmonary fibrosis is selected from idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), interstitial lung fibrosis, fibrosis associated with asthma, fibrosis associated with chronic obstructive pulmonary disease (COPD), silica-induced fibrosis, asbestos-induced fibrosis and chemotherapy-induced lung fibrosis.
- the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).
- the pulmonary fibrosis was induced by a viral infection.
- the disease or condition may be cancer, optionally wherein the cancer is selected from breast cancer, colon cancer, prostate cancer, lung cancer, hepatocellular carcinoma, glioblastoma, melanoma, and pancreatic cancer.
- the cancer is lung cancer, optionally non-small cell lung cancer.
- a method of the subject disclosure may further comprise administering a second therapeutic agent.
- the second therapeutic agent is an immunotherapeutic agent, such as a PD-1 inhibitor or a CTLA-4 inhibitor.
- the immunotherapeutic agent is selected from pembrolizumab and durvalumab.
- a method of the present disclosure may further comprise administering an effective amount of radiation.
- the compound or salt disclosed herein may be administered by inhalation.
- the present disclosure provides a compound disclosed herein for use in treating fibrosis. In certain aspects, the present disclosure provides the use of a compound disclosed herein for the manufacture of a medicament for treating fibrosis.
- C x-y or “C x -C y ” when used in conjunction with a chemical moiety, such as alkyl, alkenyl, or alkynyl, is meant to include groups that contain from x to y carbons in the chain.
- C x-y alkyl refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups, that contain from x to y carbons in the chain.
- Alkyl refers to substituted or unsubstituted saturated hydrocarbon groups, including linear and branched alkyl groups.
- An alkyl group may contain from one to twelve carbon atoms (e.g., C 1-12 alkyl), such as one to eight carbon atoms (C 1-8 alkyl) or one to six carbon atoms (C 1-6 alkyl).
- alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, septyl, octyl, nonyl, and decyl.
- An alkyl group is attached to the rest of the molecule by a single bond. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted by one or more substituents such as those substituents described herein.
- Haloalkyl refers to an alkyl group that is substituted by one or more halogens.
- exemplary haloalkyl groups include trifluoromethyl, difluoromethyl, trichloro methyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, and 1,2-dibromoethyl.
- Alkenyl refers to substituted or unsubstituted hydrocarbon groups, including linear and branched alkenyl groups, containing at least one double bond.
- An alkenyl group may contain from two to twelve carbon atoms (e.g., C 2-12 alkenyl), such as two to eight carbon atoms (C 2-8 alkenyl) or two to six carbon atoms (C 2-6 alkenyl).
- Exemplary alkenyl groups include ethenyl (i.e., vinyl), prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted by one or more substituents such as those substituents described herein.
- Alkynyl refers to substituted or unsubstituted hydrocarbon groups, including linear and branched alkynyl groups, containing at least one triple bond.
- An alkynyl group may contain from two to twelve carbon atoms (e.g., C 2-12 alkynyl), such as two to eight carbon atoms (C 2-8 alkynyl) or two to six carbon atoms (C 2-6 alkynyl).
- Exemplary alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted by one or more substituents such as those substituents described herein.
- Alkylene or “alkylene chain” refers to substituted or unsubstituted divalent saturated hydrocarbon groups, including linear alkylene and branched alkylene groups, that contain from one to twelve carbon atoms (e.g., C 1-12 alkylene), such as one to eight carbon atoms (C 1-8 alkylene) or one to six carbon atoms (C 1-6 alkylene).
- Exemplary alkylene groups include methylene, ethylene, propylene, and n-butylene.
- alkenylene and alkynylene refer to alkylene groups, as defined above, which comprise one or more carbon-carbon double or triple bonds, respectively.
- alkylene, alkenylene or alkynylene chain can be through one carbon or any two carbons of the chain.
- an alkylene, alkenylene, or alkynylene group is optionally substituted by one or more substituents such as those substituents described herein.
- Heteroalkyl refers to substituted or unsubstituted alkyl, alkenyl and alkynyl groups, respectively, in which one or more, such as 1, 2 or 3, of the carbon atoms are replaced with a heteroatom, such as O, N, P, Si, S, or combinations thereof. Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may optionally be oxidized, and any nitrogen heteroatoms may optionally be quaternized. If given, a numerical range refers to the chain length in total. For example, a 3- to 8-membered heteroalkyl group has a chain length of 3 to 8 atoms.
- Connection to the rest of the molecule may be through either a heteroatom or a carbon in the heteroalkyl, heteroalkenyl or heteroalkynyl chain.
- a heteroalkyl, heteroalkenyl, or heteroalkynyl group is optionally substituted by one or more substituents such as those substituents described herein.
- Heteroalkylene refers to substituted or unsubstituted alkylene, alkenylene and alkynylene groups, respectively, in which one or more, such as 1, 2 or 3, of the carbon atoms are replaced with a heteroatom, such as O, N, P, Si, S, or combinations thereof. Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may optionally be oxidized, and any nitrogen heteroatoms may optionally be quaternized. If given, a numerical range refers to the chain length in total. For example, a 3- to 8-membered heteroalkylene group has a chain length of 3 to 8 atoms.
- the points of attachment of the heteroalkylene, heteroalkenylene or heteroalkynylene chain to the rest of the molecule can be through either one heteroatom or one carbon, or any two heteroatoms, any two carbons, or any one heteroatom and any one carbon in the heteroalkylene, heteroalkenylene or heteroalkynylene chain.
- a heteroalkylene, heteroalkenylene, or heteroalkynylene group is optionally substituted by one or more substituents such as those substituents described herein.
- Carbocycle refers to a saturated, unsaturated or aromatic ring in which each atom of the ring is a carbon atom.
- Carbocycle may include C 3-10 monocyclic rings, C 6-12 bicyclic rings, C 6-12 spirocyclic rings, and C 6-12 bridged rings.
- Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated, and aromatic rings.
- the carbocycle is a C 6-12 aryl group, such as C 6-10 aryl.
- the carbocycle is a C 6-12 cycloalkyl group.
- the carbocycle is a C 6-12 cycloalkenyl group.
- an aromatic ring e.g., phenyl
- a saturated or unsaturated ring e.g., cyclohexane, cyclopentane, or cyclohexene.
- Any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits, are included in the definition of carbocycle.
- Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, and naphthyl.
- a carbocycle is optionally substituted by one or more substituents such as those substituents described herein.
- Heterocycle refers to a saturated, unsaturated or aromatic ring comprising one or more heteroatoms, for example 1, 2 or 3 heteroatoms selected from O, S and N. Heterocycles include 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, 6- to 12-membered spirocyclic rings, and 6- to 12-membered bridged rings. Each ring of a bicyclic heterocycle may be selected from saturated, unsaturated, and aromatic rings. The heterocycle may be attached to the rest of the molecule through any atom of the heterocycle, valence permitting, such as a carbon or nitrogen atom of the heterocycle.
- the heterocycle is a 5- to 10-membered heteroaryl group, such as 5- or 6-membered heteroaryl.
- the heterocycle is a 3- to 12-membered heterocycloalkyl group.
- a heterocycle e.g., pyridyl
- heterocycles include pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiophenyl, oxazolyl, thiazolyl, morpholinyl, indazolyl, indolyl, and quinolinyl.
- a heterocycle is optionally substituted by one or more substituents such as those substituents described herein.
- Heteroaryl refers to a 5- to 12-membered aromatic ring that comprises at least one heteroatom, such as 1, 2 or 3 heteroatoms, selected from O, S and N.
- the heteroaryl ring may be selected from monocyclic or bicyclic-including fused, spirocyclic and bridged ring systems—wherein at least one of the rings in the ring system is aromatic.
- the heteroatom(s) in the heteroaryl may optionally be oxidized.
- One or more nitrogen atoms, if present, are optionally quaternized.
- the heteroaryl may be attached to the rest of the molecule through any atom of the heteroaryl, valence permitting, such as a carbon or nitrogen atom of the heteroaryl.
- heteroaryl groups include, but are not limited to, azepinyl, benzimidazolyl, benzisothiazolyl, benzisoxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, purinyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyridazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydroquinolinyl, thiadiazolyl, thiazolyl, and thienyl groups. Unless stated otherwise,
- a waved line “ ” drawn across a bond or a dashed bond ‘ ’ are used interchangeably herein to denote where a bond disconnection or attachment occurs.
- R a is attached to the para position of a fluorophenyl ring through a single bond. If R a is 2-pyridine as in
- R a may be depicted as
- substituted refers to moieties having substituents replacing a hydrogen on one or more carbons or heteroatoms of the structure. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds.
- the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
- the permissible substituents can be one or more and the same or different for appropriate organic compounds.
- heteroatoms such as nitrogen may have any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
- a compound disclosed herein such as a compound of Formula (I), is optionally substituted by one or more, such as 1, 2 or 3 substituents selected from:
- a compound disclosed herein such as a compound of Formula (I) is optionally substituted by one or more, such as 1, 2 or 3 substituents selected from: halogen, —NO 2 , —CN, —OR 1 , —SR 1 , —N(R 1 ) 2 , —NR 2 R 3 , —S( ⁇ O)R 1 , —S( ⁇ O) 2 R 1 , —S( ⁇ O) 2 N(R 1 ) 2 , —S( ⁇ O) 2 NR 2 R 3 , —NR 1 S( ⁇ O) 2 R 1 , —NR 1 S( ⁇ O) 2 N(R 1 ) 2 , —NR 1 S( ⁇ O) 2 NR 2 R 3 , —C(O)R 1 , —C(O)OR 1 , —OC(O)R 1 , —OC(O)OR 1 , —OC(O)N(R 1 ) 2 , —OC(O)
- a compound disclosed herein such as a compound of Formula (I) is optionally substituted by one or more, such as 1, 2 or 3 substituents selected from halogen, —CN, —NO 2 , —NH 2 , —NHCH 3 , —NHCH 2 CH 3 , ⁇ O, —OH, —OCH 3 , and —OCH 2 CH 3 ; and C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, 1- to 6-membered heteroalkyl, C 3-12 carbocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted by halogen, —CN, —NO 2 , —NH 2 , —NHCH 3 , —NHCH 2 CH 3 , ⁇ O, —OH, —OCH 3 , —OCH 2 CH 3 , —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(
- bivalent substituent groups are specified herein by their conventional chemical formulae, written from left to right, they are intended to encompass the isomer that would result from writing the structure from right to left, e.g., —CH 2 O— is also intended to encompass to —OCH 2 —.
- Compounds of the present disclosure also include crystalline and amorphous forms of those compounds, pharmaceutically acceptable salts, and active metabolites having the same type of activity, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrates), conformational polymorphs, amorphous forms of the compounds, and mixtures thereof.
- the compounds described herein may exhibit their natural isotopic abundance, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
- hydrogen has three naturally occurring isotopes, denoted 1 H (protium), 2 H (deuterium), and 3 H (tritium). Protium is the most abundant isotope of hydrogen in nature.
- Enriching for deuterium may afford certain therapeutic advantages, such as increased in vivo half-life and/or exposure, or may provide a compound useful for investigating in vivo routes of drug elimination and metabolism.
- isotopes that may be incorporated into compounds of the present disclosure include, but are not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 35 S, 36 Cl, and 18 F.
- compounds of Formula (I) enriched in tritium or carbon-14 which can be used, for example, in tissue distribution studies; compounds of the disclosure enriched in deuterium especially at a site of metabolism, resulting, for example, in compounds having greater metabolic stability; and compounds of Formula (I) enriched in a positron emitting isotope, such as 11 C, 18 F, 15 O and 13 N, which can be used, for example, in Positron Emission Topography (PET) studies.
- Isotopically-enriched compounds may be prepared by conventional techniques well known to those skilled in the art.
- the phrase “of the formula” or “having the formula” or “having the structure” is not intended to be limiting and is used in the same way that the term “comprising” is commonly used. For example, if one structure is depicted, it is understood that all stereoisomer and tautomer forms are encompassed, unless stated otherwise.
- Certain compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms, the asymmetric centers of which can be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
- the carbon atoms in order to optimize the therapeutic activity of the compounds of the disclosure, e.g., to treat fibrosis, it may be desirable that the carbon atoms have a particular configuration (e.g., (R,R), (S,S), (S,R), or (R,S)) or are enriched in a stereoisomeric form having such configuration.
- the compounds of the disclosure may be provided as racemic mixtures.
- the disclosure relates to racemic mixtures, pure stereoisomers (e.g., enantiomers and diastereoisomers), stereoisomer-enriched mixtures, and the like, unless otherwise indicated.
- pure stereoisomers e.g., enantiomers and diastereoisomers
- stereoisomer-enriched mixtures and the like, unless otherwise indicated.
- a chemical structure is depicted herein without any stereochemistry, it is understood that all possible stereoisomers are encompassed by such structure.
- a particular stereoisomer is shown or named herein, it will be understood by those skilled in the art that minor amounts of other stereoisomers may be present in the compositions of the disclosure unless otherwise indicated, provided that the utility of the composition as a whole is not eliminated by the presence of such other isomers.
- stereoisomers may be obtained by numerous methods that are known in the art, including preparation using chiral synthons or chiral reagents, resolution using chiral chromatography using a suitable chiral stationary phase or support, or by chemically converting them into diastereoisomers, separating the diastereoisomers by conventional means such as chromatography or recrystallization, then regenerating the original stereoisomer.
- tautomer refers to each of two or more isomers of a compound that exist in equilibrium and which ready interconvert.
- 1,2,3-triazole exists in two tautomeric forms:
- pharmaceutically acceptable refers to a material that is not biologically or otherwise unacceptable when used in the subject compositions and methods.
- pharmaceutically acceptable carrier refers to a material—such as an adjuvant, excipient, glidant, sweetening agent, diluent, preservative, dye, colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent or emulsifier—that can be incorporated into a composition and administered to a patient without causing unacceptable biological effects or interacting in an unacceptable manner with other components of the composition.
- Such pharmaceutically acceptable materials typically have met the required standards of toxicological and manufacturing testing, and include those materials identified as suitable inactive ingredients by the U.S. Food and Drug Administration.
- salts and “pharmaceutically acceptable salt” refer to a salt prepared from a base or an acid.
- Pharmaceutically acceptable salts are suitable for administration to a patient, such as a mammal (for example, salts having acceptable mammalian safety for a given dosage regime). Salts can be formed from inorganic bases, organic bases, inorganic acids and organic acids.
- a compound contains both a basic moiety, such as an amine, pyridine or imidazole, and an acidic moiety, such as a carboxylic acid or tetrazole, zwitterions may be formed and are included within the term “salt” as used herein.
- Salts derived from inorganic bases include ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, and zinc salts, and the like.
- Salts derived from organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, tri
- Salts derived from inorganic acids include salts of boric, carbonic, hydrohalic (hydrobromic, hydrochloric, hydrofluoric or hydroiodic), nitric, phosphoric, sulfamic and sulfuric acids.
- Salts derived from organic acids include salts of aliphatic hydroxyl acids (for example, citric, gluconic, glycolic, lactic, lactobionic, malic, and tartaric acids), aliphatic monocarboxylic acids (for example, acetic, butyric, formic, propionic and trifluoroacetic acids), amino acids (for example, aspartic and glutamic acids), aromatic carboxylic acids (for example, benzoic, p-chlorobenzoic, diphenylacetic, gentisic, hippuric, and triphenylacetic acids), aromatic hydroxyl acids (for example, o-hydroxybenzoic, p-hydroxybenzoic, 1-hydroxynaphthalene-2-carboxylic and 3-
- a therapeutically effective amount for treating pulmonary fibrosis refers to that amount of a compound described herein that is sufficient to affect treatment when administered to a subject in need thereof.
- a therapeutically effective amount for treating pulmonary fibrosis is an amount of compound needed to, for example, reduce, suppress, eliminate, or prevent the formation of fibrosis in a subject, or to treat the underlying cause of pulmonary fibrosis.
- the therapeutically effective amount may vary depending upon the intended treatment application (in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- the specific dose will vary depending on the particular compound chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
- the term “effective amount” refers to an amount sufficient to obtain a desired result, which may not necessarily be a therapeutic result.
- an “effective amount” may be the amount needed to inhibit an enzyme.
- treating refers to an approach for obtaining beneficial or desired results with respect to a disease, disorder, or medical condition (such as pulmonary fibrosis) in a subject, including but not limited to the following: (a) preventing the disease or medical condition from occurring, e.g., preventing the reoccurrence of the disease or medical condition or prophylactic treatment of a subject that is pre-disposed to the disease or medical condition; (b) ameliorating the disease or medical condition, e.g., eliminating or causing regression of the disease or medical condition in a subject; (c) suppressing the disease or medical condition, e.g., slowing or arresting the development of the disease or medical condition in a subject; or (d) alleviating symptoms of the disease or medical condition in a subject.
- “treating pulmonary fibrosis” would include preventing fibrosis from occurring, ameliorating fibrosis, suppressing fibrosis, and alleviating the symptoms of fibrosis (for example, increasing oxygen levels in blood or improved lung function tests). Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder
- a prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
- antagonists are used interchangeably, and they refer to a compound having the ability to inhibit a biological function (e.g., activity, expression, binding, protein-protein interaction) of a target protein (e.g., ALK5). Accordingly, the terms “antagonist” and “inhibitor” are defined in the context of the biological role of the target protein. While preferred antagonists herein specifically interact with (e.g., bind to) the target, compounds that inhibit a biological activity of the target protein by interacting with other members of the signal transduction pathway of which the target protein is a member are also specifically included within this definition.
- selective inhibition refers to the ability of a biologically active agent to preferentially reduce the target signaling activity as compared to off-target signaling activity, via direct or indirect interaction with the target.
- an antibody refers to an immunoglobulin molecule that specifically binds to, or is immunologically reactive toward, a specific antigen.
- An antibody may be, for example, polyclonal, monoclonal, genetically engineered, or an antigen binding fragment thereof, and further may be, for example, murine, chimeric, humanized, heteroconjugate, bispecific, a diabody, a triabody, or a tetrabody.
- An antigen binding fragment includes an antigen binding domain and may be in the form of, for example, a Fab′, F(ab′) 2 , Fab, Fv, rIgG, scFv, hcAbs (heavy chain antibodies), a single domain antibody, V HH , V NAR , sdAb, or nanobody.
- antigen binding domain refers to a region of a molecule that binds to an antigen.
- An antigen binding domain may be an antigen-binding portion of an antibody or an antibody fragment.
- An antigen binding domain may be one or more fragments of an antibody that retain the ability to specifically bind to an antigen.
- An antigen binding domain can be an antigen binding fragment and may recognize a single antigen, two antigens, three antigens or more.
- “recognize” with regard to antibody interactions refers to the association or binding between an antigen binding domain of an antibody or portion thereof and an antigen.
- an “antibody construct” refers to a molecule, e.g., a protein, peptide, antibody or portion thereof, that contains an antigen binding domain and an Fc domain (e.g., an Fc domain from within the Fc region).
- An antibody construct may recognize, for example, one antigen or multiple antigens.
- a “targeting moiety” refers to a structure that has a selective affinity for a target molecule relative to other non-target molecules.
- the targeting moiety binds to a target molecule.
- a targeting moiety may include an antibody, a peptide, a ligand, a receptor, or a binding portion thereof.
- the target biological molecule may be a biological receptor or other structure of a cell, such as a tumor antigen.
- subject and “patient” refer to an animal, such as a mammal, for example a human.
- the methods described herein can be useful in both human therapeutics and veterinary applications.
- the subject is a mammal, and in some embodiments, the subject is human.
- “Mammal” includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
- Prodrug is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound described herein (e.g., compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E)).
- a prodrug refers to a precursor of a biologically active compound that is pharmaceutically acceptable.
- a prodrug is inactive when administered to a subject but is converted in vivo to an active compound, for example, by hydrolysis.
- the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam); Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” (1987) A.C.S. Symposium Series, Vol. 14; and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press) each of which is incorporated in full by reference herein.
- prodrug is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject.
- Prodrugs of an active compound, as described herein are typically prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound.
- Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
- Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of a hydroxy functional group, or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound, and the like.
- in vivo refers to an event that takes place in a subject's body.
- in vitro refers to an event that takes places outside of a subject's body.
- an in vitro assay encompasses any assay run outside of a subject.
- in vitro assays encompass cell-based assays in which cells alive or dead are employed.
- In vitro assays also encompass a cell-free assay in which no intact cells are employed.
- the disclosure is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the disclosure includes compounds produced by a process comprising administering a compound of this disclosure to a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically identified by administering a radiolabeled compound of the disclosure in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to a human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
- an animal such as rat, mouse, guinea pig, monkey, or to a human
- Lung function tests include tests to check how well the lungs work. Spirometry, for example, measures the amount of air the lungs can hold as well as how forcefully one can empty air from the lungs.
- Forced expiratory volume is a measure of the amount of air a person can exhale during a forced breath. FEV1, for example, is the amount of air a person can force from their lungs in one second.
- Forced vital capacity is the total amount of air exhaled during an FEV test.
- the ratio of FEV1/FVC also known as Index of Air Flow or Tiffeneau-Pinelli Index, is a measurement used to assess the health of a patient's lung function.
- a ratio of ⁇ 80% indicates an obstructive defect is present in the lungs, such as chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- a ratio of >80% indicates a restrictive defect is present in the lungs, such as pulmonary fibrosis.
- the ratio of >80% in restrictive lung disease results from both FEV1 and FVC being reduced but that the decline in FVC is more than that of FEV1, resulting in a higher than 80% value.
- transforming growth factor- ⁇ may also be referred to as TGF- ⁇ , transforming growth factor beta-1, or TGF-beta-1. It is also cleaved into latency-associated peptide (LAP).
- LAP latency-associated peptide
- TGF- ⁇ receptor II may also be referred to as T ⁇ RII, type II TGF- ⁇ receptor, TGF- ⁇ RII, TGF-beta receptor type-2, TGFR-2, TGF-beta type II receptor, transforming growth factor-beta receptor type II, TGF-beta receptor type II or TbetaR-II.
- TGF- ⁇ receptor I may also be referred to as T ⁇ RI, type I TGF- ⁇ receptor, TGF- ⁇ RI, TGF-beta receptor type-1, TGFR-1, activin A receptor type II-like protein kinase of 53 kD, activin receptor-like kinase 5, ALK-5, ALK5, serine/threonine-protein kinase receptor R4, SKR4, TGF-beta type I receptor, transforming growth factor-beta receptor type I, TGF-beta receptor type I, transforming growth factor beta receptor I, TGF-beta receptor 1, or TbetaR-I.
- the present disclosure provides compounds that are capable of selectively binding to and/or modulating ALK5.
- the compounds modulate ALK5 by binding to or interacting with one or more amino acids and/or one or more metal ions. The binding of these compounds may disrupt ALK5 downstream signaling.
- the present disclosure provides a compound of Formula (I′):
- R B , R C , R D and R E are each independently selected at each occurrence from halogen, —CN, —NH 2 , —NHCH 3 , —NHCH 2 CH 3 , —C(O)CH 3 , —OH, —OCH 3 , —OCH 2 CH 3 , —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 F, —CHF 2 , —CF 3 , C 3-4 carbocycle, and 3- to 4-membered heterocycle; or two R C groups or two R E groups can together optionally form a bridge or ring;
- p is 0 or 1, such as p is 0.
- R C is selected from halogen, —NH 2 and —CH 3 .
- X 1 is selected from CH and N, such as X 1 is N.
- X 2 is selected from CH, CR E , N and S, such as X 2 is N.
- X 2 is selected from CH and CR E , wherein R E is selected from —CN, —OCH 3 and —CH 3 .
- X 3 is selected from CH and CR E , such as X 3 is CH.
- X 3 is CR E , wherein R E is —OCH 3 .
- X 4 is selected from bond, CH, CR E and N, such as X 4 is CH. In some embodiments, X 4 is N. In some embodiments, X 3 and X 4 are each independently CR E , wherein the two R E groups form a ring, such as a 5- or 6-membered aryl or heteroaryl ring. Non-limiting examples wherein X 3 and X 4 are each independently CR E , wherein the two R E groups form a ring include:
- X 4 is a bond
- Non-limiting examples wherein X 4 is a bond include:
- the compound of Formula (I′) is a compound of Formula (I′-A), (I′-B), (I′-C), (I′-D) or (I′-E):
- the present disclosure provides a compound of Formula (I):
- the compound of Formula (I) is a compound of Formula (I-A), (I-B), (I-C), (I-D) or (I-E):
- A is selected from C 6-10 aryl and 5- to 10-membered heteroaryl. In some embodiments, A is selected from phenyl and 5- to 6-membered heteroaryl, such as A is phenyl.
- A is selected from phenyl, indanyl, thiazolyl, thiophenyl, pyrazolyl, pyridyl, pyrimidinyl, indazolyl, benzotriazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxanyl, and tetrahydrobenzazepinyl.
- A is selected from phenyl, pyridinyl, thiazolyl and thiophenyl.
- A is phenyl.
- A is pyridinyl.
- A is thiazolyl.
- A is thiophenyl.
- the compound of Formula (I) is a compound of the formula:
- m is 1 or 2. In some embodiments, m is 1. In some embodiments, A is C 6 aryl or 6-membered heteroaryl, m is 1 and R A is in the meta- or para-position.
- R A is independently selected at each occurrence from:
- R A is independently selected at each occurrence from:
- R A is independently selected at each occurrence from:
- R A is independently selected at each occurrence from:
- a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E) comprises a terminal ester of the formula —C(O)OR 15 or —OC(O)R 15 , wherein R 15 comprises 1 to 12 carbon atoms and at least one basic amine. In some embodiments, the molecular weight of R 15 is between 30 and 200 g/mol.
- the terminal ester may be metabolizable by one or more hydrolase (e.g., an esterase) present in human plasma and/or the human liver into a carboxylic acid and an alcohol.
- the biological activity of the compound may be greater than that of the carboxylic acid and the alcohol.
- the compound may exhibit a BEAS2B pIC 50 of at least 1 unit or greater than the carboxylic acid and the alcohol (assessed according to the assay provided in Example 46).
- R 15 is —(C 0-4 alkyl)(4- to 10-membered heterocycloalkyl), wherein the heterocycloalkyl comprises 1, 2 or 3 nitrogen atoms, and wherein the heterocycloalkyl is optionally substituted with one or more substituents selected from C 1-4 alkyl.
- R A is —N(R 1 ) 2 , such as
- R A is —NR 1 C(O)R 1 , such as
- R A is C 1-6 alkyl substituted with 4- to 8-membered heterocycle wherein the 4- to 8-membered heterocycle is substituted with —C(O)OR 1 , such as
- R A is —N(R 1 )—C 1-6 alkyl substituted with 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is optionally substituted, such as
- R A is 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is optionally substituted with one or more substituents selected from —C(O)OR 1 and R 1 , such as
- R A is —C(O)OR 1 , such as
- R A is selected from
- R A is selected from
- R A is selected from
- R A is selected from
- R 1 is independently selected at each occurrence from hydrogen; and C 1-6 alkyl, 1- to 6-membered heteroalkyl, C 0-3 alkyl-(C 3-8 carbocycle), and C 0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —CH 2 CH 2 N(CH 3 ) 2 , —C(O)CH 3 , —C(O)OH, —C(O)NH 2 , ⁇ O, —OH, —CH 2 OH, —CH 2 CH 2 OH, —OCH 3
- R 1 is independently selected at each occurrence from hydrogen; and C 1-6 alkyl and C 0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —OH, —CH 2 OH, —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , and 3- to 6-membered heterocycle.
- B is selected from C 6 10 aryl and 5- to 10-membered heteroaryl, such as B is selected from phenyl and pyridyl.
- B is pyridyl.
- B is 2-pyridyl.
- B—(R B ) n is 2-methylpyridyl.
- n is 1 or 2, such as n is 1.
- B is pyridyl
- n is 1 and R B is in the 2-position.
- R B is independently selected at each occurrence from halogen, —NH 2 , —NHCH 3 , —NHCH 2 CH 3 , —C(O)CH 3 , —OH, —OCH 3 , —OCH 2 CH 3 , —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 F, —CHF 2 , and —CF 3 .
- R B is independently selected at each occurrence from halogen, —OH, —CH 3 , and —CHF 2 .
- R B is —CH 3 .
- D and E are each independently selected from 4- to 6-membered heterocycle, each of which is independently optionally substituted with one or more —CH 3 . In some embodiments, D and E are each unsubstituted.
- A is selected from phenyl, pyridinyl, thiazolyl and thiophenyl. In some embodiments, A is phenyl. In some embodiments, A is pyridinyl. In some embodiments, A is thiazolyl. In some embodiments, A is thiophenyl.
- a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E) is provided as a substantially pure stereoisomer.
- the stereoisomer is provided in at least 80% enantiomeric excess, such as at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.9% enantiomeric excess.
- the present disclosure provides a soft ALK5 inhibitor.
- soft drug or “soft ALK5 inhibitor” refers to a biologically active compound that is converted upon entering the systemic circulation into a predictable metabolite that exhibits reduced biological activity relative to the parent compound.
- a soft drug preferably exerts its desired therapeutic effect locally at the target organ or tissue, then is rapidly converted to a predictable metabolite designed to be less active than the parent soft drug upon entering the systemic circulation, thus reducing systemic exposure to the biologically active compound.
- soft drugs have a lower potential for undesired side effects relative to non-soft drug compounds having comparable biological activity.
- a soft drug of the present disclosure exhibits good stability at the intended site of action (e.g., the lung), is rapidly metabolized upon entering systemic circulation, and displays more functional activity than the corresponding metabolite.
- a soft drug provided herein exhibits an ALK5 pK i of greater than or equal to 9, while the corresponding soft drug metabolite exhibits an ALK5 pK i of 9 or less, such as 8 or less (assessed according to the assay provided in Example 45).
- the difference in pK i of the soft drug and the corresponding soft drug metabolite is at least 0.5, such as at least 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or at least 2.0.
- a soft drug provided herein exhibits a BEAS2B pIC 50 of greater than or equal to 7, while the corresponding soft drug metabolite exhibits a BEAS2B pIC 50 of 6 or less (assessed according to the assay provided in Example 46).
- the difference in pIC 50 of the soft drug and the corresponding soft drug metabolite is at least 1.0, such as at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or at least 2.0.
- the soft drug and corresponding soft drug metabolite exhibit similar ALK5 pK i values, but the soft drug is more active in cells (e.g., the soft drug exhibits a BEAS2B pIC 50 of at least 1.0 greater than the soft drug metabolite).
- the present disclosure provides a soft ALK5 inhibitor comprising an ester.
- the ester inhibits ALK5 activity, while the corresponding carboxylic acid of the ester exhibits reduced ALK5 inhibitory activity.
- the difference in ALK5 pK i of the ester and corresponding acid may be at least 1.0.
- a soft drug ester of the present disclosure is administered to the lung, for example, by inhalation, and inhibits the activity of ALK5 in the lung. However, upon exiting the lung, the ester may be readily hydrolyzed to the corresponding carboxylic acid, thus reducing systemic exposure to the ester.
- the present disclosure provides a conjugate comprising a compound disclosed herein linked, e.g., covalently linked, either directly or through a linker to an antibody construct or targeting moiety, thereby forming a conjugate.
- the linker may be a non-cleavable linker or a cleavable linker.
- a conjugate may be represented by the formula:
- A′ is an antibody construct or targeting moiety
- L 1 is a linker
- D′ is a compound or salt disclosed herein, such as a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E);
- p is an integer from 1 to 20. In some embodiments, p is an integer from 1 to 10, such as from 1 to 8, 2 to 8, 1 to 6, 3 to 5, or from 1 to 3.
- a conjugate is represented by the formula:
- A′ is an antibody construct or targeting moiety
- D′ is a compound or salt disclosed herein, such as a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E); and
- p is an integer from 1 to 20. In some embodiments, p is an integer from 1 to 10, such as from 1 to 8, 2 to 8, 1 to 6, 3 to 5, or from 1 to 3.
- a compound or salt of the present disclosure such as a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), may be attached to A′ via a linker, L 1 , or directly attached to A′ without an intermediate linker.
- the compound or salt is covalently attached to an A′ or L 1 . It will be understood by the skilled person that not all compounds of the present disclosure are meant to be attached to L 1 or A′, only those that have suitable attachment sites. A compound or salt disclosed herein that does not have a suitable attachment site may be modified to introduce an attachment site.
- L 1 or D′ is bound to A′ via a terminus of an amino acid sequence or via a side chain of an amino acid, such as the side chain of lysine, serine, threonine, cysteine, tyrosine, aspartic acid, glutamine, a non-natural amino acid residue, or glutamic acid residue.
- L 1 or D′ is bound to A′ via one or more glycans or short peptide tags of four to six amino acids.
- L 1 or D′ may be conjugated to A′ via any suitable functional group, such as a thiol, an amine, an amide, an alcohol, a ketone, a carboxylic acid, or an ester.
- a linker may be attached to a compound or salt of the present disclosure at any available position.
- a compound of Formula (I) may comprise a linker L 1 to A′ in place of R A or through substituent R A :
- linker L 1 may be covalently bound to any suitably atom for attachment, such as a substitutable nitrogen, carbon, sulfur, phosphorous or oxygen of a compound.
- L 1 may be a cleavable or non-cleavable linker.
- the linker may further be bound to A′.
- L 1 does not affect the binding of the active portions of the conjugate to the binding target(s).
- Covalent linkages may be formed by reaction between a functional group on the linker with a functional group on the compound, and by reaction between a functional group on the linker with a functional group on A′.
- linker includes (i) unattached forms of the linker comprising a functional group capable of covalently attaching the linker to a compound disclosed herein and a functional group capable of covalently attaching the linker to an antibody construct or targeting moiety; (ii) partially attached forms of the linker bound to a compound disclosed herein, wherein the linker comprises a functional group capable of covalently attaching the linker to an antibody construct or targeting moiety; (iii) partially attached forms of the linker bound to an antibody construct or targeting moiety, wherein the linker comprises a functional group capable of covalently attaching the linker to a compound disclosed herein; and (iv) fully attached forms of the linker bound to both an antibody construct or targeting moiety and a compound disclosed herein.
- Linker L 1 may be short, flexible, rigid, cleavable (e.g., by a lysosomal enzyme), non-cleavable, hydrophilic, or hydrophobic.
- a linker may contain segments having different characteristics, such as flexible segments and rigid segments.
- a linker may be chemically stable to extracellular environments, for example, in the bloodstream, or may include moieties that are not stable or are selectively stable.
- a linker comprises a moiety that is selectively cleaved, for example, selectively cleaved in cells, a particular organ, or in plasma.
- a linker may be sensitive to enzymes, such as proteases.
- a linker may be insensitive to intracellular processes or proteases.
- a linker may be acid-labile, protease-sensitive or photolabile.
- a linker comprises a peptide, succinimide, maleimide, polyethylene glycol, alkylene, alkenylene, alkynylene, disulfide, hydrazone, polyether, polyester, polyamide, aminobenzyl-carbamate, or a combination thereof.
- the present disclosure provides a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), or a compound disclosed in Table 1 or Table 2, wherein the compound is covalently bound to A′, optionally via linker L 1 .
- the antibody construct is an antibody.
- the present disclosure provides a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), or a compound disclosed in Table 1 or Table 2, wherein the compound is covalently bound to a linker, L 1 , to form a compound-linker.
- A′ or L 1 may be covalently attached to any position of the compound, valence permitting.
- a linker L 1 disclosed herein may comprise from about 10 to about 500 atoms, such as 10 to 400 atoms, 10 to 300 atoms, 30 to 400 atoms, or 30 to 300 atoms.
- the targets of the antibody, antibody construct, or targeting moiety may depend on the desired therapeutic applications of the conjugate.
- the targets are molecules present on the surfaces of cells into which it is desirable to deliver an ALK5 inhibitor, such as T cells, and the antibodies preferably internalize upon binding to the target.
- an ALK5 inhibitor such as T cells
- the conjugates are intended to stimulate the immune system by reducing TGF- ⁇ activity, it may be desirable to generate antibodies, antibody constructs, or targeting moieties that bind to T cell surface molecules.
- the delivery of ALK5 inhibitors to T cells can activate CD4 + and/or CD8 + T cell activity and inhibit regulatory T cell activity, both of which contribute to immune tolerance of tumors.
- antibodies, antibody constructs, or targeting moieties (A′) that bind to T cell surface molecules in the conjugates of the present disclosure are useful for the treatment of various cancers, such as those described herein below.
- A′ binds to CD4 + T cells, CD8 + T cells, T REG cells, or any combination thereof.
- A′ binds to a pan T cell surface molecule, such as CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD25, CD28, CD70, CD71, CD103, CD184, Tim3, LAG3, CTLA4, or PD1.
- antibodies that bind to T cell surface molecules and are believed to be internalizing include OKT6, OKT11, OKT3, OKT4, OKT8, 7D4, OKT9, CD28.2, UCHT1, M290, FR70, pembrolizumab, nivolumab, cemiplimab, and dostarlimab.
- An antibody, antibody construct, or targeting moiety disclosed herein may comprise an antigen binding domain that specifically binds to a tumor antigen or antigen associated with the pathogenesis of fibrosis.
- the antigen binding domain specifically binds to an antigen on a T cell, a B cell, a stellate cell, an endothelial cell, a tumor cell, an APC, a fibroblast cell, a fibrocyte cell, or a cell associated with the pathogenesis of fibrosis.
- the antigen binding domain targets CTLA4, PD-1, OX40, LAG-3, GITR, GARP, CD25, CD27, PD-L1, TNFR2, ICOS, 41BB, CD70, CD73, CD38 or VTCN1.
- the antigen binding domain targets PDGFR ⁇ , integrin ⁇ v ⁇ 1, integrin ⁇ v ⁇ 3, integrin ⁇ v ⁇ 6, ⁇ v ⁇ 8, endosialin, FAP, ADAM12, LRRC15, MMP14, PDPN, CDH11, F2RL2, ASGR1, or ASGR2.
- reaction times and conditions are intended to be approximate, e.g. taking place at about atmospheric pressure within a temperature range of about ⁇ 10° C. to about 110° C. over a period of about 1 to about 24 hours; reactions left to run overnight average a period of about 16 hours.
- a compound of Formula 1i may be prepared according to Scheme 1.
- imidate 1b can be formed from nitrile 1a via a Pinner Reaction, then converted to amidine 1c in the presence of ammonium chloride.
- Cyclization with methyl 3-methoxyacrylate (1d) may proceed to give pyrimidinone 1e, which may be treated with phosphorus oxychloride to give chloropyrimidine 1f.
- Chloropyrimidine 1f can be subjected to a C—N coupling reaction—optionally a Pd-catalyzed coupling reaction such as a Buchwald-Hartwig amination—with 2-chloropyrimidin-4-amine (1g) to provide heteroaryl amine 1h.
- 1h may be subjected to one or more coupling reactions, and optionally one or more protecting group manipulations, to provide a compound of Formula 1i.
- a compound of Formula 2f may be prepared according to Scheme 2.
- nitro compound 2a can be reduced to amine 2b.
- the amine may then be subjected to a C—N coupling reaction-optionally a Pd-catalyzed coupling reaction such as a Buchwald-Hartwig amination—with bis(2-chloropyrimidin-4-yl)amine (2c) to provide heteroaryl amine 2d.
- a substitution reaction can provide heteroaryl iodide 2e, which may undergo a nucleophilic aromatic substitution reaction, and optionally one or more protecting group manipulations, to provide a compound of Formula 2f.
- a compound of the present disclosure for example, a compound of a formula given in Table 1 or 2, is synthesized according to one of the general routes outlined in Schemes 1 and 2, Examples 1-44, or by methods generally known in the art.
- exemplary compounds may include, but are not limited to, a compound or salt thereof selected from Table 1.
- exemplary compounds may include, but are not limited to, a compound or salt thereof selected from Table 2.
- the present disclosure provides a method of inhibiting TGF ⁇ signaling, comprising contacting a cell with an effective amount of a compound disclosed herein, such as a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E).
- a compound disclosed herein such as a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E).
- the present disclosure provides a method of inhibiting ALK5, comprising contacting ALK5 with an effective amount of a compound disclosed herein. Inhibition of ALK5 or TGF ⁇ signaling can be assessed by a variety of methods known in the art.
- Non-limiting examples include a showing of (a) a decrease in kinase activity of ALK5; (b) a decrease in binding affinity between the TGF ⁇ /TGF ⁇ -RII complex and ALK5; (c) a decrease in the levels of phosphorylated intracellular signaling molecules downstream in the TGF ⁇ signaling pathway, such as a decrease in pSMAD2 or pSMAD3 levels; (d) a decrease in binding of ALK5 to downstream signaling molecules, such as SMAD2 and SMAD3; and/or (e) an increase in ATP levels or a decrease in ADP levels. Kits and commercially available assays can be utilized for determining one or more of the above.
- the present disclosure provides a method of treating an ALK5-mediated disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein.
- the disease or condition is selected from fibrosis and cancer.
- the disease or condition is pulmonary fibrosis, such as idiopathic pulmonary fibrosis or virus-induced fibrosis.
- the disease or condition is intestinal fibrosis.
- the disease or condition is alopecia.
- the disease is a neurodegenerative disease, such as Alzheimer's disease.
- the present disclosure provides a method of reversing symptoms of aging. For example, the method may enhance neurogenesis, reduce neuroinflammation, improve cognitive performance, regenerate liver tissue, and reduce p16 levels.
- the present disclosure provides a method of treating fibrosis, comprising administering to a patient an effective amount of a compound disclosed herein.
- the fibrosis is mediated by ALK5.
- the fibrosis is selected from systemic sclerosis, systemic fibrosis, organ-specific fibrosis, kidney fibrosis, pulmonary fibrosis, liver fibrosis, portal vein fibrosis, skin fibrosis, bladder fibrosis, intestinal fibrosis, peritoneal fibrosis, myelofibrosis, oral submucous fibrosis, and retinal fibrosis.
- the fibrosis is pulmonary fibrosis, such as idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), interstitial lung fibrosis, fibrosis associated with asthma, fibrosis associated with chronic obstructive pulmonary disease (COPD), silica-induced fibrosis, asbestos-induced fibrosis or chemotherapy-induced lung fibrosis.
- the fibrosis is idiopathic pulmonary fibrosis (IPF).
- the fibrosis is TGF- ⁇ -mediated pulmonary fibrosis.
- the patient has been diagnosed with acute respiratory distress syndrome (ARDS).
- ARDS acute respiratory distress syndrome
- the fibrosis is acute fibrosis.
- the fibrosis is chronic fibrosis.
- the present disclosure provides a method of treating pulmonary fibrosis induced by a viral infection, comprising administering to a patient an effective amount of a compound disclosed herein.
- the pulmonary fibrosis may be induced by an erythrovirus, a dependovirus, a papillomavirus, a polyomavirus, a mastadenovirus, an alphaherpesvirinae, a varicellovirus, a gammaherpesvirinae, a betaherpesvirinae, a roseolovirus, an orthopoxvirus, a parapoxvirus, a molluscipoxvirus, an orthohepadnavirus, an enterovirus, a rhinovirus, a hepatovirus, an aphthovirus, a calicivirus, an astrovirus, an alphavirus, a rubivirus, a flavivirus, a Hepatitis C virus, a reovirus, an orb
- the fibrosis is virus-induced fibrosis, such as virus-induced pulmonary fibrosis. In some embodiments, the fibrosis is selected from EBV-induced pulmonary fibrosis, CMV-induced pulmonary fibrosis, herpesvirus-induced pulmonary fibrosis and coronavirus-induced pulmonary fibrosis.
- the fibrosis is selected from EBV-induced pulmonary fibrosis, CMV-induced pulmonary fibrosis, HHV-6-induced pulmonary fibrosis, HHV-7-induced pulmonary fibrosis, HHV-8-induced pulmonary fibrosis, H5N1 virus-induced pulmonary fibrosis, SARS-CoV-induced pulmonary fibrosis, MERS-CoV-induced pulmonary fibrosis and SARS-CoV-2-induced pulmonary fibrosis.
- the pulmonary fibrosis is coronavirus-induced pulmonary fibrosis.
- the pulmonary fibrosis is SARS-CoV-2-induced pulmonary fibrosis.
- the pulmonary fibrosis is COVID-19-induced pulmonary fibrosis.
- the present disclosure provides a method of treating acute lung injury (ALI), comprising administering to a patient an effective amount of a compound disclosed herein.
- the present disclosure provides a method of treating acute respiratory distress syndrome (ARDS), comprising administering to a patient an effective amount of a compound disclosed herein.
- the ARDS may be in the early acute injury phase or the fibroproliferative phase.
- the ARDS is fibroproliferative ARDS.
- the present disclosure provides a method of treating fibrosis resulting from ARDS, comprising administering to a patient an effective amount of a compound disclosed herein.
- the fibrosis resulting from ARDS may be pulmonary fibrosis.
- the present disclosure provides a method of treating fibrosis resulting from ALI, comprising administering to a patient an effective amount of a compound disclosed herein.
- the fibrosis resulting from ALI may be pulmonary fibrosis.
- the present disclosure provides a method of treating intestinal fibrosis, comprising administering to a patient an effective amount of a compound disclosed herein.
- the intestinal fibrosis is mediated by ALK5.
- the compound is administered in an amount effective to delay progression of, reduce the incidence of, or reduce the degree of one or more characteristics associated with intestinal fibrosis.
- the compound is administered, either in a single dose or over multiple doses, in an amount effective to reverse established fibrosis.
- the present disclosure provides a method of treating cancer, comprising administering to a patient an effective amount of a compound disclosed herein.
- the cancer is mediated by ALK5.
- the cancer is selected from breast cancer, colon cancer, prostate cancer, lung cancer, hepatocellular carcinoma, glioblastoma, melanoma and pancreatic cancer.
- the cancer is lung cancer, such as non-small cell lung cancer.
- the present disclosure provides a method of treating cancer, such as non-small cell lung cancer, comprising administering to a patient an effective amount of a compound disclosed herein and an immunotherapeutic agent.
- the cancer is stage III non-small cell lung cancer.
- the method further comprises administering radiation to the patient.
- the immunotherapeutic agent is a PD-1 inhibitor or a CTLA-4 inhibitor.
- the immunotherapeutic agent is selected from atezolizumab, avelumab, nivolumab, pembrolizumab, durvalumab, BGB-A317, tremelimumab and ipilimumab.
- the immunotherapeutic agent is selected from pembrolizumab and durvalumab.
- the compounds described herein including compounds of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), are ALK5 inhibitors that limit the activity of TGF ⁇ .
- TGF ⁇ is one of several factors involved in the initiation and development of fibrotic diseases throughout the body.
- the compounds of the disclosure are expected to be useful for the treatment, prevention and/or reduction of fibrosis in a patient by administering a therapeutically effective amount of a compound disclosed herein.
- ALK5 By inhibiting ALK5, the compound is expected to potentiate the formation of fibrosis in areas of the body that suffer from excessive deposition of the extracellular matrix. Those areas are described below.
- SSc Systemic sclerosis
- TGF- ⁇ Transforming growth factor ⁇
- the present disclosure provides a method of treating SSc, comprising administering to a subject an effective amount of a compound disclosed herein.
- Multifocal fibrosclerosis (MF) and idiopathic multifocal fibrosclerosis (IMF) are disorders characterized by fibrous lesions at varying sites and include retroperitoneal fibrosis, mediastinal fibrosis and Riedel's thyroiditis. Both multifocal fibrosclerosis and idiopathic multifocal fibrosclerosis are considered to be an outcome of IgG 4 -associated fibrosis/disease and TGF- ⁇ is believed to be one factor involved in the initiation and development of fibrosis (Pardali, E., et. al., Int. J. Mol. Sci., 18, 2157, pp. 1-22).
- the present disclosure provides a method of treating multifocal fibrosclerosis or idiopathic multifocal fibrosclerosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- the present disclosure provides a method of treating nephrogenic systemic fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- Nephrogenic systemic fibrosis is a rare disease occurring mainly in people with advanced kidney failure with or without dialysis.
- Kelly et al. J. Am. Acad. Dermatol., 2008, 58, 6, pp. 1025-1030
- TGF- ⁇ as well as Smad 2/3, appear to be associated with fibrosis seen in nephrogenic systemic fibrosis.
- Sclerodermatous graft-versus-host disease is a prevalent complication of allogeneic hematopoietic stem cell graft appearing two to three months after allogeneic bone marrow transplantation. The disease results in production of autoantibodies and fibrosis of skin and inner organs.
- TGF- ⁇ neutralizing antibodies McCormick, L. L., et al., J. Immunol., 1999, 163, pp. 5693-5699.
- the present disclosure provides a method of treating sclerodermatous GVHD, comprising administering to a subject an effective amount of a compound disclosed herein.
- Cardiac fibrosis refers to the abnormal thickening of heart valves due to the abnormal proliferation of cardiac fibroblasts resulting in excess deposition of ECM in heart muscle. Fibroblasts secrete collagen, which serves as structural support for the heart. However, when collagen is excessively secreted in the heart, wall and valve thickening can result in tissue build-up on the tricuspid and pulmonary valves. This in turn causes loss of flexibility and ultimately valvular dysfunction leading to heart failure.
- a specific type of cardiac fibrosis is hypertension-associated cardiac fibrosis as described by J. Diez ( J. Clin. Hypertens., 2007, July 9(7), pp. 546-550).
- TGF- ⁇ 1 transforming growth factor ⁇ 1
- the present disclosure provides a method of treating various forms of cardiac fibrosis, such as hypertension-associated cardiac fibrosis, post-myocardial infarction or Chagas disease-induced myocardial fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- Renal fibrosis encompasses a variety of disorders associated with the aberrant expression and activity of TGF- ⁇ , including, but not limited to, diabetic and hypertensive nephropathy, urinary tract obstruction-induced kidney fibrosis, inflammatory/autoimmune-induced kidney fibrosis, aristolochic acid nephropathy, progressive kidney fibrosis, and polysystic kidney disease.
- fibrosis involves an excess accumulation of the ECM, which in turn causes loss of function when normal tissue is replaced with scar tissue (Wynn, T. A., J Clin Invest., 2007, 117, pp. 524-529).
- the present disclosure provides a method of treating renal fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- IPF idiopathic pulmonary fibrosis
- ALK5 is an important and known component in the fibrotic disease pathway, the efficacy of ALK5 inhibitors in IPF have not been realized due to systemic adverse effects, especially in the heart.
- one of the goals of this disclosure is to develop ALK5 inhibitors with high lung selectivity and rapid clearance.
- One preferred embodiment of this disclosure is to treat patients with idiopathic pulmonary fibrosis with a compound described herein, for example, by once or twice daily administration of inhalable ALK5 inhibitor having minimal systemic exposure.
- the inhaled ALK5 inhibitor may be administered as a monotherapy or co-dosed with other orally available IPF therapies.
- the present disclosure provides a method of treating idiopathic pulmonary fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- the compound is administered by inhalation.
- Familial pulmonary fibrosis is a hereditary disease where two or more family members have confirmed IPF.
- the present disclosure provides a method of treating familial pulmonary fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- Pulmonary fibrosis is a typical clinical feature associated with viral infection, such as SARS and COVID-19.
- SARS-mediated TGF- ⁇ signaling has been shown to promote fibrosis and block apoptosis of SARS-CoV-infected host cells (Zhao, X. et al., J. Biol. Chem., 2008, 283(6), pp. 3272-3280). Increased TGF- ⁇ expression was similarly observed in patients infected with SARS-CoV-2, ultimately leading to the development of pulmonary fibrosis.
- TGF- ⁇ signaling mediated by SARS-CoV-2 can promote fibroblast proliferation and myofibroblast differentiation and block host cell apoptosis. (Xiong, Y.
- the present disclosure provides a method of treating pulmonary fibrosis induced by a viral infection, comprising administering to a subject an effective amount of a compound disclosed herein.
- the pulmonary fibrosis is induced by SARS-CoV or SARS-CoV-2.
- the compound is administered by inhalation.
- PH pulmonary hypertension
- Pulmonary hypertension is a progressive disease characterized by high blood pressure in the lungs.
- the World Health Organization (WHO) has defined five classifications of PH (WHO Group I: Pulmonary arterial hypertension (PAH); WHO Group II: Pulmonary hypertension due to left heart disease; WHO Group III: Pulmonary hypertension due to lung disease and/or hypoxia; WHO Group IV: Chronic thromboembolic pulmonary hypertension (CTEPH); and WHO Group V: Pulmonary hypertension with unclear multifactorial mechanisms).
- TGF- ⁇ signaling has been implicated in the pathogenesis of PH.
- inhibition of ALK5 in a monocrotaline (MCT) model of severe PH was shown to attenuate the development of PH and reduce pulmonary vascular remodeling in a dose-dependent manner, namely by reducing RV systolic pressure, reducing RV diastolic pressure, increasing cardiac output and reducing RV hypertrophy (Zaiman, A. L.; et al., Am. J. Respir. Crit. Care Med., 2008, 177, pp. 896-905).
- Compounds of the present disclosure are expected to inhibit TGF- ⁇ signaling in lung tissue and prevent, halt, slow or reverse the progression of PH, particularly in WHO Group III PH.
- the present disclosure provides a method of treating pulmonary hypertension, comprising administering to a subject an effective amount of a compound disclosed herein.
- the pulmonary hypertension may be WHO Group III pulmonary hypertension, such as pulmonary fibrosis-related pulmonary hypertension (PH-PF) or interstitial lung disease-related pulmonary hypertension (PH-ILD).
- the compound is administered by inhalation.
- interstitial lung diseases include, but are not limited to, (1) interstitial pneumonia caused by bacteria, viruses, or fungi; (2) nonspecific interstitial pneumonitis usually associated with autoimmune conditions such as rheumatoid arthritis or scleroderma; (3) hypersensitivity pneumonitis caused by inhalation of dust, mold, or other irritants; (4) cryptogenic organizing pneumonia; (5) acute interstitial pneumonitis; (6) desquamative interstitial pneumonitis; (7) sarcoidosis; (8) drug-induced interstitial lung disease; and (9) progressive fibrosing interstitial lung disease (PF-ILD).
- the present disclosure provides a method of treating an interstitial lung disease, comprising administering to a subject an effective amount of a compound disclosed herein.
- the present disclosure provides a method of treating asthma, comprising administering to a subject an effective amount of a compound disclosed herein.
- COPD chronic obstructive pulmonary disease
- IPF impaired diffusion capacity
- Both diseases demonstrate a progressive loss of alveolar parenchyma leading to severe impairment of respiratory function.
- Fibrosis associated with emphysema is known and research has demonstrated TGF- ⁇ 1 involvement in chronic sinus disease, pulmonary fibrosis, asthma, and COPD (Yang, Y. C., et al., Allergy, 2012, 67, pp. 1193-1202).
- the present disclosure provides a method of treating COPD, comprising administering to a subject an effective amount of a compound disclosed herein.
- lung injury that result in fibrosis
- silica-induced pneumoconiosis sicosis
- asbestos-induced pulmonary fibrosis asbestos-induced pulmonary fibrosis
- chemotherapeutic agent-induced pulmonary fibrosis chemotherapeutic agent-induced pulmonary fibrosis.
- the present disclosure provides a method of treating injury-induced fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- the present disclosure provides a method of treating liver fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- Fibrosis develops in the liver when it is repeatedly or continuously damaged, for example, in patients with chronic hepatitis.
- TGF-0 signaling participates in all stages of disease progression, from initial liver injury through inflammation and fibrosis, to cirrhosis and cancer (Fabregat, I., et al., The FEBS J., 2016, 283(12), pp. 2219-2232).
- a related condition involves fibrosis resulting from idiopathic non-cirrhotic portal hypertension (INCPH).
- IOCPH idiopathic non-cirrhotic portal hypertension
- This disease is of uncertain etiology characterized by periportal fibrosis and involvement of small and medium branches of the portal vein.
- small portal veins and skin findings are similar between patients with scleroderma and INCPH (Nakanuma, Y., Hepatol. Res., 2009, 39, pp. 1023-1031).
- TGF- ⁇ Transforming growth factor- ⁇
- connective tissue growth factor which are fibrosis-related and vascular endothelial growth factors, respectively
- TGF- ⁇ Transforming growth factor- ⁇
- connective tissue growth factor connective tissue growth factor
- EndMT endothelial mesenchymal transition
- Kitao et al. based on these findings (Kitao, A., et al., Am. J. Pathol., 2009, 175, pp. 616-626).
- the increase of TGF- ⁇ in sera may act as a potent inducer of EndMT.
- the present disclosure provides a method of treating INCPH, comprising administering to a subject an effective amount of a compound disclosed herein.
- liver fibrosis examples include alcoholic and non-alcoholic liver fibrosis, hepatitis C-induced liver fibrosis, primary biliary cirrhosis or cholangitis, and parasite-induced liver fibrosis (schistosomiasis).
- the present disclosure provides a method of treating alcoholic liver fibrosis, non-alcoholic liver fibrosis, hepatitis C-induced liver fibrosis, primary biliary cirrhosis, primary biliary cholangitis, or parasite-induced liver fibrosis (schistosomiasis), comprising administering to a subject an effective amount of a compound disclosed herein.
- PBC Primary biliary cholangitis
- PSC primary sclerosing cholangitis
- Liver biopsies of patients with PBC or PSC typically reveal inflammation and fibrosis.
- the present disclosure provides a method of treating primary biliary cholangitis or primary sclerosing cholangitis, comprising administering to a subject an effect amount of a compound described herein.
- the present disclosure provides a method of treating liver fibrosis, optionally in a subject that suffers from PBC or PSC, comprising administering to the subject an effective amount of a compound described herein.
- Fibrotic skin conditions include, but are not limited to, hypertrophic scarring, keloids, and localized or systemic sclerosis (scleroderma).
- TGF- ⁇ is a potent stimulus of connective tissue accumulation and has been implicated in the pathogenesis of scleroderma and other fibrotic disorders (Lakos, G., et al., Am. J. Pathol., 2004, 165(1), pp. 203-217).
- Lakos et. al. demonstrated that Smad3 functions as a key intracellular signal transducer for profibrotic TGF- ⁇ responses in normal skin fibroblasts and found that the targeted disruption of TGF- ⁇ /Smad3 signaling modulated skin fibrosis in the mouse model of scleroderma.
- the present disclosure provides a method of treating skin fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD) and is a serious clinical problem.
- TGF- ⁇ has been implicated as a major driving factor of intestinal fibrosis.
- TGF- ⁇ 1 signaling contributes to stricture formation in fibrostenotic Crohn's disease by inducing insulin-like growth factor I (IGF-I) and mechano-growth factor (MGF) production in intestinal smooth muscle.
- IGF-I insulin-like growth factor I
- MMF mechano-growth factor
- the present disclosure provides a method of treating intestinal fibrosis, comprising administering to a subject an effective amount of a compound described herein, for example, by once or twice daily administration of an oral ALK5 inhibitor having minimal systemic exposure.
- the subject suffers from inflammatory bowel disease, such as Crohn's disease or colitis.
- the degree of therapeutic efficacy may be with respect to a starting condition of the subject (e.g., a baseline Mayo score, baseline Lichtiger score, or severity or incidence of one or more symptoms), or with respect to a reference population (e.g., an untreated population, or a population treated with a different agent).
- Severity of intestinal fibrosis may be assessed using any suitable method, such as delayed enhancement MRI, ultrasound elastography, shear wave elastography, magnetization MRI, or by the direct detection of macromolecules such as collagen.
- treatment with a compound of the present disclosure reduces the severity of the fibrosis, such as from severe fibrosis to moderate or mild fibrosis.
- the treatment increases intestinal tissue elasticity, reduces tissue stiffness, and/or reduces collagen levels. In some embodiments, the treatment prevents myofibroblast accumulation, inhibits expression of pro-fibrotic factors, and/or inhibits accumulation of fibrotic tissue.
- organ-specific fibrosis or fibrotic diseases involving the TGF- ⁇ pathway include, but are not limited to, radiation-induced fibrosis (various organs), bladder fibrosis, intestinal fibrosis, peritoneal sclerosis, diffuse fasciitis, Dupuytren's disease, myelofibrosis, oral submucous fibrosis, and retinal fibrosis.
- the present disclosure provides a method of treating radiation-induced fibrosis, bladder fibrosis, intestinal fibrosis, peritoneal sclerosis, diffuse fasciitis, Dupuytren's disease, myelofibrosis, oral submucous fibrosis, or retinal fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- the compounds described herein may also be used to treat patients systemically.
- Diseases that may be treated systemically include, for example, oncologic diseases such as glioblastoma, pancreatic cancer and hepatocellular carcinoma, breast cancer metastasized to lungs, non-small cell lung cancer, small cell lung cancer, cystic fibrosis, and metastasis of other forms of primary cancer subtypes. Some of the forgoing diseases may also be treated locally as well.
- Alopecia includes alopecia totalis, alopecia universalis, androgenetic alopecia, alopecia areata, diffuse alopecia, postpartum alopecia, and traction alopecia.
- the present disclosure provides a method of reversing one or more symptoms of aging, comprising administering to a subject an ALK5 inhibitor.
- the method may further comprise administering an activator of the MAPK pathway, such as oxytocin.
- the method may be effective in one or more of enhancing neurogenesis in the hippocampus, reducing neuroinflammation, improving cognitive ability, reducing liver adiposity, reducing liver fibrosis, and decreasing the number of p16 + cells.
- a method described herein increases stem cell activity. The increase in stem cell activity may allow the subject to generate new muscle fibers and/or to form new neurons in the hippocampus.
- Treatment with an ALK5 inhibitor, such as a compound described herein may prevent or slow the onset of age-related diseases, such as Alzheimer's disease. (see Mehdipour, M. et al. Aging 2018, 10, 5628-5645).
- the present disclosure provides a pharmaceutical composition.
- the pharmaceutical composition may comprise a compound disclosed herein, such as a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), and a pharmaceutically acceptable carrier.
- the pharmaceutical composition is formulated for oral administration.
- the pharmaceutical composition is formulated for inhalation.
- the pharmaceutical composition comprises a compound disclosed herein and an additional therapeutic agent. Non-limiting examples of such therapeutic agents are described herein below.
- compositions typically include at least one pharmaceutically acceptable carrier, diluent or excipient and at least one compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), or a compound provided in Table 1 or 2-described herein as the active agent.
- the active agent may be provided in any form suitable for the particular mode of administration, such as a free base, a free acid, or a pharmaceutically acceptable salt.
- compositions of the present disclosure include the use of N-oxides, crystalline forms (e.g., polymorphs), as well as metabolites of these compounds having similar activity. All tautomers of the compounds described herein are included within the scope of the present disclosure. Additionally, the compounds described herein encompass unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
- Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, vaginal, aerosol, pulmonary, nasal, transmucosal, topical, transdermal, otic, ocular, and parenteral modes of administration.
- parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.
- a compound described herein is administered in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in a depot preparation or sustained release formulation.
- a long acting formulation is administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection.
- a compound described herein is provided in the form of a rapid release formulation, an extended release formulation, or an intermediate release formulation.
- a compound described herein is provided in the form of a nebulized formulation.
- a compound described herein is administered locally to the lungs by inhalation.
- Compounds of the present disclosure are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, 0.5 to 100 mg, 1 to 50 mg, or from 5 to 40 mg per day may be administered to a subject in need thereof. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.
- a compound of the present disclosure may be administered in a single dose.
- a compound of the disclosure is administered in multiple doses, such as about once, twice, three times, four times, five times, six times, or more than six times per day.
- dosing is about once a month, once every two weeks, once a week, or once every other day.
- a compound of the disclosure and an additional therapeutic agent are administered together about once per day to about 6 times per day.
- the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or more than about one year.
- a dosing schedule is maintained as long as necessary.
- a compound of the present disclosure may be administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.
- compositions of the present disclosure typically contain a therapeutically effective amount of a compound of the present disclosure.
- a pharmaceutical composition may contain more than a therapeutically effective amount, e.g., bulk compositions, or less than a therapeutically effective amount, e.g., individual unit doses designed for co-administration to achieve a therapeutically effective amount.
- compositions of the present disclosure contain from about 0.01 to about 95% by weight of the active agent; including, for example, from about 0.05 to about 30% by weight; and from about 0.1% to about 10% by weight of the active agent.
- any conventional carrier or excipient may be used in the pharmaceutical compositions of the present disclosure.
- the choice of a particular carrier or excipient, or combinations of carriers or excipients, will depend on the mode of administration being used to treat a particular patient or type of medical condition or disease state. Additionally, the carriers or excipients used in the pharmaceutical compositions of this disclosure may be commercially-available. Conventional formulation techniques are described in Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & White, Baltimore, Maryland (2000); and H. C. Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition, Lippincott Williams & White, Baltimore, Maryland (1999).
- materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, the following: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, such as microcrystalline cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-
- compositions are typically prepared by thoroughly and intimately mixing or blending the active agent with a pharmaceutically-acceptable carrier and one or more optional ingredients. The resulting uniformly blended mixture can then be shaped or loaded into tablets, capsules, pills and the like using conventional procedures and equipment.
- the pharmaceutical composition is suitable for inhaled administration.
- Pharmaceutical compositions for inhaled administration are typically in the form of an aerosol or a powder.
- Such compositions are generally administered using inhaler delivery devices, such as a dry powder inhaler (DPI), a metered-dose inhaler (MDI), a nebulizer inhaler, or a similar delivery device.
- DPI dry powder inhaler
- MDI metered-dose inhaler
- nebulizer inhaler or a similar delivery device.
- the pharmaceutical composition is administered by inhalation using a dry powder inhaler.
- dry powder inhalers typically administer the pharmaceutical composition as a free-flowing powder that is dispersed in a patient's air-stream during inspiration.
- the therapeutic agent is typically formulated with a suitable excipient such as lactose, starch, mannitol, dextrose, polylactic acid (PLA), polylactide-co-glycolide (PLGA) or combinations thereof.
- the therapeutic agent is micronized and combined with a suitable carrier to form a composition suitable for inhalation.
- a representative pharmaceutical composition for use in a dry powder inhaler comprises lactose and a micronized form of a compound disclosed herein.
- a dry powder composition can be made, for example, by combining dry milled lactose with the therapeutic agent and then dry blending the components. The composition is then typically loaded into a dry powder dispenser, or into inhalation cartridges or capsules for use with a dry powder delivery device.
- Dry powder inhaler delivery devices suitable for administering therapeutic agents by inhalation are described in the art and examples of such devices are commercially available.
- representative dry powder inhaler delivery devices or products include Aeolizer (Novartis); Airmax (IVAX); ClickHaler (Innovata Biomed); Diskhaler (GlaxoSmithKline); Diskus/Accuhaler (GlaxoSmithKline); Ellipta (GlaxoSmithKline); Easyhaler (Orion Pharma); Eclipse (Aventis); FlowCaps (Hovione); Handihaler (Boehringer Ingelheim); Pulvinal (Chiesi); Rotahaler (GlaxoSmithKline); SkyeHaler/Certihaler (SkyePharma); Twisthaler (Schering-Plough); Turbuhaler (AstraZeneca); Ultrahaler (Aventis); and the like.
- a pharmaceutical composition of the present disclosure may be administered by inhalation using a metered-dose inhaler.
- metered-dose inhalers typically discharge a measured amount of a therapeutic agent using a compressed propellant gas.
- pharmaceutical compositions administered using a metered-dose inhaler typically comprise a solution or suspension of the therapeutic agent in a liquefied propellant.
- Any suitable liquefied propellant may be employed, including hydrofluoroalkanes (HFAs), such as 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoro-n-propane, (HFA 227); and chlorofluorocarbons, such as CCl 3 F.
- the propellant is a hydrofluoroalkane.
- the hydrofluoroalkane formulation contains a co-solvent, such as ethanol or pentane, and/or a surfactant, such as sorbitan trioleate, oleic acid, lecithin, and glycerin.
- a representative pharmaceutical composition for use in a metered-dose inhaler comprises from about 0.01% to about 5% by weight of a compound of the present disclosure; from about 0% to about 20% by weight ethanol; and from about 0% to about 5% by weight surfactant; with the remainder being an HFA propellant.
- Such compositions are typically prepared by adding chilled or pressurized hydrofluoroalkane to a suitable container containing the therapeutic agent, ethanol (if present) and the surfactant (if present). To prepare a suspension, the therapeutic agent is micronized and then combined with the propellant. The composition is then loaded into an aerosol canister, which typically forms a portion of a metered-dose inhaler device.
- Metered-dose inhaler devices suitable for administering therapeutic agents by inhalation are described in the art and examples of such devices are commercially available.
- representative metered-dose inhaler devices or products include AeroBid Inhaler System (Forest Pharmaceuticals); Atrovent Inhalation Aerosol (Boehringer Ingelheim); Flovent (GlaxoSmithKline); Maxair Inhaler (3M); Proventil Inhaler (Schering); Serevent Inhalation Aerosol (GlaxoSmithKline); and the like.
- a pharmaceutical composition of the present disclosure may be administered by inhalation using a nebulizer inhaler.
- nebulizer devices typically produce a stream of high velocity air that causes the pharmaceutical composition to spray as a mist that is carried into the patient's respiratory tract.
- the therapeutic agent when formulated for use in a nebulizer inhaler, can be dissolved in a suitable carrier to form a solution.
- the therapeutic agent can be micronized or nanomilled and combined with a suitable carrier to form a suspension.
- a representative pharmaceutical composition for use in a nebulizer inhaler comprises a solution or suspension comprising from about 0.05 ⁇ g/mL to about 20 mg/mL of a compound of the present disclosure and excipients compatible with nebulized formulations.
- the solution has a pH of about 3 to about 8.
- Nebulizer devices suitable for administering therapeutic agents by inhalation are described in the art and examples of such devices are commercially available.
- representative nebulizer devices or products include the Respimat® SoftmistTM Inhalaler (Boehringer Ingelheim); the AERx® Pulmonary Delivery System (Aradigm Corp.); the PARI LC Plus® Reusable Nebulizer or PARI eFlow® rapid Nebulizer System (Pari GmbH); and the like.
- a pharmaceutical composition of the present disclosure may be prepared in a dosage form intended for oral administration.
- Suitable pharmaceutical compositions for oral administration may be in the form of capsules, tablets, pills, lozenges, cachets, dragees, powders, granules; or as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil liquid emulsion; or as an elixir or syrup; and the like; each containing a predetermined amount of a compound of the present disclosure as an active ingredient.
- the pharmaceutical compositions of the disclosure will typically comprise the active agent and one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate.
- such solid dosage forms may also comprise: fillers or extenders, binders, humectants, solution retarding agents, absorption accelerators, wetting agents, absorbents, lubricants, coloring agents, and buffering agents. Release agents, wetting agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the present pharmaceutical compositions.
- Alternative formulations may include controlled release formulations, liquid dosage forms for oral administration, transdermal patches, and parenteral formulations. Conventional excipients and methods of preparation of such alternative formulations are described, for example, in the reference by Remington, supra.
- a micronized compound of the present disclosure (1 g) is blended with milled lactose (25 g). This blended mixture is then loaded into individual blisters of a peelable blister pack in an amount sufficient to provide between about 0.1 mg to about 4 mg of the compound per dose. The contents of the blisters are administered using a dry powder inhaler.
- a micronized compound of the present disclosure (1 g) is blended with milled lactose (20 g) to form a bulk composition having a weight ratio of compound to milled lactose of 1:20.
- the blended composition is packed into a dry powder inhalation device capable of delivering between about 0.1 mg to about 4 mg of the compound per dose.
- a micronized compound of the present disclosure (10 g) is dispersed in a solution prepared by dissolving lecithin (0.2 g) in demineralized water (200 mL). The resulting suspension is spray dried and then micronized to form a micronized composition comprising particles having a mean diameter less than about 1.5 m. The micronized composition is then loaded into metered-dose inhaler cartridges containing pressurized 1,1,1,2-tetrafluoroethane in an amount sufficient to provide about 0.1 mg to about 4 mg of the compound per dose when administered by the metered dose inhaler.
- a representative nebulizer composition is as follows.
- a compound of the present disclosure (2 g of free-base equivalents) is dissolved in a solution containing 80 mL reverse-osmosis water, 0.1-1% by weight of anhydrous citric acid, and 0.5-1.5 equivalents of hydrochloric acid, followed by addition of sodium hydroxide to adjust the pH to 3.5 to 5.5. Thereafter, between 4-6% by weight of D-mannitol is added and solution q.s. to 100 mL. The solution is then filtered through a 0.2 ⁇ m filter and stored at room temperature prior to use. The solution is administered using a nebulizer device that provides about 0.1 mg to about 4 mg of the compound per dose.
- the present disclosure provides a kit comprising one or more unit doses of a compound or pharmaceutical composition described herein, optionally wherein the kit further comprises instructions for using the compound or pharmaceutical composition.
- the kit comprises a carrier, package, or container that is compartmentalized to receive one or more containers, such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein.
- Suitable containers include, for example, bottles, vials, syringes, and test tubes.
- the containers may be formed from a variety of materials, such as glass or plastic.
- the articles of manufacture provided herein may contain packaging materials.
- Packaging materials for use in packaging pharmaceutical products include those found in, e.g., U.S. Pat. Nos. 5,323,907, 5,052,558 and 5,033,252.
- Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.
- the container(s) may include one or more compounds described herein, optionally in a composition or in combination with another agent as disclosed herein.
- the container(s) may optionally have a sterile access port (for example, the container is an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- kits may optionally comprise a compound with an identifying description or label or instructions relating to its use in the methods described herein.
- a kit includes one or more containers, each with one or more of various materials (such as reagents, optionally in concentrated form, and/or devices) desirable from a commercial and user standpoint for use of a compound described herein.
- materials include, but are not limited to, buffers, diluents, filters, needles, syringes, carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use.
- a set of instructions will also typically be included.
- a label is optionally on or associated with the container.
- a label is on a container when letters, numbers or other characters forming the label are attached, molded, or etched onto the container itself, a label is associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert.
- a label is used to indicate that the contents are to be used for a specific therapeutic application.
- the label indicates directions for use of the contents, such as in the methods described herein.
- the pharmaceutical composition is presented in a pack or dispenser device which contains one or more unit dosage forms containing a compound provided herein.
- the pack may contain metal or plastic foil, such as a blister pack.
- the pack or dispenser device is accompanied by instructions for administration.
- the pack or dispenser is accompanied with a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration.
- a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration.
- Such notice for example, is the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert.
- compositions containing a compound provided herein formulated in a compatible pharmaceutical carrier are prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- the compounds and pharmaceutical compositions of the disclosure may be used in combination with one or more therapeutic agents which act by the same mechanism or by a different mechanism to treat a disease.
- the one or more agents may be administered sequentially or simultaneously, in separate compositions or in the same composition.
- Useful classes of agents for combination therapy include, but are not limited to, compounds used to treat cardiac, kidney, pulmonary, liver, skin, immunological and oncological conditions.
- an ALK5 inhibitor and a second therapeutic agent can be administered sequentially, wherein the two agents are introduced into a subject at two different time points.
- the two time points can be separated by more than 2 hours, 1 or more days, 1 or more weeks, 1 or more months, or according to any intermittent regimen schedule disclosed herein.
- the ALK5 inhibitor and the second therapeutic agent are administered simultaneously.
- the two agents may form part of the same composition, or the two agents may be provided in one or more unit doses.
- the ALK5 inhibitor or the second therapeutic agent are administered parenterally, orally, inhalatively, intraperitoneally, intravenously, intraarterially, transdermally, intramuscularly, liposomally, via local delivery by catheter or stent, subcutaneously, intraadiposally, or intrathecally.
- a therapeutically effective amount of a combination of an ALK5 inhibitor and a second therapeutic agent refers to a combination of an ALK5 inhibitor and a second therapeutic agent, wherein the combination is sufficient to affect the intended application, including but not limited to, disease treatment, as defined herein.
- Also contemplated in the subject methods is the use of a sub-therapeutic amount of an ALK5 inhibitor and a second therapeutic agent in combination for treating an intended disease condition.
- the individual components of the combination though present in sub-therapeutic amounts, synergistically yield an efficacious effect and/or reduced a side effect in an intended application.
- the amount of the ALK5 inhibitor and the second therapeutic agent administered may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- Measuring an immune response and/or the inhibition of biological effects of ALK5 can comprise performing an assay on a biological sample, such as a sample from a subject. Any of a variety of samples may be selected, depending on the assay. Examples of samples include, but are not limited to blood samples (e.g. blood plasma or serum), exhaled breath condensate samples, bronchoalveolar lavage fluid, sputum samples, urine samples, and tissue samples.
- blood samples e.g. blood plasma or serum
- exhaled breath condensate samples e.g. blood plasma or serum
- bronchoalveolar lavage fluid e.g. bronchoalveolar lavage fluid
- sputum samples e.g. urine samples, and tissue samples.
- a subject being treated with an ALK5 inhibitor and a second therapeutic agent may be monitored to determine the effectiveness of treatment, and the treatment regimen may be adjusted based on the subject's physiological response to treatment. For example, if inhibition of a biological effect of ALK5 inhibition is above or below a threshold, the dosing amount or frequency may be decreased or increased, respectively. Alternatively, the treatment regimen may be adjusted with respect to an immune response.
- the methods can further comprise continuing the therapy if the therapy is determined to be efficacious.
- the methods can comprise maintaining, tapering, reducing, or stopping the administered amount of a compound or compounds in the therapy if the therapy is determined to be efficacious.
- the methods can comprise increasing the administered amount of a compound or compounds in the therapy if it is determined not to be efficacious.
- the methods can comprise stopping therapy if it is determined not to be efficacious.
- treatment with an ALK5 inhibitor and a second therapeutic agent is discontinued if inhibition of the biological effect is above or below a threshold, such as in a lack of response or an adverse reaction.
- the biological effect may be a change in any of a variety of physiological indicators.
- RNA molecules that may be used in combination with the compounds disclosed herein include, but are not limited to, OFEV® (nintedanib) and Esbriet® (pirfenidone).
- a compound disclosed herein is administered in combination with pirfenidone, optionally wherein the pirfenidone is administered by inhalation.
- the present disclosure provides a method of treating fibrosis, such as idiopathic pulmonary fibrosis, in a subject, comprising administering to the subject an ALK5 inhibitor, such as a compound disclosed in Table 1, and nintedanib or pirfenidone.
- the present disclosure provides a method of treating cancer, such as lung cancer, in a subject, comprising administering to the subject an ALK5 inhibitor, such as a compound disclosed in Table 1, and nintedanib or pirfenidone.
- an ALK5 inhibitor such as a compound disclosed in Table 1, and nintedanib or pirfenidone.
- the present disclosure provides a method for treating a proliferative disorder (e.g., lung cancer) in a subject in need thereof, comprising administering to said subject an ALK5 inhibitor and an immunotherapeutic agent.
- a proliferative disorder e.g., lung cancer
- an immunotherapeutic agent e.g., TGF- ⁇ has been shown to regulate lymphocyte differentiation, suppress T cell proliferation and to enhance tumor growth.
- TGF- ⁇ has been shown to prevent optimal activation of the immune system in immunotherapy-resistant patients (see Ldffek, S. J. Oncolo. 2018, 1-9; incorporated herein by reference in its entirety).
- the present inventors expect that inhibition of ALK5 may enhance the efficacy of a particular immunotherapy.
- an immunotherapeutic agent such as durvalumab or pembrolizumab
- an ALK5 inhibitor such as a compound of the present disclosure
- the combination is expected to produce a synergistic effect.
- a synergistic combination is also expected for a triple combination of radiation therapy, immunotherapy, and ALK5 inhibition.
- the ALK5 inhibitor even when administered locally (e.g., to the lung by inhalation), may stimulate both local and systemic immune responses, allowing for the treatment of primary or metastatic tumors in tissues beyond the site of the local delivery.
- an inhaled ALK5 inhibitor may be administered in combination with an immunotherapeutic agent to treat melanoma, renal cell carcinoma, colon cancer, or breast cancer.
- the ALK5 inhibitor and the immunotherapeutic agent are administered sequentially or simultaneously. In some embodiments, the ALK5 inhibitor and the immunotherapeutic agent are more effective in treating the proliferative disorder than either agent alone. In some embodiments, the ALK5 inhibitor and the immunotherapeutic agent yield a synergistic effect in treating the proliferative disorder. The synergistic effect may be a therapeutic effect that is greater than either agent used alone in comparable amounts under comparable conditions. The synergistic effect may be a therapeutic effect that is greater than results expected by adding the effects of each agent alone. In some embodiments, the proliferative disorder is a cancer condition. In some embodiments, the cancer condition is lung cancer, such as non-small cell lung cancer.
- immunotherapeutic agent refers to any agent that induces, enhances, suppresses or otherwise modifies an immune response. This includes the administration of an active agent to, or any type of intervention or process performed on, the subject, with the objective of modifying an immune response.
- An immunotherapeutic agent may, for example, increase or enhance the effectiveness or potency of an existing immune response in a subject, for example, by stimulating mechanisms that enhance the endogenous host immune response or overcoming mechanisms that suppress the endogenous host immune response.
- Immuno response refers to the action of a cell of the immune system including, for example, B lymphocytes, T lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, myeloid-derived suppressor cells, dendritic cells and neutrophils and soluble macromolecules produced by any of these cells or the liver (including antibodies, cytokines and complement), that results in selective targeting, binding to, damage to, destruction of, and/or elimination of invading pathogens, cells or tissues infected with pathogens, cancerous or other abnormal cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues, from the body of a subject.
- B lymphocytes B lymphocytes, T lymphocytes, natural killer (NK) cells
- macrophages eosinophils
- mast cells myeloid-derived suppressor cells
- dendritic cells and neutrophils dendritic cells and neutrophils and soluble macromolecules produced by any of these cells or the
- an immunotherapeutic agent may comprise a PD-1 inhibitor. In another embodiment, an immunotherapeutic agent may comprise a CTLA-4 inhibitor. In still another embodiment, an immunotherapeutic agent may comprise a B7 inhibitor.
- a PD-1 inhibitor suitable for use in the subject methods can be selected from a variety of types of molecules.
- the PD-1 inhibitor can be a biological or chemical compound, such as an organic or inorganic molecule, peptide, peptide mimetic, antibody or an antigen-binding fragment of an antibody.
- Some exemplary classes of agents suitable for use in the subject methods are detailed in the sections below.
- a PD-1 inhibitor for use in the present disclosure can be any PD-1 inhibitor that is known in the art, and can include any entity that, upon administration to a patient, results in inhibition of the PD-1 pathway in the patient.
- a PD-1 inhibitor can inhibit PD-1 by any biochemical mechanism, including disruption of any one or more of PD-1/PD-L1, PD1/PD-L2 and PD-L1/CD80 interactions.
- the PD-1 inhibitor is a molecule that inhibits the binding of PD-1 to its ligand binding partners.
- the PD-1 ligand binding partners are PD-L1 and/or PD-L2.
- a PD-1 inhibitor is a molecule that inhibits the binding of PD-L1 to its binding partners.
- PD-L1 binding partners are PD1 and/or CD80.
- the PD-1 inhibitor is a molecule that inhibits the binding of PD-L2 to its binding partners.
- a PD-L2 binding partner is PD1.
- the inhibitor may be an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein or oligopeptide.
- the PD-1 inhibitor is an anti-PD-1 antibody. In some further embodiments, the anti-PD-1 antibody is capable of inhibiting binding between PD-1 and PD-L1. In another embodiment, the anti-PD-1 antibody is capable of inhibiting binding between PD-1 and PD-L2. In some embodiments, the PD-1 inhibitor is an anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is capable of inhibiting binding between PD-L1 and PD-1 and/or between PD-L1 and CD80. In some embodiments, the PD-1 inhibitor is an anti-PD-L2 antibody. In some further embodiments, the anti-PD-L2 antibody is capable of inhibiting binding between PD-1 and PD-L2.
- the PD-1 inhibitor is nivolumab or pembrolizumab. In some embodiments, the PD-1 inhibitor is selected from atezolizumab, avelumab, nivolumab, pembrolizumab, durvalumab and BGB-A317.
- Inhibition of the PD-1 pathway can enhance the immune response to cancerous cells in a patient.
- the interaction between PD-1 and PD-L1 impairs T cell response as manifested by a decrease in tumor-infiltrating lymphocytes (TILs) and a decrease in T-cell receptor mediated proliferation, resulting in T cell anergy, exhaustion or apoptosis, and immune evasion by the cancerous cells.
- TILs tumor-infiltrating lymphocytes
- This immune suppression can be reversed by inhibiting the local interaction between PD-L1 and PD-1 using a PD-1 inhibitor, including, for example, an anti-PD-1 and/or an anti-PD-L1 Ab.
- a PD-1 inhibitor may improve or restore antitumor T-cell functions.
- Anti-PD-1 antibodies suitable for use in the disclosure can be generated using methods well known in the art.
- Exemplary PD-1 inhibitors include, but are not limited to: nivolumab (BMS936558), pembrolizumab (MK-3475), pidilizumab (CT-011), AMP-224, AMP-514, BMS-936559, RG7446 (MPDL3280A), MDX-1106 (Medarex Inc.), MSB0010718C, MED14736, and HenGrui mAB005 (WO 15/085847).
- PD-1 antibodies and other PD-1 inhibitors include those described in WO 04/056875, WO 06/121168, WO 07/005874, WO 08/156712, WO 09/014708, WO 09/114335, WO 09/101611, WO 10/036959, WO 10/089411, WO 10/027827, WO 10/077634, WO 11/066342, WO 12/145493, WO 13/019906, WO 13/181452, WO 14/022758, WO 14/100079, WO 14/206107, WO 15/036394, WO 15/085847, WO 15/112900, WO 15/112805, WO 15/112800, WO 15/109124, WO 15/061668, WO 15/048520, WO 15/044900, WO 15/036927, WO 15/035606; U.
- a CTLA-4 inhibitor suitable for use in the subject methods can be selected from a variety of types of molecules.
- the CTLA-4 inhibitor can be a biological or chemical compound, such as an organic or inorganic molecule, peptide, peptide mimetic, antibody or an antigen-binding fragment of an antibody.
- Some exemplary classes of agents suitable for use in the subject methods are detailed in the sections below.
- a CTLA-4 inhibitor for use in the present disclosure can be any CTLA-4 inhibitor that is known in the art, and can include any entity that, upon administration to a patient, results in inhibition of the CTLA-4 pathway in the patient.
- a CTLA-4 inhibitor can inhibit CTLA-4 by any biochemical mechanism, including disruption of either one or both of CTLA-4/CD80 and CTLA-4/CD86 interactions.
- the CTLA-4 inhibitor is a molecule that inhibits the binding of CTLA-4 to its ligand binding partners.
- the CTLA-4 ligand binding partners are CD80 and/or CD86.
- a CTLA-4 inhibitor is a molecule that inhibits the binding of CD80 to its binding partners.
- a CD80 binding partner is CTLA-4.
- the CTLA-4 inhibitor is a molecule that inhibits the binding of CD86 to its binding partners.
- a CD86 binding partner is CTLA-4.
- the inhibitor may be an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein or oligopeptide.
- the CTLA-4 inhibitor is an anti-CTLA-4 antibody. In some further embodiments, the anti-CTLA-4 antibody is capable of inhibiting binding between CTLA-4 and CD80. In another embodiment, the anti-CTLA-4 antibody is capable of inhibiting binding between CTLA-4 and CD86. In some embodiments, the CTLA-4 inhibitor is an anti-CD80 antibody. In some embodiments, the anti-CD80 antibody is capable of inhibiting binding between CTLA-4 and CD80. In some embodiments, the CTLA-4 inhibitor is an anti-CD86 antibody. In some further embodiments, the anti-CD86 antibody is capable of inhibiting binding between CTLA-4 and CD86. In yet another embodiment, the CTLA-4 inhibitor is tremelimumab or ipilimumab.
- CTLA-4 pathway can enhance the immune response to cancerous cells in a patient.
- This immune suppression can be reversed by inhibiting the local interaction between CD80 or CD86 and CTLA-4 using a CTLA-4 inhibitor, including, for example, an anti-CTLA-4 Ab, anti-CD80 Ab or an antiCD86 Ab.
- a CTLA-4 inhibitor may improve or restore antitumor T-cell functions.
- Anti-CTLA-4 antibodies suitable for use in the disclosure can be generated using methods well known in the art.
- Exemplary CTLA-4 inhibitors include but are not limited to tremelimumab and ipilimumab (also known as 10D1 or MDX-010).
- Further CTLA-4 antibodies and other CTLA-4 inhibitors include those described in WO 98/042752, WO 00/037504, WO 01/014424 and WO 04/035607; U. S. Pub. Nos. 2002/0039581, 2002/086014 and 2005/0201994; U.S. Pat. Nos.
- a pharmaceutical composition comprising a compound of the disclosure or a pharmaceutically acceptable salt thereof and one or more other therapeutic agents.
- the therapeutic agent may be selected from the classes of agents specified above and from the lists of specific agents described above.
- the pharmaceutical composition is suitable for delivery to the lungs.
- the pharmaceutical composition is suitable for inhaled or nebulized administration.
- the pharmaceutical composition is a dry powder or a liquid composition.
- the disclosure provides a method of treating a disease or disorder in a mammal comprising administering to the mammal a compound of the disclosure or a pharmaceutically acceptable salt thereof and one or more other therapeutic agents.
- the agents When used in combination therapy, the agents may be formulated in a single pharmaceutical composition, or the agents may be provided in separate compositions that are administered simultaneously or at separate times, by the same or by different routes of administration. Such compositions can be packaged separately or may be packaged together as a kit. The two or more therapeutic agents in the kit may be administered by the same route of administration or by different routes of administration.
- reactions were run under nitrogen atmosphere, unless noted otherwise. The progress of reactions was monitored by thin layer chromatography (TLC), analytical high performance liquid chromatography (anal. HPLC), and mass spectrometry, the details of which are given in specific examples.
- TLC thin layer chromatography
- HPLC analytical high performance liquid chromatography
- mass spectrometry mass spectrometry
- reaction mixtures were worked up as described specifically in each preparation; commonly, reaction mixtures were purified by extraction and other purification methods such as temperature- and solvent-dependent crystallization, and precipitation.
- reaction mixtures were routinely purified by preparative HPLC, typically using Microsorb C18 and Microsorb BDS column packings and conventional eluents.
- Progress of reactions was typically monitored by liquid chromatography mass spectrometry (LCMS). Characterization of isomers was typically done by Nuclear Overhauser effect spectroscopy (NOE). Characterization of reaction products was routinely carried out by mass spectrometry and/or 1 H-NMR spectroscopy.
- Step A Preparation of methyl 6-methylpicolinimidate (1-2).
- 1-1 50.0 g, 423.3 mmol
- MeOH 300 ml
- 25% NaOMe 25% NaOMe in MeOH
- MeOH 100 ml, 465 mmol
- the reaction was stirred at 25° C. for 16 h.
- the reaction mixture was concentrated in vacuum and the crude residue was dissolved in EtOAc.
- Brine was added to the solution and white solid precipitation was observed.
- the suspension was filtered and the organic layer of filtrate was separated.
- the organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated to give the crude residue 1-2 (58.0 g).
- the crude product was used directly in the next step without further purification.
- [M+H] + calcd for C 8 H 10 N 2 O 150.18, found 151.05.
- Step B Preparation of 6-methylpicolinimidamide hydrogen chloride (1-3).
- 1-3 6-methylpicolinimidamide hydrogen chloride
- EtOH 250 ml
- H 2 O 25 ml
- NH 4 Cl 22.9 g, 425.02 mmol
- the reaction was stirred at 80° C. for 16 h.
- the reaction was concentrated to dryness.
- the crude residue was triturated in EtOAc and then filtered to remove non-polar impurities.
- the solid precipitate was treated with excess EtOH and filtered.
- the filtrate was concentrated to obtain an HCl salt of the desired product 1-3 (55.0 g).
- the crude product was used directly in the next step without further purification.
- [M+H] + calcd for C 7 H 9 N 3 135.17, found 136.10.
- Step C Preparation of 2-(6-methylpyridin-2-yl)pyrimidin-4(3H)-one (1-5).
- 1-3 55.0 g, 407.4 mmol
- 1-4 46.4 ml, 427.7 mmol
- EtOH 385 ml
- K 2 CO 3 112.4 g, 814.8 mmol
- the reaction was stirred at 80° C. for 16 h.
- the reaction was cooled to 25° C., filtered through a pad of Celite and concentrated to give crude product.
- the crude product was acidified with 4N HCl and triturated with EtOAc, then filtered to give an HCl salt of 1-5 (65.0 g).
- the crude product was used directly in the next step without further purification.
- [M+H] + calcd for C 10 H 9 N 3 O 187.20, found 187.17.
- Step D Preparation of 4-chloro-2-(6-methylpyridin-2-yl)pyrimidine (1-6).
- POCl 3 15.0 ml, 160.25 mmol.
- the reaction was stirred at 90° C. for 16 h, then concentrated to dryness.
- the crude residue was poured onto ice-cold water. The pH was adjusted to 8 by saturated NaHCO 3 .
- the mixture was then extracted with EtOAc.
- the organic phase was dried over sodium sulfate and concentrated to give crude product.
- the crude residue was triturated in pentane and filtered to give 1-6 (5.0 g).
- the crude product was used directly in the next step without further purification.
- [M+H] + calcd for C 10 H 8 ClN 3 205.65, found 206.09.
- Step E Preparation of 2-chloro-N-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidin-4-amine (1-8).
- 1-6 3.0 g, 14.63 mmol
- 1-7 (2.26 g, 17.56 mmol)
- DMF 15 ml
- solid crushed NaOH 1.17 g, 29.26 mmol
- the reaction was stirred at 25° C. for 16 h.
- the reaction was poured onto ice-cold water and the solid precipitated.
- the solid was collected by filtration and dried.
- the crude residue was triturated with ether and ACN to give 1-8 (3.5 g).
- the crude product was used directly in the next step without further purification.
- Step F Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(4-morpholinophenyl)pyrimidine-2,4-diamine (475).
- 1-8 250 mg, 0.84 mmol
- 1,4-dioxane 10 ml
- Pd 2 (dba) 3 77 mg, 0.08 mmol
- Xantphos 48 mg, 0.08 mmol
- Cs 2 CO 3 545 mg, 1.67 mmol
- Step A Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (4-1).
- a vial of 1-8 (238 mg, 0.797 mmol) was added ammonia solution (7N in MeOH) (4 ml, 28.0 mmol).
- the resulting suspension was heated at 80° C. for 16 h.
- the reaction mixture was concentrated in vacuum.
- the crude residue was purified by silica-gel chromatography using a gradient (0 to 15%) of MeOH in DCM to give 4-1 (108 mg) as a brown solid. [M+H] + calcd for C 13 H 13 N 7 279.31, found 280.0.
- Step B Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(2-(piperazin-1-yl)pyrimidin-5-yl)pyrimidine-2,4-diamine (86).
- TFA (1 ml) was added to the residue and heated at 50° C. for 2 h. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (17.2 mg). [M+H] + calcd for C 22 H 23 N 1 441.50, found 442.2.
- Step A Preparation of tert-butyl (R)-2-(hydroxymethyl)-4-(4-nitrophenyl)piperazine-1-carboxylate (5-3).
- a solution of 5-1 (98 mg, 0.694 mmol), 5-2 (150 mg, 0.694 mmol), and DIPEA (1.21 ml, 6.94 mmol) in DMF (3 ml) was heated at 110° C. for 16 h. The reaction was concentrated in vacuum. The crude residue was purified by silica-gel chromatography using a gradient (0 to 15%) of MeOH in DCM to give 5-3 (157 mg) as an orange oil. [M+H] + calcd for C 16 H 23 N 3 O 5 337.38, found 338.4.
- Step B Preparation of tert-butyl (R)-4-(4-aminophenyl)-2-(hydroxymethyl)piperazine-1-carboxylate (5-4).
- a solution of 5-3 (157 mg, 0.465 mmol) was taken up in ethanol (3 ml), and Pd/C (9.90 mg, 9.31 ⁇ mol) was added and the reaction mixture was purged under an atmosphere of H 2 and stirred at 25° C. for 16 h.
- the reaction mixture was filtered through a pad of Celite and concentrated in vacuum and the crude residue 5-4 (140 mg) was used directly in the next step.
- [M+H] + calcd for C 16 H 25 N 3 O 3 307.40, found 308.0.
- Step C Preparation of (R)-(4-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-2-yl)methanol (403).
- a vial of 1-8 25 mg, 0.084 mmol), 5-4 (25.7 mg, 0.084 mmol), cesium carbonate (35.4 mg, 0.109 mmol), BrettPhos (2.25 mg, 4.18 ⁇ mol), and BrettPhos Pd G4 (3.85 mg, 4.18 ⁇ mol) in degassed 1,4-dioxane (1.5 ml) was heated to 110° C. for 16 h.
- Step A Preparation of tert-butyl 3-(((4-aminophenyl)amino)methyl)azetidine-1-carboxylate (6-2).
- a solution of 5-1 (65 mg, 0.461 mmol), 6-1 (86 mg, 0.461 mmol), and DIPEA (805 ⁇ l, 4.61 mmol) in DMF (1 ml) was heated at 110° C. for 16 h. The reaction was concentrated in vacuum.
- Step B Preparation of N2-(4-((azetidin-3-ylmethyl)amino)phenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (537).
- a vial of 1-8 48 mg, 0.162 mmol), 6-2 (44 mg, 0.159 mmol), cesium carbonate (211 mg, 0.647 mmol), BrettPhos (35 mg, 0.065 mmol), and BrettPhos Pd G4 (60 mg, 0.065 mmol) in degassed 1,4-dioxane (1.62 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum.
- Step A Preparation of tert-butyl 3-(((4-aminophenyl)(methyl)amino)methyl)azetidine-1-carboxylate (7-2).
- a solution of 5-1 (65 mg, 0.461 mmol), 7-1 (92 mg, 0.461 mmol), and DIPEA (805 ⁇ l, 4.61 mmol) in DMF (1 ml) was heated at 110° C. for 16 h. The reaction was concentrated in vacuum.
- Step B Preparation of N2-(4-((azetidin-3-ylmethyl)(methyl)amino)phenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (202).
- a vial of 1-8 (97 mg, 0.323 mmol), 7-2 (113 mg, 0.159 mmol), cesium carbonate (211 mg, 0.647 mmol), BrettPhos (35 mg, 0.065 mmol), and BrettPhos Pd G4 (60 mg, 0.065 mmol) in degassed 1,4-dioxane (1.62 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum.
- TFA (1.24 ml) and DCM (1.04 ml) were added to the residue and heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 75%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (45.5 mg). [M+H] + calcd for C 25 H 27 N 9 453.55, found 454.2.
- Step A Preparation of tert-butyl (R)-3-((4-aminophenyl)amino)pyrrolidine-1-carboxylate (8-2).
- a solution of 5-1 (100 mg, 0.709 mmol), 8-1 (132 mg, 0.709 mmol), and DIPEA (1.24 ml, 7.09 mmol) in DMF (3 ml) was heated at 110° C. for 16 h. The reaction was concentrated in vacuum.
- Step B Preparation of (R)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(4-(pyrrolidin-3-ylamino)phenyl)pyrimidine-2,4-diamine (278).
- a vial of 1-8 (45 mg, 0.151 mmol), 8-2 (50.1 mg, 0.181 mmol), cesium carbonate (98 mg, 0.301 mmol), BrettPhos (8.09 mg, 0.015 mmol), and BrettPhos Pd G4 (13.87 mg, 0.015 mmol) in degassed 1,4-dioxane (4 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum.
- Step A Preparation of tert-butyl (E)-3-(4-bromobenzylidene)pyrrolidine-1-carboxylate (11-3).
- 11-1 2.0 g, 10.8 mmol
- DMF 40 ml
- NaH 561 mg, 14.0 mmol
- 11-2 11-2 (6.1 g, 11.9 mmol) in DMF (10 ml) was added.
- the reaction mixture was heated at 65° C. for 12 h.
- the mixture was poured into H 2 O (400 mL), the white suspension was extracted with EA (200 mL ⁇ 3), the combined organic phase was washed with sat.
- Step B Preparation of tert-butyl (E)-3-(4-((diphenylmethylene)amino)benzylidene)pyrrolidine-1-carboxylate (11-5).
- 11-3 800 mg, 2.36 mmol
- 11-4 472 mg, 3.60 mmol
- tBuONa 364 mg, 3.78 mmol
- Pd 2 (dba) 3 65 mg, 0.071 mmol
- BINAP 147 mg, 0.236 mmol
- Step C Preparation of tert-butyl (E)-3-(4-aminobenzylidene)pyrrolidine-1-carboxylate (11-6).
- MeOH MeOH
- HONH 2 —HCl 200 mg, 2.89 mmol
- NaOAc 323 mg, 3.94 mmol
- the reaction mixture was heated at 50° C. for 12 h.
- the reaction mixture was diluted with H 2 O (10 ml) and the product extracted in EtOAc (10 ml ⁇ 3), the combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure.
- Step D Preparation of tert-butyl 3-(4-aminobenzyl)pyrrolidine-1-carboxylate (11-7).
- 11-6 250 mg, 0.911 mmol
- MeOH MeOH
- Pd/C 30 mg, 10%
- the reaction mixture was degassed with H 2 several times, then stirred at 20° C. for 1 h.
- the reaction mixture was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure.
- the residue was purified by preparative HPLC chromatography using a gradient (23 to 53%) of acetonitrile in water with 0.225% formic acid to give 11-7 (100 mg) as a yellow solid.
- Step E Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(4-(pyrrolidin-3-ylmethyl)phenyl)pyrimidine-2,4-diamine (489).
- a vial of 1-8 (30 mg, 0.100 mmol), 11-7 (33.3 mg, 0.121 mmol), cesium carbonate (65.4 mg, 0.201 mmol), Xantphos (11.62 mg, 0.020 mmol), and Pd(OAc) 2 (4.51 mg, 0.020 mmol) in degassed 1,4-dioxane (1 ml) was heated at 110° C. for 16 h.
- Step A Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)pyrimidine-2,4-diamine (12-2).
- a vial of 1-8 35 mg, 0.117 mmol
- 12-1 (46.1 mg, 0.176 mmol)
- cesium carbonate 76 mg, 0.234 mmol
- BrettPhos Pd G4 21.57 mg, 0.023 mmol
- TFA 468 ⁇ l
- DCM 348 ⁇ l
- TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 30%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (76 mg).
- Step B Preparation of N2-(3-isopropyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (223).
- a vial of 12-2 (18 mg, 0.028 mmol), 2-bromopropane (10.18 mg, 0.083 mmol), and DIEA (48.2 ⁇ l, 0.276 mmol) in DMF (276 ⁇ l) was heated at 110° C. for 8 h.
- Step A Preparation of tert-butyl 8-(4-aminophenyl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (14-2).
- a solution of 5-1 (75 mg, 0.532 mmol), 14-1 (124 mg, 0.585 mmol), and potassium carbonate (147 mg, 1.063 mmol) in DMF (1.77 ml) was heated at 80° C. for 16 h. The reaction was concentrated in vacuum.
- Step B Preparation of N2-(4-(3,8-diazabicyclo[3.2.1]octan-8-yl)phenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (221).
- Step A Preparation of ethyl 2,3-dihydro-1H-indene-2-carboxylate (15-2).
- 15-1 10 g, 61.6 mmol
- ethanol 300 ml
- H 2 SO 4 36 ml
- the reaction mixture was heated at 75° C. for 48 h.
- the reaction mixture was concentrated and the residue was partitioned between EtOAc (200 ml) and H 2 O (200 ml).
- the aqueous layer was extracted with EtOAc (200 mL ⁇ 2) and all organic layers were combined and dried over Na 2 SO 4 . Concentration in vacuum gave 15-2 (10.5 g) as colorless oil.
- Step B Preparation of ethyl 2-allyl-2,3-dihydro-1H-indene-2-carboxylate (15-4).
- 15-2 6.0 g, 31.5 mmol
- THF 120 ml
- NaHMDS 38 mL, 37.8 mmol
- the reaction mixture was stirred at ⁇ 78° C. for 1 h under N 2 , then 15-3 (4.6 g, 37.8 mmol) was added at ⁇ 78° C.
- the reaction mixture was stirred at ⁇ 78° C. for 2 h.
- the reaction mixture was diluted with sat.
- Step C Preparation of ethyl 2-(2-oxoethyl)-2,3-dihydro-1H-indene-2-carboxylate (15-5).
- TEA 5.7 g, 56.4 mmol
- the reaction mixture was diluted with sat. NaHCO 3 aq (150 ml), then extracted with DCM (150 ml ⁇ 3).
- the combined organic layer was dried with Na 2 SO 4 , filtered and concentrated in vacuum to obtain 15-5 (6.0 g) as a light yellow oil, used directly in the next step.
- Step D Preparation of 1,3-dihydrospiro[indene-2,3′-pyrrolidin]-2′-one (15-6).
- 15-5 1.0 g, 4.30 mmol
- MeOH 25 ml
- AcOH 25 ml
- NaCNBH 3 405 mg, 6.45 mmol
- the reaction mixture was diluted with sat. NaHCO 3 aq (250 ml) and extracted with DCM (150 ml ⁇ 3).
- Step E Preparation of 5-nitro-1,3-dihydrospiro[indene-2,3′-pyrrolidin]-2′-one (15-7).
- a solution of 15-6 (900 mg, 4.80 mmol) in HNO 3 (20 ml, 70%) was stirred at 0° C. for 2 h.
- the reaction mixture was diluted with H 2 O (30 ml) and extracted with DCM (30 ml ⁇ 3).
- the combined organic layer was concentrated in vacuum and purified by silica-gel column chromatography using a gradient (10 to 80%) of EtOAc in PE to obtain 15-7 (700 mg) as light yellow solid.
- Step F Preparation of 5-nitro-1,3-dihydrospiro[indene-2,3′-pyrrolidine] (15-8).
- 15-7 100 mg, 0.43 mmol
- B 2 H 6 -Me 2 S 0.8 ml, 8.60 mmol
- the reaction mixture was quenched with MeOH (50 ml), then concentrated in vacuum and purified by preparative HPLC chromatography with acetonitrile in water with 0.05% HCl to obtain 15-8 (50 mg) as light yellow oil.
- Step G Preparation of tert-butyl 5-nitro-1,3-dihydrospiro[indene-2,3′-pyrrolidine]-1′-carboxylate (15-9).
- 15-8 (217 mg, 0.99 mmol)
- DMAP 61 mg, 0.50 mmol
- TEA 1.0 g, 9.90 mmol
- Boc 2 O (648 mg, 2.97 mmol)
- the reaction mixture was heated at 45° C. for 2 h.
- the reaction mixture was diluted with H 2 O (20 ml) and extracted with EtOAc (20 ml ⁇ 3).
- the combined organic layer was concentrated in vacuum and purified by silica-gel column chromatography using a gradient (0 to 20%) of EtOAc in PE to obtain 15-9 (250 mg) as light yellow oil.
- Step H Preparation of tert-butyl 5-amino-1,3-dihydrospiro[indene-2,3′-pyrrolidine]-1′-carboxylate (15-10).
- Pd/C 10 mg, 10%
- the reaction mixture was filtered and concentrated in vacuum.
- Step I Preparation of N2-(1,3-dihydrospiro[indene-2,3′-pyrrolidin]-5-yl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (277).
- a vial of 1-8 25 mg, 0.075 mmol), 15-10 (28 mg, 0.112 mmol), cesium carbonate (48.6 mg, 0.149 mmol), BrettPhos (8.01 mg, 0.015 mmol), and BrettPhos Pd G4 (13.73 mg, 0.015 mmol) in degassed 1,4-dioxane (1 ml) was heated to 110° C. for 16 h.
- Step A Preparation of 4-(2-(4-nitro-1H-pyrazol-1-yl)ethyl)morpholine (16-3).
- 16-1 0.5 g, 4.42 mmol
- DMF 5.0 ml
- K 2 CO 3 1.83 g, 13.26 mmol
- 16-2 1.06 g, 5.52 mmol
- the reaction mixture was stirred at 25° C. for 16 h.
- the reaction mixture was diluted with ice-cold water and extracted with EtOAc (50 ml ⁇ 3).
- Step B Preparation of 1-(2-morpholinoethyl)-1H-pyrazol-4-amine (16-4).
- 16-3 500 mg, 2.2 mmol
- EtOAc 25 ml
- 10% Pd/C 50 mg
- the reaction mixture stirred at 25° C. for 16 h under H 2 balloon pressure.
- the reaction mixture was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure to get crude residue 16-4 (275 mg) as a viscous liquid.
- the crude product was used directly in the next step without further purification.
- Step C Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (84).
- TFA (1 ml) and DCM (1 ml) were added to the residue and stirred at 25° C. for 16 h. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 20%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (10 mg). [M+H] + calcd for C 23 H 26 N 10 O 458.53, found 459.2.
- Step A Preparation of N2-(4-bromophenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (17-2).
- a vial of 1-8 (485 mg, 1.624 mmol), and 17-1 (559 mg, 3.25 mmol) in ethanol (8 ml) was heated at 80° C. for 16 h.
- the precipitate from the reaction mixture was collected by vacuum filtration to give the crude residue 17-2 (620 mg), used directly in the next step without further purification.
- [M+H] + calcd for C 20 H 16 BrN 7 434.30, found 436.2.
- Step B Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(4-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)phenyl)pyrimidine-2,4-diamine (538).
- Step A Preparation of tert-butyl (2-(4-(4-aminophenyl)-1H-pyrazol-1-yl)ethyl)(methyl)carbamate (18-2).
- a vial of 18-1 (96 mg, 0.274 mmol), 17-1 (39.3 mg, 0.228 mmol), potassium carbonate (95 mg, 0.685 mmol), and Pd(dppf)Cl 2 (33.4 mg, 0.046 mmol) in degassed 1,4-dioxane (1218 ⁇ l) and H 2 O (304 ⁇ l) was heated at 110° C. for 16 h.
- Step B Preparation of N2-(4-(1-(2-(methylamino)ethyl)-1H-pyrazol-4-yl)phenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (347).
- Step A Preparation of bis(2-chloropyrimidin-4-yl)amine (19-2).
- a suspension of 19-1 (11.5 g, 77.2 mmol), 1-7 (10.0 g, 77.2 mmol) and Cs 2 CO 3 (50.3 g, 154 mmol) in DMF (300 ml) was heated at 80° C. for 16 h.
- the reaction mixture was filtered and the filtrate was concentrated in vacuum and purified by preparative HPLC chromatography using a gradient (2 to 55%) of acetonitrile in water with 0.1% trifluoroacetic acid to yield 19-2 (4.5 g) as yellow solid.
- Step B Preparation of N4-(2-chloropyrimidin-4-yl)-N2-(4-morpholinophenyl)pyrimidine-2,4-diamine (19-3).
- 19-2 2.0 g, 8.26 mmol
- Cs 2 CO 3 3.6 g, 11.0 mmol
- Pd(OAc) 2 123 mg, 0.551 mmol
- Xantphos 319 mg, 0.551 mmol
- Step C Preparation of N4-(2-iodopyrimidin-4-yl)-N2-(4-morpholinophenyl)pyrimidine-2,4-diamine (19-4).
- 19-3 690 mg, 1.80 mmol
- NaI 1.6 g, 10.8 mmol
- CHCl 3 10 ml
- HI/H 2 O 20 ml, 45%
- EtOAc 30 ml ⁇ 2
- Step D Preparation of N4-(2-(3-methyl-1H-indazol-4-yl)pyrimidin-4-yl)-N2-(4-morpholinophenyl)pyrimidine-2,4-diamine (19-6).
- 19-4 20 mg, 0.042 mmol
- sodium carbonate 22.30 mg, 0.210 mmol
- Pd(dppf)Cl 2 6.16 mg, 0.0084 mmol
- Step A Preparation of 3-fluoro-6-iodo-2-methylpyridine (20-2).
- 20-1 2.0 g, 10.5 mmol
- MeCN MeCN
- NaI 4.8 g, 31.5 mmol
- HI aq. 2.5 ml, 47% in H 2 O
- the mixture was heated at 135° C. for 1 h under microwave.
- the reaction was poured into cold sat. NaHCO 3 (300 ml).
- the resulting mixture was extracted with EtOAc (150 ml ⁇ 3).
- the organic layers were washed with sat.
- Step B Preparation of 3-fluoro-6-iodo-2-methylpyridine 1-oxide (20-3).
- 20-2 10 g, 42.2 mmol
- toluene 200 ml
- mCPBA 17.1 g, 84.4 mmol, 85% purity
- the mixture was stirred at 25° C. for 2 h.
- the reaction mixture was poured into ice saturated NaHCO 3 aq. (500 ml).
- the resulting mixture was extracted with EtOAc (500 ml ⁇ 5).
- the combined organic layer was washed with Na 2 SO 3 aq.
- Step C Preparation of (3-fluoro-6-iodopyridin-2-yl)methanol (20-4). 20-3 (10.5 g, 41.49 mmol) was added into TFAA (100 ml) in batches. The reaction mixture was stirred at 35° C. for 16 h. The reaction mixture was poured into ice NaHCO 3 aq. (500 ml). The resulting mixture was extracted with EtOAc (200 ml ⁇ 3). The combined organic layer was concentrated to dryness to give a crude product. This crude product was dissolved in DCM (80 ml) and H 2 O (80 ml). Then K 2 CO 3 (22.9 g, 165.97 mmol) was added. The reaction mixture was heated at 40° C.
- Step D Preparation of 3-fluoro-6-iodopicolinaldehyde (20-5).
- DCM 160 ml
- DMP 24.5 g, 57.8 mmol
- the reaction was stirred at 25° C. for 2 h.
- the reaction was poured into cold sat. NaHCO 3 (500 ml).
- the mixture was extracted with EtOAc (200 ml ⁇ 5).
- Step E Preparation of 2-(difluoromethyl)-3-fluoro-6-iodopyridine (20-6).
- DCM 100 ml
- DAST 7.5 g, 46.6 mmol
- the reaction mixture was warmed slowly and stirred at 20° C. for another 2 h.
- the reaction mixture was neutralized with sat. NaHCO 3 aq. (500 ml), then the resulting mixture was extracted with EtOAc (150 ml ⁇ 3).
- Step F Preparation of (6-(difluoromethyl)-5-fluoropyridin-2-yl)boronic acid (20-8).
- 20-6 1.g, 6.59 mmol
- B(OPr-i) 3 2.5 g, 13.4 mmol
- i-PrMgCl 16.5 mL, 32.9 mmol, 2.0 M/L
- H 2 O 100 ml
- MTBE 50 ml ⁇ 3
- Step G Preparation of N4-(2-(6-(difluoromethyl)-5-fluoropyridin-2-yl)pyrimidin-4-yl)-N2-(4-morpholinophenyl)pyrimidine-2,4-diamine (426).
- 20-8 (16 mg, 0.084 mmol) followed by sodium carbonate (22.30 mg, 0.210 mmol) and Pd(dppf)Cl 2 (6.16 mg, 0.0084 mmol).
- the resulting mixture was purged with N 2 before degassed water (1 ml) and 1,4-dioxane (1 ml) was added.
- Step A Preparation of tert-butyl 4-(4-((4-((2-chloropyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate (21-1).
- a suspension of 19-2 2.6 g, 10.8 mmol
- 1,4-dioxane 72 ml
- 2-1 2.0 g, 7.21 mmol
- Cs 2 CO 3 4.7 g, 14.2 mmol
- Pd(OAc) 2 (162 mg, 0.721 mmol)
- Xantphos (417 mg, 0.721 mmol
- Step B Preparation of N4-(2-chloropyrimidin-4-yl)-N2-(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine (21-2).
- TFA 1.0 g, 15.1 mmol
- the reaction mixture was filtered and the filtrate was dried in vacuum to obtain 21-2 (520 mg) as white solid, used directly in the next step.
- Step C Preparation of N4-(2-iodopyrimidin-4-yl)-N2-(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine (21-3).
- 21-2 520 mg, 1.36 mmol
- NaI 1.2 g, 8.15 mmol
- CHCl 3 10 ml
- HI/H 2 O 20 ml, 45%
- Step D Preparation of N4-(2-(5-chloro-2,4-difluorophenyl)pyrimidin-4-yl)-N2-(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine (556).
- compound 21-3 10 mg, 0.021 mmol
- 21-4 8.08 mg, 0.042 mmol
- sodium carbonate 11.17 mg, 0.105 mmol
- Pd(dppf)Cl 2 3.09 mg, 0.0042 mmol
- the resulting mixture was purged with N 2 before degassed water (290 ⁇ l) and 1,4-dioxane (290 ⁇ l) was added.
- Step A Preparation of tert-butyl methyl(1-(4-nitrophenyl)piperidin-4-yl)carbamate (22-2).
- 5-1 4.0 g, 18.7 mmol
- DMF 60 ml
- 22-1 2.6 g, 18.7 mmol
- K 2 CO 3 5.2 g, 37.3 mmol
- the reaction mixture was stirred at 25° C. for 15 h.
- the reaction was filtrated and the cake was washed with EtOAc (80 ml ⁇ 2).
- the filtrate was poured into 250 ml of H 2 O.
- the mixture was extracted with EtOAc (150 ml ⁇ 3).
- the organic layer was washed with sat.
- Step B Preparation of tert-butyl (1-(4-aminophenyl)piperidin-4-yl)(methyl)carbamate (22-3).
- Pd/C 500 mg, 10%.
- the reaction mixture was stirred at 25° C. for 15 h under H 2 balloon.
- the reaction mixture was filtrated through a pad of Celite and the solvent was removed in vacuum to dryness to give crude residue 22-3 (4.5 g) as light pink solid, used directly in the next step.
- Step C Preparation of tert-butyl (1-(4-((4-((2-chloropyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperidin-4-yl)(methyl)carbamate (22-4).
- a suspension of 19-3 (95 mg, 0.393 mmol), 22-3 (100 mg, 0.327 mmol), Pd(OAc) 2 (7 mg, 0.033 mmol), Xantphos (19 mg, 0.033 mmol) and Cs 2 CO 3 (213 mg, 0.655 mmol) in 1,4-dioxane (9 ml) was heated at 120° C. under microwave for 3 h under N 2 .
- Step D Preparation of N4-(2-chloropyrimidin-4-yl)-N2-(4-(4-(methylamino)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine (22-5).
- a suspension of 22-4 (400 mg, 0.783 mmol) in HCl/EA (25 ml, 4M) was stirred at 0° C. for 1 h.
- the solvent was removed in vacuum to give crude residue 22-5 (500 mg) as pink solid, used directly in the next step.
- Step E Preparation of N4-(2-iodopyrimidin-4-yl)-N2-(4-(4-(methylamino)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine (22-6).
- 22-5 400 mg, 0.973 mmol
- CHCl 3 5 ml
- HI/H 2 O 30 ml, 45% in H 2 O
- the reaction mixture was stirred at 25° C. for 11 d.
- the reaction was poured into 100 ml of ice water at 0° C. 15 g of Na 2 SO 3 was added to the solution. pH of the solution was adjusted to 8 with sat. NaHCO 3 .
- Step F Preparation of 4-methyl-3-(4-((2-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)pyrimidin-2-yl)phenol (255).
- 22-6 15 mg, 0.026 mmol
- 22-7 12 mg, 0.079 mmol
- sodium carbonate 13.91 mg, 0.131 mmol
- Pd(dppf)Cl 2 3.85 mg, 0.0052 mmol
- Step A Preparation of tert-butyl 4-((2-aminothiazol-4-yl)methyl)piperazine-1-carboxylate (23-3).
- 23-1 150 mg, 0.807 mmol
- 23-2 100 mg, 0.673 mmol
- DIEA 0.59 ml, 3.36 mmol
- the reaction mixture was heated at 110° C. for 1 h.
- the reaction mixture was concentrated in vacuum and was purified by silica-gel column chromatography using a gradient (0 to 15%) of MeOH in DCM to obtain 23-3 (120 mg) as yellow oil.
- Step B Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(4-(piperazin-1-ylmethyl)thiazol-2-yl)pyrimidine-2,4-diamine (287).
- a vial of 1-8 100 mg, 0.335 mmol
- 23-3 120 mg, 0.402 mmol
- cesium carbonate 218 mg, 0.669 mmol
- Xantphos 38.7 mg, 0.067 mmol
- Pd(OAc) 2 15.03 mg, 0.067 mmol) in degassed 1,4-dioxane (3.3 ml) was heated at 110° C. for 16 h.
- the reaction mixture was concentrated in vacuum.
- Step A Preparation of methyl 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-2-carboxylate (24-2).
- 24-1 1.21 g, 4.07 mmol
- Cs 2 CO 3 3.30 g, 10.18 mmol
- reaction mixture was purged with N 2 for 5 min, followed by addition of Pd 2 (dba) 3 (233 mg, 0.25 mmol) and BINAP (317 mg, 0.05 mmol), then heated at 110° C. for 6 h in a sealed vial.
- the reaction mixture was diluted with EtOAc, filtered through a Celite bed, and concentrated to obtain the crude residue.
- the residue was purified by silica-gel column chromatography using a gradient (0 to 3%) of MeOH in DCM to obtain 24-2 (820 mg) as yellow solid. [M+H] + calcd for C 20 H 17 N 7 O 2 S 419.46, found 420.12.
- Step B Preparation of (4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophen-2-yl)methanol (24-3).
- 24-2 800 mg, 1.90 mmol
- LAH 1.90 ml, 3.81 mmol
- the reaction stirred at 25° C. for 2 h.
- the reaction mixture was cooled to ⁇ 30° C. and quenched with saturated ammonium chloride solution, diluted with EtOAc and filtered through Celite bed, then concentrated to get crude residue.
- Step C Preparation of 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-2-carbaldehyde (24-4).
- 24-3 250 mg, 0.63 mmol
- DCM 8 ml
- MnO 2 1.39 g, 15.98 mmol
- the reaction mixture was diluted with DCM, filtered through Celite bed, and concentrated to afford the crude residue which was purified by washing with diethyl ether and ACN to obtain 24-4 (180 mg) as yellow solid.
- Step D Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(5-(piperazin-1-ylmethyl)thiophen-3-yl)pyrimidine-2,4-diamine (94).
- DMA dimethyl methacrylate
- STAB a compound that was added to the reaction mixture and the resulting mixture heated at 45° C. for 30 min.
- Step A Preparation of N2-(3-aminophenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (29-2).
- IPA a mixture of 1-8 (400 mg, 1.34 mmol) and 29-1 (144 mg, 1.34 mmol) in IPA (10 ml) was added HCl (0.5 ml).
- the reaction mixture was heated at 80° C. for 16 h.
- the reaction mixture was filtered.
- the filtrate was concentrated in vacuum and purified by silica-gel column chromatography using a gradient (0 to 5%) of MeOH in DCM to give 29-2 (280 mg) as yellow solid.
- Step B Preparation of N-(3-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperidine-3-carboxamide (443).
- HATU 30.8 mg, 0.081 mmol
- DIEA 0.028 ml, 0.162 mmol
- TFA (229 ⁇ l) and DCM (191 ⁇ l) were added to the residue and heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (35.1 mg). [M+H] + calcd for C 25 H 25 N 9 O 2 483.54, found 484.0.
- Step A Preparation of 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-2-carboxylic acid (30-1).
- the cake was dried in vacuum to afford 30-1 (1.2 g) as a yellow solid.
- Step B Preparation of N2-(5-isocyanatothiophen-3-yl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (30-3).
- 30-1 1.0 g, 2.46 mmol
- TEA 1.5 g, 14.8 mmol
- THF 20 ml
- 30-2 2.1 g, 22.3 mmol
- Step C Preparation of N2-(5-aminothiophen-3-yl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (30-4).
- a solution of 30-3 (800 mg, 1.19 mmol) in HCl (10 ml, 6.0 M) was stirred at 50° C. for 12 h.
- the reaction mixture was concentrated in vacuum.
- the residue was purified by preparative HPLC chromatography using a gradient (0 to 32%) of acetonitrile in water with 0.05% HCl to obtain 30-4 (120 mg) as a white solid.
- Step D Preparation of N-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophen-2-yl)piperidine-4-carboxamide (452).
- Step A Preparation of methyl 2-(2-fluoro-5-nitrophenyl)acetate (31-2).
- 31-1 10 g, 50.25 mmol
- MeOH 70 ml
- H 2 SO 4 5.3 ml, 100 mmol
- the reaction mixture was refluxed for 16 h.
- Solvent was removed under reduced pressure and was carefully quenched using bicarbonate solution and extracted with EtOAc.
- the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product 31-2 (10 g).
- Step B Preparation of tert-butyl 4-(2-(2-methoxy-2-oxoethyl)-4-nitrophenyl)piperazine-1-carboxylate (31-3).
- DIPEA (12.61 ml, 70.41 mmol) followed by 23-1 (4.3 g, 23.47 mmol).
- the reaction mixture was heated at 100° C. for 16 h.
- the reaction mixture was then diluted with water and extracted with EtOAc (100 ml ⁇ 3).
- the combined organic layer was again washed with ice cold water followed by brine and dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure.
- Step C Preparation of 2-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-5-nitrophenyl)acetic acid (31-4).
- 31-3 1.0 g, 2.63 mmol
- H 2 O 5 ml
- LiOH ⁇ H 2 O 540 mg, 13.19 mmol
- the reaction mixture was stirred at 25° C. for 16 h, then diluted with water and extracted with EtOAc at pH ⁇ 3. The organic layer was washed with brine, dried over sodium sulphate and concentrated under reduced pressure to give the crude residue.
- Step D Preparation of tert-butyl (R)-4-(2-(2-(sec-butoxy)-2-oxoethyl)-4-nitrophenyl)piperazine-1-carboxylate (31-6).
- 31-4 550 mg, 1.50 mmol
- DCM 20 ml
- DMAP 18 mg, 0.15 mmol
- EDCHCl 573 mg, 3.01 mmol
- Step E Preparation of tert-butyl (R)-4-(4-amino-2-(2-(sec-butoxy)-2-oxoethyl)phenyl)piperazine-1-carboxylate (31-7).
- IPA IPA
- Pd/C 400 mg
- H 2 balloon pressure IPA
- the reaction mixture was allowed to stir at 25° C. for 1 h, then filtered through Celite bed and washed with MeOH. Filtrate was concentrated under vacuum to get crude residue 31-7 (350 mg), used in next step without any purification.
- [M+H] + calcd for C 21 H 33 N 3 O 4 391.51, found 392.13.
- Step F Preparation of tert-butyl (R)-4-(2-(2-(sec-butoxy)-2-oxoethyl)-4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate (31-8).
- 31-7 344 mg, 0.88 mmol
- 1,4-dioxane (10 ml) was added 1-8 (175 mg, 0.587 mmol) and Cs 2 CO 3 (381 mg, 1.17 mmol) under N 2 atmosphere.
- the reaction mixture was degassed with N 2 for 10 min, followed by addition of Brettphos (63 mg, 0.117 mmol) and Brettphos Pd G4 (54 mg, 0.058 mmol), then heated at 110° C. for 16 h.
- the reaction mixture was diluted with EtOAc and filtered through Celite bed. Filtrate was diluted with cold water and extracted with ethyl acetate (25 mL ⁇ 2). The organic layer was dried over dry Na 2 SO 4 , filtered and concentrated to get crude residue.
- the residue was purified by silica-gel column chromatography using a gradient (0 to 3%) of MeOH in DCM to obtain 31-8 (200 mg). [M+H] + calcd for C 35 H 43 N 9 O 4 653.79, found 654.17.
- Step G Preparation of (R)-sec-butyl 2-(5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)-2-(piperazin-1-yl)phenyl)acetate (13).
- TFA 1 ml
- the reaction mixture was stirred at 25° C., then concentrated under reduced pressure and further triturated with diethyl ether to get the title compound (205 mg) as an off white solid.
- Step A Preparation of methyl 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoate (32-2).
- PTSA (1.11 g, 5.87 mmol)
- the reaction mixture was concentrated to dryness and triturated using diethyl ether to get the 32-2 (4.1 g) as PTSA salt.
- Step B Preparation of (4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)methanol (32-3).
- a stirred solution 32-2 (4.1 g, 9.92 mmol) in THF (50 ml) was added LAH (15.0 ml, 29.71 mmol) dropwise at 0° C.
- the reaction mixture was allowed to stir at 0° C. for 2 h, then quenched with water:THF (6:18 ml) under cooling followed by the addition of 15% NaOH (15 ml). It was then filtered through Celite bed and the organic layer separated and concentrated to get crude residue.
- the residue was purified by silica-gel column chromatography to obtain 32-3 (3.0 g). [M+H] + calcd for C 21 H 19 N 7 O 385.43, found 386.14.
- Step C Preparation of 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzaldehyde (32-4).
- 32-3 (3.0 g, 7.8 mmol) in DMA (30 ml) was added MnO 2 (20.4 g, 234 mmol) at 25° C.
- MnO 2 (20.4 g, 234 mmol)
- the reaction mixture was allowed to stir at 25° C. for 6 h, then filtered and the filtrate concentrated to get crude residue.
- the residue obtained was triturated with ACN to obtain 32-4 (2.2 g), used in next step without further purification.
- [M+H] + calcd for C 21 H 17 N 7 O 383.42, found 384.16.
- Step D Preparation of tert-butyl 1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-4-carboxylate (32-6).
- 32-4 2.1 g, 5.48 mmol
- DMA:DCE 10:20 ml
- STAB 3.48 g, 16.44 mmol
- Step E Preparation of 1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-4-carboxylic acid (32-7).
- 32-6 1. g, 2.53 mmol
- TFA 14 ml
- the reaction mixture was stirred at 0° C. for 6 h.
- the reaction mixture was concentrated and triturated with diethyl ether and ACN to obtain 32-7 (1.2 g). [M+H] + calcd for C 27 H 28 N 8 O 2 496.58, found 497.48.
- Step F Preparation of (R)-1-methylpyrrolidin-3-yl 1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-4-carboxylate (414).
- 32-7 300 mg, 0.604 mmol
- DMF 5.0 ml
- 32-8 170 mg, 0.906 mmol
- DCC 373 mg, 1.812 mmol
- DMAP 37 mg, 0.302 mmol
- Step A Preparation of N2-(4-(chloromethyl)phenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (33-1).
- 32-2 425 mg, 1.103 mmol
- DCM 31.5 ml
- SOCl 2 177 ⁇ l, 2.426 mmol
- the reaction mixture was concentrated in vacuum to obtain 33-1 (445 mg) as a yellow solid, used directly in the next step.
- Step B Preparation of tert-butyl (R)-1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-3-carboxylate (33-3).
- 33-1 445 mg, 1.1 mmol
- DCM 18 ml
- 33-2 488 mg, 2.2 mmol
- DIEA 0.61 ml, 5.0 mmol
- the reaction mixture was concentrated in vacuum to give a crude residue.
- the residue was purified by silica-gel column chromatography using a gradient (0 to 15%) of MeOH in DCM to produce 33-3 (608 mg). [M+H] + calcd for C 31 H 36 N 8 O 2 552.68, found 553.1.
- Step C Preparation of (R)-1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-3-carboxylic acid (33-4).
- 33-3 608 mg, 1.1 mmol
- DCM 3.5 ml
- TFA 4.2 ml
- Step D Preparation of azetidin-3-ylmethyl (R)-1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-3-carboxylate (400).
- a solution of 33-4 (75 mg, 0.104 mmol), 33-5 (38.8 mg, 0.207 mmol), EDCI (39.7 mg, 0.207 mmol), and DMAP (1.27 mg, 10.4 ⁇ mol) in DCM (0.5 ml) was stirred at 25° C. for 16 h.
- TFA (279 ⁇ l) was added to the reaction mixture and was heated at 45° C. for 30 min.
- Step A Preparation of 1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)azetidine-3-carboxylic acid (34-2).
- 34-1 204 mg, 1.30 mmol
- DIEA 0.567 ml, 3.25 mmol
- Step B Preparation of azetidin-3-ylmethyl 1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)azetidine-3-carboxylate (88).
- a solution of 34-2 (23 mg, 0.033 mmol), 33-5 (9.27 mg, 0.050 mmol), HATU (18.83 mg, 0.050 mmol), DMAP (0.40 mg, 3.3 ⁇ mol), and DIEA (23.0 ⁇ l, 0.132 mmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h.
- Step A Preparation of methyl 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-4-carboxylate (35-2).
- 1-8 3.6 g, 12.2 mmol
- 1,4-dioxane 100 ml
- 35-1 2.5 g, 15.8 mmol
- Cs 2 CO 3 8.0 g, 24.4 mmol
- Pd 2 (dba) 3 1.1 g, 1.22 mmol
- BINAP 760 mg, 1.22 mmol
- Step B Preparation of (2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazol-4-yl)methanol (35-3).
- LAH 9 mg ⁇ 16, 0.238 mmol ⁇ 16
- the reaction mixture was stirred at 25° C. for 20 min.
- the reaction mixture was diluted with Rochelle salt solution (100 ml) and extracted with DCM (200 ml ⁇ 3), The organic layer was dried over Na 2 SO 4 , filtered, and concentrated in vacuum.
- Step C Preparation of N2-(4-(chloromethyl)thiazol-2-yl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (35-4).
- 35-3 101 mg, 0.257 mmol
- DCM dimethylethyl
- SOCl 2 92 mg, 0.771 mmol
- the reaction mixture was stirred at 25° C. for 2 h.
- the reaction mixture was concentrated in vacuum.
- the residue was purified by trituration to give 35-4 (50 mg) as yellow solid.
- Step D Preparation of (R)-1-((2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazol-4-yl)methyl)piperidine-3-carboxylic acid (35-6).
- 35-4 200 mg, 0.487 mmol
- 35-5 (162 mg, 0.730 mmol
- DIEA 425 ⁇ l, 2.434 mmol
- TFA 938 ⁇ l
- Step E Preparation of (S)-1-methylpyrrolidin-3-yl (R)-1-((2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazol-4-yl)methyl)piperidine-3-carboxylate (508).
- Step A Preparation of 2-(4-(tert-butoxycarbonyl)-1-(4-nitrophenyl)piperazin-2-yl)acetic acid (36-2).
- 5-1 1.0 g, 7.09 mmol
- 36-1 2.195 g, 8.51 mmol
- water 3 ml
- potassium carbonate 4.9 g, 35.46 mmol
- 18-crown-6 93 mg, 0.354 mmol
- Step B Preparation of tert-butyl 3-(2-methoxy-2-oxoethyl)-4-(4-nitrophenyl)piperazine-1-carboxylate (36-3).
- 36-2 700 mg, 1.91 mmol
- MeOH 3 ml
- TMS-CHN 2 in hexane 2M
- Step C Preparation of tert-butyl 4-(4-aminophenyl)-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate (36-4).
- 36-3 1.3 g, 3.43 mmol
- IPA IPA (20 ml, 1:1)
- 10% Pd/C 1.3 g
- the reaction mixture was filtered through Celite bed and the residue was washed with EtOAc.
- the organic layer was then evaporated under reduced pressure to get the crude product 36-4 (1.3 g), which was used directly for the next step.
- Step D Preparation of tert-butyl 3-(2-methoxy-2-oxoethyl)-4-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate (36-5).
- Step E Preparation of 2-(4-(tert-butoxycarbonyl)-1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-2-yl)acetic acid (36-6).
- 36-5 1.29 mmol
- MeOH MeOH
- THF 5 ml
- water 2.5 ml
- LiOH ⁇ H 2 O 0.48 g, 11.45 mmol
- Desired acid was extracted from the aqueous layer using 10% MeOH:DCM.
- the organic layer was dried over Na 2 SO 4 , filtered and concentrated to get crude residue.
- the residue was purified by silica-gel column chromatography using a gradient (5 to 10%) of MeOH in DCM to give 36-6 (1.12 g) as an off-white solid. [M+H] + calcd for C 31 H 35 N 9 O 4 597.68, found 598.32.
- Step F Preparation of (R)-1-methylpyrrolidin-3-yl 2-(1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-2-yl)acetate (103).
- a solution of 36-6 (30 mg, 0.050 mmol), 36-7 (7.62 mg, 0.075 mmol), EDCI (14.43 mg, 0.075 mmol), and DMAP (1.20 mg, 10.0 ⁇ mol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (193 ⁇ l) was added to the reaction mixture and was heated at 45° C.
- Step A Preparation of methyl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-3-carboxylate (38-2).
- Step B Preparation of 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-3-carboxylic acid (38-3).
- 38-2 900 mg, 2.14 mmol
- MeOH MeOH
- THF 4 ml
- water 2 ml
- KOH 240 mg, 4.29 mmol
- Step C Preparation of azetidin-3-ylmethyl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-3-carboxylate (142).
- a solution of 38-3 (25 mg, 0.062 mmol), 33-5 (17.32 mg, 0.092 mmol), EDCI (17.73 mg, 0.092 mmol), and DMAP (1.50 mg, 0.012 mmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h.
- TFA (238 ⁇ l) was added to the reaction mixture and was heated at 45° C. for 30 min.
- Step A Preparation of 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-4-carboxylic acid (39-1).
- a suspension of 35-2 (1.0 g, 2.38 mmol) and NaOH (1.9 g, 47.6 mmol) in MeOH (30 ml) and H 2 O (30 ml) was heated at 60° C. for 5 h.
- the reaction mixture was filtered.
- the cake was washed with H 2 O (50 ml) and lyophilized to obtain 39-1 (600 mg) as yellow solid.
- Step B Preparation of piperidin-4-yl 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-4-carboxylate (148).
- a solution of 39-1 (25 mg, 0.062 mmol), 39-2 (18.57 mg, 0.092 mmol), EDCI (17.69 mg, 0.092 mmol), and DMAP (1.50 mg, 0.012 mmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (351 ⁇ l) was added and the reaction mixture was heated at 45° C. for 30 min.
- Step A Preparation of ethyl 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-5-carboxylate (40-2).
- a stirred solution of 1-8 (600 mg, 2.013 mmol) and 40-1 (519 mg, 3.019 mmol) in 1,4-dioxane (12 ml) was added cesium carbonate (1.3 g, 4.026 mmol) and purged for 15 min.
- Pd2(dba)3 184 mg, 0.201 mmol
- BINAP 250 mg, 0.402 mmol
- Step B Preparation of 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-5-carboxylic acid (40-3).
- 40-2 300 mg, 0.69 mmol
- 1,4-dioxane:water 9.0:0.5 ml
- 6N HCl 1.5 ml
- the reaction mixture was heated at 90° C. for 12 h.
- the reaction mixture was concentrated completely to dryness.
- the resulting residue was triturated using MeOH, DCM, diethyl ether and ACN to get desired compound which was purified further through preparative HPLC chromatography to obtain 40-3 (70 mg).
- Step C Preparation of azetidin-3-ylmethyl 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-5-carboxylate (338).
- a solution of 40-3 (15 mg, 0.037 mmol), 33-5 (10.37 mg, 0.055 mmol), EDCI (10.61 mg, 0.055 mmol), and DMAP (0.90 mg, 7.38 ⁇ mol) in DCM (0.5 ml) was stirred at 25° C. for 16 h.
- TFA 142 ⁇ l was added to the reaction mixture and was heated at 45° C. for 30 min.
- Step A Preparation of methyl 3-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoate (41-2).
- IPA a mixture of 1-8 (600 mg, 2.01 mmol) and 41-1 (304 mg, 2.01 mmol) in IPA (10 ml) was added HCl (0.5 mL).
- the reaction mixture was heated at 80° C. for 16 h.
- the reaction mixture was quenched with H 2 O (30 ml) and filtered.
- the filter cake was evaporated to dryness to give 41-2 (820 mg) as white solid.
- Step B Preparation of 3-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoic acid (41-3).
- a mixture of 41-2 (780 mg, 1.87 mmol) in EtOH (10 ml) and aq. NaOH (10 ml) was heated at 80° C. for 16 h.
- the reaction mixture was concentrated in vacuum to remove EtOH.
- To the residue was added HCl to adjust the pH to 5, then the mixture was filtered.
- the filter cake was washed with H 2 O (30 ml) and the residue was evaporated to dryness to give 41-3 (530 mg) as yellow solid.
- Step C Preparation of azetidin-3-ylmethyl 3-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoate (178).
- a solution of 41-3 (25 mg, 0.063 mmol), 33-5 (17.58 mg, 0.094 mmol), EDCI (18.00 mg, 0.094 mmol), and DMAP (1.53 mg, 0.013 mmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h.
- TFA 240 ⁇ l was added to the reaction mixture and was heated at 45° C. for 30 min.
- Step A Preparation of 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoic acid (42-1).
- the reaction mixture was concentrated in vacuum to remove EtOH.
- To the residue was added HCl to adjust the pH to 5, then the mixture was filtered.
- the filter cake was washed with H 2 O (30 ml) and the residue evaporated to dryness to give 42-1 (530 mg) as yellow solid.
- Step B Preparation of azetidin-3-ylmethyl 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoate (33).
- a solution of 42-1 (25 mg, 0.063 mmol), 33-5 (17.58 mg, 0.094 mmol), EDCI (18.00 mg, 0.094 mmol), and DMAP (1.53 mg, 0.013 mmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h.
- TFA 240 ⁇ l was added to the reaction mixture and was heated at 45° C. for 30 min.
- Step A Preparation of methyl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)picolinate (43-2).
- a vial of 1-8 250 mg, 0.837 mmol), 44-1 (127 mg, 0.837 mmol), cesium carbonate (545 mg, 1.674 mmol), BrettPhos (44.9 mg, 0.084 mmol), and BrettPhos Pd G4 (77 mg, 0.084 mmol) in degassed 1,4-dioxane (4.2 ml) was heated to 110° C. for 16 h.
- Step B Preparation of 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)picolinic acid (43-3).
- Step C Preparation of azetidin-3-ylmethyl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)picolinate (545).
- Step A Preparation of methyl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)nicotinate (44-2).
- a vial of 1-8 250 mg, 0.837 mmol), 44-1 (127 mg, 0.837 mmol), cesium carbonate (545 mg, 1.674 mmol), BrettPhos (44.9 mg, 0.084 mmol), and BrettPhos Pd G4 (77 mg, 0.084 mmol) in degassed 1,4-dioxane (4.2 ml) was heated to 110° C. for 16 h.
- Step B Preparation of 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)nicotinic acid (44-3).
- 44-2 214 mg, 0.516 mmol
- LiOH 24.73 mg, 1.033 mmol
- THF 1291 ⁇ l
- MeOH 861 ⁇ l
- H 2 O 430 ⁇ l
- Step C Preparation of (R)-pyrrolidin-3-yl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)nicotinate (549).
- a solution of 44-3 (20 mg, 0.039 mmol), 44-4 (10.92 mg, 0.058 mmol), HATU (22.17 mg, 0.058 mmol), and DIEA (27.2 ⁇ l, 0.156 mmol) in DCM (0.5 ml) was heated to 50° C. for 1 h. TFA (120 ⁇ l) was added to the reaction mixture and stirred at 25° C. for 30 min.
- Apparent pKi values for compounds of the present disclosure were determined using a recombinant human ALK5 (TGF- ⁇ R1) protein (Product No. PR9075A or equivalent, Life Technologies) and a commercially-available kinase assay (LANCE® (lanthanide chelate excite) Ultra ULightTM kinase assay, Product Nos. TRF0130-M and TRF02108-M, Perkin Elmer) as described below.
- TGF- ⁇ R1 human ALK5 protein
- LANCE® lanthanide chelate excite
- the assays were performed in a 384-well plate (24 columns ⁇ 16 wells/rows).
- An Echo®550 Liquid Handler (Labcyte) was used to prepare various intermediate concentrations of compounds of the present disclosure in 100% DMSO. From the intermediate concentrations, a range of concentrations (from 10 ⁇ M to 25 ⁇ M corresponding to volumes up to 105 nL) were prepared and ejected into a final assay plate to be used to create individual dose response curves for each of the subject compounds.
- 105 nL of DMSO in each well was used to establish a maximum assay signal.
- 105 nL of 100 ⁇ M SD-208, a selective TGF- ⁇ R1 inhibitor (Catalog #S7624, Selleck Chemicals), was used in another column of wells to establish a minimal assay signal.
- the enzyme mixture consisted of 250 ⁇ M ALK5 enzyme and 62.5 nM peptide substrate (LANCE® (lanthanide chelate excite) Ultra ULightTM-DNA Topoisomerase 2-alpha (Thr1342)) prepared in assay buffer (50 mM HEPES, 10 mM MgCl 2 , 1 mM EGTA, 0.01% Tween-20, pH 7.5 at room temperature) with 2 mM DTT added prior to use. The plate was then sealed with an adhesive seal and allowed to equilibrate for 60 minutes at room temperature.
- assay buffer 50 mM HEPES, 10 mM MgCl 2 , 1 mM EGTA, 0.01% Tween-20, pH 7.5 at room temperature
- detection antibody LANCE® (lanthanide chelate excite) Ultra Europium-anti-phospo-DNA Topoisomerase 2-alpha (Thr1342)
- detection mixture 12 mM EDTA, 4 nM detection antibody prepared in detection buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% BSA (Fraction V), pH 7.0)
- detection buffer 50 mM Tris-HCl, 150 mM NaCl, 0.5% BSA (Fraction V), pH 7.0
- the plate was then read on a Perkin Elmer EnVision Plate Reader using europium specific reader settings with excitation and emission wavelengths set to 320 or 340 nm and 665 nm, respectively. These data were used to calculate percent enzyme inhibition values based on DMSO and SD-208 background controls.
- pIC 50 values were determined from a 4-parameter robust fit model with GraphPad Prism V5 Software (GraphPad Software, Inc., La Jolla, CA). This model obtains pIC 50 values by fitting the sigmoidal dose-response (variable slope) equation to the data. Results were expressed as pIC 50 (negative logarithm of IC 50 ) and subsequently converted to pK i (negative logarithm of dissociate constant, K i ) using the Cheng-Prusoff equation. The higher the value of pK i (lower value of K i ), the greater the inhibition of ALK5 activity. Certain compounds disclosed herein exhibited pK i values of greater than 8 or greater than 9 when tested in the biochemical ALK5 assay.
- Table 3 shows biological activities of selected compounds in a biochemical ALK5 assay.
- Compound numbers correspond to the numbers and structures provided in Tables 1 and 2 and Examples 1-44.
- Example 46 Cellular ALK5 Potency Assay to Measure pIC 50 , Inhibition of TGF- ⁇ Stimulated pSMAD3 Formation in BEAS-2B Cells
- TGF- ⁇ -stimulated SMAD3 phosphorylation was measured in BEAS-2B cells, a human lung epithelial cell line. TGF- ⁇ signals through activin receptor-like kinase 5 (ALK5) immediately prior to SMAD3 phosphorylation.
- ALK5 activin receptor-like kinase 5
- BEAS-2B cells were grown using 50% DMEM (Life Technologies) and 50% F-12 (Life Technologies) media, supplemented with 10% Fetal Bovine Serum (ATCC), 25 mM HEPES (Life Technologies), and 1 ⁇ Pen-Strep (Life Technologies). Cells were cultured in a humidified incubator set at 37° C., 5% CO 2 , and trypsonized using 0.25% Trypsin with 0.5% polyvinylpyrrolidone (PVP).
- PVP polyvinylpyrrolidone
- BEAS-2B cells were seeded at 7,500 cells/well (25 ⁇ L/well) in a 384-well plate and cultured overnight. Before dosing, growth media was aspirated and the wells were rinsed with HBSS Buffer (HBSS with Calcium and Magnesium, Life Technologies) supplemented with 25 mM HEPES (Life Technologies) and 1% Bovine Serum Albumin (Roche). Compounds were serially diluted in DMSO, then further diluted with supplemented HBSS Buffer (50 ⁇ L/well) to create a compound plate 3 ⁇ of the final assay concentration, at 0.3% DMSO.
- HBSS Buffer HBSS with Calcium and Magnesium, Life Technologies
- TGF- ⁇ R&D Systems
- HBSS Buffer was added to the cells (12 ⁇ L/well, final concentration 10 ng/mL) and incubated for a further 30 minutes, after which the cells were immediately lysed with AlphaLISA lysis buffer (PerkinElmer).
- AlphaLISA Acceptor and Detector beads (PerkinElmer) were added 2 hours apart, then incubated overnight to be read the next day.
- the potency of the compound was determined through analysis of dose-dependent quantified changes in pSMAD3 signal from baseline (non-compound treated TGF- ⁇ stimulated cells). Data are expressed as pIC 50 (negative decadic logarithm IC 50 ) values. Certain compounds disclosed herein exhibited pIC 50 values of greater than 6 or greater than 7 when tested in BEAS-2B3 cells.
- Table 4 shows biological activities of selected compounds in a cellular ALK5 potency assay.
- Compound numbers correspond to the numbers and structures provided in Tables 1 and 2 and Examples 1-44.
- ATP cellular adenosine triphosphate
- Beas2B cells were grown in 50% DMEM (Life Technologies) and 50% F-12 (Life Technologies) media, supplemented with 10% Fetal Bovine Serum (ATCC), 25 mM HEPES (Life Technologies), and 1 ⁇ Pen-Strep (Life Technologies). Cells were cultured in a humidified incubator set at 37° C., 5% CO 2 , and trypsinized using 0.25% Trypsin with 0.5% polyvinylpyrrolidone (PVP).
- PVP polyvinylpyrrolidone
- Beas2B cells were seeded at 500 cells/well (25 ⁇ L/well) in a 384-well plate and cultured overnight. Compounds were serially diluted in DMSO, then further diluted with growth media (40 ⁇ L/well) to create a compound plate 6 ⁇ of the final assay concentration, at 0.6% DMSO. The diluted compounds were then added to the cells (5 ⁇ L/well) and incubated at 37° C., 5% CO 2 for 48 hours. After the compound incubation, CellTiter-Glo (Promega) was added directly to the cells (30 ⁇ L/mL).
- the assay plate was sealed and shaken at 700 rpm for 15 minutes in a darkened environment, then centrifuged for 2 minutes at 1500 rpm to settle the lysate at the bottom of the well.
- the effect of the compound on cell viability was determined through analysis of dose-dependent quantified changes in ATP from baseline (non-compound treated cells) and wells treated with 60 ⁇ M AT9283, a well-characterized cytotoxic compound. Data are expressed as pCC 15 (negative decadic logarithm CC 15 ) values. Certain compounds disclosed herein exhibited pCC 15 values of less than 6 or less than 5.5 when tested in Beas2B cells.
- Table 5 shows cytotoxicities of selected compounds in a premature chromosome condensation assay.
- Compound numbers correspond to the numbers and structures provided in Tables 1 and 2 and Examples 1-44.
- Example 48 In Vitro Human Liver Microsome Intrinsic Clearance (HLM Cl int )
- Liver microsomes were used for in vitro determination of hepatic clearance of compounds of the present disclosure.
- a microsomal incubation cofactor solution was prepared with 100 mM potassium phosphate buffered to pH 7.4 (BD Biosciences, Woburn, MA) supplemented with 2 mM NADPH (Sigma-Aldrich, St. Louis, MO). 10 mM DMSO stocks of test compound were diluted and spiked into the cofactor solution to yield a 0.2 ⁇ M concentration (0.02% v/v DMSO). Aliquots of frozen human liver microsomes (Bioreclamation IVT, Baltimore MD) were thawed and diluted into 100 mM potassium phosphate buffer to yield microsomal protein concentrations of 0.2 mg/mL.
- HLM Cl int data was reported in units of ⁇ L/min/mg. See Riley, R. J., et al., Drug Metab. Dispos., 2005, September, 33(9), pp. 1304-1311. Certain compounds disclosed herein exhibited HLM Cl int of greater than 50 ⁇ L/min/mg or greater than 100 ⁇ L/min/mg.
- mice were challenged via oral aspiration a second time with PBS vehicle or recombinant human TGF- ⁇ 1 protein (0.01 ⁇ g per animal dissolved in 1 part 4 mM HCl and 2 parts 3% glycerol in PBS).
- animals were deeply anesthetized under isoflurane and euthanized via cervical dislocation.
- Bronchoalveolar lavage fluid (BALF), plasma and left lung lobes were collected during harvest.
- BALF Bronchoalveolar lavage fluid
- BA bioanalytical
- the lungs were flushed via the trachea with 0.7 mL of PBS 3 times.
- the BALF which consists almost entirely of tissue-derived macrophages, was immediately centrifuged at 700 ⁇ g's for 15 minutes. After centrifugation, the supernatant was removed, the BALF was re-suspended in 1 ⁇ cell lysis buffer, and immediately frozen. Prior to BA submission, the BALF was dethawed and sonicated for 30 minutes on cold water to lyse open the cells
- Left lung lobes were harvested immediately after BALF collection. Lung samples were homogenized in 500 ⁇ L of 1 ⁇ cell lysis buffer. After homogenization, the samples were split: half of the sample was immediately placed on a rotisserie for 10 minutes while the other half was immediately frozen for BA analysis. The samples placed on the rotisserie were then centrifuged at 10,000 ⁇ g's for 10 minutes in order to separate the protein in the supernatant from pelleted debris. Following collection of the supernatant, a total protein quantification assay (Bradford) was performed to normalize the concentrations of all samples. Using the Hamilton star liquid handling system, each sample was diluted in 1 ⁇ cell lysis buffer to 2 mg/mL of protein. Samples were stored at ⁇ 80° C. or immediately processed using the Meso-scale Discovery system.
- MSD Meso-scale Discovery
- a coating antibody that binds the target protein(s) within the sample.
- a primary antibody is used to bind the epitope of interest.
- a secondary-antibody with a SULFO-TAG detection is used to allow for quantification of the epitope of interest.
- the microplate is read via an electric pulse that causes the SULFO-TAG to emit light, which serves as the final read-out of the assay.
- BSA bovine serum albumin
- a one-way ANOVA fisher's uncorrected LSD was used to compare all drug treated groups with the 3% glycerol/TGF- ⁇ group to determine if statistically significant differences are observed.
- Percent pSMAD3 inhibition was calculated using the vehicle pSMAD3 as a baseline value and displayed as the final readout.
- Dose-response curves were fitted with a 4-parameter non-linear regression algorithm; the minimum response was set to 0% pSMAD3 inhibition and the maximum response set to 100% pSMAD3 inhibition. Compound potencies were obtained from the regression and reported as ID50s.
- Total macrophage concentration was normalized to the total macrophage cell volume over the total drug recovered in the BALF.
- Certain compounds disclosed herein exhibited (lung AUC 0-t ):(plasma AUC 0-t ) ratios of greater than 10, such as greater than 50, greater than 75 or greater than 100.
- a compound intended for local delivery to the lung with minimal systemic exposure preferably exhibits a (lung AUC 0-t ):(plasma AUC 0-t ) ratio of greater than 50.
- Certain compounds provided in Table 3 having pK i values of greater than 9.5 exhibited a (lung AUC 0-t ):(plasma AUC 0-t ) ratio of greater than 75.
- OA oral aspiration
- mice were challenged via tail-vein intravenous injection with PBS vehicle or recombinant human TGF- ⁇ 1 protein (1 ⁇ g per animal dissolved in 1 part 4 mM HCl and 2 parts 3% glycerol in PBS).
- animals were deeply anesthetized under isoflurane and euthanized via cervical dislocation. Plasma, left lung lobes and whole hearts were collected during harvest.
- Blood plasma was harvested as described above in the Lung PK/PD experiment. Whole hearts were processed in the same manners as left lung lobes in the Lung PK/PD experiment. Left lung lobes were homogenized in 500 ⁇ L of water and submitted for BA Analysis.
- Heart samples were processed using MSD in the same manner as the left lung lobes above. Data analysis was performed in the same manners as the lung PK/PD experiment. Plasma, lung and heart drug concentrations were quantified.
- a compound disclosed herein exhibited less than 10% target engagement systemically as measured by SMAD3 phosphorylation inhibition.
- One or more compounds disclosed herein are expected to suppress tumor growth in syngeneic cancer models when administered alone or in combination with an immunotherapeutic agent.
- a compound provided in Table 1 having an ALK5 pK i value of greater than 9.5, preferably greater than 10.5 are expected to suppress tumor growth in syngeneic cancer models when administered alone or in combination with an immunotherapeutic agent.
- Six- to 8-week old BALB/c mice are used for in vivo efficacy studies in accordance with IACUC guidelines.
- Commercially available 4T1 cells (0.5-2.0 ⁇ 10 4 cells/mouse) are implanted subcutaneously into the right flanks of BALB/c mice.
- CT26 cells 0.5-2.0 ⁇ 10 4 cells/mouse are injected intravenously into BALB/c mice to generate the cancer model.
- vehicle control e.g., a compound of the present disclosure at an appropriate amount and frequency
- an immunotherapeutic agent e.g., pembrolizumab or durvalumab
- Body weight is measured twice weekly. Following 2- to 4-weeks of treatment, the lung and liver of each animal is harvested, and the number of metastatic cells in each tissue sample determined using a clonogenic metastasis assay. Cells may be further subjected to one or more of FACS analysis, T-cell function assay, and RNA extraction. It is expected that the animal group treated with one or more of the ALK5 inhibitors disclosed herein exhibits reduction in lung tumor burden. Activation of an immune response by the ALK5 inhibitor may stimulate both local and systemic antitumor T-cell activation, thus a reduction in liver tumor burden may also be observed.
- a compound of the present disclosure When administered in combination with an immunotherapeutic agent, a compound of the present disclosure, such as a compound provided in Table 1, is expected to produce an increased reduction in lung tumor burden relative to the reduction in tumor burden observed in animals treated with either single agent alone.
- the compounds described herein are expected to interact synergistically with an immunotherapeutic agent to suppress tumor growth and increase survival.
- One or more compounds disclosed herein are expected to slow, halt or reverse the progression of intestinal fibrosis in a murine colitis model.
- Six to 8-week old male C57BL/6J mice are tagged and weighed.
- the drinking water of the animals is treated with 2.5% dextran sulfate sodium (DSS) for 7 days to induce acute colitis, followed by 2 days of normal drinking water.
- Three, 3-week cycles of 2.5% DSS treatment (1 week of 2.5% DSS in water; 2 weeks of normal water) are then completed to induce intestinal fibrosis.
- mice are treated with either vehicle control or a compound of the present disclosure at an appropriate amount and frequency via oral gavage (e.g., once daily).
- the animals are sacrificed 9 weeks after the first DSS administration, then distal, mid and proximal sections of the colon harvested for histologic analysis, RNA extraction and cytokine measurement.
- a compound of the present disclosure is expected to decrease ALK5 activity in the colon and to slow or prevent intestinal fibrosis as evidenced by one or more of (1) reduction in the ratio of colon weight to colon length; (2) reduction in deposition of extracellular matrix as observed by histology; (3) reduction in expression of collagen 1 (Colla1) and connective tissue growth factor (Ctgf) in colon tissue; and (4) reduction in production of TGF- ⁇ 1 and IL6 in the colon, relative to vehicle-treated controls.
- One or more compounds disclosed herein are expected to slow, halt or reverse the progression of intestinal fibrosis in a murine colitis model.
- Six to 8-week old male C57BL/6J mice are tagged and weighed.
- the drinking water of the animals is treated with 2.5% dextran sulfate sodium (DSS) for 7 days to induce acute colitis, followed by 2 days of normal drinking water.
- Three, 3-week cycles of 2.5% DSS treatment (1 week of 2.5% DSS in water; 2 weeks of normal water) are then completed to induce intestinal fibrosis.
- mice are treated with either vehicle control or a compound of the present disclosure at an appropriate amount and frequency via oral gavage (e.g., once daily). Animals are sacrificed at either 6, 9 or 12 weeks after the first DSS cycle, then distal, mid and proximal sections of the colon harvested for histologic analysis, RNA extraction and cytokine measurement.
- a compound of the present disclosure is expected to decrease ALK5 activity in the colon and to slow, halt or reverse intestinal fibrosis as evidenced by one or more of (1) reduction in the ratio of colon weight to colon length; (2) reduction in deposition of extracellular matrix as observed by histology; (3) reduction in expression of collagen 1 (Col1a1) and connective tissue growth factor (Ctgf) in colon tissue; and (4) reduction in production of TGF- ⁇ 1 and IL6 in the colon, relative to vehicle-treated controls.
- (1) reduction in the ratio of colon weight to colon length (2) reduction in deposition of extracellular matrix as observed by histology; (3) reduction in expression of collagen 1 (Col1a1) and connective tissue growth factor (Ctgf) in colon tissue; and (4) reduction in production of TGF- ⁇ 1 and IL6 in the colon, relative to vehicle-treated controls.
- One or more compounds disclosed herein are expected to slow, halt or reverse the progression of intestinal fibrosis in an adoptive T-cell transfer model of colitis.
- Six- to 8-week old female CB17 SCID mice are tagged and weighed, then administered CD4 + CD25 ⁇ CD62L + na ⁇ ve T cells isolated from the spleens of Balb/C mice (IP; 1 ⁇ 10 6 cells) to induce colitis.
- mice are treated with either vehicle control or a compound of the present disclosure at an appropriate amount and frequency via oral gavage (e.g., once daily). Animals are sacrificed 45 days after induction of colitis, then distal, mid and proximal sections of the colon harvested for histologic analysis, RNA extraction and cytokine measurement.
- a compound of the present disclosure is expected to decrease ALK5 activity in the colon and to slow, halt or reverse intestinal fibrosis as evidenced by one or more of (1) reduction in the ratio of colon weight to colon length; (2) reduction in deposition of extracellular matrix as observed by histology; (3) reduction in expression of collagen 1 (Col1a1) and connective tissue growth factor (Ctgf) in colon tissue; and (4) reduction in production of TGF- ⁇ 1 and IL6 in the colon, relative to vehicle-treated controls.
- (1) reduction in the ratio of colon weight to colon length (2) reduction in deposition of extracellular matrix as observed by histology; (3) reduction in expression of collagen 1 (Col1a1) and connective tissue growth factor (Ctgf) in colon tissue; and (4) reduction in production of TGF- ⁇ 1 and IL6 in the colon, relative to vehicle-treated controls.
- Example 55 Efficacy Study in Monocrotaline Model of Severe Pulmonary Hypertension
- One or more compounds disclosed herein e.g., a compound provided in Table 1 having an ALK5 pK i value of greater than 9.5, preferably greater than 10.5 (a measurement reflecting the ability of the compound to inhibit ALK5 activity, measured in accordance with Example 45), are expected to slow, halt or reverse the progression of pulmonary hypertension in a monocrotaline (MCT) model of severe pulmonary hypertension.
- MCT monocrotaline
- a compound of the present disclosure is expected to decrease ALK5 activity in the lung and slow, halt or reverse the progression of pulmonary hypertension as evidenced by one or more of (1) reduction in systolic pulmonary arterial pressure; (2) reduction in right ventricular (RV) systolic pressure; (3) reduction in RV diastolic pressure; (4) increase in cardiac output; (5) reduction in RV hypertrophy; (6) reduction in pSmad2 or pSmad3 staining within vascular and/or alveolar cells; (7) reduction in medial thickness; (8) reduction in vascular smooth muscle cell proliferation; (9) reduction in vascular smooth muscle hypertrophy; and (10) reduction in expression of matrix metalloproteinase (MMP)-2 and/or MMP-9.
- MMP matrix metalloproteinase
Abstract
The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
Description
- This application is a continuation application of U.S. Ser. No. 17/301,242, filed on Mar. 30, 2021, which claims the benefit of U.S. Provisional Application No. 63/002,658, filed Mar. 31, 2020; and U.S. Provisional Application No. 63/200,310, filed Mar. 1, 2021, each of which is incorporated herein by reference in its entirety.
- Human fibrotic diseases such as systemic sclerosis (SSc), sclerodermatous graft vs. host disease, nephrogenic system fibrosis, and radiation-induced fibrosis, as well as cardiac, pulmonary, skin, liver, bladder and kidney fibrosis, constitute a major health problem. These diseases often progress to organ dysfunction with eventual organ failure and death due to lack of treatment available, mainly because the etiologic mechanisms of runaway fibrosis are complex, heterogeneous, and difficult to decipher. Activated myofibroblasts may be responsible for replacing normal tissues with nonfunctional fibrotic tissue. Therefore, signaling pathways responsible for stimulating profibrotic reactions in myofibroblasts have potential as targets for development of therapies to treat fibrotic diseases.
- Normal tissue repair involves fibrotic reactions through homeostatic regulatory mechanisms. Uncontrolled fibrosis, however, may result in excess deposition of the extracellular matrix (ECM) macromolecules in interstitial space that stiffens over time. There are many sites along the molecular pathway leading up to myofibroblast activation, including, but not limited to, transforming growth factor-β (TGF-β) and bone morphogenic protein (BMP) signaling pathways. Of importance in this disclosure is the pathway involving transforming growth factor-β (TGF-β), TGF-β receptor I (TGF-βRI), and TGF-β receptor II (TGF-βRII).
- TGF-β signaling is typically initiated by binding of a TGF-β ligand to a TGF-βRII. This in turn may recruit and phosphorylate TGF-βRI, also known as the activin receptor-like kinase 5 (ALK5). Once phosphorylated, ALK5 typically adopts an active conformation and is free to associate with and phosphorylate Smad2 or Smad3. Once phosphorylated, Smad 2 and 3 proteins then may form heterodimeric complexes with Smad4 which can translocate across the nuclear membrane and modulate Smad-mediated gene expression, including, for example, the production of collagen. Smad proteins are intracellular regulators of transcription and therefore may serve as modulators of TGF-β-regulated genes involving, inter alia, cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis.
- ALK5 is believed to be the most relevant of the activin-like kinases (ALKs) in the fibrotic process (Rosenbloom, et al., Fibrosis: Methods and Protocols, Methods in Molecular Biology, 2017, Vol. 1627, Chapter 1, pp. 1-21). Several small molecules have been developed to inhibit the activity of ALK5 for various therapeutic indications, related mostly to oncology (see Yingling, et al., Nature Reviews: Drug Discovery, December 2004, Vol. 3, pp. 1011-1022).
- One of the main problems with ALK5 inhibitors developed to date is that these molecules have been associated with ventricular or cardiac remodeling in preclinical safety studies resulting from significant systemic exposure from oral administration. In view of the foregoing, a need exists for small molecules that target ALK5 and for use of such compounds in the treatment of various diseases, such as cancer and fibrosis, while limiting adverse side effects. The present disclosure provides these and other related advantages. One objective of the present disclosure is to deliver a potent ALK5 inhibitor locally with minimal systemic exposure in order to address any unintended and unwanted systemic side effects of ALK5 inhibition during treatment. Therefore, in some aspects, the present disclosure provides inhaled, long-acting and lung-selective ALK5 inhibitors for the treatment of idiopathic pulmonary fibrosis. Compounds of the present disclosure may be used to treat other diseases, including, but not limited to, pulmonary fibrosis, liver fibrosis, renal glomerulosclerosis, and cancer. Compounds of the present disclosure may be used as a monotherapy or co-dosed with other therapies, whether delivered by inhalation, orally, intravenously, subcutaneously, or topically.
- In certain aspects, the present disclosure provides a compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
-
- A and B are each independently selected from C3-12 carbocycle and 3- to 12-membered heterocycle;
- RA is independently selected at each occurrence from:
- halogen, —NO2, —CN, —OR1, —SR1, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1);
- C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —NO2, —CN, —OR1, —SR1, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1), C3-12 carbocycle, and 3- to 12-membered heterocycle; and
- C3-12 carbocycle and 3- to 12-membered heterocycle,
- wherein each C3-12 carbocycle and 3- to 12-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from halogen, —NO2, —CN, —OR1, —SR1, —CH2N(R1)2, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1), R1, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- RB is independently selected at each occurrence from halogen, —CN, —NH2, —NHCH3, —NHCH2CH3, —C(O)CH3, —OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2F, —CHF2, —CF3, C3-4 carbocycle, and 3- to 4-membered heterocycle;
- m and n are each independently an integer from 0 to 3;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3-12 carbocycle), and C0-3 alkyl-(3- to 12-membered heterocycle), each of which is optionally substituted by one or more substituents selected from halogen, —CN, —NO2, —NH2, —NHCH3, —N(CH3)2, —NHCH2CH3, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-12 carbocycle, and 3- to 6-membered heterocycle; and
- R2 and R3 are taken together with the nitrogen atom to which they are attached to form a heterocycle, optionally substituted with one or more R1.
- The compound of Formula (I) may be a compound of Formula (I-A):
- For a compound of Formula (I) or (I-A), A may be selected from C6-10 aryl and 5- to 10-membered heteroaryl. In some embodiments, A is selected from phenyl and 5- to 6-membered heteroaryl. In some embodiments, A is selected from phenyl, indanyl, thiazolyl, thiophenyl, pyrazolyl, pyridyl, pyrimidinyl, indazolyl, benzotriazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxanyl, and tetrahydrobenzazepinyl, such as A is phenyl. In some embodiments, A is thiazolyl. In some embodiments, A is thiophenyl. In some embodiments, A is pyridyl.
- The compound of Formula (I) may be a compound of Formula (I-B):
- The compound of Formula (I) may be a compound of Formula (I-C):
- For a compound of Formula (I), (I-A), (I-B) or (I-C), RA may independently be selected at each occurrence from:
-
- halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NRIC(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3;
- C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3, C3-8 carbocycle, and 3- to 10-membered heterocycle; and
- C3-8 carbocycle and 3- to 10-membered heterocycle,
- wherein each C3-8 carbocycle and 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from halogen, —OR1, —CH2N(R1)2, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3, R1, and C1-6 alkyl.
- In some embodiments, for a compound of Formula (I), (I-A), (I-B) or (I-C), RA is independently selected at each occurrence from:
-
- halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NRIC(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3;
- C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from —OR1, —N(R1)2, —C(O)OR1, C3-8 carbocycle, and 3- to 10-membered heterocycle; and
- C3-8 carbocycle and 3- to 10-membered heterocycle,
- wherein each C3-8 carbocycle and 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —OR1, —CH2N(R1)2, —N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —C(O)N(R1)2, R1, and C1-6 alkyl.
- For a compound of Formula (I), (I-A), (I-B) or (I-C), RA may independently be selected at each occurrence from:
-
- halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2;
- C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from —OR1, —N(R1)2, and 3- to 10-membered heterocycle; and
- 3- to 10-membered heterocycle,
- wherein each 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —OR1, —N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —C(O)N(R1)2, and R1.
- For a compound of Formula (I), (I-A), (I-B) or (I-C), RA may independently be selected at each occurrence from:
-
- —N(R1)2 and —NR1C(O)R1;
- C1-6 alkyl and —N(R1)—C1-6 alkyl, each of which is substituted with 4- to 8-membered heterocycle; and
- 4- to 8-membered heterocycle,
- wherein each 4- to 8-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —C(O)OR1 and R1.
- For a compound of Formula (I), (I-A), (I-B) or (I-C), RA may be —N(R1)2. In some embodiments, RA is —NR1C(O)R1. In some embodiments, RA is C1-6 alkyl substituted with 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is substituted with —C(O)OR1. In some embodiments, RA is —N(R1)—C1_6 alkyl substituted with 4- to 8-membered heterocycle. In some embodiments, RA is 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is optionally substituted with one or more substituents selected from —C(O)OR1 and R1.
- For a compound of Formula (I), (I-A), (I-B) or (I-C), R1 may independently be selected at each occurrence from hydrogen; and C1-6 alkyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3-s carbocycle), and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —NH2, —NHCH3, —N(CH3)2, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-8 carbocycle, and 3- to 6-membered heterocycle. In some embodiments, R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —OH, —CH2OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, and 3- to 6-membered heterocycle.
- For a compound of Formula (I), (I-A), (I-B) or (I-C), m may be 1 or 2, such as m is 1.
- For a compound of Formula (I), (I-A), (I-B) or (I-C), B may be selected from C6-10 aryl and 5- to 10-membered heteroaryl. In some embodiments, B is selected from phenyl and pyridyl. In some embodiments, B is pyridyl, such as 2-pyridyl.
- For a compound of Formula (I), (I-A), (I-B) or (I-C), RB may independently be selected at each occurrence from halogen, —NH2, —NHCH3, —NHCH2CH3, —C(O)CH3, —OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2F, —CHF2, and —CF3. In some embodiments, RB is independently selected at each occurrence from halogen, —OH, —CH3, and —CHF2, such as —CH3.
- For a compound of Formula (I), (I-A), (I-B) or (I-C), n may be 1 or 2, such as n is 1.
- The compound of Formula (I) may be a compound of Formula (I-D):
- The compound of Formula (I) may be a compound of Formula (I-E):
- In some embodiments, for a compound of Formula (I):
-
- A is selected from phenyl and 5- to 6-membered heteroaryl;
- B is pyridyl;
- RA is independently selected at each occurrence from:
- halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3;
- C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from —OR1, —N(R1)2, —C(O)OR1, C3-8 carbocycle, and 3- to 10-membered heterocycle; and
- C3-8 carbocycle and 3- to 10-membered heterocycle,
- wherein each C3-8 carbocycle and 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —OR1, —CH2N(R1)2, —N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —C(O)N(R1)2, R1, and C1-6 alkyl;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3-s carbocycle), and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —NH2, —NHCH3, —N(CH3)2, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-8 carbocycle, and 3- to 6-membered heterocycle;
- m is 1 or 2;
- RB is selected from halogen, —OH, —CH3, and —CHF2; and
- n is 1.
- In some embodiments, for a compound of Formula (I):
-
- A is phenyl;
- B is pyridyl;
- RA is independently selected at each occurrence from:
- —N(R1)2 and —NR1C(O)R1;
- C1-6 alkyl and —N(R1)—C1-6 alkyl, each of which is substituted with 4- to 8-membered heterocycle; and
- 4- to 8-membered heterocycle,
- wherein each 4- to 8-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —C(O)OR1 and R1;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —OH, —CH2OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, and 3- to 6-membered heterocycle;
- m is 1;
- RB is —CH3; and
- n is 1.
- In some embodiments, for a compound of Formula (I):
-
- A is phenyl;
- B is pyridyl;
- RA is C1-6 alkyl substituted with 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is substituted with —C(O)OR1;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —OH, —CH2OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, and 3- to 6-membered heterocycle;
- m is 1;
- RB is —CH3; and
- n is 1.
- In certain aspects, the present disclosure provides a substantially pure stereoisomer of a compound disclosed herein. The stereoisomer may be provided in at least 90% enantiomeric excess.
- In certain aspects, the present disclosure provides a compound selected from Table 1. In some embodiments, the present disclosure provides a compound selected from Table 2.
- In certain aspects, the present disclosure provides a conjugate of the formula:
- wherein:
-
- A′ is an antibody construct or targeting moiety;
- L′ is a linker;
- D′ is a compound or salt disclosed herein; and
- p is an integer from 1 to 20
- In certain aspects, the present disclosure provides a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable carrier. The pharmaceutical composition may be formulated for inhalation.
- In certain aspects, the present disclosure provides a method of inhibiting ALK5, comprising contacting ALK5 with an effective amount of a compound disclosed herein. In certain aspects, the present disclosure provides a method of treating an ALK5-mediated disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein. In practicing any of the subject methods, the disease or condition may be selected from fibrosis, alopecia and cancer. In some embodiments, the disease or condition is fibrosis. In some embodiments, the present disclosure provides a method of treating fibrosis, comprising administering to a patient a therapeutically effective amount of a compound disclosed herein. The fibrosis may be selected from systemic sclerosis, nephrogenic systemic fibrosis, organ-specific fibrosis, fibrosis associated with cancer, cystic fibrosis, and fibrosis associated with an autoimmune disease. Optionally, the organ-specific fibrosis is selected from cardiac fibrosis, kidney fibrosis, pulmonary fibrosis, liver fibrosis, portal vein fibrosis, skin fibrosis, bladder fibrosis, intestinal fibrosis, peritoneal fibrosis, myelofibrosis, oral submucous fibrosis, and retinal fibrosis. In some embodiments, the organ-specific fibrosis is intestinal fibrosis. Optionally, the pulmonary fibrosis is selected from idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), interstitial lung fibrosis, fibrosis associated with asthma, fibrosis associated with chronic obstructive pulmonary disease (COPD), silica-induced fibrosis, asbestos-induced fibrosis and chemotherapy-induced lung fibrosis. Optionally, the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). In some embodiments, the pulmonary fibrosis was induced by a viral infection.
- In practicing any of the subject methods, the disease or condition may be cancer, optionally wherein the cancer is selected from breast cancer, colon cancer, prostate cancer, lung cancer, hepatocellular carcinoma, glioblastoma, melanoma, and pancreatic cancer. In some embodiments, the cancer is lung cancer, optionally non-small cell lung cancer. A method of the subject disclosure may further comprise administering a second therapeutic agent. Optionally, the second therapeutic agent is an immunotherapeutic agent, such as a PD-1 inhibitor or a CTLA-4 inhibitor. In some embodiments, the immunotherapeutic agent is selected from pembrolizumab and durvalumab. A method of the present disclosure may further comprise administering an effective amount of radiation. In practicing any of the subject methods, the compound or salt disclosed herein may be administered by inhalation.
- In certain aspects, the present disclosure provides a compound disclosed herein for use in treating fibrosis. In certain aspects, the present disclosure provides the use of a compound disclosed herein for the manufacture of a medicament for treating fibrosis.
- All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this disclosure belongs.
- Chemical structures are named herein according to IUPAC conventions as implemented in ChemDraw® software (Perkin Elmer, Inc., Cambridge, MA).
- As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.
- The term “Cx-y” or “Cx-Cy” when used in conjunction with a chemical moiety, such as alkyl, alkenyl, or alkynyl, is meant to include groups that contain from x to y carbons in the chain. For example, the term “Cx-y alkyl” refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups, that contain from x to y carbons in the chain.
- “Alkyl” refers to substituted or unsubstituted saturated hydrocarbon groups, including linear and branched alkyl groups. An alkyl group may contain from one to twelve carbon atoms (e.g., C1-12 alkyl), such as one to eight carbon atoms (C1-8 alkyl) or one to six carbon atoms (C1-6 alkyl). Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, septyl, octyl, nonyl, and decyl. An alkyl group is attached to the rest of the molecule by a single bond. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted by one or more substituents such as those substituents described herein.
- “Haloalkyl” refers to an alkyl group that is substituted by one or more halogens. Exemplary haloalkyl groups include trifluoromethyl, difluoromethyl, trichloro methyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, and 1,2-dibromoethyl.
- “Alkenyl” refers to substituted or unsubstituted hydrocarbon groups, including linear and branched alkenyl groups, containing at least one double bond. An alkenyl group may contain from two to twelve carbon atoms (e.g., C2-12 alkenyl), such as two to eight carbon atoms (C2-8 alkenyl) or two to six carbon atoms (C2-6 alkenyl). Exemplary alkenyl groups include ethenyl (i.e., vinyl), prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted by one or more substituents such as those substituents described herein.
- “Alkynyl” refers to substituted or unsubstituted hydrocarbon groups, including linear and branched alkynyl groups, containing at least one triple bond. An alkynyl group may contain from two to twelve carbon atoms (e.g., C2-12 alkynyl), such as two to eight carbon atoms (C2-8 alkynyl) or two to six carbon atoms (C2-6 alkynyl). Exemplary alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted by one or more substituents such as those substituents described herein.
- “Alkylene” or “alkylene chain” refers to substituted or unsubstituted divalent saturated hydrocarbon groups, including linear alkylene and branched alkylene groups, that contain from one to twelve carbon atoms (e.g., C1-12 alkylene), such as one to eight carbon atoms (C1-8 alkylene) or one to six carbon atoms (C1-6 alkylene). Exemplary alkylene groups include methylene, ethylene, propylene, and n-butylene. Similarly, “alkenylene” and “alkynylene” refer to alkylene groups, as defined above, which comprise one or more carbon-carbon double or triple bonds, respectively. The points of attachment of the alkylene, alkenylene or alkynylene chain to the rest of the molecule can be through one carbon or any two carbons of the chain. Unless stated otherwise specifically in the specification, an alkylene, alkenylene, or alkynylene group is optionally substituted by one or more substituents such as those substituents described herein.
- “Heteroalkyl”, “heteroalkenyl” and “heteroalkynyl” refer to substituted or unsubstituted alkyl, alkenyl and alkynyl groups, respectively, in which one or more, such as 1, 2 or 3, of the carbon atoms are replaced with a heteroatom, such as O, N, P, Si, S, or combinations thereof. Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may optionally be oxidized, and any nitrogen heteroatoms may optionally be quaternized. If given, a numerical range refers to the chain length in total. For example, a 3- to 8-membered heteroalkyl group has a chain length of 3 to 8 atoms. Connection to the rest of the molecule may be through either a heteroatom or a carbon in the heteroalkyl, heteroalkenyl or heteroalkynyl chain. Unless stated otherwise specifically in the specification, a heteroalkyl, heteroalkenyl, or heteroalkynyl group is optionally substituted by one or more substituents such as those substituents described herein.
- “Heteroalkylene”, “heteroalkenylene” and “heteroalkynylene” refer to substituted or unsubstituted alkylene, alkenylene and alkynylene groups, respectively, in which one or more, such as 1, 2 or 3, of the carbon atoms are replaced with a heteroatom, such as O, N, P, Si, S, or combinations thereof. Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may optionally be oxidized, and any nitrogen heteroatoms may optionally be quaternized. If given, a numerical range refers to the chain length in total. For example, a 3- to 8-membered heteroalkylene group has a chain length of 3 to 8 atoms. The points of attachment of the heteroalkylene, heteroalkenylene or heteroalkynylene chain to the rest of the molecule can be through either one heteroatom or one carbon, or any two heteroatoms, any two carbons, or any one heteroatom and any one carbon in the heteroalkylene, heteroalkenylene or heteroalkynylene chain. Unless stated otherwise specifically in the specification, a heteroalkylene, heteroalkenylene, or heteroalkynylene group is optionally substituted by one or more substituents such as those substituents described herein.
- “Carbocycle” refers to a saturated, unsaturated or aromatic ring in which each atom of the ring is a carbon atom. Carbocycle may include C3-10 monocyclic rings, C6-12 bicyclic rings, C6-12 spirocyclic rings, and C6-12 bridged rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated, and aromatic rings. In some embodiments, the carbocycle is a C6-12 aryl group, such as C6-10 aryl. In some embodiments, the carbocycle is a C6-12 cycloalkyl group. In some embodiments, the carbocycle is a C6-12 cycloalkenyl group. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits, are included in the definition of carbocycle. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, and naphthyl. Unless stated otherwise specifically in the specification, a carbocycle is optionally substituted by one or more substituents such as those substituents described herein.
- “Heterocycle” refers to a saturated, unsaturated or aromatic ring comprising one or more heteroatoms, for example 1, 2 or 3 heteroatoms selected from O, S and N. Heterocycles include 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, 6- to 12-membered spirocyclic rings, and 6- to 12-membered bridged rings. Each ring of a bicyclic heterocycle may be selected from saturated, unsaturated, and aromatic rings. The heterocycle may be attached to the rest of the molecule through any atom of the heterocycle, valence permitting, such as a carbon or nitrogen atom of the heterocycle. In some embodiments, the heterocycle is a 5- to 10-membered heteroaryl group, such as 5- or 6-membered heteroaryl. In some embodiments, the heterocycle is a 3- to 12-membered heterocycloalkyl group. In an exemplary embodiment, a heterocycle, e.g., pyridyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Exemplary heterocycles include pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiophenyl, oxazolyl, thiazolyl, morpholinyl, indazolyl, indolyl, and quinolinyl. Unless stated otherwise specifically in the specification, a heterocycle is optionally substituted by one or more substituents such as those substituents described herein.
- “Heteroaryl” refers to a 5- to 12-membered aromatic ring that comprises at least one heteroatom, such as 1, 2 or 3 heteroatoms, selected from O, S and N. As used herein, the heteroaryl ring may be selected from monocyclic or bicyclic-including fused, spirocyclic and bridged ring systems—wherein at least one of the rings in the ring system is aromatic. The heteroatom(s) in the heteroaryl may optionally be oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl may be attached to the rest of the molecule through any atom of the heteroaryl, valence permitting, such as a carbon or nitrogen atom of the heteroaryl. Examples of heteroaryl groups include, but are not limited to, azepinyl, benzimidazolyl, benzisothiazolyl, benzisoxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, purinyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyridazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydroquinolinyl, thiadiazolyl, thiazolyl, and thienyl groups. Unless stated otherwise specifically in the specification, a heteroaryl is optionally substituted by one or more substituents such as those substituents described herein.
- Unless stated otherwise, hydrogen atoms are implied in structures depicted herein as necessary to satisfy the valence requirement.
-
- Ra is attached to the para position of a fluorophenyl ring through a single bond. If Ra is 2-pyridine as in
- then Ra may be depicted as
- The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons or heteroatoms of the structure. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this disclosure, heteroatoms such as nitrogen may have any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
- A compound disclosed herein, such as a compound of Formula (I), is optionally substituted by one or more, such as 1, 2 or 3 substituents selected from:
-
- halogen, —NO2, —CN, —OR1, —SR1, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1);
- C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —NO2, —CN, —OR1, —SR1, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1), C3-12 carbocycle, and 3- to 12-membered heterocycle; and
- C3-12 carbocycle and 3- to 12-membered heterocycle,
- wherein each C3-12 carbocycle and 3- to 12-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, —NO2, —CN, —OR1, —SR1, —CH2N(R1)2, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1), R1, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3-12 carbocycle), and C0-3 alkyl-(3- to 12-membered heterocycle), each of which is optionally substituted by one or more substituents selected from halogen, —CN, —NO2, —NH2, —NHCH3, —N(CH3)2, —NHCH2CH3, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-12 carbocycle, and 3- to 6-membered heterocycle; and
- R2 and R3 are taken together with the nitrogen atom to which they are attached to form a heterocycle, optionally substituted with one or more R1.
- In some embodiments, a compound disclosed herein, such as a compound of Formula (I), is optionally substituted by one or more, such as 1, 2 or 3 substituents selected from: halogen, —NO2, —CN, —OR1, —SR1, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1);
-
- C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, ═O, ═S, ═N(R1), C3-12 carbocycle, and 3- to 12-membered heterocycle; and
- C3-12 carbocycle and 3- to 12-membered heterocycle,
- wherein each C3-12 carbocycle and 3- to 12-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, ═O, ═S, ═N(R1), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3-12 carbocycle), and C0-3 alkyl-(3- to 12-membered heterocycle), each of which is optionally substituted by one or more substituents selected from halogen, —CN, —NO2, —NH2, —NHCH3, —N(CH3)2, —NHCH2CH3, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-12 carbocycle, and 3- to 6-membered heterocycle; and
- R2 and R3 are taken together with the nitrogen atom to which they are attached to form a heterocycle, optionally substituted with one or more R1.
- In some embodiments, a compound disclosed herein, such as a compound of Formula (I), is optionally substituted by one or more, such as 1, 2 or 3 substituents selected from halogen, —CN, —NO2, —NH2, —NHCH3, —NHCH2CH3, ═O, —OH, —OCH3, and —OCH2CH3; and C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, 1- to 6-membered heteroalkyl, C3-12 carbocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted by halogen, —CN, —NO2, —NH2, —NHCH3, —NHCH2CH3, ═O, —OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-12 carbocycle, or 3- to 6-membered heterocycle.
- It will be understood by those skilled in the art that substituents can themselves be substituted, if appropriate. Unless specifically stated as “unsubstituted”, references to chemical moieties herein are understood to include substituted variants. For example, reference to a “heteroaryl” group or moiety implicitly includes both substituted and unsubstituted variants.
- Where bivalent substituent groups are specified herein by their conventional chemical formulae, written from left to right, they are intended to encompass the isomer that would result from writing the structure from right to left, e.g., —CH2O— is also intended to encompass to —OCH2—.
- “Optional” or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, an “optionally substituted” group may be either unsubstituted or substituted.
- Compounds of the present disclosure also include crystalline and amorphous forms of those compounds, pharmaceutically acceptable salts, and active metabolites having the same type of activity, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrates), conformational polymorphs, amorphous forms of the compounds, and mixtures thereof.
- The compounds described herein may exhibit their natural isotopic abundance, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure. For example, hydrogen has three naturally occurring isotopes, denoted 1H (protium), 2H (deuterium), and 3H (tritium). Protium is the most abundant isotope of hydrogen in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increased in vivo half-life and/or exposure, or may provide a compound useful for investigating in vivo routes of drug elimination and metabolism. Examples of isotopes that may be incorporated into compounds of the present disclosure include, but are not limited to, 2H, 3H, 13C, 14C, 15N, 18O, 17O, 35S, 36Cl, and 18F. Of particular interest are compounds of Formula (I) enriched in tritium or carbon-14, which can be used, for example, in tissue distribution studies; compounds of the disclosure enriched in deuterium especially at a site of metabolism, resulting, for example, in compounds having greater metabolic stability; and compounds of Formula (I) enriched in a positron emitting isotope, such as 11C, 18F, 15O and 13N, which can be used, for example, in Positron Emission Topography (PET) studies. Isotopically-enriched compounds may be prepared by conventional techniques well known to those skilled in the art.
- As used herein, the phrase “of the formula” or “having the formula” or “having the structure” is not intended to be limiting and is used in the same way that the term “comprising” is commonly used. For example, if one structure is depicted, it is understood that all stereoisomer and tautomer forms are encompassed, unless stated otherwise.
- Certain compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms, the asymmetric centers of which can be defined, in terms of absolute stereochemistry, as (R)- or (S)-. In some embodiments, in order to optimize the therapeutic activity of the compounds of the disclosure, e.g., to treat fibrosis, it may be desirable that the carbon atoms have a particular configuration (e.g., (R,R), (S,S), (S,R), or (R,S)) or are enriched in a stereoisomeric form having such configuration. The compounds of the disclosure may be provided as racemic mixtures. Accordingly, the disclosure relates to racemic mixtures, pure stereoisomers (e.g., enantiomers and diastereoisomers), stereoisomer-enriched mixtures, and the like, unless otherwise indicated. When a chemical structure is depicted herein without any stereochemistry, it is understood that all possible stereoisomers are encompassed by such structure. Similarly, when a particular stereoisomer is shown or named herein, it will be understood by those skilled in the art that minor amounts of other stereoisomers may be present in the compositions of the disclosure unless otherwise indicated, provided that the utility of the composition as a whole is not eliminated by the presence of such other isomers. Individual stereoisomers may be obtained by numerous methods that are known in the art, including preparation using chiral synthons or chiral reagents, resolution using chiral chromatography using a suitable chiral stationary phase or support, or by chemically converting them into diastereoisomers, separating the diastereoisomers by conventional means such as chromatography or recrystallization, then regenerating the original stereoisomer.
- Additionally, where applicable, all cis-trans or E/Z isomers (geometric isomers), tautomeric forms and topoisomeric forms of the compounds of the invention are included within the scope of the invention unless otherwise specified.
- The term “tautomer”, as used herein, refers to each of two or more isomers of a compound that exist in equilibrium and which ready interconvert. For example, one skilled in the art would readily understand that 1,2,3-triazole exists in two tautomeric forms:
- Unless otherwise specified, chemical entities described herein are intended to include all possible tautomers, even when a structure depicts only one of them.
- The term “pharmaceutically acceptable” refers to a material that is not biologically or otherwise unacceptable when used in the subject compositions and methods. For example, the term “pharmaceutically acceptable carrier” refers to a material—such as an adjuvant, excipient, glidant, sweetening agent, diluent, preservative, dye, colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent or emulsifier—that can be incorporated into a composition and administered to a patient without causing unacceptable biological effects or interacting in an unacceptable manner with other components of the composition. Such pharmaceutically acceptable materials typically have met the required standards of toxicological and manufacturing testing, and include those materials identified as suitable inactive ingredients by the U.S. Food and Drug Administration.
- The terms “salt” and “pharmaceutically acceptable salt” refer to a salt prepared from a base or an acid. Pharmaceutically acceptable salts are suitable for administration to a patient, such as a mammal (for example, salts having acceptable mammalian safety for a given dosage regime). Salts can be formed from inorganic bases, organic bases, inorganic acids and organic acids. In addition, when a compound contains both a basic moiety, such as an amine, pyridine or imidazole, and an acidic moiety, such as a carboxylic acid or tetrazole, zwitterions may be formed and are included within the term “salt” as used herein. Salts derived from inorganic bases include ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, and zinc salts, and the like. Salts derived from organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. Salts derived from inorganic acids include salts of boric, carbonic, hydrohalic (hydrobromic, hydrochloric, hydrofluoric or hydroiodic), nitric, phosphoric, sulfamic and sulfuric acids. Salts derived from organic acids include salts of aliphatic hydroxyl acids (for example, citric, gluconic, glycolic, lactic, lactobionic, malic, and tartaric acids), aliphatic monocarboxylic acids (for example, acetic, butyric, formic, propionic and trifluoroacetic acids), amino acids (for example, aspartic and glutamic acids), aromatic carboxylic acids (for example, benzoic, p-chlorobenzoic, diphenylacetic, gentisic, hippuric, and triphenylacetic acids), aromatic hydroxyl acids (for example, o-hydroxybenzoic, p-hydroxybenzoic, 1-hydroxynaphthalene-2-carboxylic and 3-hydroxynaphthalene-2-carboxylic acids), ascorbic, dicarboxylic acids (for example, fumaric, maleic, oxalic and succinic acids), glucoronic, mandelic, mucic, nicotinic, orotic, pamoic, pantothenic, sulfonic acids (for example, benzenesulfonic, camphorsulfonic, edisylic, ethanesulfonic, isethionic, methanesulfonic, naphthalenesulfonic, naphthalene-1,5-disulfonic, naphthalene-2,6-disulfonic and p-toluenesulfonic acids), xinafoic acid, and the like.
- The term “therapeutically effective amount” refers to that amount of a compound described herein that is sufficient to affect treatment when administered to a subject in need thereof. For example, a therapeutically effective amount for treating pulmonary fibrosis is an amount of compound needed to, for example, reduce, suppress, eliminate, or prevent the formation of fibrosis in a subject, or to treat the underlying cause of pulmonary fibrosis. The therapeutically effective amount may vary depending upon the intended treatment application (in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The specific dose will vary depending on the particular compound chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried. The term “effective amount” refers to an amount sufficient to obtain a desired result, which may not necessarily be a therapeutic result. For example, an “effective amount” may be the amount needed to inhibit an enzyme.
- As used herein, “treating” or “treatment” refers to an approach for obtaining beneficial or desired results with respect to a disease, disorder, or medical condition (such as pulmonary fibrosis) in a subject, including but not limited to the following: (a) preventing the disease or medical condition from occurring, e.g., preventing the reoccurrence of the disease or medical condition or prophylactic treatment of a subject that is pre-disposed to the disease or medical condition; (b) ameliorating the disease or medical condition, e.g., eliminating or causing regression of the disease or medical condition in a subject; (c) suppressing the disease or medical condition, e.g., slowing or arresting the development of the disease or medical condition in a subject; or (d) alleviating symptoms of the disease or medical condition in a subject. For example, “treating pulmonary fibrosis” would include preventing fibrosis from occurring, ameliorating fibrosis, suppressing fibrosis, and alleviating the symptoms of fibrosis (for example, increasing oxygen levels in blood or improved lung function tests). Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder
- A “therapeutic effect”, as that term is used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
- The terms “antagonist” and “inhibitor” are used interchangeably, and they refer to a compound having the ability to inhibit a biological function (e.g., activity, expression, binding, protein-protein interaction) of a target protein (e.g., ALK5). Accordingly, the terms “antagonist” and “inhibitor” are defined in the context of the biological role of the target protein. While preferred antagonists herein specifically interact with (e.g., bind to) the target, compounds that inhibit a biological activity of the target protein by interacting with other members of the signal transduction pathway of which the target protein is a member are also specifically included within this definition.
- The term “selective inhibition” or “selectively inhibit” refers to the ability of a biologically active agent to preferentially reduce the target signaling activity as compared to off-target signaling activity, via direct or indirect interaction with the target.
- As used herein, the term “antibody” refers to an immunoglobulin molecule that specifically binds to, or is immunologically reactive toward, a specific antigen. An antibody may be, for example, polyclonal, monoclonal, genetically engineered, or an antigen binding fragment thereof, and further may be, for example, murine, chimeric, humanized, heteroconjugate, bispecific, a diabody, a triabody, or a tetrabody. An antigen binding fragment includes an antigen binding domain and may be in the form of, for example, a Fab′, F(ab′)2, Fab, Fv, rIgG, scFv, hcAbs (heavy chain antibodies), a single domain antibody, VHH, VNAR, sdAb, or nanobody.
- The term “antigen binding domain” as used herein refers to a region of a molecule that binds to an antigen. An antigen binding domain may be an antigen-binding portion of an antibody or an antibody fragment. An antigen binding domain may be one or more fragments of an antibody that retain the ability to specifically bind to an antigen. An antigen binding domain can be an antigen binding fragment and may recognize a single antigen, two antigens, three antigens or more. As used herein, “recognize” with regard to antibody interactions refers to the association or binding between an antigen binding domain of an antibody or portion thereof and an antigen.
- An “antibody construct” refers to a molecule, e.g., a protein, peptide, antibody or portion thereof, that contains an antigen binding domain and an Fc domain (e.g., an Fc domain from within the Fc region). An antibody construct may recognize, for example, one antigen or multiple antigens.
- A “targeting moiety” refers to a structure that has a selective affinity for a target molecule relative to other non-target molecules. The targeting moiety binds to a target molecule. A targeting moiety may include an antibody, a peptide, a ligand, a receptor, or a binding portion thereof. The target biological molecule may be a biological receptor or other structure of a cell, such as a tumor antigen.
- The terms “subject” and “patient” refer to an animal, such as a mammal, for example a human. The methods described herein can be useful in both human therapeutics and veterinary applications. In some embodiments, the subject is a mammal, and in some embodiments, the subject is human. “Mammal” includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
- “Prodrug” is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound described herein (e.g., compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E)). Thus, the term “prodrug” refers to a precursor of a biologically active compound that is pharmaceutically acceptable. In some aspects, a prodrug is inactive when administered to a subject but is converted in vivo to an active compound, for example, by hydrolysis. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam); Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” (1987) A.C.S. Symposium Series, Vol. 14; and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press) each of which is incorporated in full by reference herein. The term “prodrug” is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject. Prodrugs of an active compound, as described herein, are typically prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of a hydroxy functional group, or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound, and the like.
- The term “in vivo” refers to an event that takes place in a subject's body.
- The term “in vitro” refers to an event that takes places outside of a subject's body. For example, an in vitro assay encompasses any assay run outside of a subject. In vitro assays encompass cell-based assays in which cells alive or dead are employed. In vitro assays also encompass a cell-free assay in which no intact cells are employed.
- The disclosure is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the disclosure includes compounds produced by a process comprising administering a compound of this disclosure to a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically identified by administering a radiolabeled compound of the disclosure in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to a human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
- Lung function tests include tests to check how well the lungs work. Spirometry, for example, measures the amount of air the lungs can hold as well as how forcefully one can empty air from the lungs. Forced expiratory volume (FEV) is a measure of the amount of air a person can exhale during a forced breath. FEV1, for example, is the amount of air a person can force from their lungs in one second. Forced vital capacity (FVC) is the total amount of air exhaled during an FEV test. The ratio of FEV1/FVC, also known as Index of Air Flow or Tiffeneau-Pinelli Index, is a measurement used to assess the health of a patient's lung function. A ratio of <80% indicates an obstructive defect is present in the lungs, such as chronic obstructive pulmonary disease (COPD). A ratio of >80% indicates a restrictive defect is present in the lungs, such as pulmonary fibrosis. The ratio of >80% in restrictive lung disease results from both FEV1 and FVC being reduced but that the decline in FVC is more than that of FEV1, resulting in a higher than 80% value.
- The term “transforming growth factor-β” may also be referred to as TGF-β, transforming growth factor beta-1, or TGF-beta-1. It is also cleaved into latency-associated peptide (LAP).
- The term “TGF-β receptor II” may also be referred to as TβRII, type II TGF-β receptor, TGF-βRII, TGF-beta receptor type-2, TGFR-2, TGF-beta type II receptor, transforming growth factor-beta receptor type II, TGF-beta receptor type II or TbetaR-II.
- The term “TGF-β receptor I” may also be referred to as TβRI, type I TGF-β receptor, TGF-βRI, TGF-beta receptor type-1, TGFR-1, activin A receptor type II-like protein kinase of 53 kD, activin receptor-like kinase 5, ALK-5, ALK5, serine/threonine-protein kinase receptor R4, SKR4, TGF-beta type I receptor, transforming growth factor-beta receptor type I, TGF-beta receptor type I, transforming growth factor beta receptor I, TGF-beta receptor 1, or TbetaR-I.
- The present disclosure provides compounds that are capable of selectively binding to and/or modulating ALK5. In some embodiments, the compounds modulate ALK5 by binding to or interacting with one or more amino acids and/or one or more metal ions. The binding of these compounds may disrupt ALK5 downstream signaling.
- In certain aspects, the present disclosure provides a compound of Formula (I′):
- or a pharmaceutically acceptable salt thereof, wherein:
-
- A and B are each independently selected from C3-12 carbocycle and 3- to 12-membered heterocycle;
- X1 is selected from CH, CRD, N and S;
- X2 and X3 are each independently selected from CH, CRE, N and S;
- X4 is selected from bond, CH, CRE, N and S, provided that no more than one of X2, X3 and X4 is S;
- RA, RB, RC, RD and RE are each independently selected at each occurrence from:
- halogen, —NO2, —CN, —OR1, —SR1, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1);
- C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —NO2, —CN, —OR1, —SR1, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1), C3-12 carbocycle, and 3- to 12-membered heterocycle; and
- C3-12 carbocycle and 3- to 12-membered heterocycle,
- wherein each C3-12 carbocycle and 3- to 12-membered heterocycle in RA, RB, RC, RD and RE is independently optionally substituted with one or more substituents selected from halogen, —NO2, —CN, —OR1, —SR1, —CH2N(R1)2, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1), R1, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- or two RB groups, two RC groups or two RE groups can together optionally form a bridge or ring;
- m and n are each independently an integer from 0 to 3;
- p is an integer from 0 to 2;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3 12 carbocycle), and C0-3 alkyl-(3- to 12-membered heterocycle), each of which is optionally substituted by one or more substituents selected from halogen, —CN, —NO2, —NH2, —NHCH3, —N(CH3)2, —NHCH2CH3, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-12 carbocycle, and 3- to 6-membered heterocycle; and
- R2 and R3 are taken together with the nitrogen atom to which they are attached to form a heterocycle, optionally substituted with one or more R1.
- In some embodiments, for a compound of Formula (I′), RB, RC, RD and RE are each independently selected at each occurrence from halogen, —CN, —NH2, —NHCH3, —NHCH2CH3, —C(O)CH3, —OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2F, —CHF2, —CF3, C3-4 carbocycle, and 3- to 4-membered heterocycle; or two RC groups or two RE groups can together optionally form a bridge or ring;
- In some embodiments, for a compound of Formula (I′), p is 0 or 1, such as p is 0. In some embodiments, RC is selected from halogen, —NH2 and —CH3. In some embodiments, X1 is selected from CH and N, such as X1 is N. In some embodiments, X2 is selected from CH, CRE, N and S, such as X2 is N. In some embodiments, X2 is selected from CH and CRE, wherein RE is selected from —CN, —OCH3 and —CH3. In some embodiments, X3 is selected from CH and CRE, such as X3 is CH. In some embodiments, X3 is CRE, wherein RE is —OCH3.
- In some embodiments, X4 is selected from bond, CH, CRE and N, such as X4 is CH. In some embodiments, X4 is N. In some embodiments, X3 and X4 are each independently CRE, wherein the two RE groups form a ring, such as a 5- or 6-membered aryl or heteroaryl ring. Non-limiting examples wherein X3 and X4 are each independently CRE, wherein the two RE groups form a ring include:
- In some embodiments, X4 is a bond
- Non-limiting examples wherein X4 is a bond include:
- In some embodiments, the compound of Formula (I′) is a compound of Formula (I′-A), (I′-B), (I′-C), (I′-D) or (I′-E):
- In certain aspects, the present disclosure provides a compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
-
- A and B are each independently selected from C3-12 carbocycle and 3- to 12-membered heterocycle;
- RA is independently selected at each occurrence from:
- halogen, —NO2, —CN, —OR1, —SR1, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1);
- C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —NO2, —CN, —OR1, —SR1, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R1)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1), C3-12 carbocycle, and 3- to 12-membered heterocycle; and
- C3-12 carbocycle and 3- to 12-membered heterocycle,
- wherein each C3-12 carbocycle and 3- to 12-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from halogen, —NO2, —CN, —OR1, —SR1, —CH2N(R1)2, —N(R1)2, —NR2R3, —S(═O)R1, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —NR1S(═O)2NR2R3, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —OC(O)R1, —OC(O)OR1, —OC(O)N(R)2, —OC(O)NR2R3, —NR1C(O)R1, —NR1C(O)OR1, —NR1C(O)N(R1)2, —NR1C(O)NR2R3, —C(O)N(R1)2, —C(O)NR2R3, —P(O)(OR1)2, —P(O)(R1)2, ═O, ═S, ═N(R1), R1, C1_6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6alkynyl;
- RB is independently selected at each occurrence from halogen, —CN, —NH2, —NHCH3, —NHCH2CH3, —C(O)CH3, —OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2F, —CHF2, —CF3, C3-4 carbocycle, and 3- to 4-membered heterocycle;
- m and n are each independently an integer from 0 to 3;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3-12 carbocycle), and C0-3 alkyl-(3- to 12-membered heterocycle), each of which is optionally substituted by one or more substituents selected from halogen, —CN, —NO2, —NH2, —NHCH3, —N(CH3)2, —NHCH2CH3, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-12 carbocycle, and 3- to 6-membered heterocycle; and
- R2 and R3 are taken together with the nitrogen atom to which they are attached to form a heterocycle, optionally substituted with one or more R1.
- In some embodiments, the compound of Formula (I) is a compound of Formula (I-A), (I-B), (I-C), (I-D) or (I-E):
- In some embodiments, for a compound of Formula (I), (I′), (I-A) or (I′-A), A is selected from C6-10 aryl and 5- to 10-membered heteroaryl. In some embodiments, A is selected from phenyl and 5- to 6-membered heteroaryl, such as A is phenyl. In some embodiments, A is selected from phenyl, indanyl, thiazolyl, thiophenyl, pyrazolyl, pyridyl, pyrimidinyl, indazolyl, benzotriazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxanyl, and tetrahydrobenzazepinyl. In some embodiments, A is selected from phenyl, pyridinyl, thiazolyl and thiophenyl. In some embodiments, A is phenyl. In some embodiments, A is pyridinyl. In some embodiments, A is thiazolyl. In some embodiments, A is thiophenyl.
- In some embodiments, the compound of Formula (I) is a compound of the formula:
- In some embodiments, for a compound of Formula (I), (I′), (I-A) or (I′-A), m is 1 or 2. In some embodiments, m is 1. In some embodiments, A is C6 aryl or 6-membered heteroaryl, m is 1 and RA is in the meta- or para-position.
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), RA is independently selected at each occurrence from:
-
- halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3;
- C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3, C3-8 carbocycle, and 3- to 10-membered heterocycle; and
- C3-8 carbocycle and 3- to 10-membered heterocycle,
- wherein each C3-8 carbocycle and 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from halogen, —OR1, —CH2N(R1)2, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3, R1, and C1-6 alkyl.
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), RA is independently selected at each occurrence from:
-
- halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3;
- C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from —OR1, —N(R1)2, —C(O)OR1, C3-8 carbocycle, and 3- to 10-membered heterocycle; and
- C3-8 carbocycle and 3- to 10-membered heterocycle,
- wherein each C3-8 carbocycle and 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —OR1, —CH2N(R1)2, —N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —C(O)N(R1)2, R1, and C1-6 alkyl.
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), RA is independently selected at each occurrence from:
-
- halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2;
- C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from —OR1, —N(R1)2, and 3- to 10-membered heterocycle; and
- 3- to 10-membered heterocycle,
- wherein each 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —OR1, —N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —C(O)N(R1)2, and R1.
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), RA is independently selected at each occurrence from:
-
- —N(R1)2 and —NR1C(O)R1;
- C1-6 alkyl and —N(R1)—C1-6 alkyl, each of which is substituted with 4- to 8-membered heterocycle; and
- 4- to 8-membered heterocycle,
- wherein each 4- to 8-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —C(O)OR1 and R1.
- In some embodiments, a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E) comprises a terminal ester of the formula —C(O)OR15 or —OC(O)R15, wherein R15 comprises 1 to 12 carbon atoms and at least one basic amine. In some embodiments, the molecular weight of R15 is between 30 and 200 g/mol. The terminal ester may be metabolizable by one or more hydrolase (e.g., an esterase) present in human plasma and/or the human liver into a carboxylic acid and an alcohol. The biological activity of the compound may be greater than that of the carboxylic acid and the alcohol. For example, the compound may exhibit a BEAS2B pIC50 of at least 1 unit or greater than the carboxylic acid and the alcohol (assessed according to the assay provided in Example 46). In some embodiments, R15 is —(C0-4 alkyl)(4- to 10-membered heterocycloalkyl), wherein the heterocycloalkyl comprises 1, 2 or 3 nitrogen atoms, and wherein the heterocycloalkyl is optionally substituted with one or more substituents selected from C1-4 alkyl.
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E)
-
- RA is selected from
- wherein
-
- D and E are each independently selected from 3- to 8-membered heterocycle, each of which is independently optionally substituted with one or more substituents selected from —NH2, —NHCH3, —N(CH3)2, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-8 carbocycle, and 3- to 6-membered heterocycle. In some embodiments, D and E are each independently selected from 4- to 6-membered heterocycle, each of which is independently optionally substituted with one or more —CH3. In some embodiments, D and E are each unsubstituted.
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), RA is —N(R1)2, such as
- In some embodiments, RA is —NR1C(O)R1, such as
- In some embodiments, RA is C1-6 alkyl substituted with 4- to 8-membered heterocycle wherein the 4- to 8-membered heterocycle is substituted with —C(O)OR1, such as
- In some embodiments, RA is —N(R1)—C1-6 alkyl substituted with 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is optionally substituted, such as
- In some embodiments, RA is 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is optionally substituted with one or more substituents selected from —C(O)OR1 and R1, such as
- In some embodiments, RA is —C(O)OR1, such as
- In some embodiments, RA is selected from
- In some embodiments, RA is selected from
- In some embodiments, RA is selected from
- In some embodiments, RA is selected from
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3-8 carbocycle), and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —NH2, —NHCH3, —N(CH3)2, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-8 carbocycle, and 3- to 6-membered heterocycle. In some embodiments, R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —OH, —CH2OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, and 3- to 6-membered heterocycle.
- In some embodiments, for a compound of Formula (I), (I′), (I-B), (I′-B), (I-C) or (I′-C), B is selected from C6 10 aryl and 5- to 10-membered heteroaryl, such as B is selected from phenyl and pyridyl. In some embodiments, B is pyridyl. In some embodiments, B is 2-pyridyl. In some embodiments, B—(RB)n is 2-methylpyridyl.
- In some embodiments, for a compound of Formula (I), (I′), (I-B), (I′-B), (I-C) or (I′-C), n is 1 or 2, such as n is 1. In some embodiments, B is pyridyl, n is 1 and RB is in the 2-position.
- In some embodiments, for a compound of Formula (I), (I′), (I-B), (I′-B), (I-C) or (I′-C), RB is independently selected at each occurrence from halogen, —NH2, —NHCH3, —NHCH2CH3, —C(O)CH3, —OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2F, —CHF2, and —CF3. In some embodiments, RB is independently selected at each occurrence from halogen, —OH, —CH3, and —CHF2. In some embodiments, RB is —CH3.
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E):
-
- A is selected from phenyl and 5- to 6-membered heteroaryl;
- B is pyridyl;
- RA is independently selected at each occurrence from:
- halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3;
- C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from —OR1, —N(R1)2, —C(O)OR1, C3-8 carbocycle, and 3- to 10-membered heterocycle; and
- C3-8 carbocycle and 3- to 10-membered heterocycle,
- wherein each C3-8 carbocycle and 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —OR1, —CH2N(R1)2, —N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —C(O)N(R1)2, R1, and C1-6 alkyl;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3-s carbocycle), and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —NH2, —NHCH3, —N(CH3)2, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-8 carbocycle, and 3- to 6-membered heterocycle;
- m is 1 or 2;
- RB is selected from halogen, —OH, —CH3, and —CHF2; and
- n is 1.
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E):
-
- A is phenyl;
- B is pyridyl;
- RA is independently selected at each occurrence from:
- —N(R1)2 and —NR1C(O)R1;
- C1-6 alkyl and —N(R1)—C1-6 alkyl, each of which is substituted with 4- to 8-membered heterocycle; and
- 4- to 8-membered heterocycle,
- wherein each 4- to 8-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —C(O)OR1 and R1;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —OH, —CH2OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, and 3- to 6-membered heterocycle;
- m is 1;
- RB is —CH3; and
- n is 1.
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E):
-
- A is phenyl;
- B is pyridyl;
- RA is C1-6 alkyl substituted with 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is substituted with —C(O)OR1;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —OH, —CH2OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, and 3- to 6-membered heterocycle;
- m is 1;
- RB is —CH3; and
- n is 1.
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E):
-
- A is selected from phenyl and 5- to 6-membered heteroaryl;
- B is pyridyl;
- RA is selected from:
- —C(O)OR1; and
- C0-6 alkyl-(3- to 8-membered heterocycle), wherein the 3- to 8-membered heterocycle is substituted with —C(O)OR1;
- R1 is C0-3 alkyl-(3- to 8-membered heterocycle), optionally substituted by one or more substituents selected from —CH3, —CH2CH3, —CH(CH3)2, and —C(CH3)3;
- m is 1;
- RB is —CH3; and
- n is 1.
- In some embodiments, for a compound of Formula (I):
-
- A is pyridyl;
- B is pyridyl;
- RA is —C(O)OR1;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —OH, —CH2OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, and 3- to 6-membered heterocycle;
- m is 1;
- RB is —CH3; and
- n is 1.
- In some embodiments, for a compound of Formula (I):
-
- A is thiophenyl;
- B is pyridyl;
- RA is —C(O)OR1;
- R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —OH, —CH2OH, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, and 3- to 6-membered heterocycle;
- m is 1;
- RB is —CH3; and
- n is 1.
- In some embodiments, for a compound of Formula (I):
-
- A is selected from phenyl and thiophenyl;
- B is pyridyl;
- RA is —NR1C(O)R1;
- R1 is independently selected at each occurrence from hydrogen; and C0-3 alkyl-(3- to 8-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —OH, —CH2OH, —CH3, —CH2CH3, —CH(CH3)2, and —C(CH3)3;
- m is 1;
- RB is —CH3; and
- n is 1.
- In some embodiments, for a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E):
-
- A is selected from phenyl and 5- to 6-membered heteroaryl;
- B is selected from phenyl and pyridyl;
- RA is selected from
-
- D and E are each independently selected from 3- to 8-membered heterocycle, each of which is independently optionally substituted with one or more substituents selected from —NH2, —NHCH3, —N(CH3)2, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-8 carbocycle, and 3- to 6-membered heterocycle;
- m is 1;
- RB is selected from halogen, —OH, —CH3, and —CHF2; and
- n is 1.
- In some embodiments RA is selected from
- In some embodiments, D and E are each independently selected from 4- to 6-membered heterocycle, each of which is independently optionally substituted with one or more —CH3. In some embodiments, D and E are each unsubstituted. In some embodiments, A is selected from phenyl, pyridinyl, thiazolyl and thiophenyl. In some embodiments, A is phenyl. In some embodiments, A is pyridinyl. In some embodiments, A is thiazolyl. In some embodiments, A is thiophenyl.
- In some embodiments, a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E) is provided as a substantially pure stereoisomer. In some embodiments, the stereoisomer is provided in at least 80% enantiomeric excess, such as at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.9% enantiomeric excess.
- In some embodiments, the present disclosure provides a soft ALK5 inhibitor. As used herein, the term “soft drug” or “soft ALK5 inhibitor” refers to a biologically active compound that is converted upon entering the systemic circulation into a predictable metabolite that exhibits reduced biological activity relative to the parent compound. A soft drug preferably exerts its desired therapeutic effect locally at the target organ or tissue, then is rapidly converted to a predictable metabolite designed to be less active than the parent soft drug upon entering the systemic circulation, thus reducing systemic exposure to the biologically active compound. Accordingly, soft drugs have a lower potential for undesired side effects relative to non-soft drug compounds having comparable biological activity. Preferably, a soft drug of the present disclosure exhibits good stability at the intended site of action (e.g., the lung), is rapidly metabolized upon entering systemic circulation, and displays more functional activity than the corresponding metabolite.
- In some embodiments, a soft drug provided herein exhibits an ALK5 pKi of greater than or equal to 9, while the corresponding soft drug metabolite exhibits an ALK5 pKi of 9 or less, such as 8 or less (assessed according to the assay provided in Example 45). In some embodiments, the difference in pKi of the soft drug and the corresponding soft drug metabolite is at least 0.5, such as at least 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or at least 2.0. In some embodiments, a soft drug provided herein exhibits a BEAS2B pIC50 of greater than or equal to 7, while the corresponding soft drug metabolite exhibits a BEAS2B pIC50 of 6 or less (assessed according to the assay provided in Example 46). In some embodiments, the difference in pIC50 of the soft drug and the corresponding soft drug metabolite is at least 1.0, such as at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or at least 2.0. In some embodiments, the soft drug and corresponding soft drug metabolite exhibit similar ALK5 pKi values, but the soft drug is more active in cells (e.g., the soft drug exhibits a BEAS2B pIC50 of at least 1.0 greater than the soft drug metabolite).
- In some embodiments, the present disclosure provides a soft ALK5 inhibitor comprising an ester. Preferably, the ester inhibits ALK5 activity, while the corresponding carboxylic acid of the ester exhibits reduced ALK5 inhibitory activity. For example, the difference in ALK5 pKi of the ester and corresponding acid may be at least 1.0. In some embodiments, a soft drug ester of the present disclosure is administered to the lung, for example, by inhalation, and inhibits the activity of ALK5 in the lung. However, upon exiting the lung, the ester may be readily hydrolyzed to the corresponding carboxylic acid, thus reducing systemic exposure to the ester.
- In some embodiments, the present disclosure provides a conjugate comprising a compound disclosed herein linked, e.g., covalently linked, either directly or through a linker to an antibody construct or targeting moiety, thereby forming a conjugate. The linker may be a non-cleavable linker or a cleavable linker. A conjugate may be represented by the formula:
- wherein A′ is an antibody construct or targeting moiety; L1 is a linker; D′ is a compound or salt disclosed herein, such as a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E); and p is an integer from 1 to 20. In some embodiments, p is an integer from 1 to 10, such as from 1 to 8, 2 to 8, 1 to 6, 3 to 5, or from 1 to 3.
- In some embodiments, a conjugate is represented by the formula:
- wherein A′ is an antibody construct or targeting moiety; D′ is a compound or salt disclosed herein, such as a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E); and p is an integer from 1 to 20. In some embodiments, p is an integer from 1 to 10, such as from 1 to 8, 2 to 8, 1 to 6, 3 to 5, or from 1 to 3.
- Accordingly, a compound or salt of the present disclosure, such as a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), may be attached to A′ via a linker, L1, or directly attached to A′ without an intermediate linker. In some embodiments, the compound or salt is covalently attached to an A′ or L1. It will be understood by the skilled person that not all compounds of the present disclosure are meant to be attached to L1 or A′, only those that have suitable attachment sites. A compound or salt disclosed herein that does not have a suitable attachment site may be modified to introduce an attachment site.
- In some embodiments, L1 or D′ is bound to A′ via a terminus of an amino acid sequence or via a side chain of an amino acid, such as the side chain of lysine, serine, threonine, cysteine, tyrosine, aspartic acid, glutamine, a non-natural amino acid residue, or glutamic acid residue. In some embodiments, L1 or D′ is bound to A′ via one or more glycans or short peptide tags of four to six amino acids. L1 or D′ may be conjugated to A′ via any suitable functional group, such as a thiol, an amine, an amide, an alcohol, a ketone, a carboxylic acid, or an ester.
- A linker may be attached to a compound or salt of the present disclosure at any available position. For example, a compound of Formula (I) may comprise a linker L1 to A′ in place of RA or through substituent RA:
- Compounds are typically depicted herein in their unconjugated form, though it will be understood by the skilled person that linker L1 may be covalently bound to any suitably atom for attachment, such as a substitutable nitrogen, carbon, sulfur, phosphorous or oxygen of a compound. L1 may be a cleavable or non-cleavable linker. The linker may further be bound to A′. Preferably, L1 does not affect the binding of the active portions of the conjugate to the binding target(s). Covalent linkages may be formed by reaction between a functional group on the linker with a functional group on the compound, and by reaction between a functional group on the linker with a functional group on A′. As used herein in the context of conjugates, the term “linker” includes (i) unattached forms of the linker comprising a functional group capable of covalently attaching the linker to a compound disclosed herein and a functional group capable of covalently attaching the linker to an antibody construct or targeting moiety; (ii) partially attached forms of the linker bound to a compound disclosed herein, wherein the linker comprises a functional group capable of covalently attaching the linker to an antibody construct or targeting moiety; (iii) partially attached forms of the linker bound to an antibody construct or targeting moiety, wherein the linker comprises a functional group capable of covalently attaching the linker to a compound disclosed herein; and (iv) fully attached forms of the linker bound to both an antibody construct or targeting moiety and a compound disclosed herein.
- Linker L1 may be short, flexible, rigid, cleavable (e.g., by a lysosomal enzyme), non-cleavable, hydrophilic, or hydrophobic. A linker may contain segments having different characteristics, such as flexible segments and rigid segments. A linker may be chemically stable to extracellular environments, for example, in the bloodstream, or may include moieties that are not stable or are selectively stable. In some embodiments, a linker comprises a moiety that is selectively cleaved, for example, selectively cleaved in cells, a particular organ, or in plasma. A linker may be sensitive to enzymes, such as proteases. A linker may be insensitive to intracellular processes or proteases. A linker may be acid-labile, protease-sensitive or photolabile. In some embodiments, a linker comprises a peptide, succinimide, maleimide, polyethylene glycol, alkylene, alkenylene, alkynylene, disulfide, hydrazone, polyether, polyester, polyamide, aminobenzyl-carbamate, or a combination thereof.
- In some aspects, the present disclosure provides a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), or a compound disclosed in Table 1 or Table 2, wherein the compound is covalently bound to A′, optionally via linker L1. In some embodiments, the antibody construct is an antibody. In some embodiments, the present disclosure provides a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), or a compound disclosed in Table 1 or Table 2, wherein the compound is covalently bound to a linker, L1, to form a compound-linker. A′ or L1 may be covalently attached to any position of the compound, valence permitting. A linker L1 disclosed herein may comprise from about 10 to about 500 atoms, such as 10 to 400 atoms, 10 to 300 atoms, 30 to 400 atoms, or 30 to 300 atoms.
- The targets of the antibody, antibody construct, or targeting moiety may depend on the desired therapeutic applications of the conjugate. Typically, the targets are molecules present on the surfaces of cells into which it is desirable to deliver an ALK5 inhibitor, such as T cells, and the antibodies preferably internalize upon binding to the target. For applications in which the conjugates are intended to stimulate the immune system by reducing TGF-β activity, it may be desirable to generate antibodies, antibody constructs, or targeting moieties that bind to T cell surface molecules. Not wishing to be bound by any particular theory, it is believed that the delivery of ALK5 inhibitors to T cells can activate CD4+ and/or CD8+ T cell activity and inhibit regulatory T cell activity, both of which contribute to immune tolerance of tumors. Accordingly, antibodies, antibody constructs, or targeting moieties (A′) that bind to T cell surface molecules in the conjugates of the present disclosure are useful for the treatment of various cancers, such as those described herein below. In some embodiments, A′ binds to CD4+ T cells, CD8+ T cells, TREG cells, or any combination thereof. In some embodiments, A′ binds to a pan T cell surface molecule, such as CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD25, CD28, CD70, CD71, CD103, CD184, Tim3, LAG3, CTLA4, or PD1. Examples of antibodies that bind to T cell surface molecules and are believed to be internalizing include OKT6, OKT11, OKT3, OKT4, OKT8, 7D4, OKT9, CD28.2, UCHT1, M290, FR70, pembrolizumab, nivolumab, cemiplimab, and dostarlimab.
- An antibody, antibody construct, or targeting moiety disclosed herein may comprise an antigen binding domain that specifically binds to a tumor antigen or antigen associated with the pathogenesis of fibrosis. In some embodiments, the antigen binding domain specifically binds to an antigen on a T cell, a B cell, a stellate cell, an endothelial cell, a tumor cell, an APC, a fibroblast cell, a fibrocyte cell, or a cell associated with the pathogenesis of fibrosis. In some embodiments, the antigen binding domain targets CTLA4, PD-1, OX40, LAG-3, GITR, GARP, CD25, CD27, PD-L1, TNFR2, ICOS, 41BB, CD70, CD73, CD38 or VTCN1. In some embodiments, the antigen binding domain targets PDGFRβ, integrin αvβ1, integrin αvβ3, integrin αvβ6, αvβ8, endosialin, FAP, ADAM12, LRRC15, MMP14, PDPN, CDH11, F2RL2, ASGR1, or ASGR2.
- The chemical entities described herein can be synthesized according to one or more illustrative schemes herein and/or techniques known in the art. Materials used herein are either commercially available or prepared by synthetic methods generally known in the art. These schemes are not limited to the compounds listed in the examples or by any particular substituents, which are employed for illustrative purposes. Although various steps are described and depicted in Schemes 1 and 2 and Examples 1-44, the steps in some cases may be performed in a different order than the order shown in Schemes 1 and 2 and Examples 1-44. Various modifications to these synthetic reaction schemes may be made and will be suggested to one skilled in the art having referred to the present disclosure. Numberings or R groups in each scheme typically have the same meanings as those defined elsewhere herein unless otherwise indicated.
- Unless specified to the contrary, the reactions described herein take place at atmospheric pressure, generally within a temperature range from −10° C. to 200° C. Further, except as otherwise specified, reaction times and conditions are intended to be approximate, e.g. taking place at about atmospheric pressure within a temperature range of about −10° C. to about 110° C. over a period of about 1 to about 24 hours; reactions left to run overnight average a period of about 16 hours.
- In general, compounds of the disclosure may be prepared by the following reaction schemes:
- In some embodiments, a compound of Formula 1i may be prepared according to Scheme 1. For example, imidate 1b can be formed from nitrile 1a via a Pinner Reaction, then converted to amidine 1c in the presence of ammonium chloride. Cyclization with methyl 3-methoxyacrylate (1d) may proceed to give pyrimidinone 1e, which may be treated with phosphorus oxychloride to give chloropyrimidine 1f. Chloropyrimidine 1f can be subjected to a C—N coupling reaction—optionally a Pd-catalyzed coupling reaction such as a Buchwald-Hartwig amination—with 2-chloropyrimidin-4-amine (1g) to provide heteroaryl amine 1h. Optionally, 1h may be subjected to one or more coupling reactions, and optionally one or more protecting group manipulations, to provide a compound of Formula 1i.
- In some embodiments, a compound of Formula 2f may be prepared according to Scheme 2. For example, nitro compound 2a can be reduced to amine 2b. The amine may then be subjected to a C—N coupling reaction-optionally a Pd-catalyzed coupling reaction such as a Buchwald-Hartwig amination—with bis(2-chloropyrimidin-4-yl)amine (2c) to provide heteroaryl amine 2d. A substitution reaction can provide heteroaryl iodide 2e, which may undergo a nucleophilic aromatic substitution reaction, and optionally one or more protecting group manipulations, to provide a compound of Formula 2f.
- In some embodiments, a compound of the present disclosure, for example, a compound of a formula given in Table 1 or 2, is synthesized according to one of the general routes outlined in Schemes 1 and 2, Examples 1-44, or by methods generally known in the art. In some embodiments, exemplary compounds may include, but are not limited to, a compound or salt thereof selected from Table 1.
-
TABLE 1 [M + No. Structure Chemical Name H]+ 1 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [[(3S)-pyrrolidin-3- yl]amino]phenyl]pyrimidine-2,4- diamine 440.2 2 [2-chloro-6-fluoro-4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]- piperazin-1-yl- methanone 520.1 3 1-[3-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]anilino] methyl]azetidin- 1-yl]ethanone 482.3 4 N2-[4-[4-(4-methylpiperazin-1- yl)-1-piperidyl]phenyl]-N4-[2- (6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 537.2 5 N2-(4-aminophenyl)-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 371.1 6 N-[2-methoxy-5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 512.2 7 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [rac-(3R)-3-methylpiperazin-1- yl]phenyl]pyrimidine-2,4- diamine 454.1 8 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(4- thiomorpholinophenyl) pyrimidine-2,4-diamine 457.2 9 [(1R)-1-methylpropyl] 2-[1-[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]acetate 554.5 10 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-3- carboxamide 482.1 11 pyrrolidin-3-yl 1-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-3- carboxylate 552.3 12 1-[4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl] sulfonylpiperazin- 1-yl]ethanone 546.0 13 [(1R)-1-methylpropyl] 2-[5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-piperazin-1-yl-phenyl]acetate 554.3 14 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 482.1 15 N2-[4-(2,6- diazaspiro[3.3]heptan-2- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 452.2 16 3-[4-[[2-[4-[4-(dimethylamino)- 1-piperidyl]anilino]pyrimidin-4- yl]amino]pyrimidin-2-yl]-4- methyl-phenol 497.2 17 azetidin-3-yl 1-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-4-carboxylate 552.1 18 N-[2-methoxy-4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl] methanesulfonamide 479.0 19 N4-[2-(5-chloro-2,4-difluoro- phenyl)pyrimidin-4-yl]-N2-(4- morpholinophenyl)pyrimidine- 2,4-diamine 496.1 20 N-[2-methoxy-5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 3-pyridyl]methanesulfonamide 480.0 21 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(4- piperazin-1- ylsulfonylphenyl)pyrimidine- 2,4-diamine 504.2 22 4-piperidyl 1-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidine-3-carboxylate 552.3 23 N2-[4-[(4-benzylpiperazin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 544.2 24 N2-[4- [(dimethylamino)methyl]phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 413.2 25 methyl 1-[[4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazine-2-carboxylate 512.2 26 4-[[2-(4-aminoanilino)pyrimidin- 4-yl]amino]-2-(6-methyl-2- pyridyl)pyrimidine-5-carboxylic acid 415.0 27 N2-[4-(4-benzylpiperazin-1- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 530.1 28 methyl 1-[[4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-4-carboxylate 511.1 29 (1-methylpyrrolidin-3-yl) 1-[[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 580.2 30 [2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazol-5-yl]-piperazin- 1-yl-methanone 475.1 31 2-[1-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]acetic acid 498.4 32 N2-[4-[[(2R,5R)-2,5- dimethylpiperazin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.2 33 azetidin-3-ylmethyl 4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 469.1 34 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [rac-(1S,5R)-3,8- diazabicyclo[3.2.1]octan-3- yl]phenyl]pyrimidine-2,4- diamine 466.2 35 N4-[2-(2,4- difluorophenyl)pyrimidin-4-yl]- N2-(4- morpholinophenyl) pyrimidine-2,4-diamine 462.1 36 2-[4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]pyrazol-1- yl]ethanol 466.1 37 4-hydroxy-2-[2-[4-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-1-yl]- 2-oxo-ethyl]sulfanyl-butanoic acid 616.3 38 N2-[4-(4-ethylpiperazin-1- yl)sulfonylphenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 532.1 39 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[3- (thiomorpholinomethyl)phenyl] pyrimidine-2,4-diamine 471.1 40 N-[3-(hydroxymethyl)pyrrolidin- 3-yl]-4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxamide 504.2 41 isobutyl 2-[1-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]acetate 554.5 42 N-(azetidin-3-ylmethyl)-2-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4-carboxamide 474.9 43 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2- phenyl-pyrimidine-2,4-diamine 356.2 44 N-(azetidin-3-yl)-2-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4- carboxamide 461.1 45 [3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methanol 386.2 46 [(2S)-4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]methanol 470.1 47 ethyl 2-[4-[4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]pyrazol-1- yl]acetate 508.1 48 methyl 6-[[2-[4-(4- methylpiperazin-1- yl)anilino]pyrimidin-4- yl]amino]-2-(6-methyl-2- pyridyl)pyrimidine-4-carboxylate 512.2 49 N2-[4-chloro-3-(piperazin-1- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 488.2 50 azetidin-3-yl 1-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] pyrrolidine-3-carboxylate 538.1 51 [(3S)-1-methylpyrrolidin-3-yl] 4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 483.0 52 [(3R)-1-methylpyrrolidin-3-yl] 5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 489.1 53 N2-[1-(2-aminoethyl)pyrazol-4- yl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 389.2 54 2-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenoxy]ethanol 416.1 55 (1-methylpyrrolidin-3-yl) 1-[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine- 3-carboxylate 566.3 56 N2-[4-(1-methylpyrazol-4- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 436.1 57 azetidin-3-ylmethyl 2-[5-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-piperazin-1-yl-phenyl]acetate 567.1 58 3-hydroxy-N-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]pyrrolidine-3- carboxamide 484.1 59 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl] methyl]-N-[rac- (3S)-pyrrolidin-3- yl]piperidine- 3-carboxamide 565.2 60 methyl 1-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxylate 497.1 61 [2-methyl-5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methanol 400.3 62 methyl 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 414.0 63 N-(2-aminoethyl)-N-methyl-4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzenesulfonamide 492.2 64 N2-[4-[[(3R)-3- (methoxymethyl)piperazin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 498.1 65 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [[(2R)-pyrrolidin-2- yl]methylamino]phenyl] pyrimidine-2,4-diamine 454.2 66 4-piperidyl 3-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 483.2 67 azetidin-3-ylmethyl (3S)-1-[[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 566.1 68 N4-[2-(5-chloro-2-fluoro- phenyl)-5-cyclopropyl- pyrimidin-4-yl]-N2-(4-piperazin- 1-ylphenyl)pyrimidine-2,4- diamine 517.1 69 [(3R)-1-methylpyrrolidin-3-yl] 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidine-3-carboxylate 552.1 70 N-[2-(dimethylamino)ethyl]-4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzenesulfonamide 506.1 71 1-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxylic acid 482.2 72 [3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]-morpholino- methanone 469.2 73 (1-methylazetidin-3-yl)methyl (3S)-1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 580.2 74 (3S)-1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] pyrrolidin-3-ol 455.1 75 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [[rac-(1S,5R)-3,8- diazabicyclo[3.2.1]octan-3- yl]methyl]phenyl]pyrimidine- 2,4-diamine 480.2 76 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]azetidine-3- carboxamide 454.1 77 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]-1- tetrahydropyran-4-yl-piperidine- 4-carboxamide 566.2 78 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]pyrrolidine-3- carboxamide 468.0 79 N2-(3-methoxy-4-morpholino- phenyl)-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 471.2 80 N2-[4-(4-ethylpiperazin-1- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 468.2 81 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- methyl-3-[[rac-(3R,5S)-3,5- dimethylpiperazin-1- yl]methyl]phenyl]pyrimidine- 2,4-diamine 496.1 82 2-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]acetic acid 414.1 83 methyl 1-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-3- carboxylate 497.1 84 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[1- (2-morpholinoethyl)pyrazol-4- yl]pyrimidine-2,4-diamine 459.2 85 4-piperidyl 5-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-3- carboxylate 489.1 86 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(2- piperazin-1-ylpyrimidin-5- yl)pyrimidine-2,4-diamine 442.2 87 N-methyl-3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl] amino]-N-(4- piperidyl)benzenesulfonamide 532.2 88 azetidin-3-ylmethyl 1-[[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidine-3-carboxylate 538.2 89 N-(azetidin-3-ylmethyl)-4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxamide 474.0 90 N4-[2-(2- fluorophenyl)pyrimidin-4-yl]- N2-[4-[4-(methylamino)-1- piperidyl]phenyl]pyrimidine- 2,4-diamine 471.1 91 N-ethyl-2-[2-(6-methyl-2- pyridyl)-6-[[2-(4-piperazin-1- ylanilino)pyrimidin-4- yl]amino]pyrimidin-4- yl]acetamide 525.1 92 N-(azetidin-3-ylmethyl)-4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzamide 468.1 93 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine- 1-sulfonamide 519.1 94 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[5- (piperazin-1-ylmethyl)-3- thienyl]pyrimidine-2,4-diamine 460.2 95 2-[5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-piperazin-1-yl-phenyl]acetic acid 498.4 96 azetidin-3-ylmethyl 4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 475.1 97 [(3S)-1-methylpyrrolidin-3-yl] 1- [[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidine-3-carboxylate 552.1 98 N2-[4-(3-aminoazetidin-1- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 426.1 99 [3-methyl-1-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidin-3-yl]methanol 469.2 100 azetidin-3-ylmethyl 5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 475.0 101 pyrrolidin-3-yl 1-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxylate 552.2 102 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [4-(pyrrolidin-3- ylmethyl)piperazin-1- yl]phenyl]pyrimidine-2,4- diamine 523.1 103 [rac-(3R)-1-methylpyrrolidin-3- yl] 2-[1-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]acetate 581.1 104 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (thiomorpholinomethyl)phenyl] pyrimidine-2,4-diamine 471.1 105 [rac-(3R)-pyrrolidin-3-yl] 1-[[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 566.2 106 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]-1-(3- piperidyl)methanesulfonamide 532.1 107 N-isopropyl-4-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]sulfonyl- piperazine-1-carboxamide 589.1 108 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzenesulfonamide 435.0 109 N2-[4-[(4-tert-butylpiperazin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 510.3 110 4-isopropyl-N-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-1- carboxamide 525.2 111 N2-[4-fluoro-3-(piperazin-1- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 472.2 112 [1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl]-3- piperidyl]-piperazin-1-yl- methanone 565.1 113 [(1S)-1-methylpropyl] 4-[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-2- carboxylate 540.2 114 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[5- (4-piperidyl)-2- pyridyl]pyrimidine-2,4-diamine 440.3 115 [5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-thienyl]-piperazin-1-yl- methanone 474.1 116 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [methyl-[(3S)-pyrrolidin-3- yl]amino]phenyl]pyrimidine-2,4- diamine 454.3 117 N-isobutyl-2-[2-(6-methyl-2- pyridyl)-6-[[2-(4-piperazin-1- ylanilino)pyrimidin-4- yl]amino]pyrimidin-4- yl]acetamide 553.2 118 N2-[3-(azetidin-3- ylmethylamino)phenyl]-N4-[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 440.4 119 6-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-sulfonamide 436.0 120 N2-(3-fluoro-4-piperazin-1-yl- phenyl)-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 458.1 121 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(5- piperazin-1-yl-2- pyridyl)pyrimidine-2,4-diamine 441.3 122 N-methyl-4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- N-(4- piperidyl)benzenesulfonamide 532.2 123 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (4-pyrrolidin-1-yl-1- piperidyl)phenyl]pyrimidine- 2,4-diamine 508.2 124 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] pyrrolidine-3-carboxylic acid 483.0 125 1-(azetidin-3-yl)-3-[3-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]urea 469.1 126 N2-(3-amino-4-chloro-phenyl)- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 405.0 127 N2-[4-[(3-methoxyazetidin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 455.2 128 N-[2-methyl-5-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 496.2 129 N2-[4-(3,4,6,7,8,8a-hexahydro- 1H-pyrrolo[1,2-a]pyrazin-2- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 494.2 130 N2-[4-fluoro-3-[[rac-(3R,5S)- 3,5-dimethylpiperazin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 500.1 131 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidin-3-ol 441.1 132 [(2R)-1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazin-2-yl]methanol 484.1 133 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (4-piperidyl)phenyl]pyrimidine- 2,4-diamine 439.2 134 1-[2-(dimethylamino)ethyl]-N- [3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine- 4-carboxamide 553.3 135 N-[2-chloro-5-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 516.2 136 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [4-(2-pyridylmethyl)piperazin-1- yl]phenyl]pyrimidine-2,4- diamine 531.1 137 N4-[2-(5-chloro-2-fluoro- phenyl)pyrimidin-4-yl]-N2-[4- [4-(methylamino)-1- piperidyl]phenyl]pyrimidine-2,4- diamine 505.1 138 azetidin-3-yl 1-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 552.2 139 [(3S)-1-methylpyrrolidin-3-yl] (3R)-1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 580.2 140 N-[[3-(hydroxymethyl)azetidin- 3-yl]methyl]-2-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole- 4-carboxamide 505.1 141 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[3- (morpholinomethyl)phenyl] pyrimidine-2,4-diamine 455.1 142 azetidin-3-ylmethyl 5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-3- carboxylate 475.1 143 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [rac-(3S,5R)-3,5- dimethylpiperazin-1- yl]phenyl]pyrimidine-2,4- diamine 468.2 144 [(3S)-pyrrolidin-3-yl] 1-[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine- 3-carboxylate 552.3 145 1-methyl-N-[3-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 496.2 146 2-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]ethanol 400.2 147 4-piperidyl 4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 483.1 148 4-piperidyl 2-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4-carboxylate 490.0 149 3-[2-[4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-1-yl]- 2-oxo-ethyl] sulfanyltetrahydrofuran-2- one 598.3 150 1-methyl-N-[4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 496.2 151 N2-[4-(4-aminocyclohexen-1- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 451.2 152 [(3R)-pyrrolidin-3-yl] 1-[[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidine-3-carboxylate 538.1 153 N2-[4-(4-methylpiperazin-1- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 454.2 154 N-[3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]azetidine-3- carboxamide 454.1 155 azetidin-3-ylmethyl (3R)-1-[[2- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazol-4- yl]methyl]piperidine- 3-carboxylate 573.1 156 ethyl 2-[5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-piperazin-1-yl-phenyl]acetate 526.3 157 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (2-piperazin-1- ylethylamino)phenyl]pyrimidine- 2,4-diamine 483.2 158 N-[2-chloro-4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 516.0 159 azetidin-3-yl 2-[1-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]acetate 553.1 160 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2- (2,3,4,5-tetrahydro-1H-3- benzazepin-7-yl)pyrimidine-2,4- diamine 425.1 161 [(3S)-1-methylpyrrolidin-3-yl] 1- [[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] pyrrolidine-3-carboxylate 566.1 162 4-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]sulfamoyl] benzamide 554.2 163 N2-[4-(2,6- diazaspiro[3.3]heptan-2- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 466.2 164 3-(hydroxymethyl)-N-[3-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]azetidine-3- carboxamide 484.0 165 N4-[2-(5-chloro-2-fluoro- phenyl)pyrimidin-4-yl]-N2-[4- (morpholinomethyl)phenyl] pyrimidine-2,4-diamine 492.1 166 4-methyl-3-[4-[[2-(4- morpholinoanilino)pyrimidin-4- yl]amino]pyrimidin-2-yl]phenol 456.1 167 azetidin-3-yl 1-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidine-3-carboxylate 524.2 168 1-[3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]-3-pyrrolidin-3- yl-urea 483.1 169 N2-[4-[1-(2- methoxyethyl)pyrazol-4- yl]phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 480.0 170 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(p- tolyl)pyrimidine-2,4-diamine 370.1 171 methyl 1-isopropyl-4-[2-[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]anilino]ethyl] piperazine-2-carboxylate 583.1 172 methyl (2R)-4-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-2- carboxylate 498.0 173 azetidin-3-yl 1-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-3- carboxylate 538.3 174 [(3S)-pyrrolidin-3-yl] 1-[[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidine-3-carboxylate 538.2 175 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2- (1,2,3,4-tetrahydroisoquinolin-7- yl)pyrimidine-2,4-diamine 411.1 176 N2-[3-[[4-(methylamino)-1- piperidyl]sulfonyl]phenyl]-N4- [2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 532.2 177 N2-[4-(3,9- diazabicyclo[3.3.1]nonan-3- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 494.3 178 azetidin-3-ylmethyl 3-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 469.1 179 4-methyl-3-[4-[[2-(4-piperazin- 1-ylanilino)pyrimidin-4- yl]amino]pyrimidin-2-yl]phenol 455.1 180 3-hydroxy-N-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]azetidine-3- carboxamide 470.0 181 N2-[1-(azetidin-3- ylmethyl)pyrazol-4-yl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 415.1 182 (1-methylazetidin-3-yl)methyl (3R)-1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 580.1 183 [(2R)-4-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazin-2-yl]methanol 484.1 184 N-[2-chloro-6-fluoro-4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 534.1 185 [(3S)-pyrrolidin-3-yl] 1-[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine- 4-carboxylate 552.1 186 N2-[4-[3-(aminomethyl)azetidin- 1-yl]phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 440.2 187 N2-[4-(aminomethyl)phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 385.2 188 [4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-thienyl]-piperazin-1- yl-methanone 474.1 189 N2-[4-(4-isopropylpiperazin-1- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.1 190 1-[4-[3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-1- yl]ethanone 482.2 191 N2-(5-amino-2,3-dihydro-1,4- benzodioxin-7-yl)-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 429.2 192 [rac-(1R)-1-methylpropyl] 4-[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-2- carboxylate 540.2 193 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (1,2,3,6-tetrahydropyridin-4- yl)phenyl]pyrimidine-2,4- diamine 437.1 194 N2-[4-[4-(isobutylamino)-1- piperidyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 510.3 195 [(3R)-1-methylpyrrolidin-3-yl] 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] pyrrolidine-3-carboxylate 566.1 196 N2-[4-(1,4-diazepan-1- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 454.1 197 N2-[4-(3,8- diazabicyclo[3.2.1]octan-8- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 480.2 198 N2-(2-isopropyl-3,4-dihydro-1H- isoquinolin-7-yl)-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 453.2 199 N2-[4-(azetidin-3- ylamino)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 426.1 200 (2R)-4-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazine-2-carboxylic acid 498.2 201 methyl 1-methyl-4-[[4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazine-2-carboxylate 526.1 202 N2-[4-[azetidin-3- ylmethyl(methyl)amino]phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 454.2 203 3-hydroxy-N-[3-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]pyrrolidine-3- carboxamide 484.1 204 methyl 1-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-2- carboxylate 498.3 205 isobutyl 2-[5-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-piperazin-1-yl-phenyl]acetate 554.4 206 3-(hydroxymethyl)-N-[4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-thienyl]azetidine-3- carboxamide 490.2 207 azetidin-3-yl 5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-3- carboxylate 461.1 208 N-(2-aminoethyl)-4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzenesulfonamide 478.2 209 3-(hydroxymethyl)-N-[4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]azetidine-3- carboxamide 484.0 210 [(3S)-1-methylpyrrolidin-3-yl] (3S)-1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 580.2 211 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-thienyl]azetidine-3- carboxamide 460.0 212 [rac-(3S)-pyrrolidin-3-yl] 1-[[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 566.2 213 N2-[4-(4-isopropylpiperazin-1- yl)sulfonylphenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 546.1 214 N-(azetidin-3-yl)-1-[[4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxamide 551.2 215 4-piperidyl 1-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-3- carboxylate 566.2 216 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [rac-(2S)-2-methylpiperazin-1- yl]phenyl]pyrimidine-2,4- diamine 454.1 217 [(3S)-1-methylpyrrolidin-3-yl] 4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 489.1 218 4-piperidyl 1-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxylate 566.1 219 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [4-[(2- pyridylmethylamino)methyl]-1- piperidyl]phenyl]pyrimidine- 2,4-diamine 559.2 220 azetidin-3-yl 1-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine- 4-carboxylate 538.1 221 N2-[4-(3,8- diazabicyclo[3.2.1]octan-8- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 466.1 222 N4-[6-methyl-2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (4-methylpiperazin-1- yl)phenyl]pyrimidine-2,4- diamine 468.1 223 N2-(3-isopropyl-1,2,4,5- tetrahydro-3-benzazepin-7-yl)- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 467.3 224 (3S)-1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylic acid 497.2 225 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2- (1,2,3,4-tetrahydroquinolin-7- yl)pyrimidine-2,4-diamine 411.2 226 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(4- methylthiazol-2-yl)pyrimidine- 2,4-diamine 377.0 227 N-[3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]pyrrolidine-3- carboxamide 468.1 228 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine- 1-carboxamide 483.1 229 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine- 4-sulfonamide 518.2 230 [rac-(1R)-1-methylpropyl] 1-[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine- 2-carboxylate 540.2 231 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(4- pyrrolidin-3- ylphenyl)pyrimidine-2,4-diamine 425.1 232 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (5,6,7,8-tetrahydroimidazo[1,2- a]pyrazin-2- yl)phenyl]pyrimidine-2,4- diamine 477.2 233 N2-[3-(4-methylpiperazin-1- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 454.2 234 N2-(4-bromophenyl)-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 435.8 235 5-[[4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-1- yl]methyl]tetrahydrofuran-2-one 538.2 236 methyl 1-methyl-4-[2-[4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]anilino]ethyl] piperazine-2-carboxylate 555.1 237 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidine-3-carboxylic acid 469.2 238 N2-[4-chloro-3-[(4- methylpiperazin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 502.1 239 4-piperidyl 5-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 489.1 240 N2-[4-[[(3R,5S)-3,5- dimethylpiperazin-1- yl]methyl]phenyl]-N4-[2-(6 methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.2 241 ethyl 2-[1-[4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]acetate 526.4 242 N2-[3-fluoro-4- (morpholinomethyl)phenyl]-N4- [2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 473.2 243 N2-[4-[4-[methyl(2- pyridylmethyl)amino]-1- piperidyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 559.3 244 N2-[4-fluoro-3-[(4- methylpiperazin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 486.2 245 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(1- pyrrolidin-3-ylpyrazol-4- yl)pyrimidine-2,4-diamine 415.1 246 N4-[2-(5-chloro-2,4-difluoro- phenyl)pyrimidin-4-yl]-N2-[4- [4-(dimethylamino)-1- piperidyl]phenyl]pyrimidine-2,4- diamine 538.1 247 N2-[4-methyl-3-(piperazin-1- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 468.2 248 (1-methylpyrrolidin-3-yl) 1-[[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-4-carboxylate 580.2 249 N2-[4-[(3,3-dimethylpiperazin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.3 250 N2-[4-(2- methoxyethoxy)phenyl]-N4-[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 430.2 251 N2-[4-[4-(methylamino)-1- piperidyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 468.1 252 methyl 2-[5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-piperazin-1-yl-phenyl]acetate 512.4 253 N2-[4-[2- (dimethylamino)ethyl]phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 427.2 254 methyl (2S)-4-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazine-2-carboxylate 512.2 255 4-methyl-3-[4-[[2-[4-[4-(4- methylpiperazin-1-yl)-1- piperidyl]anilino]pyrimidin-4- yl]amino]pyrimidin-2-yl]phenol 552.2 256 azetidin-3-ylmethyl 2-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4-carboxylate 476.0 257 [(3S)-pyrrolidin-3-yl] 3-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 469.2 258 azetidin-3-yl 5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 461.1 259 N2-[4-(2- aminoethylamino)phenyl]-N4-[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 414.2 260 azetidin-3-yl 3-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 455.1 261 1-[4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-1- yl]ethanone 482.2 262 N2-[4-[[3-(dimethylamino)-3- methyl-azetidin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.2 263 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [2-[rac-(3S,5R)-3,5- dimethylpiperazin-1- yl]ethylamino]phenyl] pyrimidine-2,4-diamine 511.2 264 N2-[4-(4-tert-butylpiperazin-1- yl)sulfonylphenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 560.1 265 N-[2-methyl-4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine- 4-carboxamide 496.1 266 [1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidin-3-yl]methanol 455.1 267 N2-[5-(4-methylpiperazin-1-yl)- 2-pyridyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 455.1 268 methyl (2R)-4-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazine-2-carboxylate 512.2 269 1-[2-(dimethylamino)ethyl]-N- [4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 553.2 270 N2-[4-(4-methylpiperazin-1- yl)sulfonylphenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 518.2 271 (2S)-N-methyl-4-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazine-2-carboxamide 511.1 272 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl] methanesulfonamide 449.1 273 N-[2-(methylamino)ethyl]-3-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzenesulfonamide 492.1 274 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [methyl-[rac-(3R)-pyrrolidin-3- yl]amino]phenyl]pyrimidine-2,4- diamine 454.1 275 azetidin-3-ylmethyl 1-[[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-4-carboxylate 566.1 276 (3R)-3-(hydroxymethyl)-N-[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine- 1-carboxamide 513.2 277 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2- spiro[indane-2,3′-pyrrolidine]-5- yl-pyrimidine-2,4-diamine 451.1 278 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [[rac-(3R)-pyrrolidin-3- yl]amino]phenyl]pyrimidine- 2,4-diamine 440.1 279 N2-[4-[[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 466.3 280 N2-[4-(azetidin-3- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 425.3 281 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(5- morpholino-2- pyridyl)pyrimidine-2,4-diamine 442.3 282 1-(1-methyl-4-piperidyl)-N-[3- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 579.2 283 (2S)-4-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazine-2-carboxylic acid 498.2 284 N2-(1H-indazol-5-yl)-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 396.0 285 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenol 372.2 286 N2-[1-(3-aminopropyl)pyrazol- 4-yl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 403.2 287 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (piperazin-1-ylmethyl)thiazol-2- yl]pyrimidine-2,4-diamine 461.2 288 N-[3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 482.2 289 N2-[4-(3-aminopyrrolidin-1- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 440.2 290 [4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]-piperazin- 1-yl-methanone 468.1 291 [(3R)-1-methylpyrrolidin-3-yl] 2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4-carboxylate 490.0 292 (4-isopropylpiperazin-1-yl)-[3- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methanone 510.1 293 (2R)-N-methyl-4-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazine-2- carboxamide 511.1 294 [2-fluoro-5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methanol 404.2 295 [2-chloro-5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methanol 420.1 296 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]azetidine-3- sulfonamide 490.1 297 [(3S)-1-methylpyrrolidin-3-yl] 1- [[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-4-carboxylate 580.2 298 N-[3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine- 1-carboxamide 483.1 299 3-hydroxy-N-[3-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]azetidine-3- carboxamide 470.0 300 N2-(3-fluoro-4-morpholino- phenyl)-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 459.1 301 2-[4-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazin-1-yl]ethanol 498.2 302 N2-[4-[4-(aminomethyl)-1- piperidyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 468.4 303 4-methyl-N-[4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine- 1-sulfonamide 533.1 304 ethyl 2-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]acetate 442.1 305 N2-[4-[(4-methylpiperazin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 468.1 306 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(3- piperazin-1- ylsulfonylphenyl)pyrimidine- 2,4-diamine 504.2 307 methyl (2S)-4-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-2- carboxylate 498.1 308 [(3S)-1-methylpyrrolidin-3-yl] 3- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 483.1 309 N-methyl-2-[2-(6-methyl-2- pyridyl)-6-[[2-(4-piperazin-1- ylanilino)pyrimidin-4- yl]amino]pyrimidin-4- yl]acetamide 511.2 310 [3-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]anilino]methyl] azetidin-3-yl] methanol 470.2 311 N2-[4-methyl-3-[(4- methylpiperazin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.2 312 methyl 5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-piperazin-1-yl-benzoate 498.2 313 [(3R)-pyrrolidin-3-yl] 1-[[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-4-carboxylate 566.1 314 N4-[2-(5-chloro-2,4-difluoro- phenyl)pyrimidin-4-yl]-N2-[4- (4-pyrrolidin-1-yl-1- piperidyl)phenyl]pyrimidine- 2,4-diamine 563.1 315 N2-(3-aminophenyl)-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 371.2 316 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]acetamide 413.1 317 (4-isopropylpiperazin-1-yl)-[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methanone 510.2 318 azetidin-3-ylmethyl 1-[[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 566.2 319 (3R)-1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] pyrrolidin-3-ol 455.1 320 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl]-N-(4- piperidyl)piperidine-3- carboxamide 579.3 321 2-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]anilino]ethanol 415.0 322 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(3- piperazin-1-ylphenyl)pyrimidine- 2,4-diamine 440.2 323 [(3S)-1-methylpyrrolidin-3-yl] 2- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4-carboxylate 490.0 324 N2-[4-(4-amino-1- piperidyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 454.1 325 azetidin-3-yl 2-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-5-carboxylate 462.0 326 N4-[2-(5-chloro-2,4-difluoro- phenyl)pyrimidin-4-yl]-N2-[4- [4-(4-methylpiperazin-1-yl)-1- piperidyl]phenyl]pyrimidine-2,4- diamine 592.2 327 N-(azetidin-3-yl)-4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxamide 460.1 328 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (1-methyltriazol-4- yl)phenyl]pyrimidine-2,4- diamine 437.0 329 [(2R)-4-[[2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazol-4- yl]methyl]piperazin-2- yl]methanol 491.1 330 4-methyl-N-[4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-1- carboxamide 497.2 331 N2-[4-(2,5-dihydro-1H-pyrrol-3- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 423.2 332 N2-[3-(3,8- diazabicyclo[3.2.1]octan-3- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 480.2 333 N2-[4-(1-benzyltriazol-4- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 513.0 334 (2R)-N-methyl-4-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-2- carboxamide 497.1 335 N2-[3-methoxy-4-[[rac-(3S,5R)- 3,5-dimethylpiperazin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 512.3 336 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- N-[(3R)-pyrrolidin-3- yl]thiophene-2-carboxamide 474.2 337 [(3R)-pyrrolidin-3-yl] 1-[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine- 4-carboxylate 552.2 338 azetidin-3-ylmethyl 2-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-5-carboxylate 476.0 339 (3R)-1-[[2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazol-4- yl]methyl]piperidine-3- carboxylic acid 504.2 340 N4-[5-(6-methyl-2-pyridyl)-3H- triazolo[4,5-d]pyrimidin-7-yl]- N2-(4- morpholinophenyl)pyrimidine- 2,4-diamine 482.1 341 [(3R)-1-methylpyrrolidin-3-yl] (3R)-1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 580.3 342 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [[(2S)-pyrrolidin-2- yl]methylamino]phenyl] pyrimidine-2,4-diamine 454.2 343 N2-[4-(4-amino-1-piperidyl)-3- fluoro-phenyl]-N4-[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 472.2 344 N2-[4-[[(2S,5R)-2,5- dimethylpiperazin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.2 345 [(3S)-1-methylpyrrolidin-3-yl] 5- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-3- carboxylate 489.1 346 N2-[4-[2-(4-isopropylpiperazin- 1-yl)ethylamino]phenyl]-N4-[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 525.2 347 N2-[4-[1-[2- (methylamino)ethyl]pyrazol-4- yl]phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 479.2 348 N2-(2-methoxy-4-morpholino- phenyl)-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 471.3 349 [(3R)-3- (hydroxymethyl)piperazin-1-yl]- [2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazol- 4-yl]methanone 505.0 350 N2-[4-chloro-3- (thiomorpholinomethyl)phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 505.2 351 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]- N2-(4-morpholin-3- ylphenyl)pyrimidine- 2,4-diamine 441.1 352 N2-[4-[[4-(methylamino)-1- piperidyl]sulfonyl]phenyl]-N4- [2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 532.2 353 N-(azetidin-3-ylmethyl)-N-[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]acetamide 482.3 354 N4-[2-(5-fluoro-6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(4- morpholinophenyl)pyrimidine- 2,4-diamine 459.2 355 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]- N2-[4-(2- morpholinoethylamino)phenyl] pyrimidine-2,4-diamine 484.1 356 N2-[4-[1-[2- (dimethylamino)ethyl]pyrazol-4- yl]phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 493.1 357 N-[3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]-1- tetrahydropyran-4-yl-piperidine- 4-carboxamide 566.3 358 N2-[4-[4- (isopropylamino)cyclohexen-1- yl]phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 493.2 359 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]- N2-[4-(piperazin-1- ylmethyl)phenyl]pyrimidine- 2,4-diamine 454.1 360 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [[rac-(1S,6R)-3,9- diazabicyclo[4.2.1]nonan-9- yl]methyl]phenyl]pyrimidine- 2,4-diamine 494.2 361 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]- N2-[4-methyl-3- (thiomorpholinomethyl)phenyl] pyrimidine-2,4-diamine 485.1 362 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[3- (piperazin-1- ylmethyl)phenyl]pyrimidine-2,4- diamine 454.2 363 2-amino-N-[4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl] ethanesulfonamide 478.1 364 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-thienyl]pyrrolidine-3- carboxamide 474.0 365 3-[4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-1- yl]tetrahydrofuran-2-one 524.2 366 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (morpholinomethyl)phenyl] pyrimidine-2,4-diamine 455.2 367 (2S)-N-methyl-4-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-2- carboxamide 497.1 368 azetidin-3-ylmethyl 1-[4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxylate 552.1 369 methyl 4-[2-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]anilino]ethyl] piperazine-2-carboxylate 541.2 370 N2-[4-[(4-isopropylpiperazin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 496.1 371 4-[[2-[4- (dimethylsulfamoylamino) anilino]pyrimidin-4-yl] amino]-2-(6-methyl- 2-pyridyl)pyrimidine 478.2 372 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (6-oxa-2-azaspiro[3.4]octan-2- ylmethyl)phenyl]pyrimidine- 2,4-diamine 481.2 373 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[1- (3-piperidyl)pyrazol-4- yl]pyrimidine-2,4-diamine 429.2 374 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (3-piperidyl)phenyl]pyrimidine- 2,4-diamine 439.2 375 N2-[4-[[(1S,4S)-2,5- diazabicyclo[2.2.1]heptan-2- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 466.2 376 N2-[4-[[(2R,5S)-2,5- dimethylpiperazin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.2 377 N2-[4-(1,4-diazepan-1- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 468.1 378 N-[[3-(hydroxymethyl)azetidin- 3-yl]methyl]-4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxamide 504.0 379 4-methyl-3-[4-[[2-[4-[4- (methylamino)-1- piperidyl]anilino]pyrimidin-4- yl]amino]pyrimidin-2-yl]phenol 483.1 380 N2-[4-[4-(azetidin-3- ylmethyl)piperazin-1-yl]phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 509.2 381 N2-[4-chloro-3-[[rac-(3R,5S)- 3,5-dimethylpiperazin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 516.0 382 [rac-(1S)-1-methylpropyl] 4-[[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazine-2-carboxylate 554.6 383 4-piperidyl 1-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 580.2 384 N2-[3-(3,8- diazabicyclo[3.2.1]octan-8- ylmethyl)-4-fluoro-phenyl]-N4- [2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 498.1 385 2-(azetidin-3-yl)-N-[3-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]acetamide 468.1 386 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylic acid 406.0 387 N-(azetidin-3-yl)-4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzamide 454.1 388 [4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methanol 386.1 389 [5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 3-thienyl]-piperazin-1-yl- methanone 474.2 390 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[1- [2-(4-piperidyl)ethyl]pyrazol-4- yl]pyrimidine-2,4-diamine 457.2 391 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [[rac-(3R,5S)-3,5- dimethylpiperazin-1- yl]methyl]thiazol-2- yl]pyrimidine-2,4-diamine 489.1 392 2-[1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] azetidin-3-yl]oxyethanol 485.1 393 N2-[4-[4- [isobutyl(methyl)amino]-1- piperidyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 524.3 394 N2-[4-[4-(dimethylamino)-1- piperidyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.2 395 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (8-oxa-3-azabicyclo[3.2.1]octan- 3-ylmethyl)phenyl]pyrimidine- 2,4-diamine 481.2 396 (4-methylpiperazin-1-yl)-[3-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methanone 482.2 397 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (4-morpholino-1- piperidyl)phenyl]pyrimidine- 2,4-diamine 524.2 398 N4-[2-(5-chloro-2-fluoro- phenyl)pyrimidin-4-yl]-N2-(4- piperazin-1-ylphenyl)pyrimidine- 2,4-diamine 477.1 399 N4-[2-(2- fluorophenyl)pyrimidin-4-yl]- N2-(4- morpholinophenyl)pyrimidine- 2,4-diamine 444.2 400 azetidin-3-ylmethyl (3R)-1-[[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 566.1 401 N2-[4-(2-methoxyethyl)phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 414.1 402 azetidin-3-ylmethyl 2-[1-[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]acetate 567.1 403 [(2R)-4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]methanol 470.1 404 2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- N-[(3R)-pyrrolidin-3-yl]thiazole- 4-carboxamide 475.2 405 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidin-4-ol 469.1 406 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoic acid 399.9 407 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(4- morpholinosulfonylphenyl) pyrimidine-2,4-diamine 505.1 408 N4-[2-(5-chloro-2-fluoro- phenyl)pyrimidin-4-yl]- N2-[4-(2- morpholinoethylamino)phenyl] pyrimidine-2,4-diamine 521.1 409 N2-[4-[[(2S,6S)-2,6- dimethylpiperazin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.2 410 2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 5-morpholino-phenol 457.2 411 methyl 2-[4-[[3-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazin-2-yl]acetate 526.2 412 N4-[2-(5-chloro-2-fluoro- phenyl)pyrimidin-4-yl]-N2-[4- (4-pyrrolidin-1-yl-1- piperidyl)phenyl]pyrimidine-2,4- diamine 545.1 413 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]pyrrolidine- 3-sulfonamide 504.1 414 [(3R)-1-methylpyrrolidin-3-yl] 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-4-carboxylate 580.3 415 N4-[2-(5-chloro-2-fluoro- phenyl)pyrimidin-4-yl]-N2-[4- [4-(dimethylamino)-1- piperidyl]phenyl]pyrimidine- 2,4-diamine 520.1 416 N-methyl-N-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine- 4-carboxamide 496.2 417 N2-[4-[(1,1-dioxo-1,4-thiazinan- 4-yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 503.1 418 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]- N2-(4-piperazin- 1-ylphenyl)pyrimidine- 2,4-diamine 440.2 419 N-[7-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2,3-dihydro-1,4-benzodioxin-5- yl]piperidine-4-carboxamide 540.2 420 N-[2-(dimethylamino)ethyl]-3- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzenesulfonamide 506.2 421 N2-(3-amino-4-methyl-phenyl)- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 385.1 422 (2R)-4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-2- carboxylic acid 484.1 423 3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoic acid 399.9 424 N2-[3-(3,8- diazabicyclo[3.2.1]octan-8- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 480.2 425 N2-[4-(1-isopropylpyrazol-4- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 464.2 426 N4-[2-[6-(difluoromethyl)-5- fluoro-2-pyridyl]pyrimidin- 4-yl]-N2-(4- morpholinophenyl)pyrimidine- 2,4-diamine 495.0 427 N-[2-(methylamino)ethyl]-4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzenesulfonamide 492.2 428 (3R)-1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylic acid 497.2 429 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (4-pyrrolidin-3-ylpiperazin-1- yl)phenyl]pyrimidine-2,4- diamine 509.2 430 N-(2-aminoethyl)-3-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzenesulfonamide 478.1 431 N2-[4-methoxy-3-[[rac-(3R,5S)- 3,5-dimethylpiperazin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 512.2 432 N2-[4-[4- [benzyl(methyl)amino]-1- piperidyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 558.2 433 azetidin-3-ylmethyl 1-[4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-3- carboxylate 552.2 434 (4-methylpiperazin-1-yl)-[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methanone 482.2 435 rac-(3S,5R)-3,5-dimethyl-N-[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine- 1-carboxamide 511.3 436 N4-[2-(5-chloro-2-fluoro- phenyl)pyrimidin-4-yl]-N2-[4- [4-(4-methylpiperazin-1-yl)-1- piperidyl]phenyl]pyrimidine- 2,4-diamine 574.2 437 methyl 4-[[2-(4- aminoanilino)pyrimidin-4- yl]amino]-2-(6-methyl-2- pyridyl)pyrimidine-5-carboxylate 429.0 438 N2-[4-[(3-amino-3-methyl- azetidin-1-yl)methyl]phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 454.2 439 5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylic acid 406.3 440 N2-[4-[1-(2-aminoethyl)pyrazol- 4-yl]phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 465.1 441 4-[[2-[4-[[methyl(4- piperidyl)sulfamoyl]amino] anilino]pyrimidin-4-yl] amino]-2-(6-methyl-2- pyridyl)pyrimidine 547.1 442 methyl 2-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]acetate 428.1 443 N-[3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine- 3-carboxamide 482.1 444 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylic acid 497.1 445 N2-(3-chloro-4-piperazin-1-yl- phenyl)-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 474.1 446 N4-[2-(2- fluorophenyl)pyrimidin-4-yl]- N2-[4-[4-(4-methylpiperazin- 1-yl)-1- piperidyl]phenyl]pyrimidine- 2,4-diamine 540.3 447 5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-piperazin-1-yl-benzonitrile 465.2 448 4-hydroxy-2-[4-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-1- yl]butanoic acid 542.2 449 [(1S)-1-methylpropyl] 2-[1-[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]acetate 554.5 450 N2-[4-[4-(benzylamino)-1- piperidyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 544.3 451 methyl 2-[4-[[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazin-2-yl]acetate 526.2 452 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-thienyl]piperidine-4- carboxamide 488.0 453 N2-[4-[[(2S,5S)-2,5- dimethylpiperazin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.2 454 1-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-3- carboxylic acid 483.1 455 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]-1H-imidazole- 4-sulfonamide 501.0 456 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl]-N-[rac- (3R)-pyrrolidin-3-yl]piperidine- 3-carboxamide 565.2 457 N2-[4-(4-cyclopropylpiperazin- 1-yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 480.2 458 N2-[3-(3,8- diazabicyclo[3.2.1]octan-8- ylmethyl)-4-methyl-phenyl]-N4- [2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 494.1 459 [(3R)-pyrrolidin-3-yl] 3-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 469.1 460 [(3R)-1-methylpyrrolidin-3-yl] (3R)-1-[[2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazol-4- yl]methyl]piperidine- 3-carboxylate 587.2 461 N2-[4-fluoro-3- (thiomorpholinomethyl)phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 489.2 462 methyl 2-[1-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]acetate 512.4 463 [(2S)-4-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazin-2-yl]methanol 484.1 464 [(3R)-1-methylpyrrolidin-3-yl] 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 483.0 465 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]-1-pyrrolidin-3- yl-piperidine-4-carboxamide 551.2 466 [(1S)-1-methylpropyl] 2-[5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-piperazin-1-yl-phenyl]acetate 554.4 467 N2-[4-[[azetidin-3- yl(methyl)amino]methyl]thiazol- 2-yl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 461.0 468 methyl 4-[[2-(4- methoxycarbonylanilino) pyrimidin-4-yl]amino]- 2-(6-methyl-2-pyridyl) pyrimidine-5-carboxylate 472.0 469 N2-[4-(3,5-dimethylisoxazol-4- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 451.1 470 N2-[4-[[(2R,6S)-2,6- dimethylpiperazin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.2 471 N2-[4-[4- [(benzylamino)methyl]-1- piperidyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 558.1 472 (1-methylpyrrolidin-3-yl) 1-[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxylate 566.2 473 N2-[4-[4-(azetidin-3- yl)piperazin-1-yl]phenyl]-N4-[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 495.1 474 [1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl]-4- piperidyl]methanol 483.1 475 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(4- morpholinophenyl)pyrimidine- 2,4-diamine 441.4 476 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]- N2-[4-(4- piperidylmethyl)phenyl] pyrimidine-2,4-diamine 453.2 477 1-(azetidin-3-ylmethyl)-3-[3-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]urea 483.1 478 N2-[4-[4-(2- aminoethyl)piperazin-1- yl]phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 483.3 479 [(3R)-pyrrolidin-3-yl] 1-[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine- 3-carboxylate 552.2 480 N2-[4-[(2,2-dimethylpiperazin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 482.2 481 methyl 1-isopropyl-4-[[4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazine-2-carboxylate 554.2 482 N4-[6-methyl-2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(4- piperazin-1-ylphenyl)pyrimidine- 2,4-diamine 454.2 483 N2-[4-[4-[2- (methylamino)ethyl]piperazin-1- yl]phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 497.2 484 1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-4-carboxylic acid 497.1 485 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]- N2-[4-(oxazol-2- ylmethyl)phenyl]pyrimidine- 2,4-diamine 437.1 486 [(3R)-1-methylpyrrolidin-3-yl] (3S)-1-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 580.3 487 N2-[4-chloro-3-(3,8- diazabicyclo[3.2.1]octan-8- ylmethyl)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 514.0 488 (2S)-4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-2- carboxylic acid 484.1 489 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (pyrrolidin-3- ylmethyl)phenyl]pyrimidine- 2,4-diamine 439.2 490 3-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]anilino]methyl] azetidin-3-ol 456.2 491 methyl 2-[4-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin-2- yl]acetate 512.2 492 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2- (1,2,3,4-tetrahydroquinolin-6- yl)pyrimidine-2,4-diamine 411.2 493 N2-[4-[(3-methoxy-3-methyl- azetidin-1-yl)methyl]phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 469.1 494 N2-[4-(4-isobutylpiperazin-1- yl)phenyl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 496.2 495 N-(azetidin-3-ylmethyl)-1-[[4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxamide 565.3 496 N2-[4-[azetidin-3- yl(methyl)amino]phenyl]-N4-[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 440.1 497 N-methyl-N-[3-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 496.2 498 N-(2-hydroxyethyl)-2-[2-(6- methyl-2-pyridyl)-6-[[2-(4- piperazin-1-ylanilino)pyrimidin- 4-yl]amino]pyrimidin-4- yl]acetamide 541.1 499 [(3R)-1-methylpyrrolidin-3-yl] 2-[5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-piperazin-1-yl-phenyl]acetate 581.1 500 N2-(5-amino-3-thienyl)-N4-[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 377.1 501 N2-[4-[[3- (dimethylamino)azetidin-1- yl]methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 468.3 502 N2-(2-fluoro-4-morpholino- phenyl)-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 459.1 503 N2-[4- (methylaminomethyl)phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 399.2 504 [(3R)-1-methylpyrrolidin-3-yl] 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 489.0 505 [3-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]-piperazin-1-yl- methanone 468.1 506 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [rac-(2R)-2-methylpiperazin-1- yl]phenyl]pyrimidine-2,4- diamine 454.1 507 [(3S)-1-methylpyrrolidin-3-yl] 5- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 489.1 508 [(3S)-1-methylpyrrolidin-3-yl] (3R)-1-[[2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazol-4- yl]methyl]piperidine-3- carboxylate 587.1 509 4-methyl-N-[3-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-1- carboxamide 497.1 510 [2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazol-4-yl]- piperazin-1-yl-methanone 475.0 511 N-[2-methoxy-4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 512.2 512 N2-(1H-benzotriazol-5-yl)-N4- [2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 397.1 513 2-[[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methoxy] ethanol 430.2 514 N2-(4-amino-3-methyl-phenyl)- N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 385.1 515 N2-(3-methyl-4-piperazin-1-yl- phenyl)-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 454.1 516 methyl 1-[[4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperidine-3-carboxylate 511.1 517 methyl 3-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]propanoate 442.1 518 azetidin-3-ylmethyl 1-[[4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] pyrrolidine-3-carboxylate 552.1 519 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[3- [[rac-(3R,5S)-3,5- dimethylpiperazin-1- yl]methyl]phenyl]pyrimidine- 2,4-diamine 482.1 520 N-[3-(hydroxymethyl)pyrrolidin- 3-yl]-2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole- 4-carboxamide 505.1 521 N2-[3-[(4-methylpiperazin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 468.2 522 [(3R)-1-methylpyrrolidin-3-yl] 5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-3- carboxylate 489.2 523 isobutyl 4-[[4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]methyl] piperazine-2-carboxylate 554.2 524 N2-(2-aminoindan-5-yl)-N4-[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 411.1 525 N2-[4-[4- [(isobutylamino)methyl]-1- piperidyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 524.1 526 N2-(2,3-dihydro-1,4- benzodioxin-6-yl)-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 414.1 527 N2-[4-(4-cyclopropylpiperazin- 1-yl)sulfonylphenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 544.0 528 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [rac-(3S)-3-methylpiperazin-1- yl]phenyl]pyrimidine-2,4- diamine 454.1 529 ethyl 2-[2-(6-methyl-2-pyridyl)- 6-[[2-(4-piperazin-1- ylanilino)pyrimidin-4- yl]amino]pyrimidin-4-yl]acetate 526.1 530 azetidin-3-yl 2-[5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-piperazin-1-yl-phenyl]acetate 553.1 531 4-isopropyl-N-[3-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazine-1- carboxamide 525.2 532 5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-3-carboxylic acid 406.2 533 N2-[4-[(4-isobutylpiperazin-1- yl)methyl]phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 510.3 534 2-[4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]piperazin- 1-yl]ethanol 484.3 535 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (1H-pyrazol-4- yl)phenyl]pyrimidine-2,4- diamine 422.0 536 [(3R)-3- (hydroxymethyl)piperazin-1-yl]- [4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-thienyl]methanone 504.1 537 N2-[4-(azetidin-3- ylmethylamino)phenyl]-N4-[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 440.2 538 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [1-(oxetan-3-yl)pyrazol-4- yl]phenyl]pyrimidine- 2,4-diamine 478.1 539 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(4- piperazin-2-ylphenyl)pyrimidine- 2,4-diamine 440.1 540 N4-[2-(5-chloro-2,4-difluoro- phenyl)-5-cyclopropyl- pyrimidin-4-yl]-N2-(4-piperazin- 1-ylphenyl)pyrimidine-2,4- diamine 535.1 541 2-[4-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]phenyl] sulfonylpiperazin- 1-yl]ethanol 458.0 542 N4-[2-(5-fluoro-6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- [4-(4-methylpiperazin-1-yl)-1- piperidyl]phenyl]pyrimidine-2,4- diamine 555.3 543 [(3R)-pyrrolidin-3-yl] 4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 475.2 544 [(3S)-pyrrolidin-3-yl] 4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 475.1 545 azetidin-3-ylmethyl 5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 470.1 546 [(3R)-pyrrolidin-3-yl] 5-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 470.1 547 [(3S)-pyrrolidin-3-yl] 5-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 470.1 548 azetidin-3-ylmethyl 5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-carboxylate 470.1 549 [(3R)-pyrrolidin-3-yl] 5-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-carboxylate 470.1 550 [(3S)-pyrrolidin-3-yl] 5-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-carboxylate 470.2 551 2-piperazin-1-ylethyl 2-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4-carboxylate 519.2 552 2-piperazin-1-ylethyl 5-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 513.2 553 2-piperazin-1-ylethyl 3-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 512.2 554 2-piperazin-1-ylethyl 4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 518.1 555 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(5- morpholinothiazol-2- yl)pyrimidine-2,4-diamine 448.2 556 N4-[2-(5-chloro-2,4-difluoro- phenyl)pyrimidin-4-yl]-N2-(4- piperazin-1-ylphenyl)pyrimidine- 2,4-diamine 495.1 557 3-azabicyclo[3.1.0]hexan-1- ylmethyl 5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 496.2 558 2-(4-piperidyl)ethyl 5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 512.3 559 6-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3- carboxylic acid 401.1 560 2-(azetidin-3-ylamino)ethyl 4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 504.1 561 4-piperidyl 5-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 484.2 562 [(1R)-1-(4-piperidyl)ethyl] 5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 512.2 563 (4-aminocyclohexyl)methyl 4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 517.1 564 azetidin-3-ylmethyl 6-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-carboxylate 470.2 565 4-piperidyl 1-[[5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 3-pyridyl]methyl]azetidine- 3-carboxylate 553.2 566 (4-amino-4-methyl-cyclohexyl) 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 517.1 567 [(3R,6R)-6-methyl-3-piperidyl] 5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 498.2 568 2-[(3R)-3-aminopyrrolidin-1- yl]ethyl 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene- 2-carboxylate 518.1 569 1-[[5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 2-pyridyl]methyl]azetidine-3- carboxylic acid 470.1 570 [(3R)-pyrrolidin-3-yl]methyl 5- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3- carboxylate 484.2 571 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4- (1,2,3,6-tetrahydropyridin-4- yl)thiazol-2-yl]pyrimidine- 2,4-diamine 444.2 572 (4-amino-4-methyl-cyclohexyl) 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 517.2 573 [(3S)-pyrrolidin-3-yl] 1-[[5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 3-pyridyl]methyl]azetidine- 3-carboxylate 539.2 574 [(3R)-pyrrolidin-3-yl] 6-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-carboxylate 470.2 575 [(3S)-pyrrolidin-3-yl] 6-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine- 3-carboxylate 470.1 576 (1-acetylazetidin-3-yl)methyl 4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 517.1 577 [(2R)-pyrrolidin-2-yl]methyl 5- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine- 2-carboxylate 484.1 578 [(2R)-2-piperidyl]methyl 2-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-5- carboxylate 504.1 579 azetidin-3-yl 2-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-4- carboxylate 456.1 580 [(3R)-3-piperidyl]methyl 2-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4- carboxylate 504.2 581 2-piperazin-1-ylethyl 6-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-carboxylate 513.2 582 [(3S)-pyrrolidin-3-yl]methyl 5- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2- carboxylate 484.3 583 [(2R)-pyrrolidin-2-yl]methyl 4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 489.1 584 [(3R)-pyrrolidin-3-yl]methyl 5- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 484.1 585 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-2- carboxylic acid 407.1 586 [(2R)-2-piperidyl]methyl 2-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4- carboxylate 504.3 587 4-piperidylmethyl 5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2- carboxylate 498.1 588 [(2R)-2-piperidyl]methyl 4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 503.1 589 2-[(3R,5S)-3,5- dimethylpiperazin-1-yl]ethyl 5- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2- carboxylate 541.2 590 (4-aminocyclohexyl)methyl 4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 517.2 591 4-piperidyl 4-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 488.9 592 [(2R)-pyrrolidin-2-yl]methyl 2- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-5-carboxylate 490.1 593 [(2R)-pyrrolidin-2-yl]methyl 2- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4-carboxylate 490.1 594 [(3R)-3-piperidyl] 5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2- carboxylate 484.1 595 (3R)-3-piperidyl]methyl 5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-carboxylate 498.1 596 azepan-4-yl 5-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2- carboxylate 498.2 597 [(2S)-2-piperidyl]methyl 5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2- carboxylate 498.1 598 2-[(3R)-3-amino-1- piperidyl]ethyl 4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene- 2-carboxylate 532.1 599 2-(3,4,6,7,8,8a-hexahydro-1H- pyrrolo[1,2-a]pyrazin-2-yl)ethyl 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene- 2-carboxylate 558.2 600 [(3S)-3-piperidyl]methyl 4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 503.1 601 [(3R)-pyrrolidin-3-yl] 2-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-4- carboxylate 470.1 602 2-(azetidin-3-yl)ethyl 4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 489.1 603 1-[[5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 3-pyridyl]methyl]azetidine-3- carboxylic acid 470.1 604 N2-[5-[(3R,5S)-3,5- dimethylpiperazin-1-yl]thiazol-2- yl]-N4-[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 475.1 605 [(2R)-morpholin-2-yl]methyl 5- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 500.1 606 4-piperidylmethyl 5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-carboxylate 498.2 607 4-piperidylmethyl 4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 503.1 608 azetidin-3-ylmethyl 2-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-4-carboxylate 470.1 609 N2-[5-(2,5-dihydro-1H-pyrrol-3- yl)thiazol-2-yl]-N4-[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 430.2 610 4-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylic acid 401.2 611 [(3R)-pyrrolidin-3-yl]methyl 2- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4-carboxylate 490.1 612 [(2S)-pyrrolidin-2-yl]methyl 5- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 484.1 613 2-(3,4,6,7,8,8a-hexahydro-1H- pyrrolo[1,2-a]pyrazin-2-yl)ethyl 5-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 553.0 614 azetidin-3-ylmethyl 1-[[5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 3-pyridyl]methyl]azetidine-3- carboxylate 539.2 615 4-piperidylmethyl 2-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-4-carboxylate 504.3 616 azetidin-3-ylmethyl 4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 470.1 617 [(3S)-3-piperidyl] 5-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 484.4 618 [(2R)-pyrrolidin-2-yl]methyl 5- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-carboxylate 484.1 619 2-[(3S)-3-amino-1- piperidyl]ethyl 4-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene- 2-carboxylate 532.1 620 [(3S)-3-piperidyl]methyl 5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 498.2 621 [(1R,3S)-3- aminocyclohexyl]methyl 4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 517.1 622 azetidin-3-yl 6-[[4-[[2-(6- methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-carboxylate 456.1 623 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[5- (1,2,3,6-tetrahydropyridin-4- yl)thiazol-2-yl]pyrimidine-2,4- diamine 444.3 624 2-piperazin-1-ylethyl 2-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-4-carboxylate 513.2 625 [(3R)-3-piperidyl]methyl 5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 498.1 626 N2-[4-(2,5-dihydro-1H-pyrrol-3- yl)thiazol-2-yl]-N4-[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]pyrimidine-2,4-diamine 430.2 627 2-[(3S,5R)-3,5- dimethylpiperazin-1-yl]ethyl 4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 546.1 628 [(2R)-2-piperidyl]methyl 5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 498.2 629 1-[[2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazol-4- yl]methyl]azetidine-3- carboxylic acid 476.1 630 [(3R)-pyrrolidin-3-yl]methyl 2- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiazole-5-carboxylate 490.1 631 (3-aminocyclobutyl) 4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 475.1 632 [(3S)-pyrrolidin-3-yl] 2-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-4-carboxylate 470.1 633 4-piperidyl 2-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-4-carboxylate 484.1 634 4-piperidyl 6-[[4-[[2-(6-methyl- 2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3-carboxylate 484.2 635 [(1R,3R)-3- aminocyclohexyl]methyl 4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 517.1 636 2-[[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-4- carboxylic acid 401.2 637 [(2S)-pyrrolidin-2-yl]methyl 4- [[4-[[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 489.1 638 (3-aminocyclobutyl) 4-[[4-[[2- (6-methyl-2-pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 475.1 639 [(2S)-2-piperidyl]methyl 4-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylate 503.1 640 N4-[2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(5- piperazin-1-ylthiazol-2- yl)pyrimidine-2,4-diamine 447.2 641 [(2R)-2-piperidyl]methyl 5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2- yl]amino]pyridine-3- carboxylate 498.2 642 [(3R)-pyrrolidin-3-yl] 1-[[5-[[4- [[2-(6-methyl-2- pyridyl)pyrimidin-4- yl]amino]pyrimidin-2-yl]amino]- 3-pyridyl]methyl]azetidine-3- carboxylate 539.2 - In some embodiments, exemplary compounds may include, but are not limited to, a compound or salt thereof selected from Table 2.
-
TABLE 2 No. Structure Chemical Name [M + H]+ 1000 N4-[6-(6-methyl-2-pyridyl)-2- pyridyl]-N2-(4- morpholinophenyl)pyrimidine- 2,4-diamine 440.1 1001 N4-[6-(6-methyl-2-pyridyl)-1H- pyrrolo[2,3-b]pyridin-4-yl]-N2-(4- morpholinophenyl)pyrimidine- 2,4-diamine 479.3 1002 N4-[5-(6-methyl-2-pyridyl)-3H- triazolo[4,5-d]pyrimidin-7-yl]-N2- (4-morpholinophenyl)pyrimidine- 2,4-diamine 482.1 1003 2-(6-methyl-2-pyridyl)-6-[[2-(4- morpholinoanilino)pyrimidin- 4-yl]amino]pyridine-3- carbonitrile 465.2 1004 ethyl 2-[2-(6-methyl-2-pyridyl)-6- [[2-(4-piperazin-1- ylanilino)pyrimidin-4- yl]amino]pyrimidin-4-yl]acetate 526.1 1005 N4-[6-methyl-2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-(4- piperazin-1-ylphenyl)pyrimidine- 2,4-diamine 454.2 1006 N-ethyl-2-[2-(6-methyl-2-pyridyl)- 6-[[2-(4-piperazin-1- ylanilino)pyrimidin-4- yl]amino]pyrimidin-4-yl] acetamide 525.1 1007 N-(2-hydroxyethyl)-2-[2-(6-methyl- 2-pyridyl)-6-[[2-(4-piperazin-1- ylanilino)pyrimidin-4- yl]amino]pyrimidin-4-yl] acetamide 541.1 1008 N-methyl-2-[2-(6-methyl-2-pyridyl)- 6-[[2-(4-piperazin-1- ylanilino)pyrimidin-4- yl]amino]pyrimidin-4-yl] acetamide 511.2 1009 N-isobutyl-2-[2-(6-methyl-2- pyridyl)-6-[[2-(4-piperazin-1- ylanilino)pyrimidin-4- yl]amino]pyrimidin-4-yl] acetamide 553.2 1010 methyl 6-[[2-[4-(4-methylpiperazin- 1-yl)anilino]pyrimidin-4-yl]amino]- 2-(6-methyl-2-pyridyl)pyrimidine- 4-carboxylate 512.2 1011 N4-[6-methyl-2-(6-methyl-2- pyridyl)pyrimidin-4-yl]-N2-[4-(4- methylpiperazin-1- yl)phenyl]pyrimidine-2,4-diamine 468.1 1012 N4-[2-(6-methyl-2-pyridyl)-6-(1H- triazol-4-yl)pyrimidin-4-yl]-N2-(4- piperazin-1-ylphenyl)pyrimidine- 2,4-diamine 507.2 1013 N4-[2-(5-chloro-2-fluoro-phenyl)-5- cyclopropyl-pyrimidin-4-yl]-N2-(4- piperazin-1-ylphenyl)pyrimidine- 2,4-diamine 517.1 1014 N4-[2-(5-chloro-2,4-difluoro- phenyl)-5-cyclopropyl-pyrimidin-4- yl]-N2-(4-piperazin-1- ylphenyl)pyrimidine-2,4-diamine 535.1 1015 N2-(4-aminophenyl)-N4-[2-(6- methyl-2-pyridyl)pyrrolo[2,1- f][1,2,4]triazin-4-yl]pyrimidine- 2,4-diamine 410.1 1016 N2-[4-(azetidin-3- ylmethylamino)phenyl]-N4-[2-(6- methyl-2-pyridyl)pyrrolo[2,1- f][1,2,4]triazin-4-yl]pyrimidine- 2,4-diamine 479.1 1017 3-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]benzoic acid 439.1 1018 2-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]phenyl]acetic acid 453.2 1019 methyl 2-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]phenyl]acetate 467.1 1020 6-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f]]1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]pyridine-3- carboxylic acid 440.0 1021 4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]benzoic acid 439.1 1022 2-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]thiazole-4- carboxylic acid 446.0 1023 4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]thiophene-2- carboxylic acid 445.0 1024 methyl 5-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]pyridine-2-carboxylate 454.0 1025 5-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]thiophene-3- carboxylic acid 444.9 1026 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]phenyl]azetidine-3- carboxamide 493.1 1027 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]phenyl]pyrrolidine-3- carboxamide 507.1 1028 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-4- carboxamide 521.2 1029 2-(azetidin-3-yl)-N-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrrolo[2,1- f][1,2,4]triazin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]acetamide 507.1 1030 3-amino-N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]phenyl] cyclobutanecarboxamide 507.1 1031 3-(hydroxymethyl)-N-[4-[[4-[[2-(6- methyl-2-pyridyl)pyrrolo[2,1- f][1,2,4]triazin-4- yl]amino]pyrimidin-2- yl]amino]phenyl]azetidine-3- carboxamide 523.1 1032 N-[4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]phenyl]piperidine-3- carboxamide 521.2 1033 2,7-diazaspiro[3.5]nonan-7-yl-[4- [[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]phenyl]methanone 547.1 1034 N-(azetidin-3-yl)-4-[[4-[[2-(6- methyl-2-pyridyl)pyrrolo[2,1- f][1,2,4]triazin-4- yl]amino]pyrimidin-2- yl]amino]benzamide 493.0 1035 N-(azetidin-3-ylmethyl)-4-[[4-[[2- (6-methyl-2-pyridyl)pyrrolo[2,1- f][1,2,4]triazin-4- yl]amino]pyrimidin-2- yl]amino]benzamide 507.1 1036 4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2-yl]amino]- N-pyrrolidin-3-yl-benzamide 507.1 1037 4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2-yl]amino]- N-(4-piperidyl)benzamide 521.1 1038 [4-[[4-[[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]amino]pyrimidin-2- yl]amino]phenyl]-piperazin-1-yl- methanone 507.0 1039 azetidin-3-ylmethyl 4-[[4-[[2-(6- methyl-2-pyridyl)pyrrolo[2,1- f][1,2,4]triazin-4- yl]amino]pyrimidin-2- yl]amino]benzoate 508.1 1040 N2-[4-(azetidin-3-ylamino)phenyl]- N4-[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]pyrimidine-2,4-diamine 465.1 1041 N4-[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]-N2-[4-(pyrrolidin-3- ylamino)phenyl]pyrimidine- 2,4-diamine 479.1 1042 N4-[2-(6-methyl-2- pyridyl)pyrrolo[2,1-f][1,2,4]triazin- 4-yl]-N2-[4-(4- piperidylamino)phenyl] pyrimidine-2,4-diamine 493.1 1043 methyl 4-[[2-(4- methoxycarbonylanilino)pyrimidin- 4-yl]amino]-2-(6-methyl-2- pyridyl)pyrimidine-5-carboxylate 472.0 1044 4-[[2-(4-aminoanilino)pyrimidin-4- yl]amino]-2-(6-methyl-2- pyridyl)pyrimidine-5- carboxylic acid 415.0 1045 methyl 4-[[2-(4- aminoanilino)pyrimidin-4- yl]amino]-2-(6-methyl-2- pyridyl)pyrimidine-5-carboxylate 429.0 - Methods
- In some aspects, the present disclosure provides a method of inhibiting TGFβ signaling, comprising contacting a cell with an effective amount of a compound disclosed herein, such as a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E). In some embodiments, the present disclosure provides a method of inhibiting ALK5, comprising contacting ALK5 with an effective amount of a compound disclosed herein. Inhibition of ALK5 or TGFβ signaling can be assessed by a variety of methods known in the art. Non-limiting examples include a showing of (a) a decrease in kinase activity of ALK5; (b) a decrease in binding affinity between the TGFβ/TGFβ-RII complex and ALK5; (c) a decrease in the levels of phosphorylated intracellular signaling molecules downstream in the TGFβ signaling pathway, such as a decrease in pSMAD2 or pSMAD3 levels; (d) a decrease in binding of ALK5 to downstream signaling molecules, such as SMAD2 and SMAD3; and/or (e) an increase in ATP levels or a decrease in ADP levels. Kits and commercially available assays can be utilized for determining one or more of the above.
- In some aspects, the present disclosure provides a method of treating an ALK5-mediated disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein. In some embodiments, the disease or condition is selected from fibrosis and cancer. In some embodiments, the disease or condition is pulmonary fibrosis, such as idiopathic pulmonary fibrosis or virus-induced fibrosis. In some embodiments, the disease or condition is intestinal fibrosis. In some embodiments, the disease or condition is alopecia. In some embodiments, the disease is a neurodegenerative disease, such as Alzheimer's disease. In some embodiments, the present disclosure provides a method of reversing symptoms of aging. For example, the method may enhance neurogenesis, reduce neuroinflammation, improve cognitive performance, regenerate liver tissue, and reduce p16 levels.
- In some aspects, the present disclosure provides a method of treating fibrosis, comprising administering to a patient an effective amount of a compound disclosed herein. In some embodiments, the fibrosis is mediated by ALK5. In some embodiments, the fibrosis is selected from systemic sclerosis, systemic fibrosis, organ-specific fibrosis, kidney fibrosis, pulmonary fibrosis, liver fibrosis, portal vein fibrosis, skin fibrosis, bladder fibrosis, intestinal fibrosis, peritoneal fibrosis, myelofibrosis, oral submucous fibrosis, and retinal fibrosis. In some embodiments, the fibrosis is pulmonary fibrosis, such as idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), interstitial lung fibrosis, fibrosis associated with asthma, fibrosis associated with chronic obstructive pulmonary disease (COPD), silica-induced fibrosis, asbestos-induced fibrosis or chemotherapy-induced lung fibrosis. In some embodiments, the fibrosis is idiopathic pulmonary fibrosis (IPF). In some embodiments, the fibrosis is TGF-β-mediated pulmonary fibrosis. In some embodiments, the patient has been diagnosed with acute respiratory distress syndrome (ARDS). In some embodiments, the fibrosis is acute fibrosis. In some embodiments, the fibrosis is chronic fibrosis.
- In some aspects, the present disclosure provides a method of treating pulmonary fibrosis induced by a viral infection, comprising administering to a patient an effective amount of a compound disclosed herein. The pulmonary fibrosis may be induced by an erythrovirus, a dependovirus, a papillomavirus, a polyomavirus, a mastadenovirus, an alphaherpesvirinae, a varicellovirus, a gammaherpesvirinae, a betaherpesvirinae, a roseolovirus, an orthopoxvirus, a parapoxvirus, a molluscipoxvirus, an orthohepadnavirus, an enterovirus, a rhinovirus, a hepatovirus, an aphthovirus, a calicivirus, an astrovirus, an alphavirus, a rubivirus, a flavivirus, a Hepatitis C virus, a reovirus, an orbivirus, a rotavirus, an influenzavirus A, an influenzavirus B, an influenzavirus C, a paramyxovirus, a morbillivirus, a rubulavirus, a pneumovirus, a vesiculovirus, a lyssavirus, a bunyavirus, a hantavirus, a nairovirus, a phlebovirus, a coronavirus, an arenavirus, a BLV-HTLV-retrovirus, a lentivirinae, a spumavirinae or a filovirus. In some embodiments, the fibrosis is virus-induced fibrosis, such as virus-induced pulmonary fibrosis. In some embodiments, the fibrosis is selected from EBV-induced pulmonary fibrosis, CMV-induced pulmonary fibrosis, herpesvirus-induced pulmonary fibrosis and coronavirus-induced pulmonary fibrosis. In some embodiments, the fibrosis is selected from EBV-induced pulmonary fibrosis, CMV-induced pulmonary fibrosis, HHV-6-induced pulmonary fibrosis, HHV-7-induced pulmonary fibrosis, HHV-8-induced pulmonary fibrosis, H5N1 virus-induced pulmonary fibrosis, SARS-CoV-induced pulmonary fibrosis, MERS-CoV-induced pulmonary fibrosis and SARS-CoV-2-induced pulmonary fibrosis. In some embodiments, the pulmonary fibrosis is coronavirus-induced pulmonary fibrosis. In some embodiments, the pulmonary fibrosis is SARS-CoV-2-induced pulmonary fibrosis. In some embodiments, the pulmonary fibrosis is COVID-19-induced pulmonary fibrosis.
- In some aspects, the present disclosure provides a method of treating acute lung injury (ALI), comprising administering to a patient an effective amount of a compound disclosed herein. In some embodiments, the present disclosure provides a method of treating acute respiratory distress syndrome (ARDS), comprising administering to a patient an effective amount of a compound disclosed herein. The ARDS may be in the early acute injury phase or the fibroproliferative phase. In some embodiments, the ARDS is fibroproliferative ARDS. In some embodiments, the present disclosure provides a method of treating fibrosis resulting from ARDS, comprising administering to a patient an effective amount of a compound disclosed herein. The fibrosis resulting from ARDS may be pulmonary fibrosis. In some embodiments, the present disclosure provides a method of treating fibrosis resulting from ALI, comprising administering to a patient an effective amount of a compound disclosed herein. The fibrosis resulting from ALI may be pulmonary fibrosis.
- In some aspects, the present disclosure provides a method of treating intestinal fibrosis, comprising administering to a patient an effective amount of a compound disclosed herein. In some embodiments, the intestinal fibrosis is mediated by ALK5. In some embodiments, the compound is administered in an amount effective to delay progression of, reduce the incidence of, or reduce the degree of one or more characteristics associated with intestinal fibrosis. In some embodiments, the compound is administered, either in a single dose or over multiple doses, in an amount effective to reverse established fibrosis.
- In some aspects, the present disclosure provides a method of treating cancer, comprising administering to a patient an effective amount of a compound disclosed herein. In some embodiments, the cancer is mediated by ALK5. In some embodiments, the cancer is selected from breast cancer, colon cancer, prostate cancer, lung cancer, hepatocellular carcinoma, glioblastoma, melanoma and pancreatic cancer. In some embodiments, the cancer is lung cancer, such as non-small cell lung cancer. In some aspects, the present disclosure provides a method of treating cancer, such as non-small cell lung cancer, comprising administering to a patient an effective amount of a compound disclosed herein and an immunotherapeutic agent. In some embodiments, the cancer is stage III non-small cell lung cancer. In some embodiments, the method further comprises administering radiation to the patient. In some embodiments, the immunotherapeutic agent is a PD-1 inhibitor or a CTLA-4 inhibitor. In some embodiments, the immunotherapeutic agent is selected from atezolizumab, avelumab, nivolumab, pembrolizumab, durvalumab, BGB-A317, tremelimumab and ipilimumab. In some embodiments, the immunotherapeutic agent is selected from pembrolizumab and durvalumab.
- The compounds described herein, including compounds of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), are ALK5 inhibitors that limit the activity of TGFβ. TGFβ is one of several factors involved in the initiation and development of fibrotic diseases throughout the body. As such, the compounds of the disclosure are expected to be useful for the treatment, prevention and/or reduction of fibrosis in a patient by administering a therapeutically effective amount of a compound disclosed herein. By inhibiting ALK5, the compound is expected to potentiate the formation of fibrosis in areas of the body that suffer from excessive deposition of the extracellular matrix. Those areas are described below.
- Systemic Fibrotic Diseases
- Systemic sclerosis (SSc) is an autoimmune disorder that affects the skin and internal organs and results in autoantibody production, vascular endothelial activation of small blood vessels, and tissue fibrosis as a result of fibroblast dysfunction. Transforming growth factor β (TGF-β) has been identified as a regulator of pathological fibrogenesis in SSc (Ayers, N. B., et al., Journal of Biomedical Research, 2018, 32(1), pp. 3-12). According to the authors, “understanding the essential role TGF-β pathways play in the pathology of systemic sclerosis could provide a potential outlet for treatment and a better understanding of this severe disease.” In some embodiments, the present disclosure provides a method of treating SSc, comprising administering to a subject an effective amount of a compound disclosed herein.
- Multifocal fibrosclerosis (MF) and idiopathic multifocal fibrosclerosis (IMF) are disorders characterized by fibrous lesions at varying sites and include retroperitoneal fibrosis, mediastinal fibrosis and Riedel's thyroiditis. Both multifocal fibrosclerosis and idiopathic multifocal fibrosclerosis are considered to be an outcome of IgG4-associated fibrosis/disease and TGF-β is believed to be one factor involved in the initiation and development of fibrosis (Pardali, E., et. al., Int. J. Mol. Sci., 18, 2157, pp. 1-22). In some embodiments, the present disclosure provides a method of treating multifocal fibrosclerosis or idiopathic multifocal fibrosclerosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- In some embodiments, the present disclosure provides a method of treating nephrogenic systemic fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein. Nephrogenic systemic fibrosis is a rare disease occurring mainly in people with advanced kidney failure with or without dialysis. In a study performed by Kelly et al. (J. Am. Acad. Dermatol., 2008, 58, 6, pp. 1025-1030), it was shown that TGF-β, as well as Smad 2/3, appear to be associated with fibrosis seen in nephrogenic systemic fibrosis.
- Sclerodermatous graft-versus-host disease (GVHD) is a prevalent complication of allogeneic hematopoietic stem cell graft appearing two to three months after allogeneic bone marrow transplantation. The disease results in production of autoantibodies and fibrosis of skin and inner organs. Using a murine cutaneous GVHD model, it has been shown that progression of early skin and lung disease can be inhibited with TGF-β neutralizing antibodies (McCormick, L. L., et al., J. Immunol., 1999, 163, pp. 5693-5699). In some embodiments, the present disclosure provides a method of treating sclerodermatous GVHD, comprising administering to a subject an effective amount of a compound disclosed herein.
- Organ-Specific Fibrotic Diseases
- Cardiac fibrosis refers to the abnormal thickening of heart valves due to the abnormal proliferation of cardiac fibroblasts resulting in excess deposition of ECM in heart muscle. Fibroblasts secrete collagen, which serves as structural support for the heart. However, when collagen is excessively secreted in the heart, wall and valve thickening can result in tissue build-up on the tricuspid and pulmonary valves. This in turn causes loss of flexibility and ultimately valvular dysfunction leading to heart failure. A specific type of cardiac fibrosis is hypertension-associated cardiac fibrosis as described by J. Diez (J. Clin. Hypertens., 2007, July 9(7), pp. 546-550). According to Diez, changes in the composition of cardiac tissue develop in hypertensive patients with left ventricular hypertrophy and lead to structural remodeling of the heart tissue. One change relates to the disruption of the equilibrium between the synthesis and degradation of collagen types I and III molecules, resulting in excessive accumulation of collagen fibers in the heart tissue. Other types of cardiac fibrosis include post-myocardial infarction and Chagas disease-induced myocardial fibrosis. In Chagas disease, transforming growth factor β1 (TGF-β1) has been implicated in Chagas disease physiopathology, where animal models suggest that the TGF-β1-pathway is up-regulated during infection (Araujo-Jorge, T. C., et al., Clin. Pharmacol. Ther., 2012, 92(5), pp. 613-621; Curvo, E., Mem Inst Oswaldo Cruz, 2018, Vol. 113(4), e170440, pp. 1-8). In some embodiments, the present disclosure provides a method of treating various forms of cardiac fibrosis, such as hypertension-associated cardiac fibrosis, post-myocardial infarction or Chagas disease-induced myocardial fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- Renal fibrosis encompasses a variety of disorders associated with the aberrant expression and activity of TGF-β, including, but not limited to, diabetic and hypertensive nephropathy, urinary tract obstruction-induced kidney fibrosis, inflammatory/autoimmune-induced kidney fibrosis, aristolochic acid nephropathy, progressive kidney fibrosis, and polysystic kidney disease. As discussed above, fibrosis involves an excess accumulation of the ECM, which in turn causes loss of function when normal tissue is replaced with scar tissue (Wynn, T. A., J Clin Invest., 2007, 117, pp. 524-529). As early as 2005, ALK5 inhibitors were being studied in models for renal disease (Laping, N.J., Current Opinion in Pharmacology, 2003, 3, pp. 204-208). In some embodiments, the present disclosure provides a method of treating renal fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- One fibrotic disease that has been particularly difficult to treat is idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive and fatal fibrotic lung disease with survival only improved by lung transplantation. Current oral therapies such as nintedanib and pirfenidone have been shown to slow the progression of the disease, but have adverse effects that lead to discontinuation and lack of compliance by the patient. Although there are other therapies in development targeting various pathways, an unmet need remains for patients with IPF.
- Although ALK5 is an important and known component in the fibrotic disease pathway, the efficacy of ALK5 inhibitors in IPF have not been realized due to systemic adverse effects, especially in the heart. Thus, one of the goals of this disclosure is to develop ALK5 inhibitors with high lung selectivity and rapid clearance. One preferred embodiment of this disclosure is to treat patients with idiopathic pulmonary fibrosis with a compound described herein, for example, by once or twice daily administration of inhalable ALK5 inhibitor having minimal systemic exposure. The inhaled ALK5 inhibitor may be administered as a monotherapy or co-dosed with other orally available IPF therapies. In some embodiments, the present disclosure provides a method of treating idiopathic pulmonary fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein. In some embodiments, the compound is administered by inhalation.
- Familial pulmonary fibrosis is a hereditary disease where two or more family members have confirmed IPF. In some embodiments, the present disclosure provides a method of treating familial pulmonary fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- Pulmonary fibrosis is a typical clinical feature associated with viral infection, such as SARS and COVID-19. SARS-mediated TGF-β signaling has been shown to promote fibrosis and block apoptosis of SARS-CoV-infected host cells (Zhao, X. et al., J. Biol. Chem., 2008, 283(6), pp. 3272-3280). Increased TGF-β expression was similarly observed in patients infected with SARS-CoV-2, ultimately leading to the development of pulmonary fibrosis. TGF-β signaling mediated by SARS-CoV-2 can promote fibroblast proliferation and myofibroblast differentiation and block host cell apoptosis. (Xiong, Y. et al., Emerging Microbes & Infections, 2020, 9(1), pp. 761-770). Compounds of the present disclosure are expected to inhibit increased TGF-β signaling mediated by viral infection and prevent, halt, slow or reverse the progression of pulmonary fibrosis associated with the infection. Accordingly, in some embodiments, the present disclosure provides a method of treating pulmonary fibrosis induced by a viral infection, comprising administering to a subject an effective amount of a compound disclosed herein. In some embodiments, the pulmonary fibrosis is induced by SARS-CoV or SARS-CoV-2. In some embodiments, the compound is administered by inhalation.
- Chronic lung disease, such as interstitial lung disease (ILD), chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), may lead to pulmonary hypertension (PH). Pulmonary hypertension is a progressive disease characterized by high blood pressure in the lungs. The World Health Organization (WHO) has defined five classifications of PH (WHO Group I: Pulmonary arterial hypertension (PAH); WHO Group II: Pulmonary hypertension due to left heart disease; WHO Group III: Pulmonary hypertension due to lung disease and/or hypoxia; WHO Group IV: Chronic thromboembolic pulmonary hypertension (CTEPH); and WHO Group V: Pulmonary hypertension with unclear multifactorial mechanisms). TGF-β signaling has been implicated in the pathogenesis of PH. Moreover, inhibition of ALK5 in a monocrotaline (MCT) model of severe PH was shown to attenuate the development of PH and reduce pulmonary vascular remodeling in a dose-dependent manner, namely by reducing RV systolic pressure, reducing RV diastolic pressure, increasing cardiac output and reducing RV hypertrophy (Zaiman, A. L.; et al., Am. J. Respir. Crit. Care Med., 2008, 177, pp. 896-905). Compounds of the present disclosure are expected to inhibit TGF-β signaling in lung tissue and prevent, halt, slow or reverse the progression of PH, particularly in WHO Group III PH. Accordingly, in some embodiments, the present disclosure provides a method of treating pulmonary hypertension, comprising administering to a subject an effective amount of a compound disclosed herein. The pulmonary hypertension may be WHO Group III pulmonary hypertension, such as pulmonary fibrosis-related pulmonary hypertension (PH-PF) or interstitial lung disease-related pulmonary hypertension (PH-ILD). In some embodiments, the compound is administered by inhalation.
- Other types of interstitial lung diseases include, but are not limited to, (1) interstitial pneumonia caused by bacteria, viruses, or fungi; (2) nonspecific interstitial pneumonitis usually associated with autoimmune conditions such as rheumatoid arthritis or scleroderma; (3) hypersensitivity pneumonitis caused by inhalation of dust, mold, or other irritants; (4) cryptogenic organizing pneumonia; (5) acute interstitial pneumonitis; (6) desquamative interstitial pneumonitis; (7) sarcoidosis; (8) drug-induced interstitial lung disease; and (9) progressive fibrosing interstitial lung disease (PF-ILD). In some embodiments, the present disclosure provides a method of treating an interstitial lung disease, comprising administering to a subject an effective amount of a compound disclosed herein.
- Both transforming growth factor (TGF)-beta(1) and activin-A have been implicated in airway remodeling in asthma (Kariyawasam, H. H., J Allergy Clin Immunol., 2009, September, 124(3), pp. 454-462). In some embodiments, the present disclosure provides a method of treating asthma, comprising administering to a subject an effective amount of a compound disclosed herein.
- Chronic obstructive pulmonary disease (COPD) is a pulmonary disorder characterized by a poorly reversible and progressive airflow limitation caused by airway inflammation and emphysema, whereas IPF is associated with impaired diffusion capacity (Chilosi, M., et al., Respir. Res., 2012, 13(1), 3, pp. 1-9). Both diseases, however, demonstrate a progressive loss of alveolar parenchyma leading to severe impairment of respiratory function. Fibrosis associated with emphysema is known and research has demonstrated TGF-β1 involvement in chronic sinus disease, pulmonary fibrosis, asthma, and COPD (Yang, Y. C., et al., Allergy, 2012, 67, pp. 1193-1202). In some embodiments, the present disclosure provides a method of treating COPD, comprising administering to a subject an effective amount of a compound disclosed herein.
- Other types of lung injury that result in fibrosis include silica-induced pneumoconiosis (silicosis), asbestos-induced pulmonary fibrosis (asbestosis), and chemotherapeutic agent-induced pulmonary fibrosis. In some embodiments, the present disclosure provides a method of treating injury-induced fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- In some embodiments, the present disclosure provides a method of treating liver fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein. Fibrosis develops in the liver when it is repeatedly or continuously damaged, for example, in patients with chronic hepatitis. TGF-0 signaling participates in all stages of disease progression, from initial liver injury through inflammation and fibrosis, to cirrhosis and cancer (Fabregat, I., et al., The FEBS J., 2016, 283(12), pp. 2219-2232).
- A related condition involves fibrosis resulting from idiopathic non-cirrhotic portal hypertension (INCPH). This disease is of uncertain etiology characterized by periportal fibrosis and involvement of small and medium branches of the portal vein. According to Nakanuma et al., small portal veins and skin findings are similar between patients with scleroderma and INCPH (Nakanuma, Y., Hepatol. Res., 2009, 39, pp. 1023-1031). Transforming growth factor-β (TGF-β) and connective tissue growth factor, which are fibrosis-related and vascular endothelial growth factors, respectively, increase in serum, skin, and the portal vein, suggesting that these could be mechanisms of the portal vein occlusion in INCPH. Moreover, endothelial mesenchymal transition (EndMT) theory was proposed by Kitao et al. based on these findings (Kitao, A., et al., Am. J. Pathol., 2009, 175, pp. 616-626). The increase of TGF-β in sera may act as a potent inducer of EndMT. In some embodiments, the present disclosure provides a method of treating INCPH, comprising administering to a subject an effective amount of a compound disclosed herein.
- Other types of liver fibrosis include alcoholic and non-alcoholic liver fibrosis, hepatitis C-induced liver fibrosis, primary biliary cirrhosis or cholangitis, and parasite-induced liver fibrosis (schistosomiasis). In some embodiments, the present disclosure provides a method of treating alcoholic liver fibrosis, non-alcoholic liver fibrosis, hepatitis C-induced liver fibrosis, primary biliary cirrhosis, primary biliary cholangitis, or parasite-induced liver fibrosis (schistosomiasis), comprising administering to a subject an effective amount of a compound disclosed herein.
- Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are two types of chronic liver disease that often lead to cirrhosis and liver failure. Liver biopsies of patients with PBC or PSC typically reveal inflammation and fibrosis. Inhibition of integrin αvβ6, which has been shown to bind to and activate TGFβ1 on epithelial cells, suppresses biliary fibrosis in rodents. (Peng, Z-W., et al., Hepatology, 2016, 63, pp. 217-232). Accordingly, inhibition of the TGF-β pathway is also expected to suppress fibrotic processes in both PBC and PSC. Compounds of the present disclosure are expected to inhibit TGF-β signaling in liver tissue and prevent, halt, slow or reverse the progression of PBC and PSC. Thus, in some embodiments, the present disclosure provides a method of treating primary biliary cholangitis or primary sclerosing cholangitis, comprising administering to a subject an effect amount of a compound described herein. In some embodiments, the present disclosure provides a method of treating liver fibrosis, optionally in a subject that suffers from PBC or PSC, comprising administering to the subject an effective amount of a compound described herein.
- Fibrotic skin conditions include, but are not limited to, hypertrophic scarring, keloids, and localized or systemic sclerosis (scleroderma). As discussed previously, TGF-β is a potent stimulus of connective tissue accumulation and has been implicated in the pathogenesis of scleroderma and other fibrotic disorders (Lakos, G., et al., Am. J. Pathol., 2004, 165(1), pp. 203-217). Lakos et. al. demonstrated that Smad3 functions as a key intracellular signal transducer for profibrotic TGF-β responses in normal skin fibroblasts and found that the targeted disruption of TGF-β/Smad3 signaling modulated skin fibrosis in the mouse model of scleroderma. In some embodiments, the present disclosure provides a method of treating skin fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD) and is a serious clinical problem. TGF-β has been implicated as a major driving factor of intestinal fibrosis. Moreover, TGF-β1 signaling contributes to stricture formation in fibrostenotic Crohn's disease by inducing insulin-like growth factor I (IGF-I) and mechano-growth factor (MGF) production in intestinal smooth muscle. (Latella, G., Rieder, F., Curr. Opin. Gastroenterol., 2017, 33(4), pp. 239-245). Inhibition of TGF-β signaling could thus slow, halt or reverse the progression of fibrosis in the intestine. However, adverse side effects of concern to patients with IBD-such as inflammation and neoplasia-would likely result from systemic inhibition of TGF-β signaling. One goal of the present disclosure is to develop ALK5 inhibitors with high selectivity for the gastrointestinal tract and rapid clearance. In some embodiments, the present disclosure provides a method of treating intestinal fibrosis, comprising administering to a subject an effective amount of a compound described herein, for example, by once or twice daily administration of an oral ALK5 inhibitor having minimal systemic exposure. In some embodiments, the subject suffers from inflammatory bowel disease, such as Crohn's disease or colitis. The degree of therapeutic efficacy may be with respect to a starting condition of the subject (e.g., a baseline Mayo score, baseline Lichtiger score, or severity or incidence of one or more symptoms), or with respect to a reference population (e.g., an untreated population, or a population treated with a different agent). Severity of intestinal fibrosis may be assessed using any suitable method, such as delayed enhancement MRI, ultrasound elastography, shear wave elastography, magnetization MRI, or by the direct detection of macromolecules such as collagen. Preferably, treatment with a compound of the present disclosure reduces the severity of the fibrosis, such as from severe fibrosis to moderate or mild fibrosis. In some embodiments, the treatment increases intestinal tissue elasticity, reduces tissue stiffness, and/or reduces collagen levels. In some embodiments, the treatment prevents myofibroblast accumulation, inhibits expression of pro-fibrotic factors, and/or inhibits accumulation of fibrotic tissue.
- Other types of organ-specific fibrosis or fibrotic diseases involving the TGF-β pathway include, but are not limited to, radiation-induced fibrosis (various organs), bladder fibrosis, intestinal fibrosis, peritoneal sclerosis, diffuse fasciitis, Dupuytren's disease, myelofibrosis, oral submucous fibrosis, and retinal fibrosis. In some embodiments, the present disclosure provides a method of treating radiation-induced fibrosis, bladder fibrosis, intestinal fibrosis, peritoneal sclerosis, diffuse fasciitis, Dupuytren's disease, myelofibrosis, oral submucous fibrosis, or retinal fibrosis, comprising administering to a subject an effective amount of a compound disclosed herein.
- Although one of the goals of this disclosure is to treat fibrotic and pulmonary diseases locally or in a targeted way, the compounds described herein may also be used to treat patients systemically. Diseases that may be treated systemically, include, for example, oncologic diseases such as glioblastoma, pancreatic cancer and hepatocellular carcinoma, breast cancer metastasized to lungs, non-small cell lung cancer, small cell lung cancer, cystic fibrosis, and metastasis of other forms of primary cancer subtypes. Some of the forgoing diseases may also be treated locally as well.
- Other fibrotic diseases that compounds disclosed herein may treat include angioedema, anti-aging, and alopecia. Alopecia includes alopecia totalis, alopecia universalis, androgenetic alopecia, alopecia areata, diffuse alopecia, postpartum alopecia, and traction alopecia.
- Other Indications
- In certain aspects, the present disclosure provides a method of reversing one or more symptoms of aging, comprising administering to a subject an ALK5 inhibitor. The method may further comprise administering an activator of the MAPK pathway, such as oxytocin. The method may be effective in one or more of enhancing neurogenesis in the hippocampus, reducing neuroinflammation, improving cognitive ability, reducing liver adiposity, reducing liver fibrosis, and decreasing the number of p16+ cells. In some embodiments, a method described herein increases stem cell activity. The increase in stem cell activity may allow the subject to generate new muscle fibers and/or to form new neurons in the hippocampus. Treatment with an ALK5 inhibitor, such as a compound described herein, may prevent or slow the onset of age-related diseases, such as Alzheimer's disease. (see Mehdipour, M. et al. Aging 2018, 10, 5628-5645).
- Pharmaceutical Compositions
- In some aspects, the present disclosure provides a pharmaceutical composition. The pharmaceutical composition may comprise a compound disclosed herein, such as a compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is formulated for oral administration. In some embodiments, the pharmaceutical composition is formulated for inhalation. In some embodiments, the pharmaceutical composition comprises a compound disclosed herein and an additional therapeutic agent. Non-limiting examples of such therapeutic agents are described herein below.
- Pharmaceutical compositions typically include at least one pharmaceutically acceptable carrier, diluent or excipient and at least one compound of Formula (I), (I′), (I-A), (I′-A), (I-B), (I′-B), (I-C), (I′-C), (I-D), (I′-D), (I-E) or (I′-E), or a compound provided in Table 1 or 2-described herein as the active agent. The active agent may be provided in any form suitable for the particular mode of administration, such as a free base, a free acid, or a pharmaceutically acceptable salt. Additionally, the methods and pharmaceutical compositions of the present disclosure include the use of N-oxides, crystalline forms (e.g., polymorphs), as well as metabolites of these compounds having similar activity. All tautomers of the compounds described herein are included within the scope of the present disclosure. Additionally, the compounds described herein encompass unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
- Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, vaginal, aerosol, pulmonary, nasal, transmucosal, topical, transdermal, otic, ocular, and parenteral modes of administration. In addition, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.
- In certain embodiments, a compound described herein is administered in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in a depot preparation or sustained release formulation. In some embodiments, a long acting formulation is administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. In some embodiments, a compound described herein is provided in the form of a rapid release formulation, an extended release formulation, or an intermediate release formulation. In some embodiments, a compound described herein is provided in the form of a nebulized formulation. In some embodiments, a compound described herein is administered locally to the lungs by inhalation.
- Compounds of the present disclosure are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, 0.5 to 100 mg, 1 to 50 mg, or from 5 to 40 mg per day may be administered to a subject in need thereof. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.
- A compound of the present disclosure may be administered in a single dose. In some embodiments, a compound of the disclosure is administered in multiple doses, such as about once, twice, three times, four times, five times, six times, or more than six times per day. In some embodiments, dosing is about once a month, once every two weeks, once a week, or once every other day. In some embodiments, a compound of the disclosure and an additional therapeutic agent are administered together about once per day to about 6 times per day. In some embodiments, the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or more than about one year. In some embodiments, a dosing schedule is maintained as long as necessary. A compound of the present disclosure may be administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.
- Pharmaceutical compositions of the present disclosure typically contain a therapeutically effective amount of a compound of the present disclosure. Those skilled in the art will recognize, however, that a pharmaceutical composition may contain more than a therapeutically effective amount, e.g., bulk compositions, or less than a therapeutically effective amount, e.g., individual unit doses designed for co-administration to achieve a therapeutically effective amount.
- Typically, pharmaceutical compositions of the present disclosure contain from about 0.01 to about 95% by weight of the active agent; including, for example, from about 0.05 to about 30% by weight; and from about 0.1% to about 10% by weight of the active agent.
- Any conventional carrier or excipient may be used in the pharmaceutical compositions of the present disclosure. The choice of a particular carrier or excipient, or combinations of carriers or excipients, will depend on the mode of administration being used to treat a particular patient or type of medical condition or disease state. Additionally, the carriers or excipients used in the pharmaceutical compositions of this disclosure may be commercially-available. Conventional formulation techniques are described in Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & White, Baltimore, Maryland (2000); and H. C. Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition, Lippincott Williams & White, Baltimore, Maryland (1999).
- Representative examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, the following: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, such as microcrystalline cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical compositions.
- Pharmaceutical compositions are typically prepared by thoroughly and intimately mixing or blending the active agent with a pharmaceutically-acceptable carrier and one or more optional ingredients. The resulting uniformly blended mixture can then be shaped or loaded into tablets, capsules, pills and the like using conventional procedures and equipment.
- In one aspect, the pharmaceutical composition is suitable for inhaled administration. Pharmaceutical compositions for inhaled administration are typically in the form of an aerosol or a powder. Such compositions are generally administered using inhaler delivery devices, such as a dry powder inhaler (DPI), a metered-dose inhaler (MDI), a nebulizer inhaler, or a similar delivery device.
- In a particular embodiment, the pharmaceutical composition is administered by inhalation using a dry powder inhaler. Such dry powder inhalers typically administer the pharmaceutical composition as a free-flowing powder that is dispersed in a patient's air-stream during inspiration. In order to achieve a free-flowing powder composition, the therapeutic agent is typically formulated with a suitable excipient such as lactose, starch, mannitol, dextrose, polylactic acid (PLA), polylactide-co-glycolide (PLGA) or combinations thereof. Typically, the therapeutic agent is micronized and combined with a suitable carrier to form a composition suitable for inhalation.
- A representative pharmaceutical composition for use in a dry powder inhaler comprises lactose and a micronized form of a compound disclosed herein. Such a dry powder composition can be made, for example, by combining dry milled lactose with the therapeutic agent and then dry blending the components. The composition is then typically loaded into a dry powder dispenser, or into inhalation cartridges or capsules for use with a dry powder delivery device.
- Dry powder inhaler delivery devices suitable for administering therapeutic agents by inhalation are described in the art and examples of such devices are commercially available. For example, representative dry powder inhaler delivery devices or products include Aeolizer (Novartis); Airmax (IVAX); ClickHaler (Innovata Biomed); Diskhaler (GlaxoSmithKline); Diskus/Accuhaler (GlaxoSmithKline); Ellipta (GlaxoSmithKline); Easyhaler (Orion Pharma); Eclipse (Aventis); FlowCaps (Hovione); Handihaler (Boehringer Ingelheim); Pulvinal (Chiesi); Rotahaler (GlaxoSmithKline); SkyeHaler/Certihaler (SkyePharma); Twisthaler (Schering-Plough); Turbuhaler (AstraZeneca); Ultrahaler (Aventis); and the like.
- A pharmaceutical composition of the present disclosure may be administered by inhalation using a metered-dose inhaler. Such metered-dose inhalers typically discharge a measured amount of a therapeutic agent using a compressed propellant gas. Accordingly, pharmaceutical compositions administered using a metered-dose inhaler typically comprise a solution or suspension of the therapeutic agent in a liquefied propellant. Any suitable liquefied propellant may be employed, including hydrofluoroalkanes (HFAs), such as 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoro-n-propane, (HFA 227); and chlorofluorocarbons, such as CCl3F. In a particular embodiment, the propellant is a hydrofluoroalkane. In some embodiments, the hydrofluoroalkane formulation contains a co-solvent, such as ethanol or pentane, and/or a surfactant, such as sorbitan trioleate, oleic acid, lecithin, and glycerin.
- A representative pharmaceutical composition for use in a metered-dose inhaler comprises from about 0.01% to about 5% by weight of a compound of the present disclosure; from about 0% to about 20% by weight ethanol; and from about 0% to about 5% by weight surfactant; with the remainder being an HFA propellant. Such compositions are typically prepared by adding chilled or pressurized hydrofluoroalkane to a suitable container containing the therapeutic agent, ethanol (if present) and the surfactant (if present). To prepare a suspension, the therapeutic agent is micronized and then combined with the propellant. The composition is then loaded into an aerosol canister, which typically forms a portion of a metered-dose inhaler device.
- Metered-dose inhaler devices suitable for administering therapeutic agents by inhalation are described in the art and examples of such devices are commercially available. For example, representative metered-dose inhaler devices or products include AeroBid Inhaler System (Forest Pharmaceuticals); Atrovent Inhalation Aerosol (Boehringer Ingelheim); Flovent (GlaxoSmithKline); Maxair Inhaler (3M); Proventil Inhaler (Schering); Serevent Inhalation Aerosol (GlaxoSmithKline); and the like.
- A pharmaceutical composition of the present disclosure may be administered by inhalation using a nebulizer inhaler. Such nebulizer devices typically produce a stream of high velocity air that causes the pharmaceutical composition to spray as a mist that is carried into the patient's respiratory tract. Accordingly, when formulated for use in a nebulizer inhaler, the therapeutic agent can be dissolved in a suitable carrier to form a solution. Alternatively, the therapeutic agent can be micronized or nanomilled and combined with a suitable carrier to form a suspension.
- A representative pharmaceutical composition for use in a nebulizer inhaler comprises a solution or suspension comprising from about 0.05 μg/mL to about 20 mg/mL of a compound of the present disclosure and excipients compatible with nebulized formulations. In one embodiment, the solution has a pH of about 3 to about 8.
- Nebulizer devices suitable for administering therapeutic agents by inhalation are described in the art and examples of such devices are commercially available. For example, representative nebulizer devices or products include the Respimat® Softmist™ Inhalaler (Boehringer Ingelheim); the AERx® Pulmonary Delivery System (Aradigm Corp.); the PARI LC Plus® Reusable Nebulizer or PARI eFlow® rapid Nebulizer System (Pari GmbH); and the like.
- A pharmaceutical composition of the present disclosure may be prepared in a dosage form intended for oral administration. Suitable pharmaceutical compositions for oral administration may be in the form of capsules, tablets, pills, lozenges, cachets, dragees, powders, granules; or as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil liquid emulsion; or as an elixir or syrup; and the like; each containing a predetermined amount of a compound of the present disclosure as an active ingredient.
- When intended for oral administration in a solid dosage form, the pharmaceutical compositions of the disclosure will typically comprise the active agent and one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate. Optionally or alternatively, such solid dosage forms may also comprise: fillers or extenders, binders, humectants, solution retarding agents, absorption accelerators, wetting agents, absorbents, lubricants, coloring agents, and buffering agents. Release agents, wetting agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the present pharmaceutical compositions.
- Alternative formulations may include controlled release formulations, liquid dosage forms for oral administration, transdermal patches, and parenteral formulations. Conventional excipients and methods of preparation of such alternative formulations are described, for example, in the reference by Remington, supra.
- The following non-limiting examples illustrate representative pharmaceutical compositions of the present disclosure.
- Dry Powder Composition
- A micronized compound of the present disclosure (1 g) is blended with milled lactose (25 g). This blended mixture is then loaded into individual blisters of a peelable blister pack in an amount sufficient to provide between about 0.1 mg to about 4 mg of the compound per dose. The contents of the blisters are administered using a dry powder inhaler.
- Dry Powder Composition
- A micronized compound of the present disclosure (1 g) is blended with milled lactose (20 g) to form a bulk composition having a weight ratio of compound to milled lactose of 1:20. The blended composition is packed into a dry powder inhalation device capable of delivering between about 0.1 mg to about 4 mg of the compound per dose.
- Metered-Dose Inhaler Composition
- A micronized compound of the present disclosure (10 g) is dispersed in a solution prepared by dissolving lecithin (0.2 g) in demineralized water (200 mL). The resulting suspension is spray dried and then micronized to form a micronized composition comprising particles having a mean diameter less than about 1.5 m. The micronized composition is then loaded into metered-dose inhaler cartridges containing pressurized 1,1,1,2-tetrafluoroethane in an amount sufficient to provide about 0.1 mg to about 4 mg of the compound per dose when administered by the metered dose inhaler.
- Nebulizer Composition
- A representative nebulizer composition is as follows. A compound of the present disclosure (2 g of free-base equivalents) is dissolved in a solution containing 80 mL reverse-osmosis water, 0.1-1% by weight of anhydrous citric acid, and 0.5-1.5 equivalents of hydrochloric acid, followed by addition of sodium hydroxide to adjust the pH to 3.5 to 5.5. Thereafter, between 4-6% by weight of D-mannitol is added and solution q.s. to 100 mL. The solution is then filtered through a 0.2 μm filter and stored at room temperature prior to use. The solution is administered using a nebulizer device that provides about 0.1 mg to about 4 mg of the compound per dose.
- Kits
- In certain aspects, the present disclosure provides a kit comprising one or more unit doses of a compound or pharmaceutical composition described herein, optionally wherein the kit further comprises instructions for using the compound or pharmaceutical composition. In some embodiments, the kit comprises a carrier, package, or container that is compartmentalized to receive one or more containers, such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials, such as glass or plastic.
- The articles of manufacture provided herein may contain packaging materials. Packaging materials for use in packaging pharmaceutical products include those found in, e.g., U.S. Pat. Nos. 5,323,907, 5,052,558 and 5,033,252. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment. For example, the container(s) may include one or more compounds described herein, optionally in a composition or in combination with another agent as disclosed herein. The container(s) may optionally have a sterile access port (for example, the container is an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). Such kits may optionally comprise a compound with an identifying description or label or instructions relating to its use in the methods described herein.
- In some embodiments, a kit includes one or more containers, each with one or more of various materials (such as reagents, optionally in concentrated form, and/or devices) desirable from a commercial and user standpoint for use of a compound described herein. Nonlimiting examples of such materials include, but are not limited to, buffers, diluents, filters, needles, syringes, carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use. A set of instructions will also typically be included. A label is optionally on or associated with the container. For example, a label is on a container when letters, numbers or other characters forming the label are attached, molded, or etched onto the container itself, a label is associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert. In addition, a label is used to indicate that the contents are to be used for a specific therapeutic application. In addition, the label indicates directions for use of the contents, such as in the methods described herein. In certain embodiments, the pharmaceutical composition is presented in a pack or dispenser device which contains one or more unit dosage forms containing a compound provided herein. The pack may contain metal or plastic foil, such as a blister pack. In some embodiments, the pack or dispenser device is accompanied by instructions for administration. Optionally, the pack or dispenser is accompanied with a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, is the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. In some embodiments, compositions containing a compound provided herein formulated in a compatible pharmaceutical carrier are prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- Combination Therapy
- The compounds and pharmaceutical compositions of the disclosure may be used in combination with one or more therapeutic agents which act by the same mechanism or by a different mechanism to treat a disease. The one or more agents may be administered sequentially or simultaneously, in separate compositions or in the same composition. Useful classes of agents for combination therapy include, but are not limited to, compounds used to treat cardiac, kidney, pulmonary, liver, skin, immunological and oncological conditions.
- In practicing any of the subject methods, an ALK5 inhibitor and a second therapeutic agent can be administered sequentially, wherein the two agents are introduced into a subject at two different time points. The two time points can be separated by more than 2 hours, 1 or more days, 1 or more weeks, 1 or more months, or according to any intermittent regimen schedule disclosed herein.
- In some embodiments, the ALK5 inhibitor and the second therapeutic agent are administered simultaneously. The two agents may form part of the same composition, or the two agents may be provided in one or more unit doses.
- In some embodiments, the ALK5 inhibitor or the second therapeutic agent are administered parenterally, orally, inhalatively, intraperitoneally, intravenously, intraarterially, transdermally, intramuscularly, liposomally, via local delivery by catheter or stent, subcutaneously, intraadiposally, or intrathecally. As used herein, a therapeutically effective amount of a combination of an ALK5 inhibitor and a second therapeutic agent refers to a combination of an ALK5 inhibitor and a second therapeutic agent, wherein the combination is sufficient to affect the intended application, including but not limited to, disease treatment, as defined herein. Also contemplated in the subject methods is the use of a sub-therapeutic amount of an ALK5 inhibitor and a second therapeutic agent in combination for treating an intended disease condition. The individual components of the combination, though present in sub-therapeutic amounts, synergistically yield an efficacious effect and/or reduced a side effect in an intended application.
- The amount of the ALK5 inhibitor and the second therapeutic agent administered may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- Measuring an immune response and/or the inhibition of biological effects of ALK5 can comprise performing an assay on a biological sample, such as a sample from a subject. Any of a variety of samples may be selected, depending on the assay. Examples of samples include, but are not limited to blood samples (e.g. blood plasma or serum), exhaled breath condensate samples, bronchoalveolar lavage fluid, sputum samples, urine samples, and tissue samples.
- A subject being treated with an ALK5 inhibitor and a second therapeutic agent may be monitored to determine the effectiveness of treatment, and the treatment regimen may be adjusted based on the subject's physiological response to treatment. For example, if inhibition of a biological effect of ALK5 inhibition is above or below a threshold, the dosing amount or frequency may be decreased or increased, respectively. Alternatively, the treatment regimen may be adjusted with respect to an immune response. The methods can further comprise continuing the therapy if the therapy is determined to be efficacious. The methods can comprise maintaining, tapering, reducing, or stopping the administered amount of a compound or compounds in the therapy if the therapy is determined to be efficacious. The methods can comprise increasing the administered amount of a compound or compounds in the therapy if it is determined not to be efficacious. Alternatively, the methods can comprise stopping therapy if it is determined not to be efficacious. In some embodiments, treatment with an ALK5 inhibitor and a second therapeutic agent is discontinued if inhibition of the biological effect is above or below a threshold, such as in a lack of response or an adverse reaction. The biological effect may be a change in any of a variety of physiological indicators.
- Specific agents that may be used in combination with the compounds disclosed herein include, but are not limited to, OFEV® (nintedanib) and Esbriet® (pirfenidone). In some embodiments, a compound disclosed herein is administered in combination with pirfenidone, optionally wherein the pirfenidone is administered by inhalation. In some embodiments, the present disclosure provides a method of treating fibrosis, such as idiopathic pulmonary fibrosis, in a subject, comprising administering to the subject an ALK5 inhibitor, such as a compound disclosed in Table 1, and nintedanib or pirfenidone. In some embodiments, the present disclosure provides a method of treating cancer, such as lung cancer, in a subject, comprising administering to the subject an ALK5 inhibitor, such as a compound disclosed in Table 1, and nintedanib or pirfenidone.
- In some embodiments, the present disclosure provides a method for treating a proliferative disorder (e.g., lung cancer) in a subject in need thereof, comprising administering to said subject an ALK5 inhibitor and an immunotherapeutic agent. TGF-β has been shown to regulate lymphocyte differentiation, suppress T cell proliferation and to enhance tumor growth. Moreover, TGF-β has been shown to prevent optimal activation of the immune system in immunotherapy-resistant patients (see Ldffek, S. J. Oncolo. 2018, 1-9; incorporated herein by reference in its entirety). Not wishing to be bound by any particular theory, the present inventors expect that inhibition of ALK5 may enhance the efficacy of a particular immunotherapy. As such, treatment with an immunotherapeutic agent, such as durvalumab or pembrolizumab, and an ALK5 inhibitor, such as a compound of the present disclosure, is expected to improve the clinical outcome of a subject with cancer, such as a subject with non-small cell lung cancer. The combination is expected to produce a synergistic effect. A synergistic combination is also expected for a triple combination of radiation therapy, immunotherapy, and ALK5 inhibition. In addition, the ALK5 inhibitor, even when administered locally (e.g., to the lung by inhalation), may stimulate both local and systemic immune responses, allowing for the treatment of primary or metastatic tumors in tissues beyond the site of the local delivery. For example, an inhaled ALK5 inhibitor may be administered in combination with an immunotherapeutic agent to treat melanoma, renal cell carcinoma, colon cancer, or breast cancer.
- In some embodiments, the ALK5 inhibitor and the immunotherapeutic agent are administered sequentially or simultaneously. In some embodiments, the ALK5 inhibitor and the immunotherapeutic agent are more effective in treating the proliferative disorder than either agent alone. In some embodiments, the ALK5 inhibitor and the immunotherapeutic agent yield a synergistic effect in treating the proliferative disorder. The synergistic effect may be a therapeutic effect that is greater than either agent used alone in comparable amounts under comparable conditions. The synergistic effect may be a therapeutic effect that is greater than results expected by adding the effects of each agent alone. In some embodiments, the proliferative disorder is a cancer condition. In some embodiments, the cancer condition is lung cancer, such as non-small cell lung cancer.
- The term “immunotherapeutic agent” refers to any agent that induces, enhances, suppresses or otherwise modifies an immune response. This includes the administration of an active agent to, or any type of intervention or process performed on, the subject, with the objective of modifying an immune response. An immunotherapeutic agent may, for example, increase or enhance the effectiveness or potency of an existing immune response in a subject, for example, by stimulating mechanisms that enhance the endogenous host immune response or overcoming mechanisms that suppress the endogenous host immune response.
- “Immune response” refers to the action of a cell of the immune system including, for example, B lymphocytes, T lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, myeloid-derived suppressor cells, dendritic cells and neutrophils and soluble macromolecules produced by any of these cells or the liver (including antibodies, cytokines and complement), that results in selective targeting, binding to, damage to, destruction of, and/or elimination of invading pathogens, cells or tissues infected with pathogens, cancerous or other abnormal cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues, from the body of a subject.
- In one embodiment, an immunotherapeutic agent may comprise a PD-1 inhibitor. In another embodiment, an immunotherapeutic agent may comprise a CTLA-4 inhibitor. In still another embodiment, an immunotherapeutic agent may comprise a B7 inhibitor.
- Exemplary PD-1 inhibitors: A PD-1 inhibitor suitable for use in the subject methods can be selected from a variety of types of molecules. For example, the PD-1 inhibitor can be a biological or chemical compound, such as an organic or inorganic molecule, peptide, peptide mimetic, antibody or an antigen-binding fragment of an antibody. Some exemplary classes of agents suitable for use in the subject methods are detailed in the sections below. A PD-1 inhibitor for use in the present disclosure can be any PD-1 inhibitor that is known in the art, and can include any entity that, upon administration to a patient, results in inhibition of the PD-1 pathway in the patient. A PD-1 inhibitor can inhibit PD-1 by any biochemical mechanism, including disruption of any one or more of PD-1/PD-L1, PD1/PD-L2 and PD-L1/CD80 interactions.
- In some embodiments, the PD-1 inhibitor is a molecule that inhibits the binding of PD-1 to its ligand binding partners. In a specific aspect, the PD-1 ligand binding partners are PD-L1 and/or PD-L2. In another embodiment, a PD-1 inhibitor is a molecule that inhibits the binding of PD-L1 to its binding partners. In a specific aspect, PD-L1 binding partners are PD1 and/or CD80. In another embodiment, the PD-1 inhibitor is a molecule that inhibits the binding of PD-L2 to its binding partners. In a specific aspect, a PD-L2 binding partner is PD1. The inhibitor may be an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein or oligopeptide.
- In some embodiments, the PD-1 inhibitor is an anti-PD-1 antibody. In some further embodiments, the anti-PD-1 antibody is capable of inhibiting binding between PD-1 and PD-L1. In another embodiment, the anti-PD-1 antibody is capable of inhibiting binding between PD-1 and PD-L2. In some embodiments, the PD-1 inhibitor is an anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is capable of inhibiting binding between PD-L1 and PD-1 and/or between PD-L1 and CD80. In some embodiments, the PD-1 inhibitor is an anti-PD-L2 antibody. In some further embodiments, the anti-PD-L2 antibody is capable of inhibiting binding between PD-1 and PD-L2. In yet another embodiment, the PD-1 inhibitor is nivolumab or pembrolizumab. In some embodiments, the PD-1 inhibitor is selected from atezolizumab, avelumab, nivolumab, pembrolizumab, durvalumab and BGB-A317.
- Inhibition of the PD-1 pathway can enhance the immune response to cancerous cells in a patient. The interaction between PD-1 and PD-L1 impairs T cell response as manifested by a decrease in tumor-infiltrating lymphocytes (TILs) and a decrease in T-cell receptor mediated proliferation, resulting in T cell anergy, exhaustion or apoptosis, and immune evasion by the cancerous cells. This immune suppression can be reversed by inhibiting the local interaction between PD-L1 and PD-1 using a PD-1 inhibitor, including, for example, an anti-PD-1 and/or an anti-PD-L1 Ab. A PD-1 inhibitor may improve or restore antitumor T-cell functions.
- Anti-PD-1 antibodies suitable for use in the disclosure can be generated using methods well known in the art. Exemplary PD-1 inhibitors include, but are not limited to: nivolumab (BMS936558), pembrolizumab (MK-3475), pidilizumab (CT-011), AMP-224, AMP-514, BMS-936559, RG7446 (MPDL3280A), MDX-1106 (Medarex Inc.), MSB0010718C, MED14736, and HenGrui mAB005 (WO 15/085847). Further PD-1 antibodies and other PD-1 inhibitors include those described in WO 04/056875, WO 06/121168, WO 07/005874, WO 08/156712, WO 09/014708, WO 09/114335, WO 09/101611, WO 10/036959, WO 10/089411, WO 10/027827, WO 10/077634, WO 11/066342, WO 12/145493, WO 13/019906, WO 13/181452, WO 14/022758, WO 14/100079, WO 14/206107, WO 15/036394, WO 15/085847, WO 15/112900, WO 15/112805, WO 15/112800, WO 15/109124, WO 15/061668, WO 15/048520, WO 15/044900, WO 15/036927, WO 15/035606; U. S. Pub. No. 2015/0071910; and U.S. Pat. Nos. 7,488,802; 7,521,051; 7,595,048; 7,722, 868; 7,794,710; 8,008,449; 8,354,509; 8,383,796; 8,652,465; and 8,735,553; all of which are incorporated herein by reference. Some anti-PD-1 antibodies are commercially available, for example from ABCAM (AB137132), BIOLEGEND (EH12.2H7, RMP 1-14) and AFFYMETRIX EBIOSCIENCE (J105, J116, M1H4).
- Exemplary CTLA-4 inhibitors: A CTLA-4 inhibitor suitable for use in the subject methods can be selected from a variety of types of molecules. For example, the CTLA-4 inhibitor can be a biological or chemical compound, such as an organic or inorganic molecule, peptide, peptide mimetic, antibody or an antigen-binding fragment of an antibody. Some exemplary classes of agents suitable for use in the subject methods are detailed in the sections below. A CTLA-4 inhibitor for use in the present disclosure can be any CTLA-4 inhibitor that is known in the art, and can include any entity that, upon administration to a patient, results in inhibition of the CTLA-4 pathway in the patient. A CTLA-4 inhibitor can inhibit CTLA-4 by any biochemical mechanism, including disruption of either one or both of CTLA-4/CD80 and CTLA-4/CD86 interactions.
- In some embodiments, the CTLA-4 inhibitor is a molecule that inhibits the binding of CTLA-4 to its ligand binding partners. In a specific aspect, the CTLA-4 ligand binding partners are CD80 and/or CD86. In another embodiment, a CTLA-4 inhibitor is a molecule that inhibits the binding of CD80 to its binding partners. In a specific aspect, a CD80 binding partner is CTLA-4. In another embodiment, the CTLA-4 inhibitor is a molecule that inhibits the binding of CD86 to its binding partners. In a specific aspect, a CD86 binding partner is CTLA-4. The inhibitor may be an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein or oligopeptide.
- In some embodiments, the CTLA-4 inhibitor is an anti-CTLA-4 antibody. In some further embodiments, the anti-CTLA-4 antibody is capable of inhibiting binding between CTLA-4 and CD80. In another embodiment, the anti-CTLA-4 antibody is capable of inhibiting binding between CTLA-4 and CD86. In some embodiments, the CTLA-4 inhibitor is an anti-CD80 antibody. In some embodiments, the anti-CD80 antibody is capable of inhibiting binding between CTLA-4 and CD80. In some embodiments, the CTLA-4 inhibitor is an anti-CD86 antibody. In some further embodiments, the anti-CD86 antibody is capable of inhibiting binding between CTLA-4 and CD86. In yet another embodiment, the CTLA-4 inhibitor is tremelimumab or ipilimumab.
- Inhibition of the CTLA-4 pathway can enhance the immune response to cancerous cells in a patient. The interaction between CTLA-4 and one of its natural ligands, CD80 and CD86, delivers a negative regulatory signal to T cells. This immune suppression can be reversed by inhibiting the local interaction between CD80 or CD86 and CTLA-4 using a CTLA-4 inhibitor, including, for example, an anti-CTLA-4 Ab, anti-CD80 Ab or an antiCD86 Ab. A CTLA-4 inhibitor may improve or restore antitumor T-cell functions.
- Anti-CTLA-4 antibodies suitable for use in the disclosure can be generated using methods well known in the art. Exemplary CTLA-4 inhibitors include but are not limited to tremelimumab and ipilimumab (also known as 10D1 or MDX-010). Further CTLA-4 antibodies and other CTLA-4 inhibitors include those described in WO 98/042752, WO 00/037504, WO 01/014424 and WO 04/035607; U. S. Pub. Nos. 2002/0039581, 2002/086014 and 2005/0201994; U.S. Pat. Nos. 5,811,097; 5,855,887; 5,977,318; 6,051,227; 6,207,156; 6,682,736; 6,984,720; 7,109,003; 7,132,281; 7,605,238; 8,143,379; 8,318,916; 8,435,516; 8,784,815; and 8,883,984; EP Pat. No. 1212422; Hurwitz et al., PNAS 1998, 95(17): 10067-10071; Camacho et al., J Clin Oncology 2004, 22(145): abstract no. 2505 (antibody CP675206); and Mokyr, et al., Cancer Research 1998, 58:5301-5304; each of which is incorporated herein by reference.
- Also provided herein is a pharmaceutical composition comprising a compound of the disclosure or a pharmaceutically acceptable salt thereof and one or more other therapeutic agents. The therapeutic agent may be selected from the classes of agents specified above and from the lists of specific agents described above. In some embodiments, the pharmaceutical composition is suitable for delivery to the lungs. In some embodiments, the pharmaceutical composition is suitable for inhaled or nebulized administration. In some embodiments, the pharmaceutical composition is a dry powder or a liquid composition.
- Further, in a method aspect, the disclosure provides a method of treating a disease or disorder in a mammal comprising administering to the mammal a compound of the disclosure or a pharmaceutically acceptable salt thereof and one or more other therapeutic agents.
- When used in combination therapy, the agents may be formulated in a single pharmaceutical composition, or the agents may be provided in separate compositions that are administered simultaneously or at separate times, by the same or by different routes of administration. Such compositions can be packaged separately or may be packaged together as a kit. The two or more therapeutic agents in the kit may be administered by the same route of administration or by different routes of administration.
- The following examples are given for the purpose of illustrating various embodiments of the disclosure and are not meant to limit the present disclosure in any fashion. The present examples, along with the methods and compositions described herein, are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the disclosure. Changes therein and other uses which are encompassed within the spirit of the disclosure as defined by the scope of the claims will occur to those skilled in the art.
- The following abbreviations have the following meanings unless otherwise indicated and any other abbreviations used herein and not defined have their standard, generally accepted meaning:
-
- AcOH=acetic acid
- AcONa=sodium acetate
- ACN=acetonitrile
- Atm=atmosphere
- BINAP=(±)-2,2′-bis(diphenylphosphino)-1,1′-binaphthalene
- Boc2O=di-tert-butyl dicarbonate
- (Bpin)2=bis(pinacolato)diboron
- BrettPhos=2-(dicyclohexylphosphino)3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl
- BrettPhos Pd G4=N-substituted 2-aminobiphenylpalladium methanesulfonate precatalyst
- BSA=bovine serum albumin, Fraction V
- Cp*RuCl(PPh3)2=pentamethylcyclopentadienylbis (triphenylphosphine)ruthenium(II) chloride
- d=day(s)
- DAST=diethylaminosulfur trifluoride
- DCC=N,N′-dicyclohexylcarbodiimide
- DCE=1,2-dichloroethane
- DCM=dichloromethane or methylene chloride
- DHP=dihydropyran
- DIAD=diisopropyl azodicarboxylate
- DIBAH=diisobutylaluminium hydride
- DIPEA or DIEA=N,N-diisopropylethylamine
- DMA or DMAc=dimethylacetamide
- DMAP=4-dimethylaminopyridine
- DMEDA=1,2-bis(methylamino)ethane
- DMF=N,N-dimethylformamide
- DMP=Dess-Martin periodinane
- DMSO=dimethyl sulfoxide
- DPPA=diphenylphosphoryl azide
- DPPF=1,1′-bis(diphenylphosphino)ferrocene
- DTT=dithiothreitol
- EDCI=N-ethyl-N′-(3-dimethylaminopropyl) carbodiimide hydrochloride
- EDTA=ethylenediaminetetraacetic acid
- EGTA=ethylene glycol-bis(O-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
- EtOH=ethanol
- EtOAc or EA=ethyl acetate
- g=gram(s)
- h=hour(s)
- HATU=N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate
- HEPES=4-(2-hyrdroxyethyl)-1-piperazine ethanesulfonic acid
- HOBT=hydroxybenzotriazole
- i-PrOBPin=2-isopropyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
- IPA or i-PrOH=isopropyl alcohol
- KHMDS=potassium bis(trimethylsilyl)amide
- LAH=lithium aluminum hydride
- LDA=lithium diisopropylamide
- LiHDMS=hexamethyldisilazane lithium salt
- m-CPBA=meta-chloroperoxybenzoic acid
- MeCN=acetonitrile
- MeOH=methanol
- min=minute(s)
- MTBE=methyl tert-butyl ether
- NaHDMS=hexamethyldisilazane sodium salt
- NBS=N-bromosuccinimide
- n-BuLi=n-butyl lithium
- Pd(dppf)Cl2=[1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II)
- Pd(OAc)2=palladium(II) acetate
- Pd(PPh3)4=tetrakis(triphenylphosphine)palladium(0)
- Pd/C=palladium on activated carbon, 10% loading
- Pd2(dba)3=tris(dibenzylideneacetone)dipalladium(0)
- PE=petroleum ether
- PhN2=benzene diazonium ion
- PTSA=p-toluenesulfonic acid
- RT, rt, or r.t.=room temperature
- RuPhos=2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl
- RuPhos Pd G2=chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl) [2-(2′-amino-1,1′-biphenyl)]palladium(II)
- RuPhos Pd G4=ligand for Buchwald4*h generation Palladacycle
- SEMCl=2-(trimethylsilyl)ethoxymethyl chloride
- SiO2=silicon dioxide or silica
- SPhos Pd G3=(2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl) [2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate
- STAB=sodium triacetoxyborohydride
- TBAB=tetrabutylammonium bromide
- TBSCl=tert-butyldimethylchlorosilane
- t-BuOK=potassium tert-butoxide
- t-BuONa=sodium tert-butoxide
- TEA, Et3N=triethylamine
- TFA=trifluoroacetic acid
- TFAA=trifluoroacetic anhydride
- THF=tetrahydrofuran
- TMS=tetramethylsilane
- TosC1=p-toluenesulfonyl chloride
- Tris-HCl=tris(hydroxymethyl)aminomethane hydrochloride
- Tween-20=polyoxyethylene sorbitan monolaurate
- Xantphos=4,5-bis(diphenylphosphino)-9,9-dimethylxanthene
- XPhos Pd G4=Buchwald 4th generation palladacycle
- Unless noted otherwise, all materials, such as reagents, starting materials and solvents, were purchased from commercial suppliers, such as Sigma-Aldrich, Fluka Riedel-de Haen, and the like, and were used without further purification.
- Reactions were run under nitrogen atmosphere, unless noted otherwise. The progress of reactions was monitored by thin layer chromatography (TLC), analytical high performance liquid chromatography (anal. HPLC), and mass spectrometry, the details of which are given in specific examples.
- Reactions were worked up as described specifically in each preparation; commonly, reaction mixtures were purified by extraction and other purification methods such as temperature- and solvent-dependent crystallization, and precipitation. In addition, reaction mixtures were routinely purified by preparative HPLC, typically using Microsorb C18 and Microsorb BDS column packings and conventional eluents. Progress of reactions was typically monitored by liquid chromatography mass spectrometry (LCMS). Characterization of isomers was typically done by Nuclear Overhauser effect spectroscopy (NOE). Characterization of reaction products was routinely carried out by mass spectrometry and/or 1H-NMR spectroscopy. For NMR measurement, samples were dissolved in deuterated solvent (CD3OD, CDCl3, or DMSO-d6), and 1H-NMR spectra were acquired with a Varian Gemini 2000 instrument (400 MHz) under standard observation conditions. Mass spectrometric identification of compounds was typically conducted using an electrospray ionization method (ESMS) with an Applied Biosystems (Foster City, CA) model API 150 EX instrument or an Agilent (Palo Alto, CA) model 1200 LC/MSD instrument.
-
- Step A: Preparation of methyl 6-methylpicolinimidate (1-2). To a solution of 1-1 (50.0 g, 423.3 mmol) in MeOH (300 ml) was added 25% NaOMe in MeOH (100 ml, 465 mmol) at 0° C. Then the reaction was stirred at 25° C. for 16 h. The reaction mixture was concentrated in vacuum and the crude residue was dissolved in EtOAc. Brine was added to the solution and white solid precipitation was observed. The suspension was filtered and the organic layer of filtrate was separated. The organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated to give the crude residue 1-2 (58.0 g). The crude product was used directly in the next step without further purification. [M+H]+ calcd for C8H10N2O 150.18, found 151.05.
- Step B: Preparation of 6-methylpicolinimidamide hydrogen chloride (1-3). To a solution of 1-2 (58.0 g, 386.6 mmol) in EtOH (250 ml) and H2O (25 ml) was added NH4Cl (22.9 g, 425.02 mmol) and the reaction was stirred at 80° C. for 16 h. The reaction was concentrated to dryness. The crude residue was triturated in EtOAc and then filtered to remove non-polar impurities. The solid precipitate was treated with excess EtOH and filtered. The filtrate was concentrated to obtain an HCl salt of the desired product 1-3 (55.0 g). The crude product was used directly in the next step without further purification. [M+H]+ calcd for C7H9N3 135.17, found 136.10.
- Step C: Preparation of 2-(6-methylpyridin-2-yl)pyrimidin-4(3H)-one (1-5). To a solution of 1-3 (55.0 g, 407.4 mmol) and 1-4 (46.4 ml, 427.7 mmol) in EtOH (385 ml) was added K2CO3 (112.4 g, 814.8 mmol). The reaction was stirred at 80° C. for 16 h. The reaction was cooled to 25° C., filtered through a pad of Celite and concentrated to give crude product. The crude product was acidified with 4N HCl and triturated with EtOAc, then filtered to give an HCl salt of 1-5 (65.0 g). The crude product was used directly in the next step without further purification. [M+H]+ calcd for C10H9N3O 187.20, found 187.17.
- Step D: Preparation of 4-chloro-2-(6-methylpyridin-2-yl)pyrimidine (1-6). To a solution of 1-5 (10.0 g, 53.41 mmol, HCl salt) in 1,4-dioxane (70 ml) was added POCl3 (15.0 ml, 160.25 mmol). The reaction was stirred at 90° C. for 16 h, then concentrated to dryness. The crude residue was poured onto ice-cold water. The pH was adjusted to 8 by saturated NaHCO3. The mixture was then extracted with EtOAc. The organic phase was dried over sodium sulfate and concentrated to give crude product. The crude residue was triturated in pentane and filtered to give 1-6 (5.0 g). The crude product was used directly in the next step without further purification. [M+H]+ calcd for C10H8ClN3 205.65, found 206.09.
- Step E: Preparation of 2-chloro-N-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidin-4-amine (1-8). To a solution of 1-6 (3.0 g, 14.63 mmol) and 1-7 (2.26 g, 17.56 mmol) in DMF (15 ml) was added solid crushed NaOH (1.17 g, 29.26 mmol) at 0° C. The reaction was stirred at 25° C. for 16 h. The reaction was poured onto ice-cold water and the solid precipitated. The solid was collected by filtration and dried. The crude residue was triturated with ether and ACN to give 1-8 (3.5 g). The crude product was used directly in the next step without further purification. [M+H]+ calcd for C14H11ClN6 298.73, found 298.94.
- Step F: Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(4-morpholinophenyl)pyrimidine-2,4-diamine (475). To a solution of 1-8 (250 mg, 0.84 mmol) in 1,4-dioxane (10 ml) was added 1-9 (298 mg, 1.67 mmol), Pd2(dba)3 (77 mg, 0.08 mmol), Xantphos (48 mg, 0.08 mmol), Cs2CO3 (545 mg, 1.67 mmol) and the resulting mixture was heated at 100° C. for 6 h under N2. The reaction mixture was concentrated in vacuum. The residue was purified by preparative HPLC chromatography using a gradient (25 to 55%) of acetonitrile in water with 0.05% ammonia hydroxide to obtain the title compound as a white solid (62 mg). [M+H]+ calcd for C24H24N8O 440.51, found 441.4.
-
- A vial of 1-8 (20 mg, 0.067 mmol), 2-1 (30 mg, 0.100 mmol), cesium carbonate (32.7 mg, 0.100 mmol), BrettPhos (3.59 mg, 6.69 μmol), and BrettPhos Pd G4 (6.16 mg, 6.69 μmol) in degassed 1,4-dioxane (1 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (1 ml) and DCM (1 ml) were added to the residue and stirred at 25° C. for 2 h. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 30%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (27.2 mg). [M+H]+ calcd for C24H25N9 439.53, found 440.2.
-
- A vial of 1-8 (20 mg, 0.067 mmol), 3-1 (30 mg, 0.100 mmol), cesium carbonate (32.7 mg, 0.100 mmol), BrettPhos (3.59 mg, 6.69 μmol), and BrettPhos Pd G4 (6.16 mg, 6.69 μmol) in degassed 1,4-dioxane (1 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (1 ml) and DCM (1 ml) were added to the residue and stirred at 25° C. for 2 h. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 30%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (28.6 mg). [M+H]+ calcd for C23H24N10 440.52, found 441.3.
-
- Step A: Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (4-1). To a vial of 1-8 (238 mg, 0.797 mmol) was added ammonia solution (7N in MeOH) (4 ml, 28.0 mmol). The resulting suspension was heated at 80° C. for 16 h. The reaction mixture was concentrated in vacuum. The crude residue was purified by silica-gel chromatography using a gradient (0 to 15%) of MeOH in DCM to give 4-1 (108 mg) as a brown solid. [M+H]+ calcd for C13H13N7 279.31, found 280.0.
- Step B: Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(2-(piperazin-1-yl)pyrimidin-5-yl)pyrimidine-2,4-diamine (86). A vial of 4-1 (24.41 mg, 0.087 mmol), 4-2 (20 mg, 0.058 mmol), sodium tert-butoxide (11.20 mg, 0.117 mmol), BrettPhos (6.26 mg, 0.012 mmol), and BrettPhos Pd G4 (10.73 mg, 0.012 mmol) in degassed 1,4-dioxane (1 ml) was heated at 110° C. for 1 h. The reaction mixture was concentrated in vacuum. TFA (1 ml) was added to the residue and heated at 50° C. for 2 h. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (17.2 mg). [M+H]+ calcd for C22H23N1 441.50, found 442.2.
-
- Step A: Preparation of tert-butyl (R)-2-(hydroxymethyl)-4-(4-nitrophenyl)piperazine-1-carboxylate (5-3). A solution of 5-1 (98 mg, 0.694 mmol), 5-2 (150 mg, 0.694 mmol), and DIPEA (1.21 ml, 6.94 mmol) in DMF (3 ml) was heated at 110° C. for 16 h. The reaction was concentrated in vacuum. The crude residue was purified by silica-gel chromatography using a gradient (0 to 15%) of MeOH in DCM to give 5-3 (157 mg) as an orange oil. [M+H]+ calcd for C16H23N3O5 337.38, found 338.4.
- Step B: Preparation of tert-butyl (R)-4-(4-aminophenyl)-2-(hydroxymethyl)piperazine-1-carboxylate (5-4). A solution of 5-3 (157 mg, 0.465 mmol) was taken up in ethanol (3 ml), and Pd/C (9.90 mg, 9.31 μmol) was added and the reaction mixture was purged under an atmosphere of H2 and stirred at 25° C. for 16 h. The reaction mixture was filtered through a pad of Celite and concentrated in vacuum and the crude residue 5-4 (140 mg) was used directly in the next step. [M+H]+ calcd for C16H25N3O3 307.40, found 308.0.
- Step C: Preparation of (R)-(4-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-2-yl)methanol (403). A vial of 1-8 (25 mg, 0.084 mmol), 5-4 (25.7 mg, 0.084 mmol), cesium carbonate (35.4 mg, 0.109 mmol), BrettPhos (2.25 mg, 4.18 μmol), and BrettPhos Pd G4 (3.85 mg, 4.18 μmol) in degassed 1,4-dioxane (1.5 ml) was heated to 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (226 μl) and DCM (118 μl) were added to the residue and stirred at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (10.2 mg). [M+H]+ calcd for C25H27N9O 469.55, found 470.1.
-
- Step A: Preparation of tert-butyl 3-(((4-aminophenyl)amino)methyl)azetidine-1-carboxylate (6-2). A solution of 5-1 (65 mg, 0.461 mmol), 6-1 (86 mg, 0.461 mmol), and DIPEA (805 μl, 4.61 mmol) in DMF (1 ml) was heated at 110° C. for 16 h. The reaction was concentrated in vacuum. The crude product was purified by silica-gel chromatography using a gradient (0 to 60%) of EtOAc in Hexanes to give tert-butyl 3-(((4-nitrophenyl)amino)methyl)azetidine-1-carboxylate (53 mg, 37% yield) as an orange oil. [M+H]+ calcd for C15H21N3O4 307.35, found 308.6. The orange oil (53 mg, 0.172 mmol) was taken up in ethanol (3 ml), and Pd/C (2.42 mg, 0.017 mmol) was added and the reaction mixture was purged under an atmosphere of H2 and stirred at 25° C. for 16 h. The reaction mixture was filtered through a pad of Celite and concentrated in vacuum to provide 6-2 as a crude residue (44 mg, 92% yield), used directly in the next step without further purification. [M+H]+ calcd for C15H23N3O2 277.37, found 277.2.
- Step B: Preparation of N2-(4-((azetidin-3-ylmethyl)amino)phenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (537). A vial of 1-8 (48 mg, 0.162 mmol), 6-2 (44 mg, 0.159 mmol), cesium carbonate (211 mg, 0.647 mmol), BrettPhos (35 mg, 0.065 mmol), and BrettPhos Pd G4 (60 mg, 0.065 mmol) in degassed 1,4-dioxane (1.62 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (1.24 ml) and DCM (1.04 ml) were added to the residue and stirred at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 75%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (10.7 mg). [M+H]+ calcd for C24H25N9 439.53, found 440.1.
-
- Step A: Preparation of tert-butyl 3-(((4-aminophenyl)(methyl)amino)methyl)azetidine-1-carboxylate (7-2). A solution of 5-1 (65 mg, 0.461 mmol), 7-1 (92 mg, 0.461 mmol), and DIPEA (805 μl, 4.61 mmol) in DMF (1 ml) was heated at 110° C. for 16 h. The reaction was concentrated in vacuum. The crude product was purified by silica-gel chromatography using a gradient (0 to 60%) of EtOAc in Hexanes to give tert-butyl 3-((methyl(4-nitrophenyl)amino)methyl)azetidine-1-carboxylate (118 mg, 80% yield) as an orange oil. [M+H]+ calcd for C16H23N3O4 321.38, found 322.2. The orange oil (118 mg, 0.367 mmol) was taken up in ethanol (3 ml), and Pd/C (2.42 mg, 0.017 mmol) was added and the reaction mixture was purged under an atmosphere of H2 and stirred at 25° C. for 16 h. The reaction mixture was filtered through a pad of Celite and concentrated in vacuum, and the crude residue 7-2 (113 mg) was used directly in the next step. [M+H]+ calcd for C16H25N3O2 291.40, found 291.2.
- Step B: Preparation of N2-(4-((azetidin-3-ylmethyl)(methyl)amino)phenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (202). A vial of 1-8 (97 mg, 0.323 mmol), 7-2 (113 mg, 0.159 mmol), cesium carbonate (211 mg, 0.647 mmol), BrettPhos (35 mg, 0.065 mmol), and BrettPhos Pd G4 (60 mg, 0.065 mmol) in degassed 1,4-dioxane (1.62 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (1.24 ml) and DCM (1.04 ml) were added to the residue and heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 75%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (45.5 mg). [M+H]+ calcd for C25H27N9 453.55, found 454.2.
-
- Step A: Preparation of tert-butyl (R)-3-((4-aminophenyl)amino)pyrrolidine-1-carboxylate (8-2). A solution of 5-1 (100 mg, 0.709 mmol), 8-1 (132 mg, 0.709 mmol), and DIPEA (1.24 ml, 7.09 mmol) in DMF (3 ml) was heated at 110° C. for 16 h. The reaction was concentrated in vacuum. The crude product was purified by silica-gel chromatography using a gradient (0 to 60%) of EtOAc in Hexanes to give tert-butyl (R)-3-((4-nitrophenyl)amino)pyrrolidine-1-carboxylate (130 mg, 60% yield) as a yellow oil. [M+H]+ calcd for C15H21N3O4 307.35, found 308.5. The yellow oil (130 mg, 0.423 mmol) was taken up in ethanol (3 mL), Pd/C (4.55 mg, 0.032 mmol) was added and the reaction mixture was purged under an atmosphere of H2 and stirred at 25° C. for 16 h. The reaction mixture was filtered through a pad of Celite and concentrated in vacuum to afford the crude residue 8-2 (100 mg), used directly in the next step without further purification. [M+H]+ calcd for C15H23N3O2 277.37, found 277.3.
- Step B: Preparation of (R)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(4-(pyrrolidin-3-ylamino)phenyl)pyrimidine-2,4-diamine (278). A vial of 1-8 (45 mg, 0.151 mmol), 8-2 (50.1 mg, 0.181 mmol), cesium carbonate (98 mg, 0.301 mmol), BrettPhos (8.09 mg, 0.015 mmol), and BrettPhos Pd G4 (13.87 mg, 0.015 mmol) in degassed 1,4-dioxane (4 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (580 μl) and DCM (485 μl) were added to the residue and the resulting mixture heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 75%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (30.7 mg). [M+H]+ calcd for C24H25N9 439.53, found 440.1.
-
- A vial of 1-8 (30 mg, 0.100 mmol), 9-1 (21 mg, 0.121 mmol), cesium carbonate (42.5 mg, 0.131 mmol), BrettPhos (2.70 mg, 5.02 μmol), and BrettPhos Pd G4 (4.62 mg, 5.02 μmol) in degassed 1,4-dioxane (1 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 75%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (12.7 mg). [M+H]+ calcd for C20H18N8O2S 434.48, found 435.0.
-
- A vial of 1-8 (20 mg, 0.067 mmol), 10-1 (24.8 mg, 0.134 mmol), cesium carbonate (43.6 mg, 0.134 mmol), BrettPhos (7.19 mg, 0.013 mmol), and BrettPhos Pd G4 (12.33 mg, 0.013 mmol) in degassed 1,4-dioxane (1 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 65%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (7.7 mg). [M+H]+ calcd for C21H21N9OS 447.52, found 448.2.
-
- Step A: Preparation of tert-butyl (E)-3-(4-bromobenzylidene)pyrrolidine-1-carboxylate (11-3). To a solution of 11-1 (2.0 g, 10.8 mmol) in DMF (40 ml) was added NaH (561 mg, 14.0 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 30 min, then 11-2 (6.1 g, 11.9 mmol) in DMF (10 ml) was added. The reaction mixture was heated at 65° C. for 12 h. The mixture was poured into H2O (400 mL), the white suspension was extracted with EA (200 mL×3), the combined organic phase was washed with sat. NaCl (200 mL×3), dried over solid Na2SO4, and concentrated under reduced pressure. The residue was purified by silica-gel column chromatography using a gradient (0 to 5%) of EtOAc in PE to give 11-3 (800 mg) as colorless oil.
- Step B: Preparation of tert-butyl (E)-3-(4-((diphenylmethylene)amino)benzylidene)pyrrolidine-1-carboxylate (11-5). To a mixture of 11-3 (800 mg, 2.36 mmol), 11-4 (472 mg, 3.60 mmol) and tBuONa (364 mg, 3.78 mmol) in toluene (15 ml) was added Pd2(dba)3 (65 mg, 0.071 mmol) and BINAP (147 mg, 0.236 mmol) under N2 atmosphere. The reaction mixture was degassed with N2 several times, then heated at 90° C. for 4 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica-gel column chromatography using a gradient (0 to 10%) of EtOAc in PE to give 11-5 (800 mg) as yellow oil.
- Step C: Preparation of tert-butyl (E)-3-(4-aminobenzylidene)pyrrolidine-1-carboxylate (11-6). To a mixture of 11-5 (800 mg, 1.31 mmol) in MeOH (10 ml) under N2 atmosphere was added HONH2—HCl (200 mg, 2.89 mmol) and NaOAc (323 mg, 3.94 mmol). The reaction mixture was heated at 50° C. for 12 h. The reaction mixture was diluted with H2O (10 ml) and the product extracted in EtOAc (10 ml×3), the combined organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by preparative HPLC chromatography using a gradient (30 to 60%) of acetonitrile in water with 0.225% formic acid to give to give 11-6 (150 mg) as light yellow oil. [M+H]+ calcd for C16H22N2O2 274.36, found 275.2.
- Step D: Preparation of tert-butyl 3-(4-aminobenzyl)pyrrolidine-1-carboxylate (11-7). To a solution of 11-6 (250 mg, 0.911 mmol) in MeOH (15 ml) was added Pd/C (30 mg, 10%). The reaction mixture was degassed with H2 several times, then stirred at 20° C. for 1 h. The reaction mixture was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC chromatography using a gradient (23 to 53%) of acetonitrile in water with 0.225% formic acid to give 11-7 (100 mg) as a yellow solid. [M+Na]+ calcd for C16H24N2O2 299.37, found 299.2.
- Step E: Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(4-(pyrrolidin-3-ylmethyl)phenyl)pyrimidine-2,4-diamine (489). A vial of 1-8 (30 mg, 0.100 mmol), 11-7 (33.3 mg, 0.121 mmol), cesium carbonate (65.4 mg, 0.201 mmol), Xantphos (11.62 mg, 0.020 mmol), and Pd(OAc)2 (4.51 mg, 0.020 mmol) in degassed 1,4-dioxane (1 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 50%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (24.9 mg). [M+H]+ calcd for C25H26N8 438.54, found 439.2.
-
- Step A: Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)pyrimidine-2,4-diamine (12-2). A vial of 1-8 (35 mg, 0.117 mmol), 12-1 (46.1 mg, 0.176 mmol), cesium carbonate (76 mg, 0.234 mmol), BrettPhos (12.58 mg, 0.023 mmol), and BrettPhos Pd G4 (21.57 mg, 0.023 mmol) in degassed 1,4-dioxane (586 μl) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (468 μl) and DCM (348 μl) were added to the residue and heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 30%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (76 mg). [M+H]+ calcd for C24H24N8 424.51, found 425.1.
- Step B: Preparation of N2-(3-isopropyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (223). A vial of 12-2 (18 mg, 0.028 mmol), 2-bromopropane (10.18 mg, 0.083 mmol), and DIEA (48.2 μl, 0.276 mmol) in DMF (276 μl) was heated at 110° C. for 8 h. The reaction mixture was concentrated in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (2.3 mg). [M+H]+ calcd for C27H30N8 466.59, found 467.3.
-
- A vial of 1-8 (25 mg, 0.075 mmol), 13-1 (28 mg, 0.112 mmol), cesium carbonate (48.6 mg, 0.149 mmol), BrettPhos (8.01 mg, 0.015 mmol), and BrettPhos Pd G4 (13.73 mg, 0.015 mmol) in degassed 1,4-dioxane (1 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (1 ml) and DCM (1 ml) were added to the residue and stirred at 25° C. for 1 h. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 65%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (16.7 mg). [M+H]+ calcd for C23H22N8 410.49, found 411.1.
-
- Step A: Preparation of tert-butyl 8-(4-aminophenyl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (14-2). A solution of 5-1 (75 mg, 0.532 mmol), 14-1 (124 mg, 0.585 mmol), and potassium carbonate (147 mg, 1.063 mmol) in DMF (1.77 ml) was heated at 80° C. for 16 h. The reaction was concentrated in vacuum. The crude product was purified by silica-gel chromatography using a gradient (0 to 15%) of MeOH in DCM with 2.5% triethylamine to give tert-butyl 8-(4-nitrophenyl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (68 mg, 39% yield) as an orange solid. [M+H]+ calcd for C17H23N3O4 333.39, found 334.0. The orange solid (68 mg, 0.204 mmol) was taken up in ethanol (1.61 ml), and Pd/C (51.4 mg, 0.097 mmol) was added and the reaction mixture was purged under an atmosphere of H2 and stirred at 25° C. for 16 h. The reaction mixture was filtered through a pad of Celite and concentrated in vacuum to give the crude residue 14-2 (55 mg), used directly in the next step. [M+H]+ calcd for C15H25N3O2 303.41, found 304.0.
- Step B: Preparation of N2-(4-(3,8-diazabicyclo[3.2.1]octan-8-yl)phenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (221). A vial of 1-8 (25 mg, 0.084 mmol), 14-2 (25.4 mg, 0.084 mmol), cesium carbonate (35.4 mg, 0.109 mmol), BrettPhos (2.25 mg, 4.18 μmol), and BrettPhos Pd G4 (3.85 mg, 4.18 μmol) in degassed 1,4-dioxane (1.5 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (226 μl) and DCM (188 μl) were added to the residue and heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 75%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (3.6 mg). [M+H]+ calcd for C26H27N9 465.57, found 466.1.
-
- Step A: Preparation of ethyl 2,3-dihydro-1H-indene-2-carboxylate (15-2). To a mixture of 15-1 (10 g, 61.6 mmol) in ethanol (300 ml) was added H2SO4 (36 ml). The mixture was heated at 75° C. for 48 h. The reaction mixture was concentrated and the residue was partitioned between EtOAc (200 ml) and H2O (200 ml). The reaction mixture was basified by 5N NaOH aq. to pH=11, then the organic layer was separated. The aqueous layer was extracted with EtOAc (200 mL×2) and all organic layers were combined and dried over Na2SO4. Concentration in vacuum gave 15-2 (10.5 g) as colorless oil.
- Step B: Preparation of ethyl 2-allyl-2,3-dihydro-1H-indene-2-carboxylate (15-4). To a solution of 15-2 (6.0 g, 31.5 mmol) in THF (120 ml) was added NaHMDS (38 mL, 37.8 mmol) dropwise at −78° C. The reaction mixture was stirred at −78° C. for 1 h under N2, then 15-3 (4.6 g, 37.8 mmol) was added at −78° C. The reaction mixture was stirred at −78° C. for 2 h. The reaction mixture was diluted with sat. NH4Cl aq (120 mL), then extracted with EtOAC (150 ml×3). The combined organic layer was concentrated in vacuum and purified by silica-gel column chromatography using a gradient (0 to 2%) of EtOAc in PE to obtain 15-4 (6.5 g) as a colorless oil.
- Step C: Preparation of ethyl 2-(2-oxoethyl)-2,3-dihydro-1H-indene-2-carboxylate (15-5). A solution of 15-4 (6.5 g, 28.2 mmol) in DCM (80 ml) and cooled to −78° C. O3 was bubbled through the solution for 15 min, at which time a light blue color persisted. Then TEA (5.7 g, 56.4 mmol) was added dropwise and the mixture was stirred at 25° C. for 1.75 h. The reaction mixture was diluted with sat. NaHCO3 aq (150 ml), then extracted with DCM (150 ml×3). The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuum to obtain 15-5 (6.0 g) as a light yellow oil, used directly in the next step.
- Step D: Preparation of 1,3-dihydrospiro[indene-2,3′-pyrrolidin]-2′-one (15-6). To a solution of 15-5 (1.0 g, 4.30 mmol) in MeOH (25 ml) and AcOH (25 ml) was added NH4OAc (16.6 g, 215.0 mmol), the mixture was stirred at 25° C. for 4 h. Then NaCNBH3 (405 mg, 6.45 mmol) was added and the mixture was stirred at 25° C. for 12 h. The reaction mixture was diluted with sat. NaHCO3 aq (250 ml) and extracted with DCM (150 ml×3). The combined organic layer was dried with Na2SO4 and concentrated in vacuum. The residue was dissolved in toluene (10 ml) and heated at 110° C. for 2 h. The reaction mixture was concentrated in vacuum and purified by silica-gel column chromatography using a gradient (10 to 100%) of EtOAc in PE to obtain 15-6 (160 mg) as a white solid.
- Step E: Preparation of 5-nitro-1,3-dihydrospiro[indene-2,3′-pyrrolidin]-2′-one (15-7). A solution of 15-6 (900 mg, 4.80 mmol) in HNO3 (20 ml, 70%) was stirred at 0° C. for 2 h. The reaction mixture was diluted with H2O (30 ml) and extracted with DCM (30 ml×3). The combined organic layer was concentrated in vacuum and purified by silica-gel column chromatography using a gradient (10 to 80%) of EtOAc in PE to obtain 15-7 (700 mg) as light yellow solid.
- Step F: Preparation of 5-nitro-1,3-dihydrospiro[indene-2,3′-pyrrolidine] (15-8). To a solution of 15-7 (100 mg, 0.43 mmol) in THF (4 ml) was added B2H6-Me2S (0.8 ml, 8.60 mmol), then the mixture was heated at 45° C. for 16 h. The reaction mixture was quenched with MeOH (50 ml), then concentrated in vacuum and purified by preparative HPLC chromatography with acetonitrile in water with 0.05% HCl to obtain 15-8 (50 mg) as light yellow oil. [M+H]+ calcd for C12H14N2O2 218.26, found 219.1.
- Step G: Preparation of tert-butyl 5-nitro-1,3-dihydrospiro[indene-2,3′-pyrrolidine]-1′-carboxylate (15-9). To a solution of 15-8 (217 mg, 0.99 mmol), DMAP (61 mg, 0.50 mmol), and TEA (1.0 g, 9.90 mmol) in THF (10 ml) was added Boc2O (648 mg, 2.97 mmol), then the reaction mixture was heated at 45° C. for 2 h. The reaction mixture was diluted with H2O (20 ml) and extracted with EtOAc (20 ml×3). The combined organic layer was concentrated in vacuum and purified by silica-gel column chromatography using a gradient (0 to 20%) of EtOAc in PE to obtain 15-9 (250 mg) as light yellow oil.
- Step H: Preparation of tert-butyl 5-amino-1,3-dihydrospiro[indene-2,3′-pyrrolidine]-1′-carboxylate (15-10). To a solution of 15-9 (40 mg, 0.12 mmol) in MeOH (3 ml) was added Pd/C (10 mg, 10%), then the resulting mixture was stirred at 25° C. for 2 h under H2 atmosphere (15 psi). The reaction mixture was filtered and concentrated in vacuum. The residue was purified by preparative HPLC chromatography (acetonitrile in water with 0.225% formic acid), then the aqueous phase was adjusted to pH=8 by added sat. NaHCO3 aq at 0° C. and the product extracted in DCM (10 ml×3) at 0° C. The combined organic layer was washed with brine (30 ml×3) at 0° C., dried with Na2SO4 and concentrated in vacuum to obtain 15-9 (35 mg) as yellow solid. [M+Na]+ calcd for C17H24N2O2 311.38, found 311.1.
- Step I: Preparation of N2-(1,3-dihydrospiro[indene-2,3′-pyrrolidin]-5-yl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (277). A vial of 1-8 (25 mg, 0.075 mmol), 15-10 (28 mg, 0.112 mmol), cesium carbonate (48.6 mg, 0.149 mmol), BrettPhos (8.01 mg, 0.015 mmol), and BrettPhos Pd G4 (13.73 mg, 0.015 mmol) in degassed 1,4-dioxane (1 ml) was heated to 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (1 ml) and DCM (1 ml) were added to the residue and heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 65%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (16.7 mg). [M+H]+ calcd for C23H22N8 410.49, found 411.1.
-
- Step A: Preparation of 4-(2-(4-nitro-1H-pyrazol-1-yl)ethyl)morpholine (16-3). To a stirred solution of 16-1 (0.5 g, 4.42 mmol) in DMF (5.0 ml) was added K2CO3 (1.83 g, 13.26 mmol) and 16-2 (1.06 g, 5.52 mmol). The reaction mixture was stirred at 25° C. for 16 h. The reaction mixture was diluted with ice-cold water and extracted with EtOAc (50 ml×3). The combined organic layer was washed with ice cold water, brine and dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude residue 16-3 (550 mg) as a viscous liquid. The crude product was used directly in the next step without further purification.
- Step B: Preparation of 1-(2-morpholinoethyl)-1H-pyrazol-4-amine (16-4). To a solution of 16-3 (500 mg, 2.2 mmol) in EtOAc (25 ml) was added 10% Pd/C (50 mg). The reaction mixture stirred at 25° C. for 16 h under H2 balloon pressure. The reaction mixture was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure to get crude residue 16-4 (275 mg) as a viscous liquid. The crude product was used directly in the next step without further purification.
- Step C: Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (84). A vial of 1-8 (20 mg, 0.067 mmol), 16-4 (20 mg, 0.100 mmol), cesium carbonate (43.6 mg, 0.134 mmol), BrettPhos (7.19 mg, 0.013 mmol), and BrettPhos Pd G4 (12.33 mg, 0.013 mmol) in degassed 1,4-dioxane (1 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (1 ml) and DCM (1 ml) were added to the residue and stirred at 25° C. for 16 h. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 20%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (10 mg). [M+H]+ calcd for C23H26N10O 458.53, found 459.2.
-
- Step A: Preparation of N2-(4-bromophenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (17-2). A vial of 1-8 (485 mg, 1.624 mmol), and 17-1 (559 mg, 3.25 mmol) in ethanol (8 ml) was heated at 80° C. for 16 h. The precipitate from the reaction mixture was collected by vacuum filtration to give the crude residue 17-2 (620 mg), used directly in the next step without further purification. [M+H]+ calcd for C20H16BrN7 434.30, found 436.2.
- Step B: Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(4-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)phenyl)pyrimidine-2,4-diamine (538). A vial of 17-2 (25 mg, 0.058 mmol), 17-3 (21.6 mg, 0.086 mmol), potassium phosphate tribasic (36.7 mg, 0.173 mmol), palladium (II) acetate (2.58 mg, 0.012 mmol), and DPPF (5.46 mg, 0.012 mmol) in degassed 1,4-dioxane (461 μl) and H2O (115 μl) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 65%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (5.4 mg). [M+H]+ calcd for C26H23N9O 477.53, found 478.1.
-
- Step A: Preparation of tert-butyl (2-(4-(4-aminophenyl)-1H-pyrazol-1-yl)ethyl)(methyl)carbamate (18-2). A vial of 18-1 (96 mg, 0.274 mmol), 17-1 (39.3 mg, 0.228 mmol), potassium carbonate (95 mg, 0.685 mmol), and Pd(dppf)Cl2 (33.4 mg, 0.046 mmol) in degassed 1,4-dioxane (1218 μl) and H2O (304 μl) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (10 to 50%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of 18-2 (32 mg). [M+H]+ calcd for C17H24N4O2 316.41, found 317.2.
- Step B: Preparation of N2-(4-(1-(2-(methylamino)ethyl)-1H-pyrazol-4-yl)phenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (347). A vial of 1-8 (25 mg, 0.084 mmol), 18-2 (34.4 mg, 0.109 mmol), cesium carbonate (54.5 mg, 0.167 mmol), BrettPhos (8.98 mg, 0.017 mmol), and BrettPhos Pd G4 (15.41 mg, 0.017 mmol) in degassed 1,4-dioxane (418 μl) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (226 μl) and DCM (188 μl) were added to the residue and heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (26.9 mg). [M+H]+ calcd for C26H26N10 478.56, found 479.2.
-
- Step A: Preparation of bis(2-chloropyrimidin-4-yl)amine (19-2). A suspension of 19-1 (11.5 g, 77.2 mmol), 1-7 (10.0 g, 77.2 mmol) and Cs2CO3 (50.3 g, 154 mmol) in DMF (300 ml) was heated at 80° C. for 16 h. The reaction mixture was filtered and the filtrate was concentrated in vacuum and purified by preparative HPLC chromatography using a gradient (2 to 55%) of acetonitrile in water with 0.1% trifluoroacetic acid to yield 19-2 (4.5 g) as yellow solid. [M+H]+ calcd for C8H5Cl2N5 242.06, found 242.1.
- Step B: Preparation of N4-(2-chloropyrimidin-4-yl)-N2-(4-morpholinophenyl)pyrimidine-2,4-diamine (19-3). To a suspension of 19-2 (2.0 g, 8.26 mmol) in 1,4-dioxane (80 ml) was added 1-9 (982 mg, 5.51 mmol), Cs2CO3 (3.6 g, 11.0 mmol), Pd(OAc)2 (123 mg, 0.551 mmol) and Xantphos (319 mg, 0.551 mmol). The reaction mixture was degassed under vacuum and N2 was purged for 3 times. The reaction mixture was heated at 100° C. for 16 h. The reaction mixture was concentrated in vacuum and purified by silica-gel column chromatography using a gradient (10 to 50%) of EtOAc in PE to obtain 19-3 (690 mg) as yellow solid. [M+H]+ calcd for C18H18ClN7O 383.84, found 384.0.
- Step C: Preparation of N4-(2-iodopyrimidin-4-yl)-N2-(4-morpholinophenyl)pyrimidine-2,4-diamine (19-4). To a solution of 19-3 (690 mg, 1.80 mmol) and NaI (1.6 g, 10.8 mmol) in CHCl3 (10 ml) was added HI/H2O (20 ml, 45%) at 0° C. and was stirred at 25° C. for 72 h. The mixture was basified by NaOH solution (2 M) to pH=8 and extracted with EtOAc (30 ml×2). The organic layer was concentrated in vacuum and purified by preparative HPLC chromatography using a gradient (10 to 35%) of acetonitrile in water with 0.225% formic acid to yield 19-4 (720 mg) as white solid. [M+H]+ calcd for C18H18IN7O 475.29, found 475.8.
- Step D: Preparation of N4-(2-(3-methyl-1H-indazol-4-yl)pyrimidin-4-yl)-N2-(4-morpholinophenyl)pyrimidine-2,4-diamine (19-6). To a vial containing compound 19-4 (20 mg, 0.042 mmol) was added 19-5 (15 mg, 0.084 mmol) followed by sodium carbonate (22.30 mg, 0.210 mmol), and Pd(dppf)Cl2 (6.16 mg, 0.0084 mmol). The resulting mixture was purged with N2 before degassed water (1 ml) and 1,4-dioxane (1 ml) was added. The vial was capped and heated at 80° C. for 16 h. The reaction was then cooled and concentrated in vacuum. The resulting residue was purified by preparative HPLC chromatography using a gradient (5 to 65%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (3.5 mg). [M+H]+ calcd for C26H25N9O 479.55, found 480.1.
-
- Step A: Preparation of 3-fluoro-6-iodo-2-methylpyridine (20-2). To a solution of 20-1 (2.0 g, 10.5 mmol) in MeCN (10 ml) was added NaI (4.8 g, 31.5 mmol) and HI aq. (2.5 ml, 47% in H2O). The mixture was heated at 135° C. for 1 h under microwave. The reaction was poured into cold sat. NaHCO3 (300 ml). The resulting mixture was extracted with EtOAc (150 ml×3). The organic layers were washed with sat. Na2SO3 (200 ml×3) and concentrated in vacuum to dryness to give crude residue 20-2 (2.0 g) as white solid, used directly in the next step. [M+H]+ calcd for C6H5FIN 237.02, found 237.9.
- Step B: Preparation of 3-fluoro-6-iodo-2-methylpyridine 1-oxide (20-3). To a solution of 20-2 (10 g, 42.2 mmol) in toluene (200 ml) was added mCPBA (17.1 g, 84.4 mmol, 85% purity) in portions. The mixture was stirred at 25° C. for 2 h. The reaction mixture was poured into ice saturated NaHCO3 aq. (500 ml). The resulting mixture was extracted with EtOAc (500 ml×5). The combined organic layer was washed with Na2SO3 aq. (1000 ml×3), concentrated to dryness and purified by column (PE/EA=20/1 to 1/1) to give 20-3 (4.67 g) as yellow solid. [M+H]+ calcd for C6H5FINO 253.01, found 253.9.
- Step C: Preparation of (3-fluoro-6-iodopyridin-2-yl)methanol (20-4). 20-3 (10.5 g, 41.49 mmol) was added into TFAA (100 ml) in batches. The reaction mixture was stirred at 35° C. for 16 h. The reaction mixture was poured into ice NaHCO3 aq. (500 ml). The resulting mixture was extracted with EtOAc (200 ml×3). The combined organic layer was concentrated to dryness to give a crude product. This crude product was dissolved in DCM (80 ml) and H2O (80 ml). Then K2CO3 (22.9 g, 165.97 mmol) was added. The reaction mixture was heated at 40° C. for 16 h. The reaction mixture was poured into ice water (300 ml). The resulting mixture was extracted with EtOAc (200 ml×3). The combined organic layer was concentrated to dryness and purified by column (PE/EA=100/1 to 10/1) to obtain 20-4 (7.3 g) as light yellow solid. [M+H]+ calcd for C6H5FINO 253.01, found 253.9.
- Step D: Preparation of 3-fluoro-6-iodopicolinaldehyde (20-5). To a solution of 20-4 (7.3 g, 28.9 mmol) in DCM (160 ml) was added DMP (24.5 g, 57.8 mmol). The mixture was stirred at 25° C. for 2 h. The reaction was poured into cold sat. NaHCO3 (500 ml). The mixture was extracted with EtOAc (200 ml×5). The organic layer was concentrated in vacuum to dryness and purified by column (PE/EA=100/1 to 10/1) to obtain 20-5 (6.5 g) as light yellow solid.
- Step E: Preparation of 2-(difluoromethyl)-3-fluoro-6-iodopyridine (20-6). To a solution of 20-5 (6.5 g, 25.9 mmol) in DCM (100 ml) was dropwise added DAST (7.5 g, 46.6 mmol) at −20° C. The reaction mixture was warmed slowly and stirred at 20° C. for another 2 h. The reaction mixture was neutralized with sat. NaHCO3 aq. (500 ml), then the resulting mixture was extracted with EtOAc (150 ml×3). The combined organic layers were concentrated to dryness and purified by silica-gel column chromatography (PE/EA=100/1 to 10/1) to obtain 20-6 (6.5 g) as light pink solid. [M+H]+ calcd for C6H3F3IN 273.00, found 273.9.
- Step F: Preparation of (6-(difluoromethyl)-5-fluoropyridin-2-yl)boronic acid (20-8). To a solution of 20-6 (1.8 g, 6.59 mmol) and B(OPr-i)3 (2.5 g, 13.4 mmol) in THF (70 ml) was dropwise added i-PrMgCl (16.5 mL, 32.9 mmol, 2.0 M/L) at 0° C. The reaction mixture was warmed and stirred at 25° C. for 16 h. The reaction mixture was quenched with H2O (100 ml). The resulting reaction mixture was extracted with MTBE (50 ml×3). The aqueous phase was lyophilized to give a crude product. This crude product was triturated with EtOAc (100 ml×3) for 2 h at 25° C. The mother liquor was lyophilized again, and then added to H2O (50 ml) and extracted with MTBE (50 ml×3) and PE (50 ml×3). The aqueous phase was lyophilized again to give crude residue 20-8 (720 mg) as white solid, used directly in the next step. [M+H]+ calcd for C6H5BF3NO2 190.92, found 191.3.
- Step G: Preparation of N4-(2-(6-(difluoromethyl)-5-fluoropyridin-2-yl)pyrimidin-4-yl)-N2-(4-morpholinophenyl)pyrimidine-2,4-diamine (426). To a vial containing 19-6 (20 mg, 0.042 mmol) was added 20-8 (16 mg, 0.084 mmol) followed by sodium carbonate (22.30 mg, 0.210 mmol) and Pd(dppf)Cl2 (6.16 mg, 0.0084 mmol). The resulting mixture was purged with N2 before degassed water (1 ml) and 1,4-dioxane (1 ml) was added. The vial was capped and heated at 80° C. for 16 h. The reaction was then cooled and concentrated in vacuum. The resulting residue was purified by preparative HPLC chromatography using a gradient (15 to 75%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (4.7 mg). [M+H]+ calcd for C24H21F3N8O 494.48, found 495.0.
-
- Step A: Preparation of tert-butyl 4-(4-((4-((2-chloropyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate (21-1). To a suspension of 19-2 (2.6 g, 10.8 mmol) in 1,4-dioxane (72 ml) was added 2-1 (2.0 g, 7.21 mmol), Cs2CO3 (4.7 g, 14.2 mmol), Pd(OAc)2 (162 mg, 0.721 mmol) and Xantphos (417 mg, 0.721 mmol). The reaction mixture was degassed under vacuum and N2 was purged 3 times. The mixture was heated at 100° C. for 16 h. The reaction mixture was concentrated in vacuum and purified by silica gel column chromatography using a gradient (20 to 50%) of EtOAc in PE to obtain 21-1 (730 mg) as yellow solid. [M+H]+ calcd for C23H27ClN8O2 482.97, found 483.4.
- Step B: Preparation of N4-(2-chloropyrimidin-4-yl)-N2-(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine (21-2). To a solution of 21-1 (730 mg, 1.51 mmol) in DCM (8 ml) was added TFA (1.0 g, 15.1 mmol) and the resulting mixture was stirred at 25° C. for 3 h. The reaction mixture was concentrated in vacuum and the residue was basified by saturated NaHCO3 solution to pH=8. The reaction mixture was filtered and the filtrate was dried in vacuum to obtain 21-2 (520 mg) as white solid, used directly in the next step. [M+H]+ calcd for C18H19ClN8 382.86, found 383.2.
- Step C: Preparation of N4-(2-iodopyrimidin-4-yl)-N2-(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine (21-3). To a solution of 21-2 (520 mg, 1.36 mmol) and NaI (1.2 g, 8.15 mmol) in CHCl3 (10 ml) was added HI/H2O (20 ml, 45%) at 0° C. and the resulting mixture was stirred at 25° C. for 7 d. The reaction mixture was basified by sat. NaHCO3 solution to pH=8 at 0° C., washed with saturated Na2SO3 solution (20 ml) and extracted with EtOAc (30 ml×3). The organic layer was concentrated in vacuum and purified by preparative HPLC chromatography using a gradient (10 to 40%) of acetonitrile in water with 0.05% HCl to obtain 21-3 (120 mg) as yellow solid. [M+H]+ calcd for C18H191N8 474.31, found 475.83.
- Step D: Preparation of N4-(2-(5-chloro-2,4-difluorophenyl)pyrimidin-4-yl)-N2-(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine (556). To a vial containing compound 21-3 (10 mg, 0.021 mmol) was added 21-4 (8.08 mg, 0.042 mmol) followed by sodium carbonate (11.17 mg, 0.105 mmol) and Pd(dppf)Cl2 (3.09 mg, 0.0042 mmol). The resulting mixture was purged with N2 before degassed water (290 μl) and 1,4-dioxane (290 μl) was added. The vial was capped and heated at 110° C. for 1 h. The reaction was then cooled and concentrated in vacuum. The resulting residue was purified by preparative HPLC chromatography using a gradient (15 to 75%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (5.7 mg). [M+H]+ calcd for C24H21ClF2N8 494.94, found 495.1.
-
- Step A: Preparation of tert-butyl methyl(1-(4-nitrophenyl)piperidin-4-yl)carbamate (22-2). To a solution of 5-1 (4.0 g, 18.7 mmol) in DMF (60 ml) was added 22-1 (2.6 g, 18.7 mmol) and K2CO3 (5.2 g, 37.3 mmol). The reaction mixture was stirred at 25° C. for 15 h. The reaction was filtrated and the cake was washed with EtOAc (80 ml×2). The filtrate was poured into 250 ml of H2O. The mixture was extracted with EtOAc (150 ml×3). The organic layer was washed with sat. NaCl (100 ml×3), dried over with Na2SO4 and concentrated in vacuum to dryness to give crude product. The crude product was purified by column (PE:EA=50:1 to 3:1) to give 22-2 (5.8 g) as yellow solid.
- Step B: Preparation of tert-butyl (1-(4-aminophenyl)piperidin-4-yl)(methyl)carbamate (22-3). To a solution of 22-2 (5.7 g, 16.99 mmol) in MeOH (80 ml) was added Pd/C (500 mg, 10%). The reaction mixture was stirred at 25° C. for 15 h under H2 balloon. The reaction mixture was filtrated through a pad of Celite and the solvent was removed in vacuum to dryness to give crude residue 22-3 (4.5 g) as light pink solid, used directly in the next step.
- Step C: Preparation of tert-butyl (1-(4-((4-((2-chloropyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperidin-4-yl)(methyl)carbamate (22-4). A suspension of 19-3 (95 mg, 0.393 mmol), 22-3 (100 mg, 0.327 mmol), Pd(OAc)2 (7 mg, 0.033 mmol), Xantphos (19 mg, 0.033 mmol) and Cs2CO3 (213 mg, 0.655 mmol) in 1,4-dioxane (9 ml) was heated at 120° C. under microwave for 3 h under N2. The reaction mixture was filtrated and the filtrate was purified by preparative HPLC chromatography using a gradient (15 to 45%) of acetonitrile in water with 0.1% trifluoroacetic acid to give 22-4 (400 mg) as brown solid. [M+H]+ calcd for C25H31ClN8O2 511.03, found 511.4.
- Step D: Preparation of N4-(2-chloropyrimidin-4-yl)-N2-(4-(4-(methylamino)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine (22-5). A suspension of 22-4 (400 mg, 0.783 mmol) in HCl/EA (25 ml, 4M) was stirred at 0° C. for 1 h. The solvent was removed in vacuum to give crude residue 22-5 (500 mg) as pink solid, used directly in the next step. [M+H]+ calcd for C20H23ClN8 410.91, found 410.3.
- Step E: Preparation of N4-(2-iodopyrimidin-4-yl)-N2-(4-(4-(methylamino)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine (22-6). To a suspension of 22-5 (400 mg, 0.973 mmol) in CHCl3 (5 ml) was added HI/H2O (30 ml, 45% in H2O). The reaction mixture was stirred at 25° C. for 11 d. The reaction was poured into 100 ml of ice water at 0° C. 15 g of Na2SO3 was added to the solution. pH of the solution was adjusted to 8 with sat. NaHCO3. The solution was extracted with EtOAc (50 ml×6). The organic layer was dried with Na2SO4 and concentrated in vacuum to dryness to give crude residue. The residue was purified by preparative HPLC chromatography using a gradient (7 to 37%) of acetonitrile in water with 0.05% HCl to give the HCl salt of 22-6 (180 mg) as yellow solid. [M+H]+ calcd for C20H23IN8 502.36, found 503.2.
- Step F: Preparation of 4-methyl-3-(4-((2-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)pyrimidin-2-yl)phenol (255). To a vial containing compound 22-6 (15 mg, 0.026 mmol) was added 22-7 (12 mg, 0.079 mmol) followed by sodium carbonate (13.91 mg, 0.131 mmol), and Pd(dppf)Cl2 (3.85 mg, 0.0052 mmol). The resulting mixture was purged with N2 before degassed water (0.5 ml) and 1,4-dioxane (1 ml) was added. The vial was capped and heated at 100° C. for 16 h. The reaction was then cooled and concentrated in vacuum. The resulting residue was purified by preparative HPLC chromatography using a gradient (5 to 65%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (14.5 mg). [M+H]+ calcd for C31H37N9O 551.70, found 552.2.
-
- Step A: Preparation of tert-butyl 4-((2-aminothiazol-4-yl)methyl)piperazine-1-carboxylate (23-3). To a solution of 23-1 (150 mg, 0.807 mmol), and 23-2 (100 mg, 0.673 mmol) in DMF (2.7 ml) was added DIEA (0.59 ml, 3.36 mmol). The reaction mixture was heated at 110° C. for 1 h. The reaction mixture was concentrated in vacuum and was purified by silica-gel column chromatography using a gradient (0 to 15%) of MeOH in DCM to obtain 23-3 (120 mg) as yellow oil. [M+H]+ calcd for C13H22N4O2S 298.41, found 299.4.
- Step B: Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(4-(piperazin-1-ylmethyl)thiazol-2-yl)pyrimidine-2,4-diamine (287). A vial of 1-8 (100 mg, 0.335 mmol), 23-3 (120 mg, 0.402 mmol), cesium carbonate (218 mg, 0.669 mmol), Xantphos (38.7 mg, 0.067 mmol), and Pd(OAc)2 (15.03 mg, 0.067 mmol) in degassed 1,4-dioxane (3.3 ml) was heated at 110° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (903 μl) and DCM (754 μl) were added to the residue and stirred at 45° C. for 30 min TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (124 mg). [M+H]+ calcd for C22H24N10S 460.56, found 461.2.
-
- Step A: Preparation of methyl 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-2-carboxylate (24-2). To a solution of 1-8 (800 mg, 5.09 mmol) in 1,4-dioxane (10 nil) was added 24-1 (1.21 g, 4.07 mmol) under N2 atmosphere. Then Cs2CO3 (3.30 g, 10.18 mmol) was added. The reaction mixture was purged with N2 for 5 min, followed by addition of Pd2(dba)3 (233 mg, 0.25 mmol) and BINAP (317 mg, 0.05 mmol), then heated at 110° C. for 6 h in a sealed vial. The reaction mixture was diluted with EtOAc, filtered through a Celite bed, and concentrated to obtain the crude residue. The residue was purified by silica-gel column chromatography using a gradient (0 to 3%) of MeOH in DCM to obtain 24-2 (820 mg) as yellow solid. [M+H]+ calcd for C20H17N7O2S 419.46, found 420.12.
- Step B: Preparation of (4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophen-2-yl)methanol (24-3). To a solution of 24-2 (800 mg, 1.90 mmol) in dry THF (10 ml) was added LAH (1.90 ml, 3.81 mmol) under N2 atmosphere at 0° C. The reaction stirred at 25° C. for 2 h. The reaction mixture was cooled to −30° C. and quenched with saturated ammonium chloride solution, diluted with EtOAc and filtered through Celite bed, then concentrated to get crude residue. The residue was purified by silica-gel column chromatography using a gradient (0 to 8%) of MeOH in DCM to obtain 24-3 (300 mg) as off-white solid. [M+H]+ calcd for C19H17N7OS 391.45, found 392.15.
- Step C: Preparation of 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-2-carbaldehyde (24-4). To a solution of 24-3 (250 mg, 0.63 mmol) in DCM (8 ml) was added MnO2 (1.39 g, 15.98 mmol) at 25° C. The resulting suspension was stirred at 25° C. for 16 h. The reaction mixture was diluted with DCM, filtered through Celite bed, and concentrated to afford the crude residue which was purified by washing with diethyl ether and ACN to obtain 24-4 (180 mg) as yellow solid. [M+H]+ calcd for C19H15N7OS 389.44, found 390.27.
- Step D: Preparation of N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)-N2-(5-(piperazin-1-ylmethyl)thiophen-3-yl)pyrimidine-2,4-diamine (94). To a stirred solution 24-4 (75 mg, 0.193 mmol) in DMA (800 μl) was added 23-1 (30 mg, 0.161 mmol) followed by the addition of STAB (102 mg, 0.483 mmol). The reaction mixture was stirred at 25° C. for 16 h. The reaction mixture was concentrated in vacuum. DCM (400 μl) and TFA (400 μl) were added to the reaction mixture and the resulting mixture heated at 45° C. for 30 min. TFA was removed in vacuum. The residue was purified by preparative HPLC chromatography using a gradient (2 to 15%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (29.6 mg). [M+H]+ calcd for C23H25N9S 459.58, found 460.2.
-
- To a vial of 17-2 (20 mg, 0.054 mmol) and 25-1 (24 mg, 0.081 mmol) in DMF (1 ml) was added DIEA (0.028 ml, 0.162 mmol) and the resulting mixture was stirred at 25° C. for 16 h. TFA (1 ml) was added to the reaction mixture and heated at 50° C. for 1 h. The reaction mixture was concentrated in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (10.3 mg). [M+H]+ calcd for C26H29N9O2S 531.64, found 532.1.
-
- To a solution of 17-2 (25 mg, 0.067 mmol) in DCM (1 ml) was added CDI (12.04 mg, 0.074 mmol) and the resulting mixture stirred at 25° C. for 16 h. 23-1 (13.83 mg, 0.074 mmol) was added to the reaction mixture and stirred at 25° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (1 ml) and DCM (1 ml) were added to the residue and heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 65%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (11.8 mg). [M+H]+ calcd for C25H26N10O 482.55, found 483.1.
-
- To a solution of 17-2 (12 mg, 0.032 mmol) and 27-1 (14.86 mg, 0.065 mmol) in DMF (1 ml) was added HATU (18.48 mg, 0.049 mmol) and DIEA (0.017 ml, 0.097 mmol) and the resulting mixture stirred at 25° C. for 16 h. The reaction mixture was concentrated in vacuum. TFA (1 ml) and DCM (1 ml) were added to the residue and heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (5 to 65%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (19.7 mg). [M+H]+ calcd for C26H27N9O 481.56, found 482.1.
-
- To a solution of 17-2 (20 mg, 0.054 mmol) and 28-1 (18.73 mg, 0.081 mmol) in DMF (1 ml) was added HATU (30.8 mg, 0.081 mmol) and DIEA (0.028 ml, 0.162 mmol) and the resulting mixture was stirred at 25° C. for 1 h. The reaction mixture was concentrated in vacuum. TFA (229 μl) and DCM (191 μl) were added to the residue and heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (35.1 mg). [M+H]+ calcd for C25H25N9O2 483.54, found 484.0.
-
- Step A: Preparation of N2-(3-aminophenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (29-2). To a mixture of 1-8 (400 mg, 1.34 mmol) and 29-1 (144 mg, 1.34 mmol) in IPA (10 ml) was added HCl (0.5 ml). The reaction mixture was heated at 80° C. for 16 h. The reaction mixture was filtered. The filtrate was concentrated in vacuum and purified by silica-gel column chromatography using a gradient (0 to 5%) of MeOH in DCM to give 29-2 (280 mg) as yellow solid. [M+H]+ calcd for C20H18N8 370.42, found 371.2.
- Step B: Preparation of N-(3-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperidine-3-carboxamide (443). To a solution of 29-2 (20 mg, 0.054 mmol) and 29-3 (18.73 mg, 0.081 mmol) in DMF (1 ml) was added HATU (30.8 mg, 0.081 mmol) and DIEA (0.028 ml, 0.162 mmol) and the resulting mixture was stirred at 25° C. for 1 h. The reaction mixture was concentrated in vacuum. TFA (229 μl) and DCM (191 μl) were added to the residue and heated at 45° C. for 30 min. TFA was removed in vacuum and the residue was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (35.1 mg). [M+H]+ calcd for C25H25N9O2 483.54, found 484.0.
-
- Step A: Preparation of 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-2-carboxylic acid (30-1). A mixture of 24-2 (1.3 g, 3.10 mmol) and NaOH (1.2 g, 31.0 mmol) in MeOH (30 ml) and H2O (15 ml) was heated at 50° C. for 2 h. The reaction mixture was acidified with AcOH to pH=7 and filtered. The cake was dried in vacuum to afford 30-1 (1.2 g) as a yellow solid. [M+H]+ calcd for C19H15N7O2S 405.44, found 406.0.
- Step B: Preparation of N2-(5-isocyanatothiophen-3-yl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (30-3). To a solution of 30-1 (1.0 g, 2.46 mmol) and TEA (1.5 g, 14.8 mmol) in THF (20 ml) was added 30-2 (2.1 g, 22.3 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 6 h. Then NaN3 (1.0 g, 15.4 mmol) in H2O (5.0 ml) was added at 0° C. The reaction mixture was stirred at 20° C. for 12 h. The reaction mixture was concentrated in vacuum. The residue was washed with H2O (50 ml×2) and the cake was dried in vacuum to afford 30-3 (900 mg) as a white solid. [M+H]+ calcd for C19H14N8OS 402.44, found 403.0.
- Step C: Preparation of N2-(5-aminothiophen-3-yl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (30-4). A solution of 30-3 (800 mg, 1.19 mmol) in HCl (10 ml, 6.0 M) was stirred at 50° C. for 12 h. The reaction mixture was concentrated in vacuum. The residue was purified by preparative HPLC chromatography using a gradient (0 to 32%) of acetonitrile in water with 0.05% HCl to obtain 30-4 (120 mg) as a white solid. [M+H]+ calcd for C18H16N8S 376.44, found 377.1.
- Step D: Preparation of N-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophen-2-yl)piperidine-4-carboxamide (452). A solution of 30-4 (20 mg, 0.053 mmol), 27-1 (18.27 mg, 0.080 mmol), HATU (30.3 mg, 0.080 mmol), and DIEA (28.0 μl, 0.159 mmol) in DMF (1 ml) was stirred at 25° C. for 1 h. The reaction mixture was concentrated in vacuum. DCM (200 μl) and TFA (225 μl) were added to the reaction mixture and the mixture was heated at 45° C. for 30 min. TFA was removed in vacuum and the crude mixture purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (26.9 mg). [M+H]+ calcd for C24H25N9OS 487.59, found 488.0.
-
- Step A: Preparation of methyl 2-(2-fluoro-5-nitrophenyl)acetate (31-2). To a stirred solution of 31-1 (10 g, 50.25 mmol) in MeOH (70 ml) was added H2SO4 (5.3 ml, 100 mmol) at 0° C. under N2 atmosphere. The reaction mixture was refluxed for 16 h. Solvent was removed under reduced pressure and was carefully quenched using bicarbonate solution and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product 31-2 (10 g). [M+Na]+ calcd for C9H8FNO4 236.15, found 236.31.
- Step B: Preparation of tert-butyl 4-(2-(2-methoxy-2-oxoethyl)-4-nitrophenyl)piperazine-1-carboxylate (31-3). To a stirred solution of 31-2 (5.0 g, 23.47 mmol) in DMA (70 ml) was added DIPEA (12.61 ml, 70.41 mmol) followed by 23-1 (4.3 g, 23.47 mmol). The reaction mixture was heated at 100° C. for 16 h. The reaction mixture was then diluted with water and extracted with EtOAc (100 ml×3). The combined organic layer was again washed with ice cold water followed by brine and dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. Crude residue obtained was purified by silica-gel column chromatography using a gradient (20 to 25%) of acetone in hexanes to obtain 31-3 (4.05 g) as a white solid. [M+H]+ calcd for C18H25N3O6 379.41, found 380.34.
- Step C: Preparation of 2-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-5-nitrophenyl)acetic acid (31-4). To a stirred solution of 31-3 (1.0 g, 2.63 mmol) in THF (5 ml) and H2O (5 ml) was added LiOH·H2O (540 mg, 13.19 mmol). The reaction mixture was stirred at 25° C. for 16 h, then diluted with water and extracted with EtOAc at pH ˜3. The organic layer was washed with brine, dried over sodium sulphate and concentrated under reduced pressure to give the crude residue. The residue was purified by precipitating and triturating with ACN, diethyl ether and hexane to obtain 31-4 (600 mg) as a yellow solid. [M+H]+ calcd for C17H23N3O6 365.39, found 366.16.
- Step D: Preparation of tert-butyl (R)-4-(2-(2-(sec-butoxy)-2-oxoethyl)-4-nitrophenyl)piperazine-1-carboxylate (31-6). To a stirred solution of 31-4 (550 mg, 1.50 mmol) in DCM (20 ml) was added 31-5 (0.37 ml, 3.01 mmol) and DMAP (18 mg, 0.15 mmol) followed by addition of EDCHCl (573 mg, 3.01 mmol) at 0° C. The reaction mixture was allowed to stir at 25° C. for 16 h, then diluted with water and extracted three times using EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate and concentrated under vacuum to afford crude compound which was purified by silica-gel column chromatography using a gradient (10 to 15%) of EtOAc in Hexanes to obtain 31-6 (400 mg). [M+H]+ calcd for C21H31N3O6 421.49, found 422.10.
- Step E: Preparation of tert-butyl (R)-4-(4-amino-2-(2-(sec-butoxy)-2-oxoethyl)phenyl)piperazine-1-carboxylate (31-7). To a stirred solution of 31-6 (400 mg, 0.95 mmol) in IPA (10 ml) and THF (4 ml) was added 10% Pd/C (400 mg) and subjected to hydrogenation under H2 balloon pressure. The reaction mixture was allowed to stir at 25° C. for 1 h, then filtered through Celite bed and washed with MeOH. Filtrate was concentrated under vacuum to get crude residue 31-7 (350 mg), used in next step without any purification. [M+H]+ calcd for C21H33N3O4 391.51, found 392.13.
- Step F: Preparation of tert-butyl (R)-4-(2-(2-(sec-butoxy)-2-oxoethyl)-4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate (31-8). To a solution of 31-7 (344 mg, 0.88 mmol) in 1,4-dioxane (10 ml) was added 1-8 (175 mg, 0.587 mmol) and Cs2CO3 (381 mg, 1.17 mmol) under N2 atmosphere. The reaction mixture was degassed with N2 for 10 min, followed by addition of Brettphos (63 mg, 0.117 mmol) and Brettphos Pd G4 (54 mg, 0.058 mmol), then heated at 110° C. for 16 h. The reaction mixture was diluted with EtOAc and filtered through Celite bed. Filtrate was diluted with cold water and extracted with ethyl acetate (25 mL×2). The organic layer was dried over dry Na2SO4, filtered and concentrated to get crude residue. The residue was purified by silica-gel column chromatography using a gradient (0 to 3%) of MeOH in DCM to obtain 31-8 (200 mg). [M+H]+ calcd for C35H43N9O4 653.79, found 654.17.
- Step G: Preparation of (R)-sec-butyl 2-(5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)-2-(piperazin-1-yl)phenyl)acetate (13). To a stirred solution of 31-8 (200 mg, 0.306 mmol) in DCM (5 ml) was added TFA (1 ml) at 0° C. The reaction mixture was stirred at 25° C., then concentrated under reduced pressure and further triturated with diethyl ether to get the title compound (205 mg) as an off white solid. [M+H]+ calcd for C30H35N9O2 553.67, found 554.32.
-
- Step A: Preparation of methyl 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoate (32-2). To a stirred solution of 1-8 (3.5 g, 11.74 mmol) and 32-1 (2.3 g, 15.27 mmol) in n-butanol (35 ml) was added PTSA (1.11 g, 5.87 mmol) and the resulting mixture heated at 110° C. for 3 h. The reaction mixture was concentrated to dryness and triturated using diethyl ether to get the 32-2 (4.1 g) as PTSA salt. [M+H]+ calcd for C22H19N7O2 413.44, found 414.15.
- Step B: Preparation of (4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)methanol (32-3). To a stirred solution 32-2 (4.1 g, 9.92 mmol) in THF (50 ml) was added LAH (15.0 ml, 29.71 mmol) dropwise at 0° C. The reaction mixture was allowed to stir at 0° C. for 2 h, then quenched with water:THF (6:18 ml) under cooling followed by the addition of 15% NaOH (15 ml). It was then filtered through Celite bed and the organic layer separated and concentrated to get crude residue. The residue was purified by silica-gel column chromatography to obtain 32-3 (3.0 g). [M+H]+ calcd for C21H19N7O 385.43, found 386.14.
- Step C: Preparation of 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzaldehyde (32-4). To a stirred solution 32-3 (3.0 g, 7.8 mmol) in DMA (30 ml) was added MnO2 (20.4 g, 234 mmol) at 25° C. The reaction mixture was allowed to stir at 25° C. for 6 h, then filtered and the filtrate concentrated to get crude residue. The residue obtained was triturated with ACN to obtain 32-4 (2.2 g), used in next step without further purification. [M+H]+ calcd for C21H17N7O 383.42, found 384.16.
- Step D: Preparation of tert-butyl 1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-4-carboxylate (32-6). To a stirred solution of 32-4 (2.1 g, 5.48 mmol) in DMA:DCE (10:20 ml) was added 32-5 (1.52 g, 8.22 mmol) followed by the addition of STAB (3.48 g, 16.44 mmol). The reaction mixture was stirred at 25° C. for 16 h. The reaction mixture was diluted with water and extracted with 10% MeOH:DCM to obtained the crude residue. The residue was purified by silica-gel column chromatography using a gradient (0 to 5%) of MeOH in DCM to obtain 32-6 (1.4 g). [M+H]+ calcd for C31H36N8O2 552.68, found 553.33.
- Step E: Preparation of 1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-4-carboxylic acid (32-7). To a stirred solution 32-6 (1.4 g, 2.53 mmol) in DCM (20 ml) was added TFA (14 ml) dropwise at 0° C. The reaction mixture was stirred at 0° C. for 6 h. The reaction mixture was concentrated and triturated with diethyl ether and ACN to obtain 32-7 (1.2 g). [M+H]+ calcd for C27H28N8O2 496.58, found 497.48.
- Step F: Preparation of (R)-1-methylpyrrolidin-3-yl 1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-4-carboxylate (414). To the solution of, 32-7 (300 mg, 0.604 mmol) in DMF (5.0 ml) was added 32-8 (170 mg, 0.906 mmol), DCC (373 mg, 1.812 mmol) followed by addition of DMAP (37 mg, 0.302 mmol) and stirred at 25° C. for 4 h. The reaction mixture was poured onto ice water and extracted using 10% MeOH:DCM. Combined organic layers were washed with brine, dried over sodium sulfate and concentrated to get the crude residue. The residue was purified by preparative HPLC chromatography using a gradient (5 to 25%) of acetonitrile in water with 0.1% trifluoroacetic acid to yield a TFA salt of the title compound (180 mg). [M+H]+ calcd for C32H37N9O2 579.71, found 580.30.
-
- Step A: Preparation of N2-(4-(chloromethyl)phenyl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (33-1). To a solution of 32-2 (425 mg, 1.103 mmol) in DCM (31.5 ml) was added SOCl2 (177 μl, 2.426 mmol) and the resulting mixture heated at 60° C. for 1 h. The reaction mixture was concentrated in vacuum to obtain 33-1 (445 mg) as a yellow solid, used directly in the next step.
- Step B: Preparation of tert-butyl (R)-1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-3-carboxylate (33-3). To a solution of 33-1 (445 mg, 1.1 mmol) in DCM (18 ml) was added 33-2 (488 mg, 2.2 mmol) and DIEA (0.961 ml, 5.0 mmol) and the resulting mixture heated at 55° C. for 16 h. The reaction mixture was concentrated in vacuum to give a crude residue. The residue was purified by silica-gel column chromatography using a gradient (0 to 15%) of MeOH in DCM to produce 33-3 (608 mg). [M+H]+ calcd for C31H36N8O2 552.68, found 553.1.
- Step C: Preparation of (R)-1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-3-carboxylic acid (33-4). To a solution of 33-3 (608 mg, 1.1 mmol) in DCM (3.5 ml) was added TFA (4.2 ml) at 0° C. and the reaction mixture was stirred at 25° C. for 16 h. TFA was removed in vacuum. The residue was purified by preparative HPLC chromatography using a gradient (5 to 30%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of 33-4 (440 mg). [M+H]+ calcd for C27H28N8O2 496.58, found 497.1.
- Step D: Preparation of azetidin-3-ylmethyl (R)-1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)piperidine-3-carboxylate (400). A solution of 33-4 (75 mg, 0.104 mmol), 33-5 (38.8 mg, 0.207 mmol), EDCI (39.7 mg, 0.207 mmol), and DMAP (1.27 mg, 10.4 μmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (279 μl) was added to the reaction mixture and was heated at 45° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (62.1 mg). [M+H]+ calcd for C31H35N9O2 565.68, found 566.1.
-
- Step A: Preparation of 1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)azetidine-3-carboxylic acid (34-2). To a solution of 33-1 (262 mg, 0.65 mmol) in DCM (10 ml) was added 34-1 (204 mg, 1.30 mmol) and DIEA (0.567 ml, 3.25 mmol) and the resulting mixture heated at 55° C. for 16 h. The reaction mixture was concentrated in vacuum to give a crude residue. To the residue was directly added DCM (2 ml) and TFA (2 ml) and was heated at 55° C. for 1 h. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (5 to 30%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of 34-2 (118 mg). [M+H]+ calcd for C25H24N8O2 468.52, found 469.0.
- Step B: Preparation of azetidin-3-ylmethyl 1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzyl)azetidine-3-carboxylate (88). A solution of 34-2 (23 mg, 0.033 mmol), 33-5 (9.27 mg, 0.050 mmol), HATU (18.83 mg, 0.050 mmol), DMAP (0.40 mg, 3.3 μmol), and DIEA (23.0 μl, 0.132 mmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (127 μl) was added to the reaction mixture and was heated at 45° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (2 to 40%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (24.0 mg). [M+H]+ calcd for C29H31N9O2 537.63, found 538.2.
-
- Step A: Preparation of methyl 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-4-carboxylate (35-2). To a suspension of 1-8 (3.6 g, 12.2 mmol) in 1,4-dioxane (100 ml) was added 35-1 (2.5 g, 15.8 mmol), Cs2CO3 (8.0 g, 24.4 mmol), Pd2(dba)3 (1.1 g, 1.22 mmol) and BINAP (760 mg, 1.22 mmol). The reaction mixture was degassed under vacuum and N2 was purged for 3 times. The reaction mixture was heated at 110° C. for 12 h. The reaction mixture was concentrated in vacuum to give the residue. The residue was purified by preparative HPLC chromatography using a gradient (12 to 42%) of acetonitrile in water with 0.1% trifluoroacetic acid to yield a TFA salt of 35-2 (1.7 g). [M+H]+ calcd for C19H16N8O2S 420.45, found 421.0.
- Step B: Preparation of (2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazol-4-yl)methanol (35-3). To a solution of 35-2 (50 mg×16, 0.119 mmol×16) in THF (1 mL×16) was added LAH (9 mg×16, 0.238 mmol×16) at 0° C. The mixture was stirred at 25° C. for 20 min. The reaction mixture was diluted with Rochelle salt solution (100 ml) and extracted with DCM (200 ml×3), The organic layer was dried over Na2SO4, filtered, and concentrated in vacuum. The residue was purified by preparative HPLC chromatography using a gradient (10 to 35%) of acetonitrile in water with 0.225% formic acid to obtain 35-3 (86 mg) as yellow solid. [M+H]+ calcd for C18H16N8OS 392.44, found 393.1.
- Step C: Preparation of N2-(4-(chloromethyl)thiazol-2-yl)-N4-(2-(6-methylpyridin-2-yl)pyrimidin-4-yl)pyrimidine-2,4-diamine (35-4). To a solution of 35-3 (101 mg, 0.257 mmol) in DCM (6 ml) was added SOCl2 (92 mg, 0.771 mmol) dropwise at 0° C. The reaction mixture was stirred at 25° C. for 2 h. The reaction mixture was concentrated in vacuum. The residue was purified by trituration to give 35-4 (50 mg) as yellow solid. [M+H]+ calcd for C18H15ClN8OS 410.88, found 411.0.
- Step D: Preparation of (R)-1-((2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazol-4-yl)methyl)piperidine-3-carboxylic acid (35-6). To a solution of 35-4 (200 mg, 0.487 mmol), 35-5 (162 mg, 0.730 mmol), and DIEA (425 μl, 2.434 mmol) in DCM (7.8 ml) was heated at 55° C. for 2 h. TFA (938 μl) was added to the reaction mixture and was heated at 45° C. for 30 min. The reaction mixture was concentrated in vacuum. The residue was purified by preparative HPLC chromatography using a gradient (5 to 75%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of 35-6 (253 mg). [M+H]+ calcd for C24H25N9O2S 503.59, found 504.0.
- Step E: Preparation of (S)-1-methylpyrrolidin-3-yl (R)-1-((2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazol-4-yl)methyl)piperidine-3-carboxylate (508). A solution of 35-6 (25 mg, 0.034 mmol), 35-7 (5.18 mg, 0.051 mmol), EDCI (9.83 mg, 0.051 mmol), and DMAP (0.84 mg, 6.83 μmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (132 μl) was added to the reaction mixture and was heated at 45° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (2 to 50%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (18.2 mg). [M+H]+ calcd for C29H34N10O2S 586.72, found 587.1.
-
- Step A: Preparation of 2-(4-(tert-butoxycarbonyl)-1-(4-nitrophenyl)piperazin-2-yl)acetic acid (36-2). To a solution of 5-1 (1.0 g, 7.09 mmol) and 36-1 (2.195 g, 8.51 mmol) in ACN (12 ml) and water (3 ml) was added potassium carbonate (4.9 g, 35.46 mmol), followed by 18-crown-6 (93 mg, 0.354 mmol). The reaction mixture was heated at 90° C. for 48 h. The reaction mixture was concentrated and the crude mixture diluted with water (10 ml). The aqueous layer was washed with EtOAc and the pH of aqueous layer was adjusted to ˜4 using saturated citric acid solution and extracted with DCM (5 ml×2). The organic layer was concentrated to get the crude residue of 36-2 (750 mg) as a yellow solid. [M+H]+ calcd for C17H23N3O6 365.39, found 366.22.
- Step B: Preparation of tert-butyl 3-(2-methoxy-2-oxoethyl)-4-(4-nitrophenyl)piperazine-1-carboxylate (36-3). To a solution of 36-2 (700 mg, 1.91 mmol) in ACN (7 ml) and MeOH (3 ml) was added TMS-CHN2 in hexane (2M) (5.8 mL 11.5 mmol) and the reaction mixture was stirred at 25° C. for 3 h. To the reaction mixture was added excess methanol and stirred at 25° C. for 15 min, then residual solvent was distilled off to obtain the crude residue. The residue was purified by silica-gel column chromatography using a gradient (0 to 15%) of EtOAc in Hexane to give 36-3 (700 mg) as yellow solid. [M+H]+ calcd for C18H25N3O6 379.41, found 380.03.
- Step C: Preparation of tert-butyl 4-(4-aminophenyl)-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate (36-4). To a solution of 36-3 (1.3 g, 3.43 mmol) in THF:IPA (20 ml, 1:1) was added 10% Pd/C (1.3 g), then the resulting suspension was stirred at 25° C. under H2 atmosphere for 3 h. The reaction mixture was filtered through Celite bed and the residue was washed with EtOAc. The organic layer was then evaporated under reduced pressure to get the crude product 36-4 (1.3 g), which was used directly for the next step. [M+H]+ calcd for C18H27N3O4 349.43, found 350.10.
- Step D: Preparation of tert-butyl 3-(2-methoxy-2-oxoethyl)-4-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate (36-5). To a stirred solution of 1-8 (1.2 g, 4.02 mmol) and 36-4 (1.6 g, 4.83 mmol) in 1,4-dioxane (15 ml) was added Cs2CO3 (2.62 g, 8.05 mmol) and the reaction mixture was purged with N2 for 30 min. To the reaction mixture was added Brettphos Pd G4 (0.370 g, 0.40 mmol), then purging was repeated with N2 for 5 min. The reaction mixture was heated at 110° C. for 3 h. The reaction mixture was filtered through a Celite bed, washed with 5% MeOH:DCM, and concentrated to afford a crude residue. The residue was purified by silica-gel column chromatography using a gradient (0 to 100%) of EtOAc in PE to give 36-5 (1.18 g) as a white solid.
- Step E: Preparation of 2-(4-(tert-butoxycarbonyl)-1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-2-yl)acetic acid (36-6). To a stirred solution of 36-5 (1.4 g, 2.29 mmol) in MeOH (10 ml), THF (5 ml) and water (2.5 ml) was added LiOH·H2O (0.48 g, 11.45 mmol) and the reaction mixture was stirred at 25° C. for 16 h. The reaction mixture pH was adjusted to ˜3-4 by using aq. citric acid solution. Desired acid was extracted from the aqueous layer using 10% MeOH:DCM. The organic layer was dried over Na2SO4, filtered and concentrated to get crude residue. The residue was purified by silica-gel column chromatography using a gradient (5 to 10%) of MeOH in DCM to give 36-6 (1.12 g) as an off-white solid. [M+H]+ calcd for C31H35N9O4 597.68, found 598.32.
- Step F: Preparation of (R)-1-methylpyrrolidin-3-yl 2-(1-(4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)phenyl)piperazin-2-yl)acetate (103). A solution of 36-6 (30 mg, 0.050 mmol), 36-7 (7.62 mg, 0.075 mmol), EDCI (14.43 mg, 0.075 mmol), and DMAP (1.20 mg, 10.0 μmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (193 μl) was added to the reaction mixture and was heated at 45° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (2 to 50%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (11.4 mg). [M+H]+ calcd for C31H36N10O2 580.70, found 581.1.
-
- A solution of 30-1 (50 mg, 0.123 mmol), 33-5 (34.6 mg, 0.185 mmol), EDCI (35.5 mg, 0.185 mmol), and DMAP (3.01 mg, 0.025 mmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (475 μl) was added to the reaction mixture and was heated at 45° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (2 to 30%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (22.8 mg). [M+H]+ calcd for C23H22N8O2S 474.54, found 475.1.
-
- Step A: Preparation of methyl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-3-carboxylate (38-2). A solution of 1-8 (1.6 g, 5.36 mmol), 38-1 (842 mg, 5.36 mmol) and conc. HCl (0.6 ml) in IPA (16 ml) was heated at 80° C. for 12 h. The reaction mixture was then allowed to cool to 25° C., diluted with IPA and filtered to obtain the HCl salt of 38-2 (900 mg) as an off-white solid. [M+H]+ calcd for C20H17N7O2S 419.46, found 420.17.
- Step B: Preparation of 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-3-carboxylic acid (38-3). To a stirred solution of 38-2 (900 mg, 2.14 mmol) in MeOH (6 ml), THF (4 ml) and water (2 ml) was added KOH (240 mg, 4.29 mmol) and the resulting mixture stirred and heated at 65° C. for 3 h. The reaction mixture was concentrated and diluted with water and acidified with 3 N HCl to (pH 4-5) until light brown solid fell out, which was filtered and washed with acetonitrile and diethyl ether to get the desired compound 38-3 (215 mg) as a light brown solid. [M+H]+ calcd for C19H15N7O2S 405.44, found 406.03.
- Step C: Preparation of azetidin-3-ylmethyl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiophene-3-carboxylate (142). A solution of 38-3 (25 mg, 0.062 mmol), 33-5 (17.32 mg, 0.092 mmol), EDCI (17.73 mg, 0.092 mmol), and DMAP (1.50 mg, 0.012 mmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (238 μl) was added to the reaction mixture and was heated at 45° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (5 to 50%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (17.3 mg). [M+H]+ calcd for C23H22N8O2S 474.54, found 475.1.
-
- Step A: Preparation of 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-4-carboxylic acid (39-1). A suspension of 35-2 (1.0 g, 2.38 mmol) and NaOH (1.9 g, 47.6 mmol) in MeOH (30 ml) and H2O (30 ml) was heated at 60° C. for 5 h. The reaction mixture was concentrated in vacuum to remove MeOH and acidified by 2M HCl to pH=6-7. The reaction mixture was filtered. The cake was washed with H2O (50 ml) and lyophilized to obtain 39-1 (600 mg) as yellow solid. [M+H]+ calcd for C18H14N8O2S 406.42, found 407.0.
- Step B: Preparation of piperidin-4-yl 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-4-carboxylate (148). A solution of 39-1 (25 mg, 0.062 mmol), 39-2 (18.57 mg, 0.092 mmol), EDCI (17.69 mg, 0.092 mmol), and DMAP (1.50 mg, 0.012 mmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (351 μl) was added and the reaction mixture was heated at 45° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (5 to 65%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (9.2 mg). [M+H]+ calcd for C23H23N9O2S 489.56, found 490.0.
-
- Step A: Preparation of ethyl 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-5-carboxylate (40-2). To a stirred solution of 1-8 (600 mg, 2.013 mmol) and 40-1 (519 mg, 3.019 mmol) in 1,4-dioxane (12 ml) was added cesium carbonate (1.3 g, 4.026 mmol) and purged for 15 min. Pd2(dba)3 (184 mg, 0.201 mmol) and BINAP (250 mg, 0.402 mmol) were then added. The reaction mixture was then heated at 110° C. for 3 h. The reaction mixture was diluted with 10% MeOH in DCM, filtered through Celite bed and concentrated to get crude residue. The residue was purified by silica-gel column chromatography using a gradient (0 to 5%) of MeOH in DCM to give 40-2 (430 mg). [M+H]+ calcd for C20H18N8O2S 434.48, found 435.10.
- Step B: Preparation of 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-5-carboxylic acid (40-3). To the solution of 40-2 (300 mg, 0.69 mmol) in 1,4-dioxane:water (9.0:0.5 ml) was added 6N HCl (1.5 ml). The reaction mixture was heated at 90° C. for 12 h. The reaction mixture was concentrated completely to dryness. The resulting residue was triturated using MeOH, DCM, diethyl ether and ACN to get desired compound which was purified further through preparative HPLC chromatography to obtain 40-3 (70 mg). [M+H]+ calcd for C18H14N8O2S 406.42, found 407.18.
- Step C: Preparation of azetidin-3-ylmethyl 2-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)thiazole-5-carboxylate (338). A solution of 40-3 (15 mg, 0.037 mmol), 33-5 (10.37 mg, 0.055 mmol), EDCI (10.61 mg, 0.055 mmol), and DMAP (0.90 mg, 7.38 μmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (142 μl) was added to the reaction mixture and was heated at 45° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (5 to 50%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (5.7 mg). [M+H]+ calcd for C25H24N8O2S 475.53, found 476.0.
-
- Step A: Preparation of methyl 3-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoate (41-2). To a mixture of 1-8 (600 mg, 2.01 mmol) and 41-1 (304 mg, 2.01 mmol) in IPA (10 ml) was added HCl (0.5 mL). The reaction mixture was heated at 80° C. for 16 h. The reaction mixture was quenched with H2O (30 ml) and filtered. The filter cake was evaporated to dryness to give 41-2 (820 mg) as white solid. [M+H]+ calcd for C22H19N7O2 413.44, found 414.2.
- Step B: Preparation of 3-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoic acid (41-3). A mixture of 41-2 (780 mg, 1.87 mmol) in EtOH (10 ml) and aq. NaOH (10 ml) was heated at 80° C. for 16 h. The reaction mixture was concentrated in vacuum to remove EtOH. To the residue was added HCl to adjust the pH to 5, then the mixture was filtered. The filter cake was washed with H2O (30 ml) and the residue was evaporated to dryness to give 41-3 (530 mg) as yellow solid. [M+H]+ calcd for C21H17N7O2 399.41, found 399.9.
- Step C: Preparation of azetidin-3-ylmethyl 3-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoate (178). A solution of 41-3 (25 mg, 0.063 mmol), 33-5 (17.58 mg, 0.094 mmol), EDCI (18.00 mg, 0.094 mmol), and DMAP (1.53 mg, 0.013 mmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (240 μl) was added to the reaction mixture and was heated at 45° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (5 to 50%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (29.5 mg). [M+H]+ calcd for C25H24N8O2 468.52, found 469.1.
-
- Step A: Preparation of 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoic acid (42-1). A mixture of 32-2 (780 mg, 1.87 mmol) in EtOH (10 ml) and aq. NaOH (10 ml) was stirred at 80° C. for 16 h. The reaction mixture was concentrated in vacuum to remove EtOH. To the residue was added HCl to adjust the pH to 5, then the mixture was filtered. The filter cake was washed with H2O (30 ml) and the residue evaporated to dryness to give 42-1 (530 mg) as yellow solid. [M+H]+ calcd for C21H17N7O2 399.41, found 399.9.
- Step B: Preparation of azetidin-3-ylmethyl 4-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)benzoate (33). A solution of 42-1 (25 mg, 0.063 mmol), 33-5 (17.58 mg, 0.094 mmol), EDCI (18.00 mg, 0.094 mmol), and DMAP (1.53 mg, 0.013 mmol) in DCM (0.5 ml) was stirred at 25° C. for 16 h. TFA (240 μl) was added to the reaction mixture and was heated at 45° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (5 to 65%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (21.1 mg). [M+H]+ calcd for C25H24N8O2 468.52, found 469.1.
-
- Step A: Preparation of methyl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)picolinate (43-2). A vial of 1-8 (250 mg, 0.837 mmol), 44-1 (127 mg, 0.837 mmol), cesium carbonate (545 mg, 1.674 mmol), BrettPhos (44.9 mg, 0.084 mmol), and BrettPhos Pd G4 (77 mg, 0.084 mmol) in degassed 1,4-dioxane (4.2 ml) was heated to 110° C. for 16 h. The reaction mixture was concentrated in vacuum and purified by silica-gel column chromatography using a gradient (0 to 15%) of MeOH in DCM to obtain 43-2 (164 mg) as an orange oil. [M+H]+ calcd for C21H18N8O2 414.43, found 415.
- Step B: Preparation of 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)picolinic acid (43-3). A solution of 43-2 (164 mg, 0.396 mmol), and LiOH (24.73 mg, 1.033 mmol) in a 3:2:1 mixture of THF (1291 μl), MeOH (861 μl), and H2O (430 μl) was heated to 65° C. for 3 h. The reaction mixture was concentrated in vacuum and purified by preparative HPLC chromatography using a gradient (5 to 30%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of 43-3 (129 mg). [M+H]+ calcd for C20H16N8O2 400.40, found 401.1.
- Step C: Preparation of azetidin-3-ylmethyl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)picolinate (545). A solution of 43-3 (20 mg, 0.039 mmol), 33-5 (10.92 mg, 0.058 mmol), HATU (22.17 mg, 0.058 mmol), and DIEA (27.2 μl, 0.156 mmol) in DCM (0.5 ml) was heated to 50° C. for 1 h. TFA (120 μl) was added to the reaction mixture and stirred at 25° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (22.8 mg). [M+H]+ calcd for C24H23N9O2 469.51, found 470.1.
-
- Step A: Preparation of methyl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)nicotinate (44-2). A vial of 1-8 (250 mg, 0.837 mmol), 44-1 (127 mg, 0.837 mmol), cesium carbonate (545 mg, 1.674 mmol), BrettPhos (44.9 mg, 0.084 mmol), and BrettPhos Pd G4 (77 mg, 0.084 mmol) in degassed 1,4-dioxane (4.2 ml) was heated to 110° C. for 16 h. The reaction mixture was concentrated in vacuum and purified by silica-gel column chromatography using a gradient (0 to 15%) of MeOH in DCM to obtain 44-2 (214 mg) as an orange oil. [M+H]+ calcd for C21H18N8O2 414.43, found 415.
- Step B: Preparation of 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)nicotinic acid (44-3). A solution of 44-2 (214 mg, 0.516 mmol) and LiOH (24.73 mg, 1.033 mmol) in a 3:2:1 mixture of THF (1291 μl), MeOH (861 μl), and H2O (430 μl) was heated to 65° C. for 3 h. The reaction mixture was concentrated in vacuum and purified by preparative HPLC chromatography using a gradient (5 to 30%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of 44-3 (77 mg). [M+H]+ calcd for C20H16N8O2 400.40, found 401.1.
- Step C: Preparation of (R)-pyrrolidin-3-yl 5-((4-((2-(6-methylpyridin-2-yl)pyrimidin-4-yl)amino)pyrimidin-2-yl)amino)nicotinate (549). A solution of 44-3 (20 mg, 0.039 mmol), 44-4 (10.92 mg, 0.058 mmol), HATU (22.17 mg, 0.058 mmol), and DIEA (27.2 μl, 0.156 mmol) in DCM (0.5 ml) was heated to 50° C. for 1 h. TFA (120 μl) was added to the reaction mixture and stirred at 25° C. for 30 min. The reaction mixture was concentrated in vacuum and was purified by preparative HPLC chromatography using a gradient (2 to 60%) of acetonitrile in water with 0.05% trifluoroacetic acid to yield a TFA salt of the title compound (12.8 mg). [M+H]+ calcd for C24H23N9O2 469.51, found 470.1.
- Apparent pKi values for compounds of the present disclosure were determined using a recombinant human ALK5 (TGF-βR1) protein (Product No. PR9075A or equivalent, Life Technologies) and a commercially-available kinase assay (LANCE® (lanthanide chelate excite) Ultra ULight™ kinase assay, Product Nos. TRF0130-M and TRF02108-M, Perkin Elmer) as described below.
- The assays were performed in a 384-well plate (24 columns×16 wells/rows). An Echo®550 Liquid Handler (Labcyte) was used to prepare various intermediate concentrations of compounds of the present disclosure in 100% DMSO. From the intermediate concentrations, a range of concentrations (from 10 μM to 25 μM corresponding to volumes up to 105 nL) were prepared and ejected into a final assay plate to be used to create individual dose response curves for each of the subject compounds. To a separate column within the assay plate, 105 nL of DMSO in each well was used to establish a maximum assay signal. Additionally, 105 nL of 100 μM SD-208, a selective TGF-βR1 inhibitor (Catalog #S7624, Selleck Chemicals), was used in another column of wells to establish a minimal assay signal.
- With a multidrop dispenser, 8 μL of enzyme mixture (1.25× final) was added to each well. The enzyme mixture consisted of 250 μM ALK5 enzyme and 62.5 nM peptide substrate (LANCE® (lanthanide chelate excite) Ultra ULight™-DNA Topoisomerase 2-alpha (Thr1342)) prepared in assay buffer (50 mM HEPES, 10 mM MgCl2, 1 mM EGTA, 0.01% Tween-20, pH 7.5 at room temperature) with 2 mM DTT added prior to use. The plate was then sealed with an adhesive seal and allowed to equilibrate for 60 minutes at room temperature.
- Next, 2 μL of 125 μM ATP (5×final, 125 μM ATP prepared in assay buffer with 2 mM DTT) was added to the incubated mixtures, covered with a MicroClime® Environmental Lid (Product No. LLS-0310, Labcyte) and immediately transferred to 37° C. The reactions were allowed to proceed at 37° C. for 60 minutes before terminating with the addition of 10 μL of detection antibody (LANCE® (lanthanide chelate excite) Ultra Europium-anti-phospo-DNA Topoisomerase 2-alpha (Thr1342)) in detection mixture (12 mM EDTA, 4 nM detection antibody prepared in detection buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% BSA (Fraction V), pH 7.0)) at room temperature. The plate was then read on a Perkin Elmer EnVision Plate Reader using europium specific reader settings with excitation and emission wavelengths set to 320 or 340 nm and 665 nm, respectively. These data were used to calculate percent enzyme inhibition values based on DMSO and SD-208 background controls.
- For dose-response analyses, percent inhibition versus compound concentrations were plotted, and pIC50 values were determined from a 4-parameter robust fit model with GraphPad Prism V5 Software (GraphPad Software, Inc., La Jolla, CA). This model obtains pIC50 values by fitting the sigmoidal dose-response (variable slope) equation to the data. Results were expressed as pIC50 (negative logarithm of IC50) and subsequently converted to pKi (negative logarithm of dissociate constant, Ki) using the Cheng-Prusoff equation. The higher the value of pKi (lower value of Ki), the greater the inhibition of ALK5 activity. Certain compounds disclosed herein exhibited pKi values of greater than 8 or greater than 9 when tested in the biochemical ALK5 assay.
- Table 3 shows biological activities of selected compounds in a biochemical ALK5 assay. Compound numbers correspond to the numbers and structures provided in Tables 1 and 2 and Examples 1-44.
-
TABLE 3 7.5 to 8.4 (+) 8.5 to 9.4 (++) 9.5 to 10.4 (+++) ≥10.5 (++++) ALK5 19, 30, 35, 87, 2, 3, 5, 16, 18, 1, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 24, 29, 42, 46, pKi 119, 165, 166, 20, 26, 36, 43, 21, 22, 23, 25, 27, 28, 31, 32, 33, 34, 37, 89, 94, 99, 226, 234, 306, 47, 54, 56, 62, 38, 39, 40, 41, 44, 45, 48, 49, 50, 51, 52, 123, 144, 153, 309, 325, 333, 66, 72, 82, 86, 53, 55, 57, 58, 59, 60, 61, 63, 64, 65, 67, 175, 188, 189, 338, 348, 399, 90, 91, 103, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 208, 223, 252, 410, 426, 468, 107, 114, 117, 80, 81, 83, 84, 85, 88, 92, 93, 95, 96, 97, 261, 319, 327, 502, 526, 529, 121, 126, 146, 98, 100, 101, 102, 104, 105, 106, 108, 331, 336, 343, 535, 564, 574, 148, 155, 162, 109, 110, 111, 112, 113, 115, 116, 118, 364, 373, 378, 575, 578, 579, 169, 170, 171, 120, 122, 124, 125, 127, 128, 129, 130, 385, 404, 405, 581, 585, 592, 176, 178, 179, 131, 132, 133, 134, 135, 136, 137, 138, 474, 503, 539 601, 604, 608, 191, 201, 230, 139, 140, 141, 142, 143, 145, 147, 149, 622, 624, 630, 236, 250, 255, 150, 151, 152, 154, 156, 157, 158, 159, 632, 633, 634, 256, 257, 267, 160, 161, 163, 164, 167, 168, 172, 173, 636, 640, 281, 284, 285, 174, 177, 180, 181, 182, 183, 184, 185, 1000, 1003, 287, 291, 292, 186, 187, 190, 192, 193, 194, 195, 196, 1004, 1008, 296, 303, 304, 197, 198, 199, 200, 202, 203, 204, 205, 1020, 1043 308, 310, 316, 206, 207, 209, 210, 211, 212, 213, 214, 321, 323, 329, 215, 216, 217, 218, 219, 220, 221, 222, 339, 349, 350, 224, 225, 227, 228, 229, 231, 232, 233, 354, 355, 363, 235, 237, 238, 239, 240, 241, 242, 243, 369, 371, 379, 244, 245, 246, 247, 248, 249, 251, 253, 386, 388, 391, 254, 258, 259, 260, 262, 263, 264, 265, 396, 401, 402, 266, 268, 269, 270, 271, 272, 273, 274, 406, 408, 413, 275, 276, 277, 278, 279, 280, 282, 283, 423, 425, 437, 286, 288, 289, 290, 293, 294, 295, 297, 439, 442, 446, 298, 299, 300, 301, 302, 305, 307, 311, 455, 459, 461, 312, 313, 314, 315, 317, 318, 320, 322, 467, 469, 471, 324, 326, 328, 330, 332, 334, 335, 337, 481, 485, 492, 340, 341, 342, 344, 345, 346, 347, 351, 498, 500, 505, 352, 353, 356, 357, 358, 359, 360, 361, 508, 511, 512, 362, 365, 366, 367, 368, 370, 372, 374, 513, 514, 517, 375, 376, 377, 380, 381, 382, 383, 384, 525, 527, 532, 387, 389, 390, 392, 393, 394, 395, 397, 548, 549, 550, 398, 400, 403, 407, 409, 411, 412, 414, 551, 553, 570, 415, 416, 417, 418, 419, 420, 421, 422, 580, 586, 589, 424, 427, 428, 429, 430, 431, 432, 433, 593, 595, 606, 434, 435, 436, 438, 440, 441, 443, 444, 609, 611, 613, 445, 447, 448, 449, 450, 451, 452, 453, 615, 616, 618, 454, 456, 457, 458, 460, 462, 463, 464, 623, 641, 465, 466, 470, 472, 473, 475, 476, 477, 1001, 1006, 478, 479, 480, 482, 483, 484, 486, 487, 1007, 1009, 488, 489, 490, 491, 493, 494, 495, 496, 1017, 1019, 497, 499, 501, 504, 506, 507, 509, 510, 1021, 1022, 515, 516, 518, 519, 520, 521, 522, 523, 1023, 1044, 524, 528, 530, 531, 533, 534, 536, 537, 1045 538, 540, 541, 542, 543, 544, 545, 546, 547, 552, 554, 556, 557, 558, 560, 561, 562, 563, 565, 566, 567, 568, 569, 571, 572, 573, 576, 577, 582, 583, 584, 587, 588, 590, 591, 594, 596, 597, 598, 599, 600, 602, 603, 605, 607, 610, 612, 614, 617, 619, 620, 621, 625, 626, 627, 628, 629, 631, 635, 637, 638, 639, 642, 1002, 1005, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1018, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042 - The potency of compounds of the present disclosure for inhibition of TGF-β-stimulated SMAD3 phosphorylation was measured in BEAS-2B cells, a human lung epithelial cell line. TGF-β signals through activin receptor-like kinase 5 (ALK5) immediately prior to SMAD3 phosphorylation. As the AlphaLISA SureFire Ultra kit (Perkin Elmer) quantitatively measures pSMAD3 levels in lysate, the assay demonstrates the ALK5 cellular potency of a test compound.
- BEAS-2B cells were grown using 50% DMEM (Life Technologies) and 50% F-12 (Life Technologies) media, supplemented with 10% Fetal Bovine Serum (ATCC), 25 mM HEPES (Life Technologies), and 1×Pen-Strep (Life Technologies). Cells were cultured in a humidified incubator set at 37° C., 5% CO2, and trypsonized using 0.25% Trypsin with 0.5% polyvinylpyrrolidone (PVP).
- For the assay, BEAS-2B cells were seeded at 7,500 cells/well (25 μL/well) in a 384-well plate and cultured overnight. Before dosing, growth media was aspirated and the wells were rinsed with HBSS Buffer (HBSS with Calcium and Magnesium, Life Technologies) supplemented with 25 mM HEPES (Life Technologies) and 1% Bovine Serum Albumin (Roche). Compounds were serially diluted in DMSO, then further diluted with supplemented HBSS Buffer (50 μL/well) to create a compound plate 3× of the final assay concentration, at 0.3% DMSO. The diluted compounds were then added to the cells (8 μL/well) and incubated at 37° C., 5% CO2 for 1 hour. After the compound incubation, TGF-β (R&D Systems) reconstituted in supplemented HBSS Buffer was added to the cells (12 μL/well, final concentration 10 ng/mL) and incubated for a further 30 minutes, after which the cells were immediately lysed with AlphaLISA lysis buffer (PerkinElmer). AlphaLISA Acceptor and Detector beads (PerkinElmer) were added 2 hours apart, then incubated overnight to be read the next day. The potency of the compound was determined through analysis of dose-dependent quantified changes in pSMAD3 signal from baseline (non-compound treated TGF-β stimulated cells). Data are expressed as pIC50 (negative decadic logarithm IC50) values. Certain compounds disclosed herein exhibited pIC50 values of greater than 6 or greater than 7 when tested in BEAS-2B3 cells.
- Table 4 shows biological activities of selected compounds in a cellular ALK5 potency assay. Compound numbers correspond to the numbers and structures provided in Tables 1 and 2 and Examples 1-44.
-
TABLE 4 5 to 5.8 (+) 5.9 to 6.7 (++) 6.8 to 7.6 (+++) ≥7.7 (++++) BEAS2B 26, 82, 386, 11, 30, 31, 37, 1, 2, 3, 4, 6, 7, 8, 9, 12, 13, 15, 16, 17, 5, 10, 14, 20, pIC50 423, 540, 603, 48, 53, 57, 68, 18, 19, 21, 22, 23, 24, 25, 27, 32, 33, 34, 28, 29, 43, 45, 610, 629, 636, 86, 87, 91, 93, 35, 36, 38, 39, 40, 41, 42, 44, 46, 47, 49, 58, 76, 78, 89, 1012, 1014, 95, 103, 107, 50, 51, 52, 54, 55, 56, 59, 60, 61, 62, 63, 92, 94, 126, 1044 114, 117, 155, 64, 65, 66, 67, 69, 70, 71, 72, 73, 74, 75, 128, 135, 139, 157, 159, 162, 77, 79, 80, 81, 83, 84, 85, 88, 90, 96, 97, 161, 193, 203, 181, 200, 206, 98, 99, 100, 101, 102, 104, 105, 106, 208, 209, 210, 215, 224, 237, 108, 109, 110, 111, 112, 113, 115, 116, 227, 235, 254, 245, 251, 256, 118, 119, 120, 121, 122, 123, 124, 125, 261, 265, 268, 269, 283, 286, 127, 129, 130, 131, 132, 133, 134, 136, 284, 288, 294, 296, 297, 308, 137, 138, 140, 141, 142, 143, 144, 145, 315, 328, 331, 309, 326, 338, 146, 147, 148, 149, 150, 151, 152, 153, 351, 364, 365, 339, 340, 348, 154, 156, 158, 160, 163, 164, 165, 166, 387, 388, 421, 349, 358, 363, 167, 168, 169, 170, 171, 172, 173, 174, 443, 452, 465, 373, 379, 390, 175, 176, 177, 178, 179, 180, 182, 183, 475, 477, 514, 394, 402, 406, 184, 185, 186, 187, 188, 189, 190, 191, 523, 535, 571 413, 416, 422, 192, 194, 195, 196, 197, 198, 199, 201, 428, 429, 439, 202, 204, 205, 207, 211, 212, 213, 214, 450, 454, 455, 216, 217, 218, 219, 220, 221, 222, 223, 468, 471, 473, 225, 226, 228, 229, 230, 231, 232, 233, 478, 483, 484, 234, 236, 238, 239, 240, 241, 242, 243, 488, 497, 498, 244, 246, 247, 248, 249, 250, 252, 253, 499, 517, 530, 255, 257, 258, 259, 260, 262, 263, 264, 532, 551, 557, 267, 270, 271, 272, 273, 274, 275, 276, 562, 563, 564, 277, 278, 279, 280, 281, 282, 285, 287, 569, 574, 575, 289, 290, 291, 292, 293, 295, 298, 299, 578, 580, 585, 300, 301, 302, 303, 304, 305, 306, 307, 594, 596, 601, 310, 311, 312, 313, 314, 316, 317, 318, 604, 605, 608, 320, 321, 322, 323, 324, 325, 327, 329, 611, 615, 624, 330, 332, 333, 334, 335, 336, 337, 341, 630, 633, 342, 343, 344, 345, 346, 347, 350, 352, 1001, 1002, 353, 354, 355, 356, 357, 359, 360, 361, 1003, 1006, 362, 366, 367, 368, 369, 370, 371, 372, 1007, 1008, 374, 375, 376, 377, 378, 380, 381, 382, 1009, 1010, 383, 384, 385, 389, 391, 392, 393, 395, 1013, 1017, 396, 397, 398, 399, 400, 401, 403, 404, 1019, 1020, 405, 407, 408, 409, 410, 411, 412, 414, 1022, 1023, 415, 417, 418, 419, 420, 424, 425, 426, 1043 427, 430, 431, 432, 433, 434, 435, 436, 437, 438, 440, 441, 442, 444, 445, 446, 447, 448, 449, 451, 453, 456, 457, 458, 459, 460, 461, 462, 463, 464, 466, 467, 469, 470, 472, 474, 476, 479, 480, 481, 482, 485, 486, 487, 489, 490, 491, 492, 493, 494, 495, 496, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 515, 516, 518, 519, 520, 521, 522, 524, 525, 526, 527, 528, 529, 531, 533, 534, 536, 537, 538, 539, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 552, 553, 554, 556, 558, 560, 561, 565, 566, 567, 568, 570, 572, 573, 576, 577, 579, 581, 582, 583, 584, 586, 587, 588, 589, 590, 591, 592, 593, 595, 597, 598, 599, 600, 602, 606, 607, 609, 612, 613, 614, 616, 617, 618, 619, 620, 621, 622, 623, 625, 626, 627, 628, 631, 632, 634, 635, 637, 638, 639, 641, 642, 1000, 1004, 1005, 1011, 1015, 1016, 1018, 1021, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1045 - The impact of a compound of the present disclosure on cellular adenosine triphosphate (ATP) levels was measured in Beas2B cells, a human lung epithelial cell line. Levels of ATP are correlated with the viability of cells and are often measured to determine the potential cytotoxicity of compounds. CellTiter-Glo, which lyses the cells and produces a luminescent signal proportional to the amount of ATP present, was used to determine the effect of test compound on cell viability.
- Beas2B cells were grown in 50% DMEM (Life Technologies) and 50% F-12 (Life Technologies) media, supplemented with 10% Fetal Bovine Serum (ATCC), 25 mM HEPES (Life Technologies), and 1× Pen-Strep (Life Technologies). Cells were cultured in a humidified incubator set at 37° C., 5% CO2, and trypsinized using 0.25% Trypsin with 0.5% polyvinylpyrrolidone (PVP).
- For the assay, Beas2B cells were seeded at 500 cells/well (25 μL/well) in a 384-well plate and cultured overnight. Compounds were serially diluted in DMSO, then further diluted with growth media (40 μL/well) to create a compound plate 6× of the final assay concentration, at 0.6% DMSO. The diluted compounds were then added to the cells (5 μL/well) and incubated at 37° C., 5% CO2 for 48 hours. After the compound incubation, CellTiter-Glo (Promega) was added directly to the cells (30 μL/mL). The assay plate was sealed and shaken at 700 rpm for 15 minutes in a darkened environment, then centrifuged for 2 minutes at 1500 rpm to settle the lysate at the bottom of the well. The effect of the compound on cell viability was determined through analysis of dose-dependent quantified changes in ATP from baseline (non-compound treated cells) and wells treated with 60 μM AT9283, a well-characterized cytotoxic compound. Data are expressed as pCC15 (negative decadic logarithm CC15) values. Certain compounds disclosed herein exhibited pCC15 values of less than 6 or less than 5.5 when tested in Beas2B cells.
- Table 5 shows cytotoxicities of selected compounds in a premature chromosome condensation assay. Compound numbers correspond to the numbers and structures provided in Tables 1 and 2 and Examples 1-44.
-
TABLE 5 ≤5(+++) 5.1 to 5.7 (++) 5.8 to 6.4 (+) Cytotoxicity 5, 6, 10, 12, 14, 17, 19, 22, 26, 29, 30, 1, 2, 3, 4, 7, 8, 9, 11, 15, 18, 13, 16, 35, 46, pCC15 31, 33, 36, 37, 40, 42, 43, 44, 47, 48, 20, 21, 23, 24, 25, 27, 28, 90, 99, 109, 50, 52, 53, 54, 56, 57, 58, 59, 60, 62, 32, 34, 38, 39, 41, 45, 49, 123, 137, 143, 63, 67, 69, 71, 73, 76, 78, 82, 83, 84, 51, 55, 61, 64, 65, 66, 68, 151, 153, 156, 86, 87, 88, 89, 92, 93, 95, 97, 98, 100, 70, 72, 74, 75, 77, 79, 80, 160, 179, 197, 101, 103, 105, 106, 107, 108, 114, 81, 85, 91, 94, 96, 102, 104, 223, 231, 246, 118, 119, 121, 122, 124, 125, 126, 110, 111, 112, 113, 115, 252, 253, 255, 128, 130, 134, 135, 136, 138, 139, 116, 117, 120, 127, 129, 314, 326, 343, 140, 141, 142, 146, 148, 149, 150, 131, 132, 133, 144, 145, 351, 379, 393, 152, 154, 155, 157, 159, 161, 162, 147, 158, 165, 166, 175, 398, 412, 415, 163, 164, 167, 168, 169, 170, 171, 177, 183, 187, 188, 189, 418, 436, 445, 172, 173, 174, 176, 178, 180, 181, 190, 191, 192, 193, 194, 446, 447, 450, 182, 184, 185, 186, 195, 200, 201, 196, 198, 199, 202, 204, 466, 470, 493, 203, 206, 208, 209, 210, 211, 212, 205, 207, 213, 216, 217, 496, 515, 556, 214, 215, 220, 222, 224, 225, 226, 218, 219, 221, 233, 234, 1039 227, 228, 229, 230, 232, 235, 236, 239, 240, 241, 242, 243, 237, 238, 244, 245, 248, 250, 254, 247, 249, 251, 257, 259, 256, 258, 261, 264, 265, 267, 268, 260, 262, 263, 266, 270, 269, 271, 272, 273, 275, 276, 281, 274, 277, 278, 279, 280, 282, 283, 284, 287, 288, 290, 292, 285, 286, 289, 291, 293, 294, 295, 296, 297, 298, 299, 303, 300, 301, 302, 304, 305, 306, 307, 308, 309, 310, 311, 313, 312, 315, 317, 319, 321, 316, 318, 320, 323, 325, 327, 328, 322, 324, 331, 332, 333, 329, 330, 336, 337, 338, 339, 340, 334, 335, 342, 344, 345, 341, 348, 349, 353, 354, 357, 358, 346, 347, 350, 352, 355, 363, 364, 365, 368, 369, 371, 373, 356, 359, 360, 361, 362, 378, 380, 383, 385, 386, 387, 388, 366, 367, 370, 372, 374, 390, 391, 392, 400, 401, 402, 404, 375, 376, 377, 381, 382, 406, 407, 410, 411, 413, 416, 419, 384, 389, 394, 395, 396, 420, 421, 422, 423, 425, 426, 427, 397, 399, 403, 405, 408, 428, 430, 431, 433, 435, 437, 439, 409, 414, 417, 424, 429, 440, 441, 443, 444, 448, 452, 454, 432, 434, 438, 442, 449, 455, 456, 458, 460, 465, 467, 468, 451, 453, 457, 459, 461, 472, 473, 475, 477, 483, 484, 485, 462, 463, 464, 469, 471, 486, 488, 490, 491, 495, 497, 498, 474, 476, 478, 479, 480, 502, 505, 507, 508, 510, 511, 512, 481, 482, 487, 489, 492, 513, 517, 518, 520, 527, 530, 532, 494, 499, 500, 501, 503, 535, 536, 537, 538, 541, 545, 546, 504, 506, 509, 514, 516, 547, 548, 549, 550, 551, 552, 555, 519, 521, 522, 523, 524, 557, 558, 560, 561, 562, 564, 565, 525, 526, 528, 529, 531, 567, 569, 570, 573, 574, 575, 576, 533, 534, 539, 540, 542, 577, 578, 579, 580, 581, 582, 584, 543, 544, 553, 554, 563, 585, 587, 589, 592, 593, 594, 595, 566, 568, 571, 572, 583, 596, 597, 601, 602, 603, 605, 606, 586, 588, 590, 591, 598, 608, 610, 611, 612, 613, 614, 615, 599, 600, 604, 607, 609, 616, 617, 618, 620, 622, 624, 625, 619, 621, 623, 626, 627, 628, 629, 630, 632, 633, 634, 636, 631, 635, 637, 638, 639, 641, 642, 1000, 1001, 1002, 1007, 640, 1003, 1004, 1005, 1008, 1010, 1011, 1012, 1017, 1018, 1006, 1009, 1013, 1014, 1019, 1020, 1021, 1022, 1023, 1024, 1015, 1016, 1026, 1027, 1025, 1029, 1034, 1035, 1036, 1043, 1028, 1030, 1031, 1032, 1044, 1045 1033, 1037, 1038, 1040, 1041, 1042 - Liver microsomes were used for in vitro determination of hepatic clearance of compounds of the present disclosure. A microsomal incubation cofactor solution was prepared with 100 mM potassium phosphate buffered to pH 7.4 (BD Biosciences, Woburn, MA) supplemented with 2 mM NADPH (Sigma-Aldrich, St. Louis, MO). 10 mM DMSO stocks of test compound were diluted and spiked into the cofactor solution to yield a 0.2 μM concentration (0.02% v/v DMSO). Aliquots of frozen human liver microsomes (Bioreclamation IVT, Baltimore MD) were thawed and diluted into 100 mM potassium phosphate buffer to yield microsomal protein concentrations of 0.2 mg/mL. Cofactor/drug and microsomal solutions were pre-warmed separately for 4 minutes in a water bath held at 37° C. Incubations (n=1) were started by the combination of equal volumes of cofactor/drug solution with microsomal solution. The final concentration of test compound was 0.1 μM with a final protein concentration of 0.1 mg/mL and final NADPH concentration of 1 mM. Samples were collected at times 0, 3, 8, 15, 30, and 45 minutes to monitor the disappearance of test compound. At each time point, 50 μL of incubation sample was removed and spiked into 25 μL of water plus 3% formic acid plus Internal Standard for reaction termination. Samples were then injected onto an AB Sciex API 4000 triple quadrupole mass spectrometer for quantitation by LC-MS/MS. Mobile Phase A consisted of HPLC grade water with 0.2% formic acid and Mobile Phase B consisted of HPLC grade acetonitrile with 0.2% formic acid with all samples run through a Thermo HyPURITY C18 50×2.1 mm column (Waltham, MA). HLM Clint data was reported in units of μL/min/mg. See Riley, R. J., et al., Drug Metab. Dispos., 2005, September, 33(9), pp. 1304-1311. Certain compounds disclosed herein exhibited HLM Clint of greater than 50 μL/min/mg or greater than 100 μL/min/mg.
- In-Life Portion
- C57bl/6n mice were acclimated for at least 3 days before use. On the day of the experiment, animals were grouped into sample sizes of 5 (n=10 for the TGF-β stimulated group). Compounds of the present disclosure (formulated in 3% glycerol in PBS; pH=4) were pre-treated via oral aspiration (OA; animals are forced to aspirate solution into the lungs by covering their nose). All oral aspirations were performed using a 50 μL dosing volume and accompanied by the appropriate vehicle control groups. Following compound OA treatment, the animals were returned to their home cages and monitored. Compound pre-treatment occurred 4 hours prior to harvest for screening and dose-response studies; duration studies had variable compound pre-treatment times. One hour prior to harvest, animals were challenged via oral aspiration a second time with PBS vehicle or recombinant human TGF-β1 protein (0.01 μg per animal dissolved in 1 part 4 mM HCl and 2 parts 3% glycerol in PBS). Five minutes prior to harvest, animals were deeply anesthetized under isoflurane and euthanized via cervical dislocation. Bronchoalveolar lavage fluid (BALF), plasma and left lung lobes were collected during harvest.
- Sample Collection and Processing
- Blood plasma was collected via open cardiac puncture. After whole blood collection, the samples were placed in EDTA-coated tubes to prevent coagulation. Blood samples were spun at 15300×g's for 4 minutes at 4° C. to separate the plasma. Plasma was immediately isolated, frozen and submitted for bioanalytical (BA) analysis.
- In order to collect BALF, the lungs were flushed via the trachea with 0.7 mL of PBS 3 times. The BALF, which consists almost entirely of tissue-derived macrophages, was immediately centrifuged at 700×g's for 15 minutes. After centrifugation, the supernatant was removed, the BALF was re-suspended in 1×cell lysis buffer, and immediately frozen. Prior to BA submission, the BALF was dethawed and sonicated for 30 minutes on cold water to lyse open the cells
- Left lung lobes were harvested immediately after BALF collection. Lung samples were homogenized in 500 μL of 1×cell lysis buffer. After homogenization, the samples were split: half of the sample was immediately placed on a rotisserie for 10 minutes while the other half was immediately frozen for BA analysis. The samples placed on the rotisserie were then centrifuged at 10,000×g's for 10 minutes in order to separate the protein in the supernatant from pelleted debris. Following collection of the supernatant, a total protein quantification assay (Bradford) was performed to normalize the concentrations of all samples. Using the Hamilton star liquid handling system, each sample was diluted in 1×cell lysis buffer to 2 mg/mL of protein. Samples were stored at −80° C. or immediately processed using the Meso-scale Discovery system.
- Phospho-SMAD3 (pSMAD3) and Total-SMAD3 (tSMAD3) Quantification using Meso-Scale Discovery
- Meso-scale Discovery (MSD) is an electrochemical protein quantification assay that requires specialized microplates with carbon electrodes attached to the bottom. These carbon electrodes allow for greater attachment of biological reagent to microplates, thus allowing for a more sensitive read-out when compared to a traditional ELISA. Similar to a standard sandwich ELISA, MSD requires use of a coating antibody that binds the target protein(s) within the sample. After sample incubation, a primary antibody is used to bind the epitope of interest. Following addition of the primary antibody, a secondary-antibody with a SULFO-TAG detection is used to allow for quantification of the epitope of interest. Lastly, the microplate is read via an electric pulse that causes the SULFO-TAG to emit light, which serves as the final read-out of the assay.
- The coating antibody (SMAD3, clone=5G-11) was incubated overnight in the specialized MSD microplates at 4° C. The next day, the microplates were blocked in 3% BSA (bovine serum albumin) for 70 minutes to prevent non-specific protein binding to the bottom of the microplate. After a wash step, 50 μg of lung samples were loaded into the MSD-plate and incubated for 2 hours at room temperature. The plates were washed again to remove unbound sample; either phospo-SMAD3 (pSMAD3; clone=EP568Y) or total-SMAD3 (tSMAD3) primary antibody were incubated for 1 hour. Following a wash step, the anti-rabbit SULFO-tag detection antibody was incubated for 50 minutes. After a final wash step, MSD-read buffer was added to each sample. pSMAD3 and tSMAD3 quantification was performed using an MSD-specific plate reader (Sector S 600).
- Data Analysis
- Samples were immediately analyzed using an outlier analysis (Grubbs test, α=0.05). After outlier removal, the raw pSMAD3 were divided by the tSMAD3 luminescent readings. In screening and dose-response studies, the pSMAD3/tSMAD3 ratio was normalized to the TGF-β induction group (set to 100%) in order to minimize the variability between stimulation. First, the 3% glycerol/PBS group was compared with the 3% glycerol/TGF-β with a student's t-test (cut-off: p=0.05) to ensure a pSMAD3 window was present. A one-way ANOVA (fisher's uncorrected LSD) was used to compare all drug treated groups with the 3% glycerol/TGF-β group to determine if statistically significant differences are observed. Percent pSMAD3 inhibition was calculated using the vehicle pSMAD3 as a baseline value and displayed as the final readout. Dose-response curves were fitted with a 4-parameter non-linear regression algorithm; the minimum response was set to 0% pSMAD3 inhibition and the maximum response set to 100% pSMAD3 inhibition. Compound potencies were obtained from the regression and reported as ID50s.
- PK Study
- Plasma, lung and macrophage drug concentrations were quantified. Total macrophage concentration was normalized to the total macrophage cell volume over the total drug recovered in the BALF. The alveolar macrophage volume used in the calculation was based on a publication by Krombach et al. (Environmental Health Perspectives, September 1997, Vol. 105, Supplement 5, pp. 1261-1263) which estimated the rat alveolar macrophage volume to be approximately 1200 μm3 or 1.2e−9 mL. The assumption was made that the mouse alveolar macrophage volume is similar to that of the rat. Normalized total macrophage concentration recovered=(total drug recovered from BALF)/(total cell counts*1.2e−9 mL).
- Certain compounds disclosed herein exhibited (lung AUC0-t):(plasma AUC0-t) ratios of greater than 10, such as greater than 50, greater than 75 or greater than 100. A compound intended for local delivery to the lung with minimal systemic exposure preferably exhibits a (lung AUC0-t):(plasma AUC0-t) ratio of greater than 50. Certain compounds provided in Table 3 having pKi values of greater than 9.5 exhibited a (lung AUC0-t):(plasma AUC0-t) ratio of greater than 75.
- In-Life Portion
- C57bl/6n mice were acclimated for at least 3 days before use. On the day of the experiment, animals were grouped into sample sizes of 5-10. Test compounds were pre-treated via oral aspiration (OA; animals are forced to aspirate solution into the lungs by covering their nose). All oral aspirations were performed using a 50 μL dosing volume and accompanied by a vehicle control group (3% glycerol in PBS, pH=4). Following compound OA treatment, the animals were returned to their home cages and monitored. Compound pre-treatment occurred either 2 or 4 hours prior to harvest. One hour prior to harvest, animals were challenged via tail-vein intravenous injection with PBS vehicle or recombinant human TGF-β1 protein (1 μg per animal dissolved in 1 part 4 mM HCl and 2 parts 3% glycerol in PBS). Five minutes prior to harvest, animals were deeply anesthetized under isoflurane and euthanized via cervical dislocation. Plasma, left lung lobes and whole hearts were collected during harvest.
- Sample Collection and Processing
- Blood plasma was harvested as described above in the Lung PK/PD experiment. Whole hearts were processed in the same manners as left lung lobes in the Lung PK/PD experiment. Left lung lobes were homogenized in 500 μL of water and submitted for BA Analysis.
- Phospho-SMAD3 (pSMAD3) and Total-SMAD3 (tSMAD3) Quantification Using Meso-Scale Discovery
- Heart samples were processed using MSD in the same manner as the left lung lobes above. Data analysis was performed in the same manners as the lung PK/PD experiment. Plasma, lung and heart drug concentrations were quantified.
- There was minimal target engagement systemically following treatment with one or more compound disclosed herein, as measured by SMAD3 phosphorylation inhibition. In some examples, a compound disclosed herein exhibited less than 10% target engagement systemically as measured by SMAD3 phosphorylation inhibition.
- One or more compounds disclosed herein, e.g., a compound provided in Table 1 having an ALK5 pKi value of greater than 9.5, preferably greater than 10.5 (a measurement reflecting the ability of the compound to inhibit ALK5 activity, measured in accordance with Example 45), are expected to suppress tumor growth in syngeneic cancer models when administered alone or in combination with an immunotherapeutic agent. Six- to 8-week old BALB/c mice are used for in vivo efficacy studies in accordance with IACUC guidelines. Commercially available 4T1 cells (0.5-2.0×104 cells/mouse) are implanted subcutaneously into the right flanks of BALB/c mice. When the tumor reaches a palpable size of approximately 8-10 mm in diameter, the primary tumors are surgically removed, and the mice are randomly assigned to vehicle control or compound treatment groups. Alternatively, CT26 cells (0.5-2.0×104 cells/mouse) are injected intravenously into BALB/c mice to generate the cancer model. Two days following the surgery, or 7 days following injection of CT26 cells, the mice are treated with either (1) vehicle control, (2) a compound of the present disclosure at an appropriate amount and frequency (formulated in 3% glycerol in PBS; pH=4) via oral aspiration or intranasally, (3) an immunotherapeutic agent (e.g., pembrolizumab or durvalumab) at an appropriate amount and frequency, or (4) a compound of the present disclosure and an immunotherapeutic agent, each at an appropriate amount and frequency.
- Body weight is measured twice weekly. Following 2- to 4-weeks of treatment, the lung and liver of each animal is harvested, and the number of metastatic cells in each tissue sample determined using a clonogenic metastasis assay. Cells may be further subjected to one or more of FACS analysis, T-cell function assay, and RNA extraction. It is expected that the animal group treated with one or more of the ALK5 inhibitors disclosed herein exhibits reduction in lung tumor burden. Activation of an immune response by the ALK5 inhibitor may stimulate both local and systemic antitumor T-cell activation, thus a reduction in liver tumor burden may also be observed. When administered in combination with an immunotherapeutic agent, a compound of the present disclosure, such as a compound provided in Table 1, is expected to produce an increased reduction in lung tumor burden relative to the reduction in tumor burden observed in animals treated with either single agent alone. The compounds described herein are expected to interact synergistically with an immunotherapeutic agent to suppress tumor growth and increase survival.
- One or more compounds disclosed herein, e.g., a compound provided in Table 1 having an ALK5 pKi value of greater than 9.5, preferably greater than 10.5 (a measurement reflecting the ability of the compound to inhibit ALK5 activity, measured in accordance with Example 45), are expected to slow, halt or reverse the progression of intestinal fibrosis in a murine colitis model. Six to 8-week old male C57BL/6J mice are tagged and weighed. The drinking water of the animals is treated with 2.5% dextran sulfate sodium (DSS) for 7 days to induce acute colitis, followed by 2 days of normal drinking water. Three, 3-week cycles of 2.5% DSS treatment (1 week of 2.5% DSS in water; 2 weeks of normal water) are then completed to induce intestinal fibrosis.
- Starting on day one of DSS administration, mice are treated with either vehicle control or a compound of the present disclosure at an appropriate amount and frequency via oral gavage (e.g., once daily). The animals are sacrificed 9 weeks after the first DSS administration, then distal, mid and proximal sections of the colon harvested for histologic analysis, RNA extraction and cytokine measurement. A compound of the present disclosure, such as a compound provided in Table 1, is expected to decrease ALK5 activity in the colon and to slow or prevent intestinal fibrosis as evidenced by one or more of (1) reduction in the ratio of colon weight to colon length; (2) reduction in deposition of extracellular matrix as observed by histology; (3) reduction in expression of collagen 1 (Colla1) and connective tissue growth factor (Ctgf) in colon tissue; and (4) reduction in production of TGF-β1 and IL6 in the colon, relative to vehicle-treated controls.
- One or more compounds disclosed herein, e.g., a compound provided in Table 1 having an ALK5 pKi value of greater than 9.5, preferably greater than 10.5 (a measurement reflecting the ability of the compound to inhibit ALK5 activity, measured in accordance with Example 45), are expected to slow, halt or reverse the progression of intestinal fibrosis in a murine colitis model. Six to 8-week old male C57BL/6J mice are tagged and weighed. The drinking water of the animals is treated with 2.5% dextran sulfate sodium (DSS) for 7 days to induce acute colitis, followed by 2 days of normal drinking water. Three, 3-week cycles of 2.5% DSS treatment (1 week of 2.5% DSS in water; 2 weeks of normal water) are then completed to induce intestinal fibrosis.
- Following the second of the 3 cycles of DSS administration, mice are treated with either vehicle control or a compound of the present disclosure at an appropriate amount and frequency via oral gavage (e.g., once daily). Animals are sacrificed at either 6, 9 or 12 weeks after the first DSS cycle, then distal, mid and proximal sections of the colon harvested for histologic analysis, RNA extraction and cytokine measurement. A compound of the present disclosure, such as a compound provided in Table 1, is expected to decrease ALK5 activity in the colon and to slow, halt or reverse intestinal fibrosis as evidenced by one or more of (1) reduction in the ratio of colon weight to colon length; (2) reduction in deposition of extracellular matrix as observed by histology; (3) reduction in expression of collagen 1 (Col1a1) and connective tissue growth factor (Ctgf) in colon tissue; and (4) reduction in production of TGF-β1 and IL6 in the colon, relative to vehicle-treated controls.
- One or more compounds disclosed herein, e.g., a compound provided in Table 1 having an ALK5 pKi value of greater than 9.5, preferably greater than 10.5 (a measurement reflecting the ability of the compound to inhibit ALK5 activity, measured in accordance with Example 45), are expected to slow, halt or reverse the progression of intestinal fibrosis in an adoptive T-cell transfer model of colitis. Six- to 8-week old female CB17 SCID mice are tagged and weighed, then administered CD4+ CD25− CD62L+ naïve T cells isolated from the spleens of Balb/C mice (IP; 1×106 cells) to induce colitis.
- Once diarrhea and a 10% or greater decrease in body weight are observed (typically around week 2), mice are treated with either vehicle control or a compound of the present disclosure at an appropriate amount and frequency via oral gavage (e.g., once daily). Animals are sacrificed 45 days after induction of colitis, then distal, mid and proximal sections of the colon harvested for histologic analysis, RNA extraction and cytokine measurement. A compound of the present disclosure, such as a compound provided in Table 1, is expected to decrease ALK5 activity in the colon and to slow, halt or reverse intestinal fibrosis as evidenced by one or more of (1) reduction in the ratio of colon weight to colon length; (2) reduction in deposition of extracellular matrix as observed by histology; (3) reduction in expression of collagen 1 (Col1a1) and connective tissue growth factor (Ctgf) in colon tissue; and (4) reduction in production of TGF-β1 and IL6 in the colon, relative to vehicle-treated controls.
- One or more compounds disclosed herein, e.g., a compound provided in Table 1 having an ALK5 pKi value of greater than 9.5, preferably greater than 10.5 (a measurement reflecting the ability of the compound to inhibit ALK5 activity, measured in accordance with Example 45), are expected to slow, halt or reverse the progression of pulmonary hypertension in a monocrotaline (MCT) model of severe pulmonary hypertension. Male Sprague-Dawley rats are tagged, weighed, and randomly divided into control and MCT-treated groups. The rats in the MCT-treated group are administered a single dose of MCT (60 mg/kg, s.c.), then treated with either (1) vehicle control; (2) sildenafil (30 mg/kg, p.o., b.i.d.); or (3) a compound of the present disclosure at an appropriate amount and frequency (formulated in 3% glycerol in PBS; pH=4) via oral aspiration.
- Following 2-weeks of treatment, the animals are anesthetized with ketamine/xylazine for terminal monitoring of pulmonary and systemic arterial pressures along with heart rate. The lungs of each animal are then harvested for histologic analysis. A compound of the present disclosure, such as a compound provided in Table 1, is expected to decrease ALK5 activity in the lung and slow, halt or reverse the progression of pulmonary hypertension as evidenced by one or more of (1) reduction in systolic pulmonary arterial pressure; (2) reduction in right ventricular (RV) systolic pressure; (3) reduction in RV diastolic pressure; (4) increase in cardiac output; (5) reduction in RV hypertrophy; (6) reduction in pSmad2 or pSmad3 staining within vascular and/or alveolar cells; (7) reduction in medial thickness; (8) reduction in vascular smooth muscle cell proliferation; (9) reduction in vascular smooth muscle hypertrophy; and (10) reduction in expression of matrix metalloproteinase (MMP)-2 and/or MMP-9.
Claims (38)
1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
A is selected from phenyl, 5- to 6-membered heteroaryl, indanyl, indazolyl, benzotriazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxanyl, and tetrahydrobenzazepinyl;
B is selected from phenyl and 5- to 6-membered heteroaryl;
RA is independently selected at each occurrence from:
halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3;
C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from —OR1, —N(R1)2, —C(O)OR1, C3-8 carbocycle, and 3- to 10-membered heterocycle; and
C3-8 carbocycle and 3- to 10-membered heterocycle,
wherein each C3-8 carbocycle and 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —OR1, —CH2N(R1)2, —N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —C(O)N(R1)2, R1, and C1-6 alkyl;
RB is independently selected at each occurrence from halogen, —CN, —NH2, —NHCH3, —NHCH2CH3, —C(O)CH3, —OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2F, —CHF2, —CF3, C3-4 carbocycle, and 3- to 4-membered heterocycle;
m is 0, 1 or 2;
n is 0, 1, 2, or 3;
R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3-8 carbocycle), and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —NH2, —NHCH3, —N(CH3)2, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-8 carbocycle, and 3- to 6-membered heterocycle; and
R2 and R3 are taken together with the nitrogen atom to which they are attached to form a heterocycle, optionally substituted with one or more R1.
2.-3. (canceled)
4. The compound or salt of claim 1 , wherein A is selected from phenyl and 5- to 6-membered heteroaryl.
5. The compound or salt of claim 1 , wherein A is selected from phenyl, indanyl, thiazolyl, thiophenyl, pyrazolyl, pyridyl, pyrimidinyl, indazolyl, benzotriazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxanyl, and tetrahydrobenzazepinyl.
6. The compound or salt of claim 1 , wherein A is phenyl.
9.-10. (canceled)
11. The compound or salt of claim 1 , wherein RA is independently selected at each occurrence from:
halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2;
C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from —OR1, —N(R1)2, and 3- to 10-membered heterocycle; and
3- to 10-membered heterocycle,
wherein each 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —OR1, —N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —C(O)N(R1)2, and R1.
12.-13. (canceled)
14. The compound or salt of claim 1 , wherein RA is —NR1C(O)R1.
15. The compound or salt of claim 1 , wherein RA is —C(O)OR1.
16. The compound or salt of claim 1 , wherein RA is C1-6 alkyl substituted with 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is substituted with —C(O)OR1.
17.-21. (canceled)
22. The compound or salt of claim 1 , wherein m is 1.
23. (canceled)
24. The compound or salt of claim 1 , wherein B is selected from phenyl and pyridyl.
25. (canceled)
26. The compound or salt of claim 1 , wherein B is 2-pyridyl.
27. (canceled)
28. The compound or salt of claim 1 , wherein RB is independently selected at each occurrence from halogen, —OH, —CH3, and —CHF2.
29. The compound or salt of claim 1 , wherein RB is —CH3.
30. (canceled)
31. The compound or salt of claim 1 , wherein n is 1.
32. (canceled)
34.-40. (canceled)
41. A pharmaceutical composition comprising the compound or salt of claim 1 a pharmaceutically acceptable carrier.
42.-43. (canceled)
44. A method of treating an ALK5-mediated disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of the compound or salt of claim 1 .
45. (canceled)
46. The method of claim 44 , wherein the disease or condition is fibrosis.
47.-50. (canceled)
51. The method of claim 46 , where the fibrosis is idiopathic pulmonary fibrosis (IPF).
52. The method of claim 46 , wherein the fibrosis is intestinal fibrosis.
53. (canceled)
54. The method of claim 44 , wherein the disease or condition is selected from breast cancer, colon cancer, prostate cancer, lung cancer, hepatocellular carcinoma, glioblastoma, melanoma, and pancreatic cancer.
55.-63. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/140,423 US20230399312A1 (en) | 2020-03-31 | 2023-04-27 | Substituted pyrimidines and methods of use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063002658P | 2020-03-31 | 2020-03-31 | |
US202163200310P | 2021-03-01 | 2021-03-01 | |
US17/301,242 US11673879B2 (en) | 2020-03-31 | 2021-03-30 | Substituted pyrimidines and methods of use |
US18/140,423 US20230399312A1 (en) | 2020-03-31 | 2023-04-27 | Substituted pyrimidines and methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/301,242 Continuation US11673879B2 (en) | 2020-03-31 | 2021-03-30 | Substituted pyrimidines and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230399312A1 true US20230399312A1 (en) | 2023-12-14 |
Family
ID=75640051
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/301,242 Active 2041-07-20 US11673879B2 (en) | 2020-03-31 | 2021-03-30 | Substituted pyrimidines and methods of use |
US18/140,423 Pending US20230399312A1 (en) | 2020-03-31 | 2023-04-27 | Substituted pyrimidines and methods of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/301,242 Active 2041-07-20 US11673879B2 (en) | 2020-03-31 | 2021-03-30 | Substituted pyrimidines and methods of use |
Country Status (6)
Country | Link |
---|---|
US (2) | US11673879B2 (en) |
EP (1) | EP4126824A1 (en) |
JP (1) | JP2023519673A (en) |
CN (1) | CN115443269A (en) |
TW (1) | TW202204339A (en) |
WO (1) | WO2021203131A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022206797A1 (en) * | 2021-03-30 | 2022-10-06 | 贝达药业股份有限公司 | Egfr inhibitor, and composition and use thereof |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207A (en) | 1849-03-20 | Improved spriing snap-hook | ||
US156A (en) | 1837-03-30 | Improvement in machines for packing and pressing flour | ||
US868A (en) | 1838-08-01 | Improvement in brewing beer and ale | ||
US7722A (en) | 1850-10-15 | Machine for folding paper | ||
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
JP2001523958A (en) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | CTLA-4 binding peptides for immunotherapy |
HU229566B1 (en) | 1998-12-23 | 2014-02-28 | Pfizer | Human monoclonal antibodies to ctla-4 |
EE05627B1 (en) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | Human monoclonal antibodies to CTLA-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CN1371416B (en) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | Human CTLA-4 antibodies and their uses |
AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
WO2002086083A2 (en) | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
PT1537878E (en) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Immunopotentiating compositions |
PL216630B1 (en) | 2002-10-17 | 2014-04-30 | Genmab As | Human monoclonal antibodies against cd20 |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
US20060069110A1 (en) | 2004-09-27 | 2006-03-30 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
US20060161001A1 (en) | 2004-12-20 | 2006-07-20 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
KR101498834B1 (en) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
NZ564243A (en) | 2005-06-08 | 2011-03-31 | Dana Farber Cancer Inst Inc | Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
WO2008006583A1 (en) | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
ES2639857T3 (en) | 2008-02-11 | 2017-10-30 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
HUE035029T2 (en) | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Phosphorous derivatives as kinase inhibitors |
WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
TWI686405B (en) | 2008-12-09 | 2020-03-01 | 建南德克公司 | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
CA2777226A1 (en) | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
EA026924B1 (en) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
BR112014029887A8 (en) | 2012-05-31 | 2021-09-14 | Genentech Inc | Method to treat or slow the progression of cancer, kits and use of a pd-1 axis binding antagonist, oxaliplatin, leucovorin and 5-fu |
JP6403166B2 (en) | 2012-08-03 | 2018-10-10 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Single antigen anti-PD-L1 and PD-L2 double-binding antibodies and methods of use thereof |
AR093984A1 (en) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN |
AR095363A1 (en) | 2013-03-15 | 2015-10-14 | Genentech Inc | BIOMARKERS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO PD-1 AND PD-L1 |
CN104250302B (en) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | The anti-antibody of PD 1 and its application |
WO2015036394A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune Limited | Antibodies against pd-1 and uses thereof |
WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
HUE060420T2 (en) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
HUE047194T2 (en) | 2013-09-27 | 2020-04-28 | Hoffmann La Roche | Anti-pdl1 antibody formulations |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
CA2926856A1 (en) | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
SG11201604738TA (en) | 2013-12-12 | 2016-07-28 | Shanghai Hengrui Pharm Co Ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
CN113637692A (en) | 2014-01-15 | 2021-11-12 | 卡德门企业有限公司 | Immunomodulator |
TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
CA2959347C (en) | 2014-08-25 | 2023-03-07 | Salk Institute For Biological Studies | Ulk1 inhibitors and methods using same |
KR101876514B1 (en) | 2016-11-08 | 2018-07-10 | 한국화학연구원 | Novel pyrimidine compounds, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer and inflammation disease containing the same as an active ingredient |
-
2021
- 2021-03-30 US US17/301,242 patent/US11673879B2/en active Active
- 2021-03-30 CN CN202180025712.7A patent/CN115443269A/en active Pending
- 2021-03-30 WO PCT/US2021/070337 patent/WO2021203131A1/en unknown
- 2021-03-30 JP JP2022558112A patent/JP2023519673A/en active Pending
- 2021-03-30 EP EP21720964.2A patent/EP4126824A1/en active Pending
- 2021-03-30 TW TW110111504A patent/TW202204339A/en unknown
-
2023
- 2023-04-27 US US18/140,423 patent/US20230399312A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11673879B2 (en) | 2023-06-13 |
TW202204339A (en) | 2022-02-01 |
CN115443269A (en) | 2022-12-06 |
EP4126824A1 (en) | 2023-02-08 |
JP2023519673A (en) | 2023-05-12 |
WO2021203131A1 (en) | 2021-10-07 |
US20220372015A1 (en) | 2022-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11542251B2 (en) | IRAK degraders and uses thereof | |
US10952996B2 (en) | ALK5 inhibitors | |
US11590116B2 (en) | Substituted pyridines and methods of use | |
AU2012382373A1 (en) | Pyridinone and pyridazinone derivatives | |
CN115916194A (en) | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors | |
US20240034723A1 (en) | Piperidinyl small molecule degraders of helios and methods of use | |
US20230399312A1 (en) | Substituted pyrimidines and methods of use | |
EA033571B1 (en) | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | |
WO2022251359A1 (en) | Bicyclic inhibitors of alk5 and methods of use | |
US20210387983A1 (en) | Crystalline alk5 inhibitors and uses thereof | |
US20230365551A1 (en) | Inhibitors of human respiratory syncytial virus and metapneumovirus | |
US20230365531A1 (en) | Inhibitors of human respiratory syncytial virus and metapneumo virus | |
NZ786969A (en) | Beta-lactamase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |